#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Early postpartum resting-state functional connectivity for mothers receiving buprenorphine treatment for opioid use disorder: A pilot study
#Text=Between 1999 and 2014, the prevalence of opioid use disorder (OUD) among pregnant women quadrupled in the USA.
1-1	0-5	Early	_	
1-2	6-16	postpartum	_	
1-3	17-30	resting-state	_	
1-4	31-41	functional	_	
1-5	42-54	connectivity	_	
1-6	55-58	for	_	
1-7	59-66	mothers	_	
1-8	67-76	receiving	_	
1-9	77-90	buprenorphine	_	
1-10	91-100	treatment	_	
1-11	101-104	for	_	
1-12	105-111	opioid	_	
1-13	112-115	use	_	
1-14	116-124	disorder	_	
1-15	124-125	:	_	
1-16	126-127	A	_	
1-17	128-133	pilot	_	
1-18	134-139	study	_	
1-19	140-147	Between	_	
1-20	148-152	1999	_	
1-21	153-156	and	_	
1-22	157-161	2014	_	
1-23	161-162	,	_	
1-24	163-166	the	_	
1-25	167-177	prevalence	_	
1-26	178-180	of	_	
1-27	181-187	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-28	188-191	use	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-29	192-200	disorder	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-30	201-202	(	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-31	202-205	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-32	205-206	)	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-33	207-212	among	_	
1-34	213-221	pregnant	_	
1-35	222-227	women	_	
1-36	228-238	quadrupled	_	
1-37	239-241	in	_	
1-38	242-245	the	_	
1-39	246-249	USA	_	
1-40	249-250	.	_	

#Text=The standard treatment for peripartum women with OUD is buprenorphine.
2-1	251-254	The	_	
2-2	255-263	standard	_	
2-3	264-273	treatment	_	
2-4	274-277	for	_	
2-5	278-288	peripartum	_	
2-6	289-294	women	_	
2-7	295-299	with	_	
2-8	300-303	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
2-9	304-306	is	_	
2-10	307-320	buprenorphine	_	
2-11	320-321	.	_	

#Text=However, the maternal behavior neurocircuit that regulates maternal behavior and mother-infant bonding has not been previously studied for human mothers receiving buprenorphine treatment for OUD (BT).
3-1	322-329	However	_	
3-2	329-330	,	_	
3-3	331-334	the	_	
3-4	335-343	maternal	_	
3-5	344-352	behavior	_	
3-6	353-365	neurocircuit	_	
3-7	366-370	that	_	
3-8	371-380	regulates	_	
3-9	381-389	maternal	_	
3-10	390-398	behavior	_	
3-11	399-402	and	_	
3-12	403-416	mother-infant	_	
3-13	417-424	bonding	_	
3-14	425-428	has	_	
3-15	429-432	not	_	
3-16	433-437	been	_	
3-17	438-448	previously	_	
3-18	449-456	studied	_	
3-19	457-460	for	_	
3-20	461-466	human	_	
3-21	467-474	mothers	_	
3-22	475-484	receiving	_	
3-23	485-498	buprenorphine	_	
3-24	499-508	treatment	_	
3-25	509-512	for	_	
3-26	513-516	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
3-27	517-518	(	_	
3-28	518-520	BT	_	
3-29	520-521	)	_	
3-30	521-522	.	_	

#Text=Rodent research shows opioid effects on reciprocal inhibition between maternal care and defence maternal brain subsystems: the hypothalamus and periaqueductal gray, respectively.
4-1	523-529	Rodent	_	
4-2	530-538	research	_	
4-3	539-544	shows	_	
4-4	545-551	opioid	_	
4-5	552-559	effects	_	
4-6	560-562	on	_	
4-7	563-573	reciprocal	_	
4-8	574-584	inhibition	_	
4-9	585-592	between	_	
4-10	593-601	maternal	_	
4-11	602-606	care	_	
4-12	607-610	and	_	
4-13	611-618	defence	_	
4-14	619-627	maternal	_	
4-15	628-633	brain	_	
4-16	634-644	subsystems	_	
4-17	644-645	:	_	
4-18	646-649	the	_	
4-19	650-662	hypothalamus	_	
4-20	663-666	and	_	
4-21	667-681	periaqueductal	_	
4-22	682-686	gray	_	
4-23	686-687	,	_	
4-24	688-700	respectively	_	
4-25	700-701	.	_	

#Text=We conducted a longitudinal functional magnetic resonance imaging (fMRI) pilot study in humans to specifically examine resting-state functional connectivity (rs-FC) between the periaqueductal gray and hypothalamus, as well as to explore associations with maternal bonding for BT.
5-1	702-704	We	_	
5-2	705-714	conducted	_	
5-3	715-716	a	_	
5-4	717-729	longitudinal	_	
5-5	730-740	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-6	741-749	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-7	750-759	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-8	760-767	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-9	768-769	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-10	769-773	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-11	773-774	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
5-12	775-780	pilot	_	
5-13	781-786	study	_	
5-14	787-789	in	_	
5-15	790-796	humans	_	
5-16	797-799	to	_	
5-17	800-812	specifically	_	
5-18	813-820	examine	_	
5-19	821-834	resting-state	_	
5-20	835-845	functional	_	
5-21	846-858	connectivity	_	
5-22	859-860	(	_	
5-23	860-865	rs-FC	_	
5-24	865-866	)	_	
5-25	867-874	between	_	
5-26	875-878	the	_	
5-27	879-893	periaqueductal	_	
5-28	894-898	gray	_	
5-29	899-902	and	_	
5-30	903-915	hypothalamus	_	
5-31	915-916	,	_	
5-32	917-919	as	_	
5-33	920-924	well	_	
5-34	925-927	as	_	
5-35	928-930	to	_	
5-36	931-938	explore	_	
5-37	939-951	associations	_	
5-38	952-956	with	_	
5-39	957-965	maternal	_	
5-40	966-973	bonding	_	
5-41	974-977	for	_	
5-42	978-980	BT	_	
5-43	980-981	.	_	

#Text=We studied 32 mothers who completed fMRI scans at 1 month (T1) and 4 months postpartum (T2), including seven mothers receiving buprenorphine for OUD and 25 non-OUD mothers as a comparison group (CG).
6-1	982-984	We	_	
6-2	985-992	studied	_	
6-3	993-995	32	_	
6-4	996-1003	mothers	_	
6-5	1004-1007	who	_	
6-6	1008-1017	completed	_	
6-7	1018-1022	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
6-8	1023-1028	scans	_	
6-9	1029-1031	at	_	
6-10	1032-1033	1	_	
6-11	1034-1039	month	_	
6-12	1040-1041	(	_	
6-13	1041-1043	T1	_	
6-14	1043-1044	)	_	
6-15	1045-1048	and	_	
6-16	1049-1050	4	_	
6-17	1051-1057	months	_	
6-18	1058-1068	postpartum	_	
6-19	1069-1070	(	_	
6-20	1070-1072	T2	_	
6-21	1072-1073	)	_	
6-22	1073-1074	,	_	
6-23	1075-1084	including	_	
6-24	1085-1090	seven	_	
6-25	1091-1098	mothers	_	
6-26	1099-1108	receiving	_	
6-27	1109-1122	buprenorphine	_	
6-28	1123-1126	for	_	
6-29	1127-1130	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
6-30	1131-1134	and	_	
6-31	1135-1137	25	_	
6-32	1138-1145	non-OUD	_	
6-33	1146-1153	mothers	_	
6-34	1154-1156	as	_	
6-35	1157-1158	a	_	
6-36	1159-1169	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-37	1170-1175	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-38	1176-1177	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-39	1177-1179	CG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-40	1179-1180	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-41	1180-1181	.	_	

#Text=The participants underwent a 6-minute resting-state fMRI scan at each time point.
7-1	1182-1185	The	_	
7-2	1186-1198	participants	_	
7-3	1199-1208	underwent	_	
7-4	1209-1210	a	_	
7-5	1211-1212	6	_	
7-6	1212-1213	-	_	
7-7	1213-1219	minute	_	
7-8	1220-1233	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
7-9	1234-1238	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
7-10	1239-1243	scan	_	
7-11	1244-1246	at	_	
7-12	1247-1251	each	_	
7-13	1252-1256	time	_	
7-14	1257-1262	point	_	
7-15	1262-1263	.	_	

#Text=We measured potential bonding impairments using the Postpartum Bonding Questionnaire to explore how rs-FC with periaqueductal gray is associated with bonding impairments.
8-1	1264-1266	We	_	
8-2	1267-1275	measured	_	
8-3	1276-1285	potential	_	
8-4	1286-1293	bonding	_	
8-5	1294-1305	impairments	_	
8-6	1306-1311	using	_	
8-7	1312-1315	the	_	
8-8	1316-1326	Postpartum	_	
8-9	1327-1334	Bonding	_	
8-10	1335-1348	Questionnaire	_	
8-11	1349-1351	to	_	
8-12	1352-1359	explore	_	
8-13	1360-1363	how	_	
8-14	1364-1369	rs-FC	_	
8-15	1370-1374	with	_	
8-16	1375-1389	periaqueductal	_	
8-17	1390-1394	gray	_	
8-18	1395-1397	is	_	
8-19	1398-1408	associated	_	
8-20	1409-1413	with	_	
8-21	1414-1421	bonding	_	
8-22	1422-1433	impairments	_	
8-23	1433-1434	.	_	

#Text=Compared to CG, BT mothers differed in periaqueductal gray-dependent rs-FC with the hypothalamus, amygdala, insular cortex and other brain regions at T1, with many of these differences disappearing at T2, suggesting potential therapeutic effects of continuing buprenorphine treatment.
9-1	1435-1443	Compared	_	
9-2	1444-1446	to	_	
9-3	1447-1449	CG	_	
9-4	1449-1450	,	_	
9-5	1451-1453	BT	_	
9-6	1454-1461	mothers	_	
9-7	1462-1470	differed	_	
9-8	1471-1473	in	_	
9-9	1474-1488	periaqueductal	_	
9-10	1489-1503	gray-dependent	_	
9-11	1504-1509	rs-FC	_	
9-12	1510-1514	with	_	
9-13	1515-1518	the	_	
9-14	1519-1531	hypothalamus	_	
9-15	1531-1532	,	_	
9-16	1533-1541	amygdala	_	
9-17	1541-1542	,	_	
9-18	1543-1550	insular	_	
9-19	1551-1557	cortex	_	
9-20	1558-1561	and	_	
9-21	1562-1567	other	_	
9-22	1568-1573	brain	_	
9-23	1574-1581	regions	_	
9-24	1582-1584	at	_	
9-25	1585-1587	T1	_	
9-26	1587-1588	,	_	
9-27	1589-1593	with	_	
9-28	1594-1598	many	_	
9-29	1599-1601	of	_	
9-30	1602-1607	these	_	
9-31	1608-1619	differences	_	
9-32	1620-1632	disappearing	_	
9-33	1633-1635	at	_	
9-34	1636-1638	T2	_	
9-35	1638-1639	,	_	
9-36	1640-1650	suggesting	_	
9-37	1651-1660	potential	_	
9-38	1661-1672	therapeutic	_	
9-39	1673-1680	effects	_	
9-40	1681-1683	of	_	
9-41	1684-1694	continuing	_	
9-42	1695-1708	buprenorphine	_	
9-43	1709-1718	treatment	_	
9-44	1718-1719	.	_	

#Text=In contrast, the “rejection and pathological anger” subscale of the Postpartum Bonding Questionnaire at T1 and T2 was associated with the T1-to-T2 increases in periaqueductal gray-dependent rs-FC with the hypothalamus and amygdala.
10-1	1720-1722	In	_	
10-2	1723-1731	contrast	_	
10-3	1731-1732	,	_	
10-4	1733-1736	the	_	
10-5	1737-1738	“	_	
10-6	1738-1747	rejection	_	
10-7	1748-1751	and	_	
10-8	1752-1764	pathological	_	
10-9	1765-1770	anger	_	
10-10	1770-1771	”	_	
10-11	1772-1780	subscale	_	
10-12	1781-1783	of	_	
10-13	1784-1787	the	_	
10-14	1788-1798	Postpartum	_	
10-15	1799-1806	Bonding	_	
10-16	1807-1820	Questionnaire	_	
10-17	1821-1823	at	_	
10-18	1824-1826	T1	_	
10-19	1827-1830	and	_	
10-20	1831-1833	T2	_	
10-21	1834-1837	was	_	
10-22	1838-1848	associated	_	
10-23	1849-1853	with	_	
10-24	1854-1857	the	_	
10-25	1858-1860	T1	_	
10-26	1860-1861	-	_	
10-27	1861-1866	to-T2	_	
10-28	1867-1876	increases	_	
10-29	1877-1879	in	_	
10-30	1880-1894	periaqueductal	_	
10-31	1895-1909	gray-dependent	_	
10-32	1910-1915	rs-FC	_	
10-33	1916-1920	with	_	
10-34	1921-1924	the	_	
10-35	1925-1937	hypothalamus	_	
10-36	1938-1941	and	_	
10-37	1942-1950	amygdala	_	
10-38	1950-1951	.	_	

#Text=Preliminary evidence links maternal bonding problems for mothers with OUD early in the postpartum to connectivity between specific care and defence maternal brain circuits, which may be mitigated by buprenorphine treatment.
11-1	1952-1963	Preliminary	_	
11-2	1964-1972	evidence	_	
11-3	1973-1978	links	_	
11-4	1979-1987	maternal	_	
11-5	1988-1995	bonding	_	
11-6	1996-2004	problems	_	
11-7	2005-2008	for	_	
11-8	2009-2016	mothers	_	
11-9	2017-2021	with	_	
11-10	2022-2025	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
11-11	2026-2031	early	_	
11-12	2032-2034	in	_	
11-13	2035-2038	the	_	
11-14	2039-2049	postpartum	_	
11-15	2050-2052	to	_	
11-16	2053-2065	connectivity	_	
11-17	2066-2073	between	_	
11-18	2074-2082	specific	_	
11-19	2083-2087	care	_	
11-20	2088-2091	and	_	
11-21	2092-2099	defence	_	
11-22	2100-2108	maternal	_	
11-23	2109-2114	brain	_	
11-24	2115-2123	circuits	_	
11-25	2123-2124	,	_	
11-26	2125-2130	which	_	
11-27	2131-2134	may	_	
11-28	2135-2137	be	_	
11-29	2138-2147	mitigated	_	
11-30	2148-2150	by	_	
11-31	2151-2164	buprenorphine	_	
11-32	2165-2174	treatment	_	
11-33	2174-2175	.	_	

#Text=This exploratory study supports a potential mechanism for investigating both the therapeutic benefits and risks of opioids for maternal care and bonding with infants.
12-1	2176-2180	This	_	
12-2	2181-2192	exploratory	_	
12-3	2193-2198	study	_	
12-4	2199-2207	supports	_	
12-5	2208-2209	a	_	
12-6	2210-2219	potential	_	
12-7	2220-2229	mechanism	_	
12-8	2230-2233	for	_	
12-9	2234-2247	investigating	_	
12-10	2248-2252	both	_	
12-11	2253-2256	the	_	
12-12	2257-2268	therapeutic	_	
12-13	2269-2277	benefits	_	
12-14	2278-2281	and	_	
12-15	2282-2287	risks	_	
12-16	2288-2290	of	_	
12-17	2291-2298	opioids	_	
12-18	2299-2302	for	_	
12-19	2303-2311	maternal	_	
12-20	2312-2316	care	_	
12-21	2317-2320	and	_	
12-22	2321-2328	bonding	_	
12-23	2329-2333	with	_	
12-24	2334-2341	infants	_	
12-25	2341-2342	.	_	

#Text=INTRODUCTION
#Text=The opioid epidemic in the USA directly affects millions of women, with approximately 20% of all pregnant women being prescribed opioids and 2.5% chronically using opioids, and the number of pregnant women with opioid use disorder (OUD) having more than quadrupled from 1999 to 2014 (from 1.5 per 1,000 delivery hospitalisations to 6.5).
13-1	2343-2355	INTRODUCTION	_	
13-2	2356-2359	The	_	
13-3	2360-2366	opioid	_	
13-4	2367-2375	epidemic	_	
13-5	2376-2378	in	_	
13-6	2379-2382	the	_	
13-7	2383-2386	USA	_	
13-8	2387-2395	directly	_	
13-9	2396-2403	affects	_	
13-10	2404-2412	millions	_	
13-11	2413-2415	of	_	
13-12	2416-2421	women	_	
13-13	2421-2422	,	_	
13-14	2423-2427	with	_	
13-15	2428-2441	approximately	_	
13-16	2442-2445	20%	_	
13-17	2446-2448	of	_	
13-18	2449-2452	all	_	
13-19	2453-2461	pregnant	_	
13-20	2462-2467	women	_	
13-21	2468-2473	being	_	
13-22	2474-2484	prescribed	_	
13-23	2485-2492	opioids	_	
13-24	2493-2496	and	_	
13-25	2497-2501	2.5%	_	
13-26	2502-2513	chronically	_	
13-27	2514-2519	using	_	
13-28	2520-2527	opioids	_	
13-29	2527-2528	,	_	
13-30	2529-2532	and	_	
13-31	2533-2536	the	_	
13-32	2537-2543	number	_	
13-33	2544-2546	of	_	
13-34	2547-2555	pregnant	_	
13-35	2556-2561	women	_	
13-36	2562-2566	with	_	
13-37	2567-2573	opioid	_	
13-38	2574-2577	use	_	
13-39	2578-2586	disorder	_	
13-40	2587-2588	(	_	
13-41	2588-2591	OUD	_	
13-42	2591-2592	)	_	
13-43	2593-2599	having	_	
13-44	2600-2604	more	_	
13-45	2605-2609	than	_	
13-46	2610-2620	quadrupled	_	
13-47	2621-2625	from	_	
13-48	2626-2630	1999	_	
13-49	2631-2633	to	_	
13-50	2634-2638	2014	_	
13-51	2639-2640	(	_	
13-52	2640-2644	from	_	
13-53	2645-2648	1.5	_	
13-54	2649-2652	per	_	
13-55	2653-2658	1,000	_	
13-56	2659-2667	delivery	_	
13-57	2668-2684	hospitalisations	_	
13-58	2685-2687	to	_	
13-59	2688-2691	6.5	_	
13-60	2691-2692	)	_	
13-61	2692-2693	.	_	

#Text=The standard of care for OUD among pregnant women is opioid maintenance therapy with buprenorphine.
14-1	2694-2697	The	_	
14-2	2698-2706	standard	_	
14-3	2707-2709	of	_	
14-4	2710-2714	care	_	
14-5	2715-2718	for	_	
14-6	2719-2722	OUD	_	
14-7	2723-2728	among	_	
14-8	2729-2737	pregnant	_	
14-9	2738-2743	women	_	
14-10	2744-2746	is	_	
14-11	2747-2753	opioid	_	
14-12	2754-2765	maintenance	_	
14-13	2766-2773	therapy	_	
14-14	2774-2778	with	_	
14-15	2779-2792	buprenorphine	_	
14-16	2792-2793	.	_	

#Text=Buprenorphine treatment for OUD (BT) is a common choice of treatment to mitigate the physiological stress associated with repeated cycles of maternal/foetal intoxication and withdrawal, preserving uterine stability via receptor occupancy.
15-1	2794-2807	Buprenorphine	_	
15-2	2808-2817	treatment	_	
15-3	2818-2821	for	_	
15-4	2822-2825	OUD	_	
15-5	2826-2827	(	_	
15-6	2827-2829	BT	_	
15-7	2829-2830	)	_	
15-8	2831-2833	is	_	
15-9	2834-2835	a	_	
15-10	2836-2842	common	_	
15-11	2843-2849	choice	_	
15-12	2850-2852	of	_	
15-13	2853-2862	treatment	_	
15-14	2863-2865	to	_	
15-15	2866-2874	mitigate	_	
15-16	2875-2878	the	_	
15-17	2879-2892	physiological	_	
15-18	2893-2899	stress	_	
15-19	2900-2910	associated	_	
15-20	2911-2915	with	_	
15-21	2916-2924	repeated	_	
15-22	2925-2931	cycles	_	
15-23	2932-2934	of	_	
15-24	2935-2943	maternal	_	
15-25	2943-2944	/	_	
15-26	2944-2950	foetal	_	
15-27	2951-2963	intoxication	_	
15-28	2964-2967	and	_	
15-29	2968-2978	withdrawal	_	
15-30	2978-2979	,	_	
15-31	2980-2990	preserving	_	
15-32	2991-2998	uterine	_	
15-33	2999-3008	stability	_	
15-34	3009-3012	via	_	
15-35	3013-3021	receptor	_	
15-36	3022-3031	occupancy	_	
15-37	3031-3032	.	_	

#Text=Compared to detoxification and possibly methadone treatment, BT may result in milder neonatal abstinence syndrome.
16-1	3033-3041	Compared	_	
16-2	3042-3044	to	_	
16-3	3045-3059	detoxification	_	
16-4	3060-3063	and	_	
16-5	3064-3072	possibly	_	
16-6	3073-3082	methadone	_	
16-7	3083-3092	treatment	_	
16-8	3092-3093	,	_	
16-9	3094-3096	BT	_	
16-10	3097-3100	may	_	
16-11	3101-3107	result	_	
16-12	3108-3110	in	_	
16-13	3111-3117	milder	_	
16-14	3118-3126	neonatal	_	
16-15	3127-3137	abstinence	_	
16-16	3138-3146	syndrome	_	
16-17	3146-3147	.	_	

#Text=However, the effects of buprenorphine treatment (BT) on the human maternal brain affected by OUD are not well understood.
17-1	3148-3155	However	_	
17-2	3155-3156	,	_	
17-3	3157-3160	the	_	
17-4	3161-3168	effects	_	
17-5	3169-3171	of	_	
17-6	3172-3185	buprenorphine	_	
17-7	3186-3195	treatment	_	
17-8	3196-3197	(	_	
17-9	3197-3199	BT	_	
17-10	3199-3200	)	_	
17-11	3201-3203	on	_	
17-12	3204-3207	the	_	
17-13	3208-3213	human	_	
17-14	3214-3222	maternal	_	
17-15	3223-3228	brain	_	
17-16	3229-3237	affected	_	
17-17	3238-3240	by	_	
17-18	3241-3244	OUD	_	
17-19	3245-3248	are	_	
17-20	3249-3252	not	_	
17-21	3253-3257	well	_	
17-22	3258-3268	understood	_	
17-23	3268-3269	.	_	

#Text=So far, there is just one study of mothers with polysubstance addictions showing reduced activation in reward regions of the brain in response to their own infant’s face cues; and one of mothers with BT for OUD vs depressed controls showing increased own vs other baby cry responses in multiple motivation brain regions.
18-1	3270-3272	So	_	
18-2	3273-3276	far	_	
18-3	3276-3277	,	_	
18-4	3278-3283	there	_	
18-5	3284-3286	is	_	
18-6	3287-3291	just	_	
18-7	3292-3295	one	_	
18-8	3296-3301	study	_	
18-9	3302-3304	of	_	
18-10	3305-3312	mothers	_	
18-11	3313-3317	with	_	
18-12	3318-3331	polysubstance	_	
18-13	3332-3342	addictions	_	
18-14	3343-3350	showing	_	
18-15	3351-3358	reduced	_	
18-16	3359-3369	activation	_	
18-17	3370-3372	in	_	
18-18	3373-3379	reward	_	
18-19	3380-3387	regions	_	
18-20	3388-3390	of	_	
18-21	3391-3394	the	_	
18-22	3395-3400	brain	_	
18-23	3401-3403	in	_	
18-24	3404-3412	response	_	
18-25	3413-3415	to	_	
18-26	3416-3421	their	_	
18-27	3422-3425	own	_	
18-28	3426-3432	infant	_	
18-29	3432-3433	’	_	
18-30	3433-3434	s	_	
18-31	3435-3439	face	_	
18-32	3440-3444	cues	_	
18-33	3444-3445	;	_	
18-34	3446-3449	and	_	
18-35	3450-3453	one	_	
18-36	3454-3456	of	_	
18-37	3457-3464	mothers	_	
18-38	3465-3469	with	_	
18-39	3470-3472	BT	_	
18-40	3473-3476	for	_	
18-41	3477-3480	OUD	_	
18-42	3481-3483	vs	_	
18-43	3484-3493	depressed	_	
18-44	3494-3502	controls	_	
18-45	3503-3510	showing	_	
18-46	3511-3520	increased	_	
18-47	3521-3524	own	_	
18-48	3525-3527	vs	_	
18-49	3528-3533	other	_	
18-50	3534-3538	baby	_	
18-51	3539-3542	cry	_	
18-52	3543-3552	responses	_	
18-53	3553-3555	in	_	
18-54	3556-3564	multiple	_	
18-55	3565-3575	motivation	_	
18-56	3576-3581	brain	_	
18-57	3582-3589	regions	_	
18-58	3589-3590	.	_	

#Text=Maternal substance use in general places their infants at a four-fold increased risk for abuse or neglect, contributing to as much as 80% of child maltreatment cases and 60% of infant out-of-home placements.
19-1	3591-3599	Maternal	_	
19-2	3600-3609	substance	_	
19-3	3610-3613	use	_	
19-4	3614-3616	in	_	
19-5	3617-3624	general	_	
19-6	3625-3631	places	_	
19-7	3632-3637	their	_	
19-8	3638-3645	infants	_	
19-9	3646-3648	at	_	
19-10	3649-3650	a	_	
19-11	3651-3660	four-fold	_	
19-12	3661-3670	increased	_	
19-13	3671-3675	risk	_	
19-14	3676-3679	for	_	
19-15	3680-3685	abuse	_	
19-16	3686-3688	or	_	
19-17	3689-3696	neglect	_	
19-18	3696-3697	,	_	
19-19	3698-3710	contributing	_	
19-20	3711-3713	to	_	
19-21	3714-3716	as	_	
19-22	3717-3721	much	_	
19-23	3722-3724	as	_	
19-24	3725-3728	80%	_	
19-25	3729-3731	of	_	
19-26	3732-3737	child	_	
19-27	3738-3750	maltreatment	_	
19-28	3751-3756	cases	_	
19-29	3757-3760	and	_	
19-30	3761-3764	60%	_	
19-31	3765-3767	of	_	
19-32	3768-3774	infant	_	
19-33	3775-3786	out-of-home	_	
19-34	3787-3797	placements	_	
19-35	3797-3798	.	_	

#Text=Opioid-induced deficits in homologous maternal behaviours have also been established in animal models.
20-1	3799-3813	Opioid-induced	_	
20-2	3814-3822	deficits	_	
20-3	3823-3825	in	_	
20-4	3826-3836	homologous	_	
20-5	3837-3845	maternal	_	
20-6	3846-3856	behaviours	_	
20-7	3857-3861	have	_	
20-8	3862-3866	also	_	
20-9	3867-3871	been	_	
20-10	3872-3883	established	_	
20-11	3884-3886	in	_	
20-12	3887-3893	animal	_	
20-13	3894-3900	models	_	
20-14	3900-3901	.	_	

#Text=These effects appear to be mediated in part by activation of mu-opioid receptors in the hypothalamic medial preoptic area (mPOA).
21-1	3902-3907	These	_	
21-2	3908-3915	effects	_	
21-3	3916-3922	appear	_	
21-4	3923-3925	to	_	
21-5	3926-3928	be	_	
21-6	3929-3937	mediated	_	
21-7	3938-3940	in	_	
21-8	3941-3945	part	_	
21-9	3946-3948	by	_	
21-10	3949-3959	activation	_	
21-11	3960-3962	of	_	
21-12	3963-3972	mu-opioid	_	
21-13	3973-3982	receptors	_	
21-14	3983-3985	in	_	
21-15	3986-3989	the	_	
21-16	3990-4002	hypothalamic	_	
21-17	4003-4009	medial	_	
21-18	4010-4018	preoptic	_	
21-19	4019-4023	area	_	
21-20	4024-4025	(	_	
21-21	4025-4029	mPOA	_	
21-22	4029-4030	)	_	
21-23	4030-4031	.	_	

#Text=More recent findings have implicated the activation of select opioid receptor subtypes within the periaqueductal gray (PAG) in dysregulating maternal behaviour.
22-1	4032-4036	More	_	
22-2	4037-4043	recent	_	
22-3	4044-4052	findings	_	
22-4	4053-4057	have	_	
22-5	4058-4068	implicated	_	
22-6	4069-4072	the	_	
22-7	4073-4083	activation	_	
22-8	4084-4086	of	_	
22-9	4087-4093	select	_	
22-10	4094-4100	opioid	_	
22-11	4101-4109	receptor	_	
22-12	4110-4118	subtypes	_	
22-13	4119-4125	within	_	
22-14	4126-4129	the	_	
22-15	4130-4144	periaqueductal	_	
22-16	4145-4149	gray	_	
22-17	4150-4151	(	_	
22-18	4151-4154	PAG	_	
22-19	4154-4155	)	_	
22-20	4156-4158	in	_	
22-21	4159-4172	dysregulating	_	
22-22	4173-4181	maternal	_	
22-23	4182-4191	behaviour	_	
22-24	4191-4192	.	_	

#Text=The PAG plays a pivotal role in switching from maternal caregiving behaviours to defensive/aggressive behaviours such as predation in rodents that are known to be regulated by mu and kappa opioid receptor activity.
23-1	4193-4196	The	_	
23-2	4197-4200	PAG	_	
23-3	4201-4206	plays	_	
23-4	4207-4208	a	_	
23-5	4209-4216	pivotal	_	
23-6	4217-4221	role	_	
23-7	4222-4224	in	_	
23-8	4225-4234	switching	_	
23-9	4235-4239	from	_	
23-10	4240-4248	maternal	_	
23-11	4249-4259	caregiving	_	
23-12	4260-4270	behaviours	_	
23-13	4271-4273	to	_	
23-14	4274-4283	defensive	_	
23-15	4283-4284	/	_	
23-16	4284-4294	aggressive	_	
23-17	4295-4305	behaviours	_	
23-18	4306-4310	such	_	
23-19	4311-4313	as	_	
23-20	4314-4323	predation	_	
23-21	4324-4326	in	_	
23-22	4327-4334	rodents	_	
23-23	4335-4339	that	_	
23-24	4340-4343	are	_	
23-25	4344-4349	known	_	
23-26	4350-4352	to	_	
23-27	4353-4355	be	_	
23-28	4356-4365	regulated	_	
23-29	4366-4368	by	_	
23-30	4369-4371	mu	_	
23-31	4372-4375	and	_	
23-32	4376-4381	kappa	_	
23-33	4382-4388	opioid	_	
23-34	4389-4397	receptor	_	
23-35	4398-4406	activity	_	
23-36	4406-4407	.	_	

#Text=Indeed, infusion of a mu-opioid receptor agonist into the ventrolateral PAG disrupts the balance of maternal care and aggression and kappa-opioid receptor antagonism, shifting behaviours from maternal caring to predation behaviours in rodents.
24-1	4408-4414	Indeed	_	
24-2	4414-4415	,	_	
24-3	4416-4424	infusion	_	
24-4	4425-4427	of	_	
24-5	4428-4429	a	_	
24-6	4430-4439	mu-opioid	_	
24-7	4440-4448	receptor	_	
24-8	4449-4456	agonist	_	
24-9	4457-4461	into	_	
24-10	4462-4465	the	_	
24-11	4466-4479	ventrolateral	_	
24-12	4480-4483	PAG	_	
24-13	4484-4492	disrupts	_	
24-14	4493-4496	the	_	
24-15	4497-4504	balance	_	
24-16	4505-4507	of	_	
24-17	4508-4516	maternal	_	
24-18	4517-4521	care	_	
24-19	4522-4525	and	_	
24-20	4526-4536	aggression	_	
24-21	4537-4540	and	_	
24-22	4541-4553	kappa-opioid	_	
24-23	4554-4562	receptor	_	
24-24	4563-4573	antagonism	_	
24-25	4573-4574	,	_	
24-26	4575-4583	shifting	_	
24-27	4584-4594	behaviours	_	
24-28	4595-4599	from	_	
24-29	4600-4608	maternal	_	
24-30	4609-4615	caring	_	
24-31	4616-4618	to	_	
24-32	4619-4628	predation	_	
24-33	4629-4639	behaviours	_	
24-34	4640-4642	in	_	
24-35	4643-4650	rodents	_	
24-36	4650-4651	.	_	

#Text=These recent results are particularly relevant for mothers receiving buprenorphine for OUD (BT) because buprenorphine is both a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist.
25-1	4652-4657	These	_	
25-2	4658-4664	recent	_	
25-3	4665-4672	results	_	
25-4	4673-4676	are	_	
25-5	4677-4689	particularly	_	
25-6	4690-4698	relevant	_	
25-7	4699-4702	for	_	
25-8	4703-4710	mothers	_	
25-9	4711-4720	receiving	_	
25-10	4721-4734	buprenorphine	_	
25-11	4735-4738	for	_	
25-12	4739-4742	OUD	_	
25-13	4743-4744	(	_	
25-14	4744-4746	BT	_	
25-15	4746-4747	)	_	
25-16	4748-4755	because	_	
25-17	4756-4769	buprenorphine	_	
25-18	4770-4772	is	_	
25-19	4773-4777	both	_	
25-20	4778-4779	a	_	
25-21	4780-4787	partial	_	
25-22	4788-4797	mu-opioid	_	
25-23	4798-4806	receptor	_	
25-24	4807-4814	agonist	_	
25-25	4815-4818	and	_	
25-26	4819-4831	kappa-opioid	_	
25-27	4832-4840	receptor	_	
25-28	4841-4851	antagonist	_	
25-29	4851-4852	.	_	

#Text=The hypothalamus and PAG are key parts of a maternal behaviour neurocircuit (MBN) (Figure 1) that is necessary for the survival of mammals from well-developed rodent models.
26-1	4853-4856	The	_	
26-2	4857-4869	hypothalamus	_	
26-3	4870-4873	and	_	
26-4	4874-4877	PAG	_	
26-5	4878-4881	are	_	
26-6	4882-4885	key	_	
26-7	4886-4891	parts	_	
26-8	4892-4894	of	_	
26-9	4895-4896	a	_	
26-10	4897-4905	maternal	_	
26-11	4906-4915	behaviour	_	
26-12	4916-4928	neurocircuit	_	
26-13	4929-4930	(	_	
26-14	4930-4933	MBN	_	
26-15	4933-4934	)	_	
26-16	4935-4936	(	_	
26-17	4936-4942	Figure	_	
26-18	4943-4944	1	_	
26-19	4944-4945	)	_	
26-20	4946-4950	that	_	
26-21	4951-4953	is	_	
26-22	4954-4963	necessary	_	
26-23	4964-4967	for	_	
26-24	4968-4971	the	_	
26-25	4972-4980	survival	_	
26-26	4981-4983	of	_	
26-27	4984-4991	mammals	_	
26-28	4992-4996	from	_	
26-29	4997-5011	well-developed	_	
26-30	5012-5018	rodent	_	
26-31	5019-5025	models	_	
26-32	5025-5026	.	_	

#Text=In this scheme, maternal caregiving and defensive/aggressive systems are balanced with reciprocal inhibition of the hypothalamic mPOA and PAG respectively.
27-1	5027-5029	In	_	
27-2	5030-5034	this	_	
27-3	5035-5041	scheme	_	
27-4	5041-5042	,	_	
27-5	5043-5051	maternal	_	
27-6	5052-5062	caregiving	_	
27-7	5063-5066	and	_	
27-8	5067-5076	defensive	_	
27-9	5076-5077	/	_	
27-10	5077-5087	aggressive	_	
27-11	5088-5095	systems	_	
27-12	5096-5099	are	_	
27-13	5100-5108	balanced	_	
27-14	5109-5113	with	_	
27-15	5114-5124	reciprocal	_	
27-16	5125-5135	inhibition	_	
27-17	5136-5138	of	_	
27-18	5139-5142	the	_	
27-19	5143-5155	hypothalamic	_	
27-20	5156-5160	mPOA	_	
27-21	5161-5164	and	_	
27-22	5165-5168	PAG	_	
27-23	5169-5181	respectively	_	
27-24	5181-5182	.	_	

#Text=Thus, mothers would not be distracted from sensitive maternal care in the absence of threat or exhibit insensitive or aggressive behaviour toward their infant.
28-1	5183-5187	Thus	_	
28-2	5187-5188	,	_	
28-3	5189-5196	mothers	_	
28-4	5197-5202	would	_	
28-5	5203-5206	not	_	
28-6	5207-5209	be	_	
28-7	5210-5220	distracted	_	
28-8	5221-5225	from	_	
28-9	5226-5235	sensitive	_	
28-10	5236-5244	maternal	_	
28-11	5245-5249	care	_	
28-12	5250-5252	in	_	
28-13	5253-5256	the	_	
28-14	5257-5264	absence	_	
28-15	5265-5267	of	_	
28-16	5268-5274	threat	_	
28-17	5275-5277	or	_	
28-18	5278-5285	exhibit	_	
28-19	5286-5297	insensitive	_	
28-20	5298-5300	or	_	
28-21	5301-5311	aggressive	_	
28-22	5312-5321	behaviour	_	
28-23	5322-5328	toward	_	
28-24	5329-5334	their	_	
28-25	5335-5341	infant	_	
28-26	5341-5342	.	_	

#Text=We postulate that human mothers have a homologous MBN (Figure 1), including opposing maternal “care” and “defence” subsystems, that reciprocally inhibit each other to balance maternal sensitive infant care behaviours with need for defensive/aggressive behaviours that maintain safety.
29-1	5343-5345	We	_	
29-2	5346-5355	postulate	_	
29-3	5356-5360	that	_	
29-4	5361-5366	human	_	
29-5	5367-5374	mothers	_	
29-6	5375-5379	have	_	
29-7	5380-5381	a	_	
29-8	5382-5392	homologous	_	
29-9	5393-5396	MBN	_	
29-10	5397-5398	(	_	
29-11	5398-5404	Figure	_	
29-12	5405-5406	1	_	
29-13	5406-5407	)	_	
29-14	5407-5408	,	_	
29-15	5409-5418	including	_	
29-16	5419-5427	opposing	_	
29-17	5428-5436	maternal	_	
29-18	5437-5438	“	_	
29-19	5438-5442	care	_	
29-20	5442-5443	”	_	
29-21	5444-5447	and	_	
29-22	5448-5449	“	_	
29-23	5449-5456	defence	_	
29-24	5456-5457	”	_	
29-25	5458-5468	subsystems	_	
29-26	5468-5469	,	_	
29-27	5470-5474	that	_	
29-28	5475-5487	reciprocally	_	
29-29	5488-5495	inhibit	_	
29-30	5496-5500	each	_	
29-31	5501-5506	other	_	
29-32	5507-5509	to	_	
29-33	5510-5517	balance	_	
29-34	5518-5526	maternal	_	
29-35	5527-5536	sensitive	_	
29-36	5537-5543	infant	_	
29-37	5544-5548	care	_	
29-38	5549-5559	behaviours	_	
29-39	5560-5564	with	_	
29-40	5565-5569	need	_	
29-41	5570-5573	for	_	
29-42	5574-5583	defensive	_	
29-43	5583-5584	/	_	
29-44	5584-5594	aggressive	_	
29-45	5595-5605	behaviours	_	
29-46	5606-5610	that	_	
29-47	5611-5619	maintain	_	
29-48	5620-5626	safety	_	
29-49	5626-5627	.	_	

#Text=The care subsystem includes the mPOA in hypothalamus, ventral tegmental area, nucleus accumbens and ventral pallidum that regulate maternal caregiving behaviours such as licking and grooming for rodents, as well as sensitive, attuned care, gentle gaze, voice, touch and movement for humans.
30-1	5628-5631	The	_	
30-2	5632-5636	care	_	
30-3	5637-5646	subsystem	_	
30-4	5647-5655	includes	_	
30-5	5656-5659	the	_	
30-6	5660-5664	mPOA	_	
30-7	5665-5667	in	_	
30-8	5668-5680	hypothalamus	_	
30-9	5680-5681	,	_	
30-10	5682-5689	ventral	_	
30-11	5690-5699	tegmental	_	
30-12	5700-5704	area	_	
30-13	5704-5705	,	_	
30-14	5706-5713	nucleus	_	
30-15	5714-5723	accumbens	_	
30-16	5724-5727	and	_	
30-17	5728-5735	ventral	_	
30-18	5736-5744	pallidum	_	
30-19	5745-5749	that	_	
30-20	5750-5758	regulate	_	
30-21	5759-5767	maternal	_	
30-22	5768-5778	caregiving	_	
30-23	5779-5789	behaviours	_	
30-24	5790-5794	such	_	
30-25	5795-5797	as	_	
30-26	5798-5805	licking	_	
30-27	5806-5809	and	_	
30-28	5810-5818	grooming	_	
30-29	5819-5822	for	_	
30-30	5823-5830	rodents	_	
30-31	5830-5831	,	_	
30-32	5832-5834	as	_	
30-33	5835-5839	well	_	
30-34	5840-5842	as	_	
30-35	5843-5852	sensitive	_	
30-36	5852-5853	,	_	
30-37	5854-5861	attuned	_	
30-38	5862-5866	care	_	
30-39	5866-5867	,	_	
30-40	5868-5874	gentle	_	
30-41	5875-5879	gaze	_	
30-42	5879-5880	,	_	
30-43	5881-5886	voice	_	
30-44	5886-5887	,	_	
30-45	5888-5893	touch	_	
30-46	5894-5897	and	_	
30-47	5898-5906	movement	_	
30-48	5907-5910	for	_	
30-49	5911-5917	humans	_	
30-50	5917-5918	.	_	

#Text=In the defence subsystem, the PAG may activate maternal defensive behaviours, such as aggression toward intruders and predatory behaviours.
31-1	5919-5921	In	_	
31-2	5922-5925	the	_	
31-3	5926-5933	defence	_	
31-4	5934-5943	subsystem	_	
31-5	5943-5944	,	_	
31-6	5945-5948	the	_	
31-7	5949-5952	PAG	_	
31-8	5953-5956	may	_	
31-9	5957-5965	activate	_	
31-10	5966-5974	maternal	_	
31-11	5975-5984	defensive	_	
31-12	5985-5995	behaviours	_	
31-13	5995-5996	,	_	
31-14	5997-6001	such	_	
31-15	6002-6004	as	_	
31-16	6005-6015	aggression	_	
31-17	6016-6022	toward	_	
31-18	6023-6032	intruders	_	
31-19	6033-6036	and	_	
31-20	6037-6046	predatory	_	
31-21	6047-6057	behaviours	_	
31-22	6057-6058	.	_	

#Text=Among humans, PAG has been activated a baby distress cry, with such activity being related to mental state talk.
32-1	6059-6064	Among	_	
32-2	6065-6071	humans	_	
32-3	6071-6072	,	_	
32-4	6073-6076	PAG	_	
32-5	6077-6080	has	_	
32-6	6081-6085	been	_	
32-7	6086-6095	activated	_	
32-8	6096-6097	a	_	
32-9	6098-6102	baby	_	
32-10	6103-6111	distress	_	
32-11	6112-6115	cry	_	
32-12	6115-6116	,	_	
32-13	6117-6121	with	_	
32-14	6122-6126	such	_	
32-15	6127-6135	activity	_	
32-16	6136-6141	being	_	
32-17	6142-6149	related	_	
32-18	6150-6152	to	_	
32-19	6153-6159	mental	_	
32-20	6160-6165	state	_	
32-21	6166-6170	talk	_	
32-22	6170-6171	.	_	

#Text=This is interesting because a mother would need to balance caring and defensive behaviours in response to a cry which may solicit care or signal emergent concerns for safety.
33-1	6172-6176	This	_	
33-2	6177-6179	is	_	
33-3	6180-6191	interesting	_	
33-4	6192-6199	because	_	
33-5	6200-6201	a	_	
33-6	6202-6208	mother	_	
33-7	6209-6214	would	_	
33-8	6215-6219	need	_	
33-9	6220-6222	to	_	
33-10	6223-6230	balance	_	
33-11	6231-6237	caring	_	
33-12	6238-6241	and	_	
33-13	6242-6251	defensive	_	
33-14	6252-6262	behaviours	_	
33-15	6263-6265	in	_	
33-16	6266-6274	response	_	
33-17	6275-6277	to	_	
33-18	6278-6279	a	_	
33-19	6280-6283	cry	_	
33-20	6284-6289	which	_	
33-21	6290-6293	may	_	
33-22	6294-6301	solicit	_	
33-23	6302-6306	care	_	
33-24	6307-6309	or	_	
33-25	6310-6316	signal	_	
33-26	6317-6325	emergent	_	
33-27	6326-6334	concerns	_	
33-28	6335-6338	for	_	
33-29	6339-6345	safety	_	
33-30	6345-6346	.	_	

#Text=The regulation of other regions of the two subsystems of the MBN to orchestrate parenting has been demonstrated with human functional magnetic resonance imaging (fMRI) studies, including for the amygdala, insular cortex, orbitofrontal cortex (OFC) and hypothalamus in response to infant cues.
34-1	6347-6350	The	_	
34-2	6351-6361	regulation	_	
34-3	6362-6364	of	_	
34-4	6365-6370	other	_	
34-5	6371-6378	regions	_	
34-6	6379-6381	of	_	
34-7	6382-6385	the	_	
34-8	6386-6389	two	_	
34-9	6390-6400	subsystems	_	
34-10	6401-6403	of	_	
34-11	6404-6407	the	_	
34-12	6408-6411	MBN	_	
34-13	6412-6414	to	_	
34-14	6415-6426	orchestrate	_	
34-15	6427-6436	parenting	_	
34-16	6437-6440	has	_	
34-17	6441-6445	been	_	
34-18	6446-6458	demonstrated	_	
34-19	6459-6463	with	_	
34-20	6464-6469	human	_	
34-21	6470-6480	functional	_	
34-22	6481-6489	magnetic	_	
34-23	6490-6499	resonance	_	
34-24	6500-6507	imaging	_	
34-25	6508-6509	(	_	
34-26	6509-6513	fMRI	_	
34-27	6513-6514	)	_	
34-28	6515-6522	studies	_	
34-29	6522-6523	,	_	
34-30	6524-6533	including	_	
34-31	6534-6537	for	_	
34-32	6538-6541	the	_	
34-33	6542-6550	amygdala	_	
34-34	6550-6551	,	_	
34-35	6552-6559	insular	_	
34-36	6560-6566	cortex	_	
34-37	6566-6567	,	_	
34-38	6568-6581	orbitofrontal	_	
34-39	6582-6588	cortex	_	
34-40	6589-6590	(	_	
34-41	6590-6593	OFC	_	
34-42	6593-6594	)	_	
34-43	6595-6598	and	_	
34-44	6599-6611	hypothalamus	_	
34-45	6612-6614	in	_	
34-46	6615-6623	response	_	
34-47	6624-6626	to	_	
34-48	6627-6633	infant	_	
34-49	6634-6638	cues	_	
34-50	6638-6639	.	_	

#Text=These regions may also be affected by addiction and polysubstance use, suggesting the need for more research on task-based brain physiology in the maternal brain.
35-1	6640-6645	These	_	
35-2	6646-6653	regions	_	
35-3	6654-6657	may	_	
35-4	6658-6662	also	_	
35-5	6663-6665	be	_	
35-6	6666-6674	affected	_	
35-7	6675-6677	by	_	
35-8	6678-6687	addiction	_	
35-9	6688-6691	and	_	
35-10	6692-6705	polysubstance	_	
35-11	6706-6709	use	_	
35-12	6709-6710	,	_	
35-13	6711-6721	suggesting	_	
35-14	6722-6725	the	_	
35-15	6726-6730	need	_	
35-16	6731-6734	for	_	
35-17	6735-6739	more	_	
35-18	6740-6748	research	_	
35-19	6749-6751	on	_	
35-20	6752-6762	task-based	_	
35-21	6763-6768	brain	_	
35-22	6769-6779	physiology	_	
35-23	6780-6782	in	_	
35-24	6783-6786	the	_	
35-25	6787-6795	maternal	_	
35-26	6796-6801	brain	_	
35-27	6801-6802	.	_	

#Text=There is growing recognition, however, that high-order cognitive and emotional function, such as required for human parenting, may depend on coherent activity between key brain regions within neurocircuits, rather than single regions.
36-1	6803-6808	There	_	
36-2	6809-6811	is	_	
36-3	6812-6819	growing	_	
36-4	6820-6831	recognition	_	
36-5	6831-6832	,	_	
36-6	6833-6840	however	_	
36-7	6840-6841	,	_	
36-8	6842-6846	that	_	
36-9	6847-6857	high-order	_	
36-10	6858-6867	cognitive	_	
36-11	6868-6871	and	_	
36-12	6872-6881	emotional	_	
36-13	6882-6890	function	_	
36-14	6890-6891	,	_	
36-15	6892-6896	such	_	
36-16	6897-6899	as	_	
36-17	6900-6908	required	_	
36-18	6909-6912	for	_	
36-19	6913-6918	human	_	
36-20	6919-6928	parenting	_	
36-21	6928-6929	,	_	
36-22	6930-6933	may	_	
36-23	6934-6940	depend	_	
36-24	6941-6943	on	_	
36-25	6944-6952	coherent	_	
36-26	6953-6961	activity	_	
36-27	6962-6969	between	_	
36-28	6970-6973	key	_	
36-29	6974-6979	brain	_	
36-30	6980-6987	regions	_	
36-31	6988-6994	within	_	
36-32	6995-7008	neurocircuits	_	
36-33	7008-7009	,	_	
36-34	7010-7016	rather	_	
36-35	7017-7021	than	_	
36-36	7022-7028	single	_	
36-37	7029-7036	regions	_	
36-38	7036-7037	.	_	

#Text=Resting-state functional connectivity (rs-FC) is a method that is used in fMRI to examine regional interactions during a resting or task-negative state, during which time an explicit task is not being performed.
37-1	7038-7051	Resting-state	_	
37-2	7052-7062	functional	_	
37-3	7063-7075	connectivity	_	
37-4	7076-7077	(	_	
37-5	7077-7082	rs-FC	_	
37-6	7082-7083	)	_	
37-7	7084-7086	is	_	
37-8	7087-7088	a	_	
37-9	7089-7095	method	_	
37-10	7096-7100	that	_	
37-11	7101-7103	is	_	
37-12	7104-7108	used	_	
37-13	7109-7111	in	_	
37-14	7112-7116	fMRI	_	
37-15	7117-7119	to	_	
37-16	7120-7127	examine	_	
37-17	7128-7136	regional	_	
37-18	7137-7149	interactions	_	
37-19	7150-7156	during	_	
37-20	7157-7158	a	_	
37-21	7159-7166	resting	_	
37-22	7167-7169	or	_	
37-23	7170-7183	task-negative	_	
37-24	7184-7189	state	_	
37-25	7189-7190	,	_	
37-26	7191-7197	during	_	
37-27	7198-7203	which	_	
37-28	7204-7208	time	_	
37-29	7209-7211	an	_	
37-30	7212-7220	explicit	_	
37-31	7221-7225	task	_	
37-32	7226-7228	is	_	
37-33	7229-7232	not	_	
37-34	7233-7238	being	_	
37-35	7239-7248	performed	_	
37-36	7248-7249	.	_	

#Text=Resting brain state conditions are observed through changes in blood-oxygen-level-dependent (BOLD) signals.
38-1	7250-7257	Resting	_	
38-2	7258-7263	brain	_	
38-3	7264-7269	state	_	
38-4	7270-7280	conditions	_	
38-5	7281-7284	are	_	
38-6	7285-7293	observed	_	
38-7	7294-7301	through	_	
38-8	7302-7309	changes	_	
38-9	7310-7312	in	_	
38-10	7313-7341	blood-oxygen-level-dependent	_	
38-11	7342-7343	(	_	
38-12	7343-7347	BOLD	_	
38-13	7347-7348	)	_	
38-14	7349-7356	signals	_	
38-15	7356-7357	.	_	

#Text=Despite limitations of low temporal resolution and regional variation in neurovascular physiology, the resting state approach is useful to explore the brain’s functional organisation in terms of apparent functional connectivity It has revealed networks of synchronous activity that are consistently found in healthy subjects, as well as in different stages of consciousness, in mental disorders and across species.
39-1	7358-7365	Despite	_	
39-2	7366-7377	limitations	_	
39-3	7378-7380	of	_	
39-4	7381-7384	low	_	
39-5	7385-7393	temporal	_	
39-6	7394-7404	resolution	_	
39-7	7405-7408	and	_	
39-8	7409-7417	regional	_	
39-9	7418-7427	variation	_	
39-10	7428-7430	in	_	
39-11	7431-7444	neurovascular	_	
39-12	7445-7455	physiology	_	
39-13	7455-7456	,	_	
39-14	7457-7460	the	_	
39-15	7461-7468	resting	_	
39-16	7469-7474	state	_	
39-17	7475-7483	approach	_	
39-18	7484-7486	is	_	
39-19	7487-7493	useful	_	
39-20	7494-7496	to	_	
39-21	7497-7504	explore	_	
39-22	7505-7508	the	_	
39-23	7509-7514	brain	_	
39-24	7514-7515	’	_	
39-25	7515-7516	s	_	
39-26	7517-7527	functional	_	
39-27	7528-7540	organisation	_	
39-28	7541-7543	in	_	
39-29	7544-7549	terms	_	
39-30	7550-7552	of	_	
39-31	7553-7561	apparent	_	
39-32	7562-7572	functional	_	
39-33	7573-7585	connectivity	_	
39-34	7586-7588	It	_	
39-35	7589-7592	has	_	
39-36	7593-7601	revealed	_	
39-37	7602-7610	networks	_	
39-38	7611-7613	of	_	
39-39	7614-7625	synchronous	_	
39-40	7626-7634	activity	_	
39-41	7635-7639	that	_	
39-42	7640-7643	are	_	
39-43	7644-7656	consistently	_	
39-44	7657-7662	found	_	
39-45	7663-7665	in	_	
39-46	7666-7673	healthy	_	
39-47	7674-7682	subjects	_	
39-48	7682-7683	,	_	
39-49	7684-7686	as	_	
39-50	7687-7691	well	_	
39-51	7692-7694	as	_	
39-52	7695-7697	in	_	
39-53	7698-7707	different	_	
39-54	7708-7714	stages	_	
39-55	7715-7717	of	_	
39-56	7718-7731	consciousness	_	
39-57	7731-7732	,	_	
39-58	7733-7735	in	_	
39-59	7736-7742	mental	_	
39-60	7743-7752	disorders	_	
39-61	7753-7756	and	_	
39-62	7757-7763	across	_	
39-63	7764-7771	species	_	
39-64	7771-7772	.	_	

#Text=As in the present study, rs-FC may be particularly to pursue a priori hypotheses in established circuits.
40-1	7773-7775	As	_	
40-2	7776-7778	in	_	
40-3	7779-7782	the	_	
40-4	7783-7790	present	_	
40-5	7791-7796	study	_	
40-6	7796-7797	,	_	
40-7	7798-7803	rs-FC	_	
40-8	7804-7807	may	_	
40-9	7808-7810	be	_	
40-10	7811-7823	particularly	_	
40-11	7824-7826	to	_	
40-12	7827-7833	pursue	_	
40-13	7834-7835	a	_	
40-14	7836-7842	priori	_	
40-15	7843-7853	hypotheses	_	
40-16	7854-7856	in	_	
40-17	7857-7868	established	_	
40-18	7869-7877	circuits	_	
40-19	7877-7878	.	_	

#Text=So far, there are just one rodent and two human maternal brain studies using resting-state connectivity methods described above.
41-1	7879-7881	So	_	
41-2	7882-7885	far	_	
41-3	7885-7886	,	_	
41-4	7887-7892	there	_	
41-5	7893-7896	are	_	
41-6	7897-7901	just	_	
41-7	7902-7905	one	_	
41-8	7906-7912	rodent	_	
41-9	7913-7916	and	_	
41-10	7917-7920	two	_	
41-11	7921-7926	human	_	
41-12	7927-7935	maternal	_	
41-13	7936-7941	brain	_	
41-14	7942-7949	studies	_	
41-15	7950-7955	using	_	
41-16	7956-7969	resting-state	_	
41-17	7970-7982	connectivity	_	
41-18	7983-7990	methods	_	
41-19	7991-8000	described	_	
41-20	8001-8006	above	_	
41-21	8006-8007	.	_	

#Text=Rat dams with early-life chronic social stress showed depressed maternal care specifically during early lactation, and changes in functional connectivity in regions associated with sensory processing, maternal and emotional responsiveness, memory and the reward pathway, including reduced PAG-anterior cingulate connectivity.
42-1	8008-8011	Rat	_	
42-2	8012-8016	dams	_	
42-3	8017-8021	with	_	
42-4	8022-8032	early-life	_	
42-5	8033-8040	chronic	_	
42-6	8041-8047	social	_	
42-7	8048-8054	stress	_	
42-8	8055-8061	showed	_	
42-9	8062-8071	depressed	_	
42-10	8072-8080	maternal	_	
42-11	8081-8085	care	_	
42-12	8086-8098	specifically	_	
42-13	8099-8105	during	_	
42-14	8106-8111	early	_	
42-15	8112-8121	lactation	_	
42-16	8121-8122	,	_	
42-17	8123-8126	and	_	
42-18	8127-8134	changes	_	
42-19	8135-8137	in	_	
42-20	8138-8148	functional	_	
42-21	8149-8161	connectivity	_	
42-22	8162-8164	in	_	
42-23	8165-8172	regions	_	
42-24	8173-8183	associated	_	
42-25	8184-8188	with	_	
42-26	8189-8196	sensory	_	
42-27	8197-8207	processing	_	
42-28	8207-8208	,	_	
42-29	8209-8217	maternal	_	
42-30	8218-8221	and	_	
42-31	8222-8231	emotional	_	
42-32	8232-8246	responsiveness	_	
42-33	8246-8247	,	_	
42-34	8248-8254	memory	_	
42-35	8255-8258	and	_	
42-36	8259-8262	the	_	
42-37	8263-8269	reward	_	
42-38	8270-8277	pathway	_	
42-39	8277-8278	,	_	
42-40	8279-8288	including	_	
42-41	8289-8296	reduced	_	
42-42	8297-8309	PAG-anterior	_	
42-43	8310-8319	cingulate	_	
42-44	8320-8332	connectivity	_	
42-45	8332-8333	.	_	

#Text=Among human mothers, eight with depression vs nine healthy at 9 weeks postpartum, there was decreased functional connectivity in numerous corticolimbic circuits, such as coupling within the default mode network (DMN), including anterior cingulate cortex (ACC), inferior parietal cortex and precuneus, as well as between DMN nodes and amygdala.
43-1	8334-8339	Among	_	
43-2	8340-8345	human	_	
43-3	8346-8353	mothers	_	
43-4	8353-8354	,	_	
43-5	8355-8360	eight	_	
43-6	8361-8365	with	_	
43-7	8366-8376	depression	_	
43-8	8377-8379	vs	_	
43-9	8380-8384	nine	_	
43-10	8385-8392	healthy	_	
43-11	8393-8395	at	_	
43-12	8396-8397	9	_	
43-13	8398-8403	weeks	_	
43-14	8404-8414	postpartum	_	
43-15	8414-8415	,	_	
43-16	8416-8421	there	_	
43-17	8422-8425	was	_	
43-18	8426-8435	decreased	_	
43-19	8436-8446	functional	_	
43-20	8447-8459	connectivity	_	
43-21	8460-8462	in	_	
43-22	8463-8471	numerous	_	
43-23	8472-8485	corticolimbic	_	
43-24	8486-8494	circuits	_	
43-25	8494-8495	,	_	
43-26	8496-8500	such	_	
43-27	8501-8503	as	_	
43-28	8504-8512	coupling	_	
43-29	8513-8519	within	_	
43-30	8520-8523	the	_	
43-31	8524-8531	default	_	
43-32	8532-8536	mode	_	
43-33	8537-8544	network	_	
43-34	8545-8546	(	_	
43-35	8546-8549	DMN	_	
43-36	8549-8550	)	_	
43-37	8550-8551	,	_	
43-38	8552-8561	including	_	
43-39	8562-8570	anterior	_	
43-40	8571-8580	cingulate	_	
43-41	8581-8587	cortex	_	
43-42	8588-8589	(	_	
43-43	8589-8592	ACC	_	
43-44	8592-8593	)	_	
43-45	8593-8594	,	_	
43-46	8595-8603	inferior	_	
43-47	8604-8612	parietal	_	
43-48	8613-8619	cortex	_	
43-49	8620-8623	and	_	
43-50	8624-8633	precuneus	_	
43-51	8633-8634	,	_	
43-52	8635-8637	as	_	
43-53	8638-8642	well	_	
43-54	8643-8645	as	_	
43-55	8646-8653	between	_	
43-56	8654-8657	DMN	_	
43-57	8658-8663	nodes	_	
43-58	8664-8667	and	_	
43-59	8668-8676	amygdala	_	
43-60	8676-8677	.	_	

#Text=In another human study performed at 10 weeks postpartum, 14 depressed vs 23 healthy mothers showed decreased DMN activity using a PCC seed region.
44-1	8678-8680	In	_	
44-2	8681-8688	another	_	
44-3	8689-8694	human	_	
44-4	8695-8700	study	_	
44-5	8701-8710	performed	_	
44-6	8711-8713	at	_	
44-7	8714-8716	10	_	
44-8	8717-8722	weeks	_	
44-9	8723-8733	postpartum	_	
44-10	8733-8734	,	_	
44-11	8735-8737	14	_	
44-12	8738-8747	depressed	_	
44-13	8748-8750	vs	_	
44-14	8751-8753	23	_	
44-15	8754-8761	healthy	_	
44-16	8762-8769	mothers	_	
44-17	8770-8776	showed	_	
44-18	8777-8786	decreased	_	
44-19	8787-8790	DMN	_	
44-20	8791-8799	activity	_	
44-21	8800-8805	using	_	
44-22	8806-8807	a	_	
44-23	8808-8811	PCC	_	
44-24	8812-8816	seed	_	
44-25	8817-8823	region	_	
44-26	8823-8824	.	_	

#Text=These results may be interpreted to reflect diminished self-reflection and social cognition, as well as thoughts about duties and responsibilities to others, which are important to parenting.
45-1	8825-8830	These	_	
45-2	8831-8838	results	_	
45-3	8839-8842	may	_	
45-4	8843-8845	be	_	
45-5	8846-8857	interpreted	_	
45-6	8858-8860	to	_	
45-7	8861-8868	reflect	_	
45-8	8869-8879	diminished	_	
45-9	8880-8895	self-reflection	_	
45-10	8896-8899	and	_	
45-11	8900-8906	social	_	
45-12	8907-8916	cognition	_	
45-13	8916-8917	,	_	
45-14	8918-8920	as	_	
45-15	8921-8925	well	_	
45-16	8926-8928	as	_	
45-17	8929-8937	thoughts	_	
45-18	8938-8943	about	_	
45-19	8944-8950	duties	_	
45-20	8951-8954	and	_	
45-21	8955-8971	responsibilities	_	
45-22	8972-8974	to	_	
45-23	8975-8981	others	_	
45-24	8981-8982	,	_	
45-25	8983-8988	which	_	
45-26	8989-8992	are	_	
45-27	8993-9002	important	_	
45-28	9003-9005	to	_	
45-29	9006-9015	parenting	_	
45-30	9015-9016	.	_	

#Text=Additional research related to the content of maternal thoughts during the resting phase may be important to clarify the relationship between maternal thoughts moods and caregiving in health and mental illness.
46-1	9017-9027	Additional	_	
46-2	9028-9036	research	_	
46-3	9037-9044	related	_	
46-4	9045-9047	to	_	
46-5	9048-9051	the	_	
46-6	9052-9059	content	_	
46-7	9060-9062	of	_	
46-8	9063-9071	maternal	_	
46-9	9072-9080	thoughts	_	
46-10	9081-9087	during	_	
46-11	9088-9091	the	_	
46-12	9092-9099	resting	_	
46-13	9100-9105	phase	_	
46-14	9106-9109	may	_	
46-15	9110-9112	be	_	
46-16	9113-9122	important	_	
46-17	9123-9125	to	_	
46-18	9126-9133	clarify	_	
46-19	9134-9137	the	_	
46-20	9138-9150	relationship	_	
46-21	9151-9158	between	_	
46-22	9159-9167	maternal	_	
46-23	9168-9176	thoughts	_	
46-24	9177-9182	moods	_	
46-25	9183-9186	and	_	
46-26	9187-9197	caregiving	_	
46-27	9198-9200	in	_	
46-28	9201-9207	health	_	
46-29	9208-9211	and	_	
46-30	9212-9218	mental	_	
46-31	9219-9226	illness	_	
46-32	9226-9227	.	_	

#Text=In the present study, we hypothesise that the specific functional connectivity between the hypothalamus and PAG, which are two functionally opposing regions in MBN, may be decreased in mothers receiving buprenorphine for OUD and relate to impaired bonding, consistent with rodent deficits in maternal behaviour with opioids.
47-1	9228-9230	In	_	
47-2	9231-9234	the	_	
47-3	9235-9242	present	_	
47-4	9243-9248	study	_	
47-5	9248-9249	,	_	
47-6	9250-9252	we	_	
47-7	9253-9264	hypothesise	_	
47-8	9265-9269	that	_	
47-9	9270-9273	the	_	
47-10	9274-9282	specific	_	
47-11	9283-9293	functional	_	
47-12	9294-9306	connectivity	_	
47-13	9307-9314	between	_	
47-14	9315-9318	the	_	
47-15	9319-9331	hypothalamus	_	
47-16	9332-9335	and	_	
47-17	9336-9339	PAG	_	
47-18	9339-9340	,	_	
47-19	9341-9346	which	_	
47-20	9347-9350	are	_	
47-21	9351-9354	two	_	
47-22	9355-9367	functionally	_	
47-23	9368-9376	opposing	_	
47-24	9377-9384	regions	_	
47-25	9385-9387	in	_	
47-26	9388-9391	MBN	_	
47-27	9391-9392	,	_	
47-28	9393-9396	may	_	
47-29	9397-9399	be	_	
47-30	9400-9409	decreased	_	
47-31	9410-9412	in	_	
47-32	9413-9420	mothers	_	
47-33	9421-9430	receiving	_	
47-34	9431-9444	buprenorphine	_	
47-35	9445-9448	for	_	
47-36	9449-9452	OUD	_	
47-37	9453-9456	and	_	
47-38	9457-9463	relate	_	
47-39	9464-9466	to	_	
47-40	9467-9475	impaired	_	
47-41	9476-9483	bonding	_	
47-42	9483-9484	,	_	
47-43	9485-9495	consistent	_	
47-44	9496-9500	with	_	
47-45	9501-9507	rodent	_	
47-46	9508-9516	deficits	_	
47-47	9517-9519	in	_	
47-48	9520-9528	maternal	_	
47-49	9529-9538	behaviour	_	
47-50	9539-9543	with	_	
47-51	9544-9551	opioids	_	
47-52	9551-9552	.	_	

#Text=We thus examined rs-FC between the PAG and hypothalamus in BT mothers with reference to a comparison group (CG) of mothers who did not have OUD or receive any psychotrophic medication.
48-1	9553-9555	We	_	
48-2	9556-9560	thus	_	
48-3	9561-9569	examined	_	
48-4	9570-9575	rs-FC	_	
48-5	9576-9583	between	_	
48-6	9584-9587	the	_	
48-7	9588-9591	PAG	_	
48-8	9592-9595	and	_	
48-9	9596-9608	hypothalamus	_	
48-10	9609-9611	in	_	
48-11	9612-9614	BT	_	
48-12	9615-9622	mothers	_	
48-13	9623-9627	with	_	
48-14	9628-9637	reference	_	
48-15	9638-9640	to	_	
48-16	9641-9642	a	_	
48-17	9643-9653	comparison	_	
48-18	9654-9659	group	_	
48-19	9660-9661	(	_	
48-20	9661-9663	CG	_	
48-21	9663-9664	)	_	
48-22	9665-9667	of	_	
48-23	9668-9675	mothers	_	
48-24	9676-9679	who	_	
48-25	9680-9683	did	_	
48-26	9684-9687	not	_	
48-27	9688-9692	have	_	
48-28	9693-9696	OUD	_	
48-29	9697-9699	or	_	
48-30	9700-9707	receive	_	
48-31	9708-9711	any	_	
48-32	9712-9725	psychotrophic	_	
48-33	9726-9736	medication	_	
48-34	9736-9737	.	_	

#Text=Furthermore, to examine the roles of functional connectivity between PAG and hypothalamus in possible dysregulation of maternal behaviours, we also explored how the PAG-dependent rs-FC may be related to symptoms of mother-infant bonding impairments, as measured by the Postpartum Bonding Questionnaire (PBQ), in BT and CG mothers in the early postpartum period.
49-1	9738-9749	Furthermore	_	
49-2	9749-9750	,	_	
49-3	9751-9753	to	_	
49-4	9754-9761	examine	_	
49-5	9762-9765	the	_	
49-6	9766-9771	roles	_	
49-7	9772-9774	of	_	
49-8	9775-9785	functional	_	
49-9	9786-9798	connectivity	_	
49-10	9799-9806	between	_	
49-11	9807-9810	PAG	_	
49-12	9811-9814	and	_	
49-13	9815-9827	hypothalamus	_	
49-14	9828-9830	in	_	
49-15	9831-9839	possible	_	
49-16	9840-9853	dysregulation	_	
49-17	9854-9856	of	_	
49-18	9857-9865	maternal	_	
49-19	9866-9876	behaviours	_	
49-20	9876-9877	,	_	
49-21	9878-9880	we	_	
49-22	9881-9885	also	_	
49-23	9886-9894	explored	_	
49-24	9895-9898	how	_	
49-25	9899-9902	the	_	
49-26	9903-9916	PAG-dependent	_	
49-27	9917-9922	rs-FC	_	
49-28	9923-9926	may	_	
49-29	9927-9929	be	_	
49-30	9930-9937	related	_	
49-31	9938-9940	to	_	
49-32	9941-9949	symptoms	_	
49-33	9950-9952	of	_	
49-34	9953-9966	mother-infant	_	
49-35	9967-9974	bonding	_	
49-36	9975-9986	impairments	_	
49-37	9986-9987	,	_	
49-38	9988-9990	as	_	
49-39	9991-9999	measured	_	
49-40	10000-10002	by	_	
49-41	10003-10006	the	_	
49-42	10007-10017	Postpartum	_	
49-43	10018-10025	Bonding	_	
49-44	10026-10039	Questionnaire	_	
49-45	10040-10041	(	_	
49-46	10041-10044	PBQ	_	
49-47	10044-10045	)	_	
49-48	10045-10046	,	_	
49-49	10047-10049	in	_	
49-50	10050-10052	BT	_	
49-51	10053-10056	and	_	
49-52	10057-10059	CG	_	
49-53	10060-10067	mothers	_	
49-54	10068-10070	in	_	
49-55	10071-10074	the	_	
49-56	10075-10080	early	_	
49-57	10081-10091	postpartum	_	
49-58	10092-10098	period	_	
49-59	10098-10099	.	_	

#Text=The PBQ was chosen for this purpose because its subscales of Impaired Bonding (IB), Rejection and Pathological Anger (RPA) and Infant-Focused Anxiety (IFA) have been linked to maternal psychological abuse of infants and maternal depression in multiple cultures.
50-1	10100-10103	The	_	
50-2	10104-10107	PBQ	_	
50-3	10108-10111	was	_	
50-4	10112-10118	chosen	_	
50-5	10119-10122	for	_	
50-6	10123-10127	this	_	
50-7	10128-10135	purpose	_	
50-8	10136-10143	because	_	
50-9	10144-10147	its	_	
50-10	10148-10157	subscales	_	
50-11	10158-10160	of	_	
50-12	10161-10169	Impaired	_	
50-13	10170-10177	Bonding	_	
50-14	10178-10179	(	_	
50-15	10179-10181	IB	_	
50-16	10181-10182	)	_	
50-17	10182-10183	,	_	
50-18	10184-10193	Rejection	_	
50-19	10194-10197	and	_	
50-20	10198-10210	Pathological	_	
50-21	10211-10216	Anger	_	
50-22	10217-10218	(	_	
50-23	10218-10221	RPA	_	
50-24	10221-10222	)	_	
50-25	10223-10226	and	_	
50-26	10227-10241	Infant-Focused	_	
50-27	10242-10249	Anxiety	_	
50-28	10250-10251	(	_	
50-29	10251-10254	IFA	_	
50-30	10254-10255	)	_	
50-31	10256-10260	have	_	
50-32	10261-10265	been	_	
50-33	10266-10272	linked	_	
50-34	10273-10275	to	_	
50-35	10276-10284	maternal	_	
50-36	10285-10298	psychological	_	
50-37	10299-10304	abuse	_	
50-38	10305-10307	of	_	
50-39	10308-10315	infants	_	
50-40	10316-10319	and	_	
50-41	10320-10328	maternal	_	
50-42	10329-10339	depression	_	
50-43	10340-10342	in	_	
50-44	10343-10351	multiple	_	
50-45	10352-10360	cultures	_	
50-46	10360-10361	.	_	

#Text=We know that depression is common comorbidity of OUD and that depressive symptoms, even if not meeting the clinical threshold, can seriously risk adverse child outcomes across cognitive, behavioural and social domains.
51-1	10362-10364	We	_	
51-2	10365-10369	know	_	
51-3	10370-10374	that	_	
51-4	10375-10385	depression	_	
51-5	10386-10388	is	_	
51-6	10389-10395	common	_	
51-7	10396-10407	comorbidity	_	
51-8	10408-10410	of	_	
51-9	10411-10414	OUD	_	
51-10	10415-10418	and	_	
51-11	10419-10423	that	_	
51-12	10424-10434	depressive	_	
51-13	10435-10443	symptoms	_	
51-14	10443-10444	,	_	
51-15	10445-10449	even	_	
51-16	10450-10452	if	_	
51-17	10453-10456	not	_	
51-18	10457-10464	meeting	_	
51-19	10465-10468	the	_	
51-20	10469-10477	clinical	_	
51-21	10478-10487	threshold	_	
51-22	10487-10488	,	_	
51-23	10489-10492	can	_	
51-24	10493-10502	seriously	_	
51-25	10503-10507	risk	_	
51-26	10508-10515	adverse	_	
51-27	10516-10521	child	_	
51-28	10522-10530	outcomes	_	
51-29	10531-10537	across	_	
51-30	10538-10547	cognitive	_	
51-31	10547-10548	,	_	
51-32	10549-10560	behavioural	_	
51-33	10561-10564	and	_	
51-34	10565-10571	social	_	
51-35	10572-10579	domains	_	
51-36	10579-10580	.	_	

#Text=MATERIALS AND METHODS
#Text=Procedures
#Text=Participants were recruited from community health clinics, primary care clinics, and the University of Michigan Medicine Centers.
52-1	10581-10590	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
52-2	10591-10594	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
52-3	10595-10602	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
52-4	10603-10613	Procedures	_	
52-5	10614-10626	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-6	10627-10631	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-7	10632-10641	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-8	10642-10646	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-9	10647-10656	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-10	10657-10663	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-11	10664-10671	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-12	10671-10672	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-13	10673-10680	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-14	10681-10685	care	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-15	10686-10693	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-16	10693-10694	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-17	10695-10698	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-18	10699-10702	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-19	10703-10713	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-20	10714-10716	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-21	10717-10725	Michigan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-22	10726-10734	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-23	10735-10742	Centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
52-24	10742-10743	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=They received an initial screening in the third trimester of pregnancy and completed questionnaires before undergoing two fMRI scanning sessions, at 1 month postpartum (T1) and 4 months postpartum (T2).
53-1	10744-10748	They	_	
53-2	10749-10757	received	_	
53-3	10758-10760	an	_	
53-4	10761-10768	initial	_	
53-5	10769-10778	screening	_	
53-6	10779-10781	in	_	
53-7	10782-10785	the	_	
53-8	10786-10791	third	_	
53-9	10792-10801	trimester	_	
53-10	10802-10804	of	_	
53-11	10805-10814	pregnancy	_	
53-12	10815-10818	and	_	
53-13	10819-10828	completed	_	
53-14	10829-10843	questionnaires	_	
53-15	10844-10850	before	_	
53-16	10851-10861	undergoing	_	
53-17	10862-10865	two	_	
53-18	10866-10870	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
53-19	10871-10879	scanning	_	
53-20	10880-10888	sessions	_	
53-21	10888-10889	,	_	
53-22	10890-10892	at	_	
53-23	10893-10894	1	_	
53-24	10895-10900	month	_	
53-25	10901-10911	postpartum	_	
53-26	10912-10913	(	_	
53-27	10913-10915	T1	_	
53-28	10915-10916	)	_	
53-29	10917-10920	and	_	
53-30	10921-10922	4	_	
53-31	10923-10929	months	_	
53-32	10930-10940	postpartum	_	
53-33	10941-10942	(	_	
53-34	10942-10944	T2	_	
53-35	10944-10945	)	_	
53-36	10945-10946	.	_	

#Text=Participants with OUD were prescribed BT as part of routine medical care and there were no infant admissions for medical complications after initial neonatal abstinence syndrome.
54-1	10947-10959	Participants	_	
54-2	10960-10964	with	_	
54-3	10965-10968	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
54-4	10969-10973	were	_	
54-5	10974-10984	prescribed	_	
54-6	10985-10987	BT	_	
54-7	10988-10990	as	_	
54-8	10991-10995	part	_	
54-9	10996-10998	of	_	
54-10	10999-11006	routine	_	
54-11	11007-11014	medical	_	
54-12	11015-11019	care	_	
54-13	11020-11023	and	_	
54-14	11024-11029	there	_	
54-15	11030-11034	were	_	
54-16	11035-11037	no	_	
54-17	11038-11044	infant	_	
54-18	11045-11055	admissions	_	
54-19	11056-11059	for	_	
54-20	11060-11067	medical	_	
54-21	11068-11081	complications	_	
54-22	11082-11087	after	_	
54-23	11088-11095	initial	_	
54-24	11096-11104	neonatal	_	
54-25	11105-11115	abstinence	_	
54-26	11116-11124	syndrome	_	
54-27	11124-11125	.	_	

#Text=All procedures were approved by the Human Subject Institutional Review Board at University of Michigan.
55-1	11126-11129	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-2	11130-11140	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-3	11141-11145	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-4	11146-11154	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-5	11155-11157	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-6	11158-11161	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-7	11162-11167	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-8	11168-11175	Subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-9	11176-11189	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-10	11190-11196	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-11	11197-11202	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-12	11203-11205	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-13	11206-11216	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-14	11217-11219	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-15	11220-11228	Michigan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
55-16	11228-11229	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Participants
#Text=For the sample in the present study (n = 32), we included group of mothers who were maintained on buprenorphine replacement therapy for their OUD (BT) (n = 7, years of age; mean ± SD 29.86 ± 6.62 years) and a comparison group (CG) of mothers who reported no opioid or other substance uses or any psychotrophic medications (CG, n = 25, years of age; mean ± SD 27.62 ± 8.46 years).
56-1	11230-11242	Participants	_	
56-2	11243-11246	For	_	
56-3	11247-11250	the	_	
56-4	11251-11257	sample	_	
56-5	11258-11260	in	_	
56-6	11261-11264	the	_	
56-7	11265-11272	present	_	
56-8	11273-11278	study	_	
56-9	11279-11280	(	_	
56-10	11280-11281	n	_	
56-11	11282-11283	=	_	
56-12	11284-11286	32	_	
56-13	11286-11287	)	_	
56-14	11287-11288	,	_	
56-15	11289-11291	we	_	
56-16	11292-11300	included	_	
56-17	11301-11306	group	_	
56-18	11307-11309	of	_	
56-19	11310-11317	mothers	_	
56-20	11318-11321	who	_	
56-21	11322-11326	were	_	
56-22	11327-11337	maintained	_	
56-23	11338-11340	on	_	
56-24	11341-11354	buprenorphine	_	
56-25	11355-11366	replacement	_	
56-26	11367-11374	therapy	_	
56-27	11375-11378	for	_	
56-28	11379-11384	their	_	
56-29	11385-11388	OUD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
56-30	11389-11390	(	_	
56-31	11390-11392	BT	_	
56-32	11392-11393	)	_	
56-33	11394-11395	(	_	
56-34	11395-11396	n	_	
56-35	11397-11398	=	_	
56-36	11399-11400	7	_	
56-37	11400-11401	,	_	
56-38	11402-11407	years	_	
56-39	11408-11410	of	_	
56-40	11411-11414	age	_	
56-41	11414-11415	;	_	
56-42	11416-11420	mean	_	
56-43	11421-11422	±	_	
56-44	11423-11425	SD	_	
56-45	11426-11431	29.86	_	
56-46	11432-11433	±	_	
56-47	11434-11438	6.62	_	
56-48	11439-11444	years	_	
56-49	11444-11445	)	_	
56-50	11446-11449	and	_	
56-51	11450-11451	a	_	
56-52	11452-11462	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
56-53	11463-11468	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
56-54	11469-11470	(	_	
56-55	11470-11472	CG	_	
56-56	11472-11473	)	_	
56-57	11474-11476	of	_	
56-58	11477-11484	mothers	_	
56-59	11485-11488	who	_	
56-60	11489-11497	reported	_	
56-61	11498-11500	no	_	
56-62	11501-11507	opioid	_	
56-63	11508-11510	or	_	
56-64	11511-11516	other	_	
56-65	11517-11526	substance	_	
56-66	11527-11531	uses	_	
56-67	11532-11534	or	_	
56-68	11535-11538	any	_	
56-69	11539-11552	psychotrophic	_	
56-70	11553-11564	medications	_	
56-71	11565-11566	(	_	
56-72	11566-11568	CG	_	
56-73	11568-11569	,	_	
56-74	11570-11571	n	_	
56-75	11572-11573	=	_	
56-76	11574-11576	25	_	
56-77	11576-11577	,	_	
56-78	11578-11583	years	_	
56-79	11584-11586	of	_	
56-80	11587-11590	age	_	
56-81	11590-11591	;	_	
56-82	11592-11596	mean	_	
56-83	11597-11598	±	_	
56-84	11599-11601	SD	_	
56-85	11602-11607	27.62	_	
56-86	11608-11609	±	_	
56-87	11610-11614	8.46	_	
56-88	11615-11620	years	_	
56-89	11620-11621	)	_	
56-90	11621-11622	.	_	

#Text=Mean ± SD ages for infants of early postpartum mothers were 0.08 ± 0.01 years for BT and 0.07 ± 0.27 years for CG.
57-1	11623-11627	Mean	_	
57-2	11628-11629	±	_	
57-3	11630-11632	SD	_	
57-4	11633-11637	ages	_	
57-5	11638-11641	for	_	
57-6	11642-11649	infants	_	
57-7	11650-11652	of	_	
57-8	11653-11658	early	_	
57-9	11659-11669	postpartum	_	
57-10	11670-11677	mothers	_	
57-11	11678-11682	were	_	
57-12	11683-11687	0.08	_	
57-13	11688-11689	±	_	
57-14	11690-11694	0.01	_	
57-15	11695-11700	years	_	
57-16	11701-11704	for	_	
57-17	11705-11707	BT	_	
57-18	11708-11711	and	_	
57-19	11712-11716	0.07	_	
57-20	11717-11718	±	_	
57-21	11719-11723	0.27	_	
57-22	11724-11729	years	_	
57-23	11730-11733	for	_	
57-24	11734-11736	CG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
57-25	11736-11737	.	_	

#Text=The BT mothers received buprenorphine medication during pregnancy and continued throughout the time of the study.
58-1	11738-11741	The	_	
58-2	11742-11744	BT	_	
58-3	11745-11752	mothers	_	
58-4	11753-11761	received	_	
58-5	11762-11775	buprenorphine	_	
58-6	11776-11786	medication	_	
58-7	11787-11793	during	_	
58-8	11794-11803	pregnancy	_	
58-9	11804-11807	and	_	
58-10	11808-11817	continued	_	
58-11	11818-11828	throughout	_	
58-12	11829-11832	the	_	
58-13	11833-11837	time	_	
58-14	11838-11840	of	_	
58-15	11841-11844	the	_	
58-16	11845-11850	study	_	
58-17	11850-11851	.	_	

#Text=The mean ± SD dose recorded every 2 weeks postpartum was 14.18 ± 3.35 mg, with six out of seven mothers stabilising between 12 and 16 mg.
59-1	11852-11855	The	_	
59-2	11856-11860	mean	_	
59-3	11861-11862	±	_	
59-4	11863-11865	SD	_	
59-5	11866-11870	dose	_	
59-6	11871-11879	recorded	_	
59-7	11880-11885	every	_	
59-8	11886-11887	2	_	
59-9	11888-11893	weeks	_	
59-10	11894-11904	postpartum	_	
59-11	11905-11908	was	_	
59-12	11909-11914	14.18	_	
59-13	11915-11916	±	_	
59-14	11917-11921	3.35	_	
59-15	11922-11924	mg	_	
59-16	11924-11925	,	_	
59-17	11926-11930	with	_	
59-18	11931-11934	six	_	
59-19	11935-11938	out	_	
59-20	11939-11941	of	_	
59-21	11942-11947	seven	_	
59-22	11948-11955	mothers	_	
59-23	11956-11967	stabilising	_	
59-24	11968-11975	between	_	
59-25	11976-11978	12	_	
59-26	11979-11982	and	_	
59-27	11983-11985	16	_	
59-28	11986-11988	mg	_	
59-29	11988-11989	.	_	

#Text=Self-reported measure
#Text=Postpartum bonding questionnaire
#Text=The PBQ is a 25-item self-report questionnaire developed to screen early postpartum women for potential parent-infant bonding disorders.
60-1	11990-12003	Self-reported	_	
60-2	12004-12011	measure	_	
60-3	12012-12022	Postpartum	_	
60-4	12023-12030	bonding	_	
60-5	12031-12044	questionnaire	_	
60-6	12045-12048	The	_	
60-7	12049-12052	PBQ	_	
60-8	12053-12055	is	_	
60-9	12056-12057	a	_	
60-10	12058-12060	25	_	
60-11	12060-12061	-	_	
60-12	12061-12065	item	_	
60-13	12066-12077	self-report	_	
60-14	12078-12091	questionnaire	_	
60-15	12092-12101	developed	_	
60-16	12102-12104	to	_	
60-17	12105-12111	screen	_	
60-18	12112-12117	early	_	
60-19	12118-12128	postpartum	_	
60-20	12129-12134	women	_	
60-21	12135-12138	for	_	
60-22	12139-12148	potential	_	
60-23	12149-12162	parent-infant	_	
60-24	12163-12170	bonding	_	
60-25	12171-12180	disorders	_	
60-26	12180-12181	.	_	

#Text=The PBQ consists of four subscales to indicate factors of clinical relevance, namely IB (subscale 1 with sensitivity of 0.82 for detecting mothers with bonding disorders) (e.g.
61-1	12182-12185	The	_	
61-2	12186-12189	PBQ	_	
61-3	12190-12198	consists	_	
61-4	12199-12201	of	_	
61-5	12202-12206	four	_	
61-6	12207-12216	subscales	_	
61-7	12217-12219	to	_	
61-8	12220-12228	indicate	_	
61-9	12229-12236	factors	_	
61-10	12237-12239	of	_	
61-11	12240-12248	clinical	_	
61-12	12249-12258	relevance	_	
61-13	12258-12259	,	_	
61-14	12260-12266	namely	_	
61-15	12267-12269	IB	_	
61-16	12270-12271	(	_	
61-17	12271-12279	subscale	_	
61-18	12280-12281	1	_	
61-19	12282-12286	with	_	
61-20	12287-12298	sensitivity	_	
61-21	12299-12301	of	_	
61-22	12302-12306	0.82	_	
61-23	12307-12310	for	_	
61-24	12311-12320	detecting	_	
61-25	12321-12328	mothers	_	
61-26	12329-12333	with	_	
61-27	12334-12341	bonding	_	
61-28	12342-12351	disorders	_	
61-29	12351-12352	)	_	
61-30	12353-12354	(	_	
61-31	12354-12357	e.g	_	
61-32	12357-12358	.	_	

#Text=“I feel distant from my baby”); RPA (subscale 2 with sensitivity of 0.88 for infant rejection and 0.67 for severe anger), identifies mothers with serious infant-oriented hostility (e.g.
62-1	12359-12360	“	_	
62-2	12360-12361	I	_	
62-3	12362-12366	feel	_	
62-4	12367-12374	distant	_	
62-5	12375-12379	from	_	
62-6	12380-12382	my	_	
62-7	12383-12387	baby	_	
62-8	12387-12388	”	_	
62-9	12388-12389	)	_	
62-10	12389-12390	;	_	
62-11	12391-12394	RPA	_	
62-12	12395-12396	(	_	
62-13	12396-12404	subscale	_	
62-14	12405-12406	2	_	
62-15	12407-12411	with	_	
62-16	12412-12423	sensitivity	_	
62-17	12424-12426	of	_	
62-18	12427-12431	0.88	_	
62-19	12432-12435	for	_	
62-20	12436-12442	infant	_	
62-21	12443-12452	rejection	_	
62-22	12453-12456	and	_	
62-23	12457-12461	0.67	_	
62-24	12462-12465	for	_	
62-25	12466-12472	severe	_	
62-26	12473-12478	anger	_	
62-27	12478-12479	)	_	
62-28	12479-12480	,	_	
62-29	12481-12491	identifies	_	
62-30	12492-12499	mothers	_	
62-31	12500-12504	with	_	
62-32	12505-12512	serious	_	
62-33	12513-12528	infant-oriented	_	
62-34	12529-12538	hostility	_	
62-35	12539-12540	(	_	
62-36	12540-12543	e.g	_	
62-37	12543-12544	.	_	

#Text=“I resent my baby”); IFA (subscale 3), which may be useful in anxious mothers (e.g.
63-1	12545-12546	“	_	
63-2	12546-12547	I	_	
63-3	12548-12554	resent	_	
63-4	12555-12557	my	_	
63-5	12558-12562	baby	_	
63-6	12562-12563	”	_	
63-7	12563-12564	)	_	
63-8	12564-12565	;	_	
63-9	12566-12569	IFA	_	
63-10	12570-12571	(	_	
63-11	12571-12579	subscale	_	
63-12	12580-12581	3	_	
63-13	12581-12582	)	_	
63-14	12582-12583	,	_	
63-15	12584-12589	which	_	
63-16	12590-12593	may	_	
63-17	12594-12596	be	_	
63-18	12597-12603	useful	_	
63-19	12604-12606	in	_	
63-20	12607-12614	anxious	_	
63-21	12615-12622	mothers	_	
63-22	12623-12624	(	_	
63-23	12624-12627	e.g	_	
63-24	12627-12628	.	_	

#Text=“My baby makes me feel anxious”); and subscale 4, which signals the presence of incipient abuse that would require urgent intervention (e.g.
64-1	12629-12630	“	_	
64-2	12630-12632	My	_	
64-3	12633-12637	baby	_	
64-4	12638-12643	makes	_	
64-5	12644-12646	me	_	
64-6	12647-12651	feel	_	
64-7	12652-12659	anxious	_	
64-8	12659-12660	”	_	
64-9	12660-12661	)	_	
64-10	12661-12662	;	_	
64-11	12663-12666	and	_	
64-12	12667-12675	subscale	_	
64-13	12676-12677	4	_	
64-14	12677-12678	,	_	
64-15	12679-12684	which	_	
64-16	12685-12692	signals	_	
64-17	12693-12696	the	_	
64-18	12697-12705	presence	_	
64-19	12706-12708	of	_	
64-20	12709-12718	incipient	_	
64-21	12719-12724	abuse	_	
64-22	12725-12729	that	_	
64-23	12730-12735	would	_	
64-24	12736-12743	require	_	
64-25	12744-12750	urgent	_	
64-26	12751-12763	intervention	_	
64-27	12764-12765	(	_	
64-28	12765-12768	e.g	_	
64-29	12768-12769	.	_	

#Text=“I have done harmful things to my baby”).
65-1	12770-12771	“	_	
65-2	12771-12772	I	_	
65-3	12773-12777	have	_	
65-4	12778-12782	done	_	
65-5	12783-12790	harmful	_	
65-6	12791-12797	things	_	
65-7	12798-12800	to	_	
65-8	12801-12803	my	_	
65-9	12804-12808	baby	_	
65-10	12808-12809	”	_	
65-11	12809-12810	)	_	
65-12	12810-12811	.	_	

#Text=None of the participants indicated abuse from subscale 4 and only the first three subscales (IB, RPA and IFA) were examined in the current study.
66-1	12812-12816	None	_	
66-2	12817-12819	of	_	
66-3	12820-12823	the	_	
66-4	12824-12836	participants	_	
66-5	12837-12846	indicated	_	
66-6	12847-12852	abuse	_	
66-7	12853-12857	from	_	
66-8	12858-12866	subscale	_	
66-9	12867-12868	4	_	
66-10	12869-12872	and	_	
66-11	12873-12877	only	_	
66-12	12878-12881	the	_	
66-13	12882-12887	first	_	
66-14	12888-12893	three	_	
66-15	12894-12903	subscales	_	
66-16	12904-12905	(	_	
66-17	12905-12907	IB	_	
66-18	12907-12908	,	_	
66-19	12909-12912	RPA	_	
66-20	12913-12916	and	_	
66-21	12917-12920	IFA	_	
66-22	12920-12921	)	_	
66-23	12922-12926	were	_	
66-24	12927-12935	examined	_	
66-25	12936-12938	in	_	
66-26	12939-12942	the	_	
66-27	12943-12950	current	_	
66-28	12951-12956	study	_	
66-29	12956-12957	.	_	

#Text=Functional and structural magnetic resonance imaging
#Text=Imaging data acquisition
#Text=During the fMRI scanning session, each participant was positioned in a supine orientation with her head positioned in a head coil.
67-1	12958-12968	Functional	_	
67-2	12969-12972	and	_	
67-3	12973-12983	structural	_	
67-4	12984-12992	magnetic	_	
67-5	12993-13002	resonance	_	
67-6	13003-13010	imaging	_	
67-7	13011-13018	Imaging	_	
67-8	13019-13023	data	_	
67-9	13024-13035	acquisition	_	
67-10	13036-13042	During	_	
67-11	13043-13046	the	_	
67-12	13047-13051	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
67-13	13052-13060	scanning	_	
67-14	13061-13068	session	_	
67-15	13068-13069	,	_	
67-16	13070-13074	each	_	
67-17	13075-13086	participant	_	
67-18	13087-13090	was	_	
67-19	13091-13101	positioned	_	
67-20	13102-13104	in	_	
67-21	13105-13106	a	_	
67-22	13107-13113	supine	_	
67-23	13114-13125	orientation	_	
67-24	13126-13130	with	_	
67-25	13131-13134	her	_	
67-26	13135-13139	head	_	
67-27	13140-13150	positioned	_	
67-28	13151-13153	in	_	
67-29	13154-13155	a	_	
67-30	13156-13160	head	_	
67-31	13161-13165	coil	_	
67-32	13165-13166	.	_	

#Text=Visual stimuli (a cross at the centre) were presented via a goggle system and NordicNeuroLab (Bergen, Norway) audio system.
68-1	13167-13173	Visual	_	
68-2	13174-13181	stimuli	_	
68-3	13182-13183	(	_	
68-4	13183-13184	a	_	
68-5	13185-13190	cross	_	
68-6	13191-13193	at	_	
68-7	13194-13197	the	_	
68-8	13198-13204	centre	_	
68-9	13204-13205	)	_	
68-10	13206-13210	were	_	
68-11	13211-13220	presented	_	
68-12	13221-13224	via	_	
68-13	13225-13226	a	_	
68-14	13227-13233	goggle	_	
68-15	13234-13240	system	_	
68-16	13241-13244	and	_	
68-17	13245-13259	NordicNeuroLab	_	
68-18	13260-13261	(	_	
68-19	13261-13267	Bergen	_	
68-20	13267-13268	,	_	
68-21	13269-13275	Norway	_	
68-22	13275-13276	)	_	
68-23	13277-13282	audio	_	
68-24	13283-13289	system	_	
68-25	13289-13290	.	_	

#Text=The fMRI scanning was performed with a 3.0 Tesla Philips magnetic resonance imaging scanner (Philips, Eindhoven, The Netherlands) using a standard eight-channel radiofrequency SENSE head coil. with the following acquisitions: (i) a high-resolution T1 scan was acquired to provide precise anatomical localisation (TR of 9.8 ms, TE = 459 ms, FA = 8°, FOV of 256 mm, slice thickness of 1.0 mm, 180 slices with 288 × 288 matrix per slice) and (ii) A run of T2*-weighted BOLD echo planar imaging sequence volumes was acquired for whole-brain fMRI during the resting-state task (180 frames, TR = 2000 ms, TE = 30 ms, FA = 90°, FOV = 220 mm, 42 contiguous axial slices, slice thickness = 2.8 mm with 64 × 64 matrix per slice, voxel size = 3.44 × 3.44 × 2.8 mm3), after discarding the first five initial frames to allow for equilibration of scanner signal.
69-1	13291-13294	The	_	
69-2	13295-13299	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
69-3	13300-13308	scanning	_	
69-4	13309-13312	was	_	
69-5	13313-13322	performed	_	
69-6	13323-13327	with	_	
69-7	13328-13329	a	_	
69-8	13330-13333	3.0	_	
69-9	13334-13339	Tesla	_	
69-10	13340-13347	Philips	_	
69-11	13348-13356	magnetic	_	
69-12	13357-13366	resonance	_	
69-13	13367-13374	imaging	_	
69-14	13375-13382	scanner	_	
69-15	13383-13384	(	_	
69-16	13384-13391	Philips	_	
69-17	13391-13392	,	_	
69-18	13393-13402	Eindhoven	_	
69-19	13402-13403	,	_	
69-20	13404-13407	The	_	
69-21	13408-13419	Netherlands	_	
69-22	13419-13420	)	_	
69-23	13421-13426	using	_	
69-24	13427-13428	a	_	
69-25	13429-13437	standard	_	
69-26	13438-13451	eight-channel	_	
69-27	13452-13466	radiofrequency	_	
69-28	13467-13472	SENSE	_	
69-29	13473-13477	head	_	
69-30	13478-13482	coil	_	
69-31	13482-13483	.	_	
69-32	13484-13488	with	_	
69-33	13489-13492	the	_	
69-34	13493-13502	following	_	
69-35	13503-13515	acquisitions	_	
69-36	13515-13516	:	_	
69-37	13517-13518	(	_	
69-38	13518-13519	i	_	
69-39	13519-13520	)	_	
69-40	13521-13522	a	_	
69-41	13523-13538	high-resolution	_	
69-42	13539-13541	T1	_	
69-43	13542-13546	scan	_	
69-44	13547-13550	was	_	
69-45	13551-13559	acquired	_	
69-46	13560-13562	to	_	
69-47	13563-13570	provide	_	
69-48	13571-13578	precise	_	
69-49	13579-13589	anatomical	_	
69-50	13590-13602	localisation	_	
69-51	13603-13604	(	_	
69-52	13604-13606	TR	_	
69-53	13607-13609	of	_	
69-54	13610-13613	9.8	_	
69-55	13614-13616	ms	_	
69-56	13616-13617	,	_	
69-57	13618-13620	TE	_	
69-58	13621-13622	=	_	
69-59	13623-13626	459	_	
69-60	13627-13629	ms	_	
69-61	13629-13630	,	_	
69-62	13631-13633	FA	_	
69-63	13634-13635	=	_	
69-64	13636-13637	8	_	
69-65	13637-13638	°	_	
69-66	13638-13639	,	_	
69-67	13640-13643	FOV	_	
69-68	13644-13646	of	_	
69-69	13647-13650	256	_	
69-70	13651-13653	mm	_	
69-71	13653-13654	,	_	
69-72	13655-13660	slice	_	
69-73	13661-13670	thickness	_	
69-74	13671-13673	of	_	
69-75	13674-13677	1.0	_	
69-76	13678-13680	mm	_	
69-77	13680-13681	,	_	
69-78	13682-13685	180	_	
69-79	13686-13692	slices	_	
69-80	13693-13697	with	_	
69-81	13698-13701	288	_	
69-82	13702-13703	×	_	
69-83	13704-13707	288	_	
69-84	13708-13714	matrix	_	
69-85	13715-13718	per	_	
69-86	13719-13724	slice	_	
69-87	13724-13725	)	_	
69-88	13726-13729	and	_	
69-89	13730-13731	(	_	
69-90	13731-13733	ii	_	
69-91	13733-13734	)	_	
69-92	13735-13736	A	_	
69-93	13737-13740	run	_	
69-94	13741-13743	of	_	
69-95	13744-13746	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[9]	
69-96	13746-13747	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[9]	
69-97	13747-13748	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[9]	
69-98	13748-13756	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[9]	
69-99	13757-13761	BOLD	_	
69-100	13762-13766	echo	_	
69-101	13767-13773	planar	_	
69-102	13774-13781	imaging	_	
69-103	13782-13790	sequence	_	
69-104	13791-13798	volumes	_	
69-105	13799-13802	was	_	
69-106	13803-13811	acquired	_	
69-107	13812-13815	for	_	
69-108	13816-13827	whole-brain	_	
69-109	13828-13832	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
69-110	13833-13839	during	_	
69-111	13840-13843	the	_	
69-112	13844-13857	resting-state	_	
69-113	13858-13862	task	_	
69-114	13863-13864	(	_	
69-115	13864-13867	180	_	
69-116	13868-13874	frames	_	
69-117	13874-13875	,	_	
69-118	13876-13878	TR	_	
69-119	13879-13880	=	_	
69-120	13881-13885	2000	_	
69-121	13886-13888	ms	_	
69-122	13888-13889	,	_	
69-123	13890-13892	TE	_	
69-124	13893-13894	=	_	
69-125	13895-13897	30	_	
69-126	13898-13900	ms	_	
69-127	13900-13901	,	_	
69-128	13902-13904	FA	_	
69-129	13905-13906	=	_	
69-130	13907-13909	90	_	
69-131	13909-13910	°	_	
69-132	13910-13911	,	_	
69-133	13912-13915	FOV	_	
69-134	13916-13917	=	_	
69-135	13918-13921	220	_	
69-136	13922-13924	mm	_	
69-137	13924-13925	,	_	
69-138	13926-13928	42	_	
69-139	13929-13939	contiguous	_	
69-140	13940-13945	axial	_	
69-141	13946-13952	slices	_	
69-142	13952-13953	,	_	
69-143	13954-13959	slice	_	
69-144	13960-13969	thickness	_	
69-145	13970-13971	=	_	
69-146	13972-13975	2.8	_	
69-147	13976-13978	mm	_	
69-148	13979-13983	with	_	
69-149	13984-13986	64	_	
69-150	13987-13988	×	_	
69-151	13989-13991	64	_	
69-152	13992-13998	matrix	_	
69-153	13999-14002	per	_	
69-154	14003-14008	slice	_	
69-155	14008-14009	,	_	
69-156	14010-14015	voxel	_	
69-157	14016-14020	size	_	
69-158	14021-14022	=	_	
69-159	14023-14027	3.44	_	
69-160	14028-14029	×	_	
69-161	14030-14034	3.44	_	
69-162	14035-14036	×	_	
69-163	14037-14040	2.8	_	
69-164	14041-14044	mm3	_	
69-165	14044-14045	)	_	
69-166	14045-14046	,	_	
69-167	14047-14052	after	_	
69-168	14053-14063	discarding	_	
69-169	14064-14067	the	_	
69-170	14068-14073	first	_	
69-171	14074-14078	five	_	
69-172	14079-14086	initial	_	
69-173	14087-14093	frames	_	
69-174	14094-14096	to	_	
69-175	14097-14102	allow	_	
69-176	14103-14106	for	_	
69-177	14107-14120	equilibration	_	
69-178	14121-14123	of	_	
69-179	14124-14131	scanner	_	
69-180	14132-14138	signal	_	
69-181	14138-14139	.	_	

#Text=Imaging data processing and analysis
#Text=Functional MRI data were pre-processed and analysed using statistical parametric mapping software (SPM8; Welcome Department of Imaging Neuroscience, London, UK).
70-1	14140-14147	Imaging	_	
70-2	14148-14152	data	_	
70-3	14153-14163	processing	_	
70-4	14164-14167	and	_	
70-5	14168-14176	analysis	_	
70-6	14177-14187	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
70-7	14188-14191	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
70-8	14192-14196	data	_	
70-9	14197-14201	were	_	
70-10	14202-14215	pre-processed	_	
70-11	14216-14219	and	_	
70-12	14220-14228	analysed	_	
70-13	14229-14234	using	_	
70-14	14235-14246	statistical	_	
70-15	14247-14257	parametric	_	
70-16	14258-14265	mapping	_	
70-17	14266-14274	software	_	
70-18	14275-14276	(	_	
70-19	14276-14280	SPM8	_	
70-20	14280-14281	;	_	
70-21	14282-14289	Welcome	_	
70-22	14290-14300	Department	_	
70-23	14301-14303	of	_	
70-24	14304-14311	Imaging	_	
70-25	14312-14324	Neuroscience	_	
70-26	14324-14325	,	_	
70-27	14326-14332	London	_	
70-28	14332-14333	,	_	
70-29	14334-14336	UK	_	
70-30	14336-14337	)	_	
70-31	14337-14338	.	_	

#Text=Slice timing correction was performed using a middle slice as a reference (slice 21).
71-1	14339-14344	Slice	_	
71-2	14345-14351	timing	_	
71-3	14352-14362	correction	_	
71-4	14363-14366	was	_	
71-5	14367-14376	performed	_	
71-6	14377-14382	using	_	
71-7	14383-14384	a	_	
71-8	14385-14391	middle	_	
71-9	14392-14397	slice	_	
71-10	14398-14400	as	_	
71-11	14401-14402	a	_	
71-12	14403-14412	reference	_	
71-13	14413-14414	(	_	
71-14	14414-14419	slice	_	
71-15	14420-14422	21	_	
71-16	14422-14423	)	_	
71-17	14423-14424	.	_	

#Text=After slice time correction, images within each run were realigned to the mean image of the first run to correct for movement.
72-1	14425-14430	After	_	
72-2	14431-14436	slice	_	
72-3	14437-14441	time	_	
72-4	14442-14452	correction	_	
72-5	14452-14453	,	_	
72-6	14454-14460	images	_	
72-7	14461-14467	within	_	
72-8	14468-14472	each	_	
72-9	14473-14476	run	_	
72-10	14477-14481	were	_	
72-11	14482-14491	realigned	_	
72-12	14492-14494	to	_	
72-13	14495-14498	the	_	
72-14	14499-14503	mean	_	
72-15	14504-14509	image	_	
72-16	14510-14512	of	_	
72-17	14513-14516	the	_	
72-18	14517-14522	first	_	
72-19	14523-14526	run	_	
72-20	14527-14529	to	_	
72-21	14530-14537	correct	_	
72-22	14538-14541	for	_	
72-23	14542-14550	movement	_	
72-24	14550-14551	.	_	

#Text=Realigned functional images and structural images were spatially normalised using the DARTEL method in SPM8.
73-1	14552-14561	Realigned	_	
73-2	14562-14572	functional	_	
73-3	14573-14579	images	_	
73-4	14580-14583	and	_	
73-5	14584-14594	structural	_	
73-6	14595-14601	images	_	
73-7	14602-14606	were	_	
73-8	14607-14616	spatially	_	
73-9	14617-14627	normalised	_	
73-10	14628-14633	using	_	
73-11	14634-14637	the	_	
73-12	14638-14644	DARTEL	_	
73-13	14645-14651	method	_	
73-14	14652-14654	in	_	
73-15	14655-14659	SPM8	_	
73-16	14659-14660	.	_	

#Text=The normalised functional images were re-sliced to 2 × 2×2 mm voxels.
74-1	14661-14664	The	_	
74-2	14665-14675	normalised	_	
74-3	14676-14686	functional	_	
74-4	14687-14693	images	_	
74-5	14694-14698	were	_	
74-6	14699-14708	re-sliced	_	
74-7	14709-14711	to	_	
74-8	14712-14713	2	_	
74-9	14714-14715	×	_	
74-10	14716-14717	2	_	
74-11	14717-14718	×	_	
74-12	14718-14719	2	_	
74-13	14720-14722	mm	_	
74-14	14723-14729	voxels	_	
74-15	14729-14730	.	_	

#Text=Images were then spatially smoothed using a Gaussian filter with a full-width half-maximum value of 8 mm.
75-1	14731-14737	Images	_	
75-2	14738-14742	were	_	
75-3	14743-14747	then	_	
75-4	14748-14757	spatially	_	
75-5	14758-14766	smoothed	_	
75-6	14767-14772	using	_	
75-7	14773-14774	a	_	
75-8	14775-14783	Gaussian	_	
75-9	14784-14790	filter	_	
75-10	14791-14795	with	_	
75-11	14796-14797	a	_	
75-12	14798-14808	full-width	_	
75-13	14809-14821	half-maximum	_	
75-14	14822-14827	value	_	
75-15	14828-14830	of	_	
75-16	14831-14832	8	_	
75-17	14833-14835	mm	_	
75-18	14835-14836	.	_	

#Text=To assess and mitigate movement artifact, we calculated the frame-wise displacement (FD), defined as the sum (in millimetres) of the absolute values of frame displacement in successive functional volumes, based on six translation and rotation parameters from the realignment file.
76-1	14837-14839	To	_	
76-2	14840-14846	assess	_	
76-3	14847-14850	and	_	
76-4	14851-14859	mitigate	_	
76-5	14860-14868	movement	_	
76-6	14869-14877	artifact	_	
76-7	14877-14878	,	_	
76-8	14879-14881	we	_	
76-9	14882-14892	calculated	_	
76-10	14893-14896	the	_	
76-11	14897-14907	frame-wise	_	
76-12	14908-14920	displacement	_	
76-13	14921-14922	(	_	
76-14	14922-14924	FD	_	
76-15	14924-14925	)	_	
76-16	14925-14926	,	_	
76-17	14927-14934	defined	_	
76-18	14935-14937	as	_	
76-19	14938-14941	the	_	
76-20	14942-14945	sum	_	
76-21	14946-14947	(	_	
76-22	14947-14949	in	_	
76-23	14950-14961	millimetres	_	
76-24	14961-14962	)	_	
76-25	14963-14965	of	_	
76-26	14966-14969	the	_	
76-27	14970-14978	absolute	_	
76-28	14979-14985	values	_	
76-29	14986-14988	of	_	
76-30	14989-14994	frame	_	
76-31	14995-15007	displacement	_	
76-32	15008-15010	in	_	
76-33	15011-15021	successive	_	
76-34	15022-15032	functional	_	
76-35	15033-15040	volumes	_	
76-36	15040-15041	,	_	
76-37	15042-15047	based	_	
76-38	15048-15050	on	_	
76-39	15051-15054	six	_	
76-40	15055-15066	translation	_	
76-41	15067-15070	and	_	
76-42	15071-15079	rotation	_	
76-43	15080-15090	parameters	_	
76-44	15091-15095	from	_	
76-45	15096-15099	the	_	
76-46	15100-15111	realignment	_	
76-47	15112-15116	file	_	
76-48	15116-15117	.	_	

#Text=Rotational displacements were converted from degrees to millimeters moved on the surface of a 50-mm sphere.
77-1	15118-15128	Rotational	_	
77-2	15129-15142	displacements	_	
77-3	15143-15147	were	_	
77-4	15148-15157	converted	_	
77-5	15158-15162	from	_	
77-6	15163-15170	degrees	_	
77-7	15171-15173	to	_	
77-8	15174-15185	millimeters	_	
77-9	15186-15191	moved	_	
77-10	15192-15194	on	_	
77-11	15195-15198	the	_	
77-12	15199-15206	surface	_	
77-13	15207-15209	of	_	
77-14	15210-15211	a	_	
77-15	15212-15214	50	_	
77-16	15214-15215	-	_	
77-17	15215-15217	mm	_	
77-18	15218-15224	sphere	_	
77-19	15224-15225	.	_	

#Text=A frame-scrubbing routine was used to censor out any frame with FD > 0.5 mm from the regression analysis described below, yielding a scrub ratio for each subject, with a cut-off of 60% censored-out frames for sample exclusion, in accordance with the literature showing that as many as 60% of frames can be removed and still yield analysable results.
78-1	15226-15227	A	_	
78-2	15228-15243	frame-scrubbing	_	
78-3	15244-15251	routine	_	
78-4	15252-15255	was	_	
78-5	15256-15260	used	_	
78-6	15261-15263	to	_	
78-7	15264-15270	censor	_	
78-8	15271-15274	out	_	
78-9	15275-15278	any	_	
78-10	15279-15284	frame	_	
78-11	15285-15289	with	_	
78-12	15290-15292	FD	_	
78-13	15293-15294	>	_	
78-14	15295-15298	0.5	_	
78-15	15299-15301	mm	_	
78-16	15302-15306	from	_	
78-17	15307-15310	the	_	
78-18	15311-15321	regression	_	
78-19	15322-15330	analysis	_	
78-20	15331-15340	described	_	
78-21	15341-15346	below	_	
78-22	15346-15347	,	_	
78-23	15348-15356	yielding	_	
78-24	15357-15358	a	_	
78-25	15359-15364	scrub	_	
78-26	15365-15370	ratio	_	
78-27	15371-15374	for	_	
78-28	15375-15379	each	_	
78-29	15380-15387	subject	_	
78-30	15387-15388	,	_	
78-31	15389-15393	with	_	
78-32	15394-15395	a	_	
78-33	15396-15403	cut-off	_	
78-34	15404-15406	of	_	
78-35	15407-15410	60%	_	
78-36	15411-15423	censored-out	_	
78-37	15424-15430	frames	_	
78-38	15431-15434	for	_	
78-39	15435-15441	sample	_	
78-40	15442-15451	exclusion	_	
78-41	15451-15452	,	_	
78-42	15453-15455	in	_	
78-43	15456-15466	accordance	_	
78-44	15467-15471	with	_	
78-45	15472-15475	the	_	
78-46	15476-15486	literature	_	
78-47	15487-15494	showing	_	
78-48	15495-15499	that	_	
78-49	15500-15502	as	_	
78-50	15503-15507	many	_	
78-51	15508-15510	as	_	
78-52	15511-15514	60%	_	
78-53	15515-15517	of	_	
78-54	15518-15524	frames	_	
78-55	15525-15528	can	_	
78-56	15529-15531	be	_	
78-57	15532-15539	removed	_	
78-58	15540-15543	and	_	
78-59	15544-15549	still	_	
78-60	15550-15555	yield	_	
78-61	15556-15566	analysable	_	
78-62	15567-15574	results	_	
78-63	15574-15575	.	_	

#Text=There was no BT vs CG difference in the averaged FD before scrubbing (BT: mean ± SD: 0.379 ± 0.063; CG: mean ± SD: 0.300 ± 0.028; F1,40 = 1.284, MSerror = 0.056, P = .264).
79-1	15576-15581	There	_	
79-2	15582-15585	was	_	
79-3	15586-15588	no	_	
79-4	15589-15591	BT	_	
79-5	15592-15594	vs	_	
79-6	15595-15597	CG	_	
79-7	15598-15608	difference	_	
79-8	15609-15611	in	_	
79-9	15612-15615	the	_	
79-10	15616-15624	averaged	_	
79-11	15625-15627	FD	_	
79-12	15628-15634	before	_	
79-13	15635-15644	scrubbing	_	
79-14	15645-15646	(	_	
79-15	15646-15648	BT	_	
79-16	15648-15649	:	_	
79-17	15650-15654	mean	_	
79-18	15655-15656	±	_	
79-19	15657-15659	SD	_	
79-20	15659-15660	:	_	
79-21	15661-15666	0.379	_	
79-22	15667-15668	±	_	
79-23	15669-15674	0.063	_	
79-24	15674-15675	;	_	
79-25	15676-15678	CG	_	
79-26	15678-15679	:	_	
79-27	15680-15684	mean	_	
79-28	15685-15686	±	_	
79-29	15687-15689	SD	_	
79-30	15689-15690	:	_	
79-31	15691-15696	0.300	_	
79-32	15697-15698	±	_	
79-33	15699-15704	0.028	_	
79-34	15704-15705	;	_	
79-35	15706-15711	F1,40	_	
79-36	15712-15713	=	_	
79-37	15714-15719	1.284	_	
79-38	15719-15720	,	_	
79-39	15721-15728	MSerror	_	
79-40	15729-15730	=	_	
79-41	15731-15736	0.056	_	
79-42	15736-15737	,	_	
79-43	15738-15739	P	_	
79-44	15740-15741	=	_	
79-45	15742-15746	.264	_	
79-46	15746-15747	)	_	
79-47	15747-15748	.	_	

#Text=This suggests no significant head movement as a potential confounding factor between groups.
80-1	15749-15753	This	_	
80-2	15754-15762	suggests	_	
80-3	15763-15765	no	_	
80-4	15766-15777	significant	_	
80-5	15778-15782	head	_	
80-6	15783-15791	movement	_	
80-7	15792-15794	as	_	
80-8	15795-15796	a	_	
80-9	15797-15806	potential	_	
80-10	15807-15818	confounding	_	
80-11	15819-15825	factor	_	
80-12	15826-15833	between	_	
80-13	15834-15840	groups	_	
80-14	15840-15841	.	_	

#Text=Three-compartment segmentation of the high-resolution structural image from the DARTEL normalisation were applied to the functional time series to extract cerebral spinal volume and white matter compartments, which then were subjected to a principal component analysis to identify the top five components in each, which should correspond to heart rate and respiratory effects on the BOLD signal.
81-1	15842-15859	Three-compartment	_	
81-2	15860-15872	segmentation	_	
81-3	15873-15875	of	_	
81-4	15876-15879	the	_	
81-5	15880-15895	high-resolution	_	
81-6	15896-15906	structural	_	
81-7	15907-15912	image	_	
81-8	15913-15917	from	_	
81-9	15918-15921	the	_	
81-10	15922-15928	DARTEL	_	
81-11	15929-15942	normalisation	_	
81-12	15943-15947	were	_	
81-13	15948-15955	applied	_	
81-14	15956-15958	to	_	
81-15	15959-15962	the	_	
81-16	15963-15973	functional	_	
81-17	15974-15978	time	_	
81-18	15979-15985	series	_	
81-19	15986-15988	to	_	
81-20	15989-15996	extract	_	
81-21	15997-16005	cerebral	_	
81-22	16006-16012	spinal	_	
81-23	16013-16019	volume	_	
81-24	16020-16023	and	_	
81-25	16024-16029	white	_	
81-26	16030-16036	matter	_	
81-27	16037-16049	compartments	_	
81-28	16049-16050	,	_	
81-29	16051-16056	which	_	
81-30	16057-16061	then	_	
81-31	16062-16066	were	_	
81-32	16067-16076	subjected	_	
81-33	16077-16079	to	_	
81-34	16080-16081	a	_	
81-35	16082-16091	principal	_	
81-36	16092-16101	component	_	
81-37	16102-16110	analysis	_	
81-38	16111-16113	to	_	
81-39	16114-16122	identify	_	
81-40	16123-16126	the	_	
81-41	16127-16130	top	_	
81-42	16131-16135	five	_	
81-43	16136-16146	components	_	
81-44	16147-16149	in	_	
81-45	16150-16154	each	_	
81-46	16154-16155	,	_	
81-47	16156-16161	which	_	
81-48	16162-16168	should	_	
81-49	16169-16179	correspond	_	
81-50	16180-16182	to	_	
81-51	16183-16188	heart	_	
81-52	16189-16193	rate	_	
81-53	16194-16197	and	_	
81-54	16198-16209	respiratory	_	
81-55	16210-16217	effects	_	
81-56	16218-16220	on	_	
81-57	16221-16224	the	_	
81-58	16225-16229	BOLD	_	
81-59	16230-16236	signal	_	
81-60	16236-16237	.	_	

#Text=Adjusted time courses were derived from sequential regressions of the time series with the following regressors: linear trend of six motion parameters, their temporal derivatives, the quadratics of these 12 parameters, five components from the principal components analysis of cerebral spinal volume, five components of white matter, followed by band-pass filtering from 0.01 to 0.1 Hz, and then motion scrubbing.
82-1	16238-16246	Adjusted	_	
82-2	16247-16251	time	_	
82-3	16252-16259	courses	_	
82-4	16260-16264	were	_	
82-5	16265-16272	derived	_	
82-6	16273-16277	from	_	
82-7	16278-16288	sequential	_	
82-8	16289-16300	regressions	_	
82-9	16301-16303	of	_	
82-10	16304-16307	the	_	
82-11	16308-16312	time	_	
82-12	16313-16319	series	_	
82-13	16320-16324	with	_	
82-14	16325-16328	the	_	
82-15	16329-16338	following	_	
82-16	16339-16349	regressors	_	
82-17	16349-16350	:	_	
82-18	16351-16357	linear	_	
82-19	16358-16363	trend	_	
82-20	16364-16366	of	_	
82-21	16367-16370	six	_	
82-22	16371-16377	motion	_	
82-23	16378-16388	parameters	_	
82-24	16388-16389	,	_	
82-25	16390-16395	their	_	
82-26	16396-16404	temporal	_	
82-27	16405-16416	derivatives	_	
82-28	16416-16417	,	_	
82-29	16418-16421	the	_	
82-30	16422-16432	quadratics	_	
82-31	16433-16435	of	_	
82-32	16436-16441	these	_	
82-33	16442-16444	12	_	
82-34	16445-16455	parameters	_	
82-35	16455-16456	,	_	
82-36	16457-16461	five	_	
82-37	16462-16472	components	_	
82-38	16473-16477	from	_	
82-39	16478-16481	the	_	
82-40	16482-16491	principal	_	
82-41	16492-16502	components	_	
82-42	16503-16511	analysis	_	
82-43	16512-16514	of	_	
82-44	16515-16523	cerebral	_	
82-45	16524-16530	spinal	_	
82-46	16531-16537	volume	_	
82-47	16537-16538	,	_	
82-48	16539-16543	five	_	
82-49	16544-16554	components	_	
82-50	16555-16557	of	_	
82-51	16558-16563	white	_	
82-52	16564-16570	matter	_	
82-53	16570-16571	,	_	
82-54	16572-16580	followed	_	
82-55	16581-16583	by	_	
82-56	16584-16593	band-pass	_	
82-57	16594-16603	filtering	_	
82-58	16604-16608	from	_	
82-59	16609-16613	0.01	_	
82-60	16614-16616	to	_	
82-61	16617-16620	0.1	_	
82-62	16621-16623	Hz	_	
82-63	16623-16624	,	_	
82-64	16625-16628	and	_	
82-65	16629-16633	then	_	
82-66	16634-16640	motion	_	
82-67	16641-16650	scrubbing	_	
82-68	16650-16651	.	_	

#Text=The seed mask of PAG, as a region of interest (ROI), in rs-fMRI analysis was generated using PICKATLAS software (WFU PickAtlas; http://fmri.wfubmc.edu/software/pickatlas) as a box-shaped mask centered at the ventrolateral PAG (MNI: x = 0, y = −27, z = −8, with 3 × 1 × 1 mm extensions), in accordance with the literature.
83-1	16652-16655	The	_	
83-2	16656-16660	seed	_	
83-3	16661-16665	mask	_	
83-4	16666-16668	of	_	
83-5	16669-16672	PAG	_	
83-6	16672-16673	,	_	
83-7	16674-16676	as	_	
83-8	16677-16678	a	_	
83-9	16679-16685	region	_	
83-10	16686-16688	of	_	
83-11	16689-16697	interest	_	
83-12	16698-16699	(	_	
83-13	16699-16702	ROI	_	
83-14	16702-16703	)	_	
83-15	16703-16704	,	_	
83-16	16705-16707	in	_	
83-17	16708-16715	rs-fMRI	_	
83-18	16716-16724	analysis	_	
83-19	16725-16728	was	_	
83-20	16729-16738	generated	_	
83-21	16739-16744	using	_	
83-22	16745-16754	PICKATLAS	_	
83-23	16755-16763	software	_	
83-24	16764-16765	(	_	
83-25	16765-16768	WFU	_	
83-26	16769-16778	PickAtlas	_	
83-27	16778-16779	;	_	
83-28	16780-16784	http	_	
83-29	16784-16785	:	_	
83-30	16785-16786	/	_	
83-31	16786-16787	/	_	
83-32	16787-16802	fmri.wfubmc.edu	_	
83-33	16802-16803	/	_	
83-34	16803-16811	software	_	
83-35	16811-16812	/	_	
83-36	16812-16821	pickatlas	_	
83-37	16821-16822	)	_	
83-38	16823-16825	as	_	
83-39	16826-16827	a	_	
83-40	16828-16838	box-shaped	_	
83-41	16839-16843	mask	_	
83-42	16844-16852	centered	_	
83-43	16853-16855	at	_	
83-44	16856-16859	the	_	
83-45	16860-16873	ventrolateral	_	
83-46	16874-16877	PAG	_	
83-47	16878-16879	(	_	
83-48	16879-16882	MNI	_	
83-49	16882-16883	:	_	
83-50	16884-16885	x	_	
83-51	16886-16887	=	_	
83-52	16888-16889	0	_	
83-53	16889-16890	,	_	
83-54	16891-16892	y	_	
83-55	16893-16894	=	_	
83-56	16895-16896	−	_	
83-57	16896-16898	27	_	
83-58	16898-16899	,	_	
83-59	16900-16901	z	_	
83-60	16902-16903	=	_	
83-61	16904-16905	−	_	
83-62	16905-16906	8	_	
83-63	16906-16907	,	_	
83-64	16908-16912	with	_	
83-65	16913-16914	3	_	
83-66	16915-16916	×	_	
83-67	16917-16918	1	_	
83-68	16919-16920	×	_	
83-69	16921-16922	1	_	
83-70	16923-16925	mm	_	
83-71	16926-16936	extensions	_	
83-72	16936-16937	)	_	
83-73	16937-16938	,	_	
83-74	16939-16941	in	_	
83-75	16942-16952	accordance	_	
83-76	16953-16957	with	_	
83-77	16958-16961	the	_	
83-78	16962-16972	literature	_	
83-79	16972-16973	.	_	

#Text=In the first-level analysis, adjusted time courses were averaged across all voxels in the seed mask.
84-1	16974-16976	In	_	
84-2	16977-16980	the	_	
84-3	16981-16992	first-level	_	
84-4	16993-17001	analysis	_	
84-5	17001-17002	,	_	
84-6	17003-17011	adjusted	_	
84-7	17012-17016	time	_	
84-8	17017-17024	courses	_	
84-9	17025-17029	were	_	
84-10	17030-17038	averaged	_	
84-11	17039-17045	across	_	
84-12	17046-17049	all	_	
84-13	17050-17056	voxels	_	
84-14	17057-17059	in	_	
84-15	17060-17063	the	_	
84-16	17064-17068	seed	_	
84-17	17069-17073	mask	_	
84-18	17073-17074	.	_	

#Text=The average time course in the seed was correlated with time courses from all other voxels in the brain, Fisher r-to-Z transformed, and taken to second level, between-group analyses.
85-1	17075-17078	The	_	
85-2	17079-17086	average	_	
85-3	17087-17091	time	_	
85-4	17092-17098	course	_	
85-5	17099-17101	in	_	
85-6	17102-17105	the	_	
85-7	17106-17110	seed	_	
85-8	17111-17114	was	_	
85-9	17115-17125	correlated	_	
85-10	17126-17130	with	_	
85-11	17131-17135	time	_	
85-12	17136-17143	courses	_	
85-13	17144-17148	from	_	
85-14	17149-17152	all	_	
85-15	17153-17158	other	_	
85-16	17159-17165	voxels	_	
85-17	17166-17168	in	_	
85-18	17169-17172	the	_	
85-19	17173-17178	brain	_	
85-20	17178-17179	,	_	
85-21	17180-17186	Fisher	_	
85-22	17187-17193	r-to-Z	_	
85-23	17194-17205	transformed	_	
85-24	17205-17206	,	_	
85-25	17207-17210	and	_	
85-26	17211-17216	taken	_	
85-27	17217-17219	to	_	
85-28	17220-17226	second	_	
85-29	17227-17232	level	_	
85-30	17232-17233	,	_	
85-31	17234-17247	between-group	_	
85-32	17248-17256	analyses	_	
85-33	17256-17257	.	_	

#Text=In the second-level analysis, statistical parametric maps in the first model were submitted to general linear models (GLMs) to test for the effects of interest.
86-1	17258-17260	In	_	
86-2	17261-17264	the	_	
86-3	17265-17277	second-level	_	
86-4	17278-17286	analysis	_	
86-5	17286-17287	,	_	
86-6	17288-17299	statistical	_	
86-7	17300-17310	parametric	_	
86-8	17311-17315	maps	_	
86-9	17316-17318	in	_	
86-10	17319-17322	the	_	
86-11	17323-17328	first	_	
86-12	17329-17334	model	_	
86-13	17335-17339	were	_	
86-14	17340-17349	submitted	_	
86-15	17350-17352	to	_	
86-16	17353-17360	general	_	
86-17	17361-17367	linear	_	
86-18	17368-17374	models	_	
86-19	17375-17376	(	_	
86-20	17376-17380	GLMs	_	
86-21	17380-17381	)	_	
86-22	17382-17384	to	_	
86-23	17385-17389	test	_	
86-24	17390-17393	for	_	
86-25	17394-17397	the	_	
86-26	17398-17405	effects	_	
86-27	17406-17408	of	_	
86-28	17409-17417	interest	_	
86-29	17417-17418	.	_	

#Text=The effects of interest included the group difference (BT vs Controls) in the sample of 32 mothers and each of the three PBQ subscales in a subsample of BT and CG mothers (n = 5 in each group).
87-1	17419-17422	The	_	
87-2	17423-17430	effects	_	
87-3	17431-17433	of	_	
87-4	17434-17442	interest	_	
87-5	17443-17451	included	_	
87-6	17452-17455	the	_	
87-7	17456-17461	group	_	
87-8	17462-17472	difference	_	
87-9	17473-17474	(	_	
87-10	17474-17476	BT	_	
87-11	17477-17479	vs	_	
87-12	17480-17488	Controls	_	
87-13	17488-17489	)	_	
87-14	17490-17492	in	_	
87-15	17493-17496	the	_	
87-16	17497-17503	sample	_	
87-17	17504-17506	of	_	
87-18	17507-17509	32	_	
87-19	17510-17517	mothers	_	
87-20	17518-17521	and	_	
87-21	17522-17526	each	_	
87-22	17527-17529	of	_	
87-23	17530-17533	the	_	
87-24	17534-17539	three	_	
87-25	17540-17543	PBQ	_	
87-26	17544-17553	subscales	_	
87-27	17554-17556	in	_	
87-28	17557-17558	a	_	
87-29	17559-17568	subsample	_	
87-30	17569-17571	of	_	
87-31	17572-17574	BT	_	
87-32	17575-17578	and	_	
87-33	17579-17581	CG	_	
87-34	17582-17589	mothers	_	
87-35	17590-17591	(	_	
87-36	17591-17592	n	_	
87-37	17593-17594	=	_	
87-38	17595-17596	5	_	
87-39	17597-17599	in	_	
87-40	17600-17604	each	_	
87-41	17605-17610	group	_	
87-42	17610-17611	)	_	
87-43	17611-17612	.	_	

#Text=All of the second-level models were controlled for whole-brain multiple comparisons at the cluster level for voxel-wise intensity threshold at P < .001, which is considered to yield reliable statistical inference.
88-1	17613-17616	All	_	
88-2	17617-17619	of	_	
88-3	17620-17623	the	_	
88-4	17624-17636	second-level	_	
88-5	17637-17643	models	_	
88-6	17644-17648	were	_	
88-7	17649-17659	controlled	_	
88-8	17660-17663	for	_	
88-9	17664-17675	whole-brain	_	
88-10	17676-17684	multiple	_	
88-11	17685-17696	comparisons	_	
88-12	17697-17699	at	_	
88-13	17700-17703	the	_	
88-14	17704-17711	cluster	_	
88-15	17712-17717	level	_	
88-16	17718-17721	for	_	
88-17	17722-17732	voxel-wise	_	
88-18	17733-17742	intensity	_	
88-19	17743-17752	threshold	_	
88-20	17753-17755	at	_	
88-21	17756-17757	P	_	
88-22	17758-17759	<	_	
88-23	17760-17764	.001	_	
88-24	17764-17765	,	_	
88-25	17766-17771	which	_	
88-26	17772-17774	is	_	
88-27	17775-17785	considered	_	
88-28	17786-17788	to	_	
88-29	17789-17794	yield	_	
88-30	17795-17803	reliable	_	
88-31	17804-17815	statistical	_	
88-32	17816-17825	inference	_	
88-33	17825-17826	.	_	

#Text=We also used Threshold-Free Cluster Enhancement (TFCE) method to perform family-wise small volume correction (s.v.c.) in a ROI mask of the hypothalamus (MNI: x =±4, y = −2, z = −12, with a 4-mm radius) to examine the PAG-hypothalamus functional connectivity in accordance with the hypothesis that the reciprocal inhibition between PAG and hypothalamus plays a key role with respect to regulating maternal behaviours.
89-1	17827-17829	We	_	
89-2	17830-17834	also	_	
89-3	17835-17839	used	_	
89-4	17840-17854	Threshold-Free	_	
89-5	17855-17862	Cluster	_	
89-6	17863-17874	Enhancement	_	
89-7	17875-17876	(	_	
89-8	17876-17880	TFCE	_	
89-9	17880-17881	)	_	
89-10	17882-17888	method	_	
89-11	17889-17891	to	_	
89-12	17892-17899	perform	_	
89-13	17900-17911	family-wise	_	
89-14	17912-17917	small	_	
89-15	17918-17924	volume	_	
89-16	17925-17935	correction	_	
89-17	17936-17937	(	_	
89-18	17937-17942	s.v.c	_	
89-19	17942-17943	.	_	
89-20	17943-17944	)	_	
89-21	17945-17947	in	_	
89-22	17948-17949	a	_	
89-23	17950-17953	ROI	_	
89-24	17954-17958	mask	_	
89-25	17959-17961	of	_	
89-26	17962-17965	the	_	
89-27	17966-17978	hypothalamus	_	
89-28	17979-17980	(	_	
89-29	17980-17983	MNI	_	
89-30	17983-17984	:	_	
89-31	17985-17986	x	_	
89-32	17987-17988	=	_	
89-33	17988-17989	±	_	
89-34	17989-17990	4	_	
89-35	17990-17991	,	_	
89-36	17992-17993	y	_	
89-37	17994-17995	=	_	
89-38	17996-17997	−	_	
89-39	17997-17998	2	_	
89-40	17998-17999	,	_	
89-41	18000-18001	z	_	
89-42	18002-18003	=	_	
89-43	18004-18005	−	_	
89-44	18005-18007	12	_	
89-45	18007-18008	,	_	
89-46	18009-18013	with	_	
89-47	18014-18015	a	_	
89-48	18016-18017	4	_	
89-49	18017-18018	-	_	
89-50	18018-18020	mm	_	
89-51	18021-18027	radius	_	
89-52	18027-18028	)	_	
89-53	18029-18031	to	_	
89-54	18032-18039	examine	_	
89-55	18040-18043	the	_	
89-56	18044-18060	PAG-hypothalamus	_	
89-57	18061-18071	functional	_	
89-58	18072-18084	connectivity	_	
89-59	18085-18087	in	_	
89-60	18088-18098	accordance	_	
89-61	18099-18103	with	_	
89-62	18104-18107	the	_	
89-63	18108-18118	hypothesis	_	
89-64	18119-18123	that	_	
89-65	18124-18127	the	_	
89-66	18128-18138	reciprocal	_	
89-67	18139-18149	inhibition	_	
89-68	18150-18157	between	_	
89-69	18158-18161	PAG	_	
89-70	18162-18165	and	_	
89-71	18166-18178	hypothalamus	_	
89-72	18179-18184	plays	_	
89-73	18185-18186	a	_	
89-74	18187-18190	key	_	
89-75	18191-18195	role	_	
89-76	18196-18200	with	_	
89-77	18201-18208	respect	_	
89-78	18209-18211	to	_	
89-79	18212-18222	regulating	_	
89-80	18223-18231	maternal	_	
89-81	18232-18242	behaviours	_	
89-82	18242-18243	.	_	

#Text=Behavioural data analysis
#Text=We investigated the associations between the PAG-hypothalamus functional connectivity and three subscales of PBQ (IB, RPA and IFA) at T1 and T2 in the early postpartum mothers, using bivariate Pearson’s r correlation analysis in SPSS, version 24 (IBM Corp., Armonk, NY, USA).
90-1	18244-18255	Behavioural	_	
90-2	18256-18260	data	_	
90-3	18261-18269	analysis	_	
90-4	18270-18272	We	_	
90-5	18273-18285	investigated	_	
90-6	18286-18289	the	_	
90-7	18290-18302	associations	_	
90-8	18303-18310	between	_	
90-9	18311-18314	the	_	
90-10	18315-18331	PAG-hypothalamus	_	
90-11	18332-18342	functional	_	
90-12	18343-18355	connectivity	_	
90-13	18356-18359	and	_	
90-14	18360-18365	three	_	
90-15	18366-18375	subscales	_	
90-16	18376-18378	of	_	
90-17	18379-18382	PBQ	_	
90-18	18383-18384	(	_	
90-19	18384-18386	IB	_	
90-20	18386-18387	,	_	
90-21	18388-18391	RPA	_	
90-22	18392-18395	and	_	
90-23	18396-18399	IFA	_	
90-24	18399-18400	)	_	
90-25	18401-18403	at	_	
90-26	18404-18406	T1	_	
90-27	18407-18410	and	_	
90-28	18411-18413	T2	_	
90-29	18414-18416	in	_	
90-30	18417-18420	the	_	
90-31	18421-18426	early	_	
90-32	18427-18437	postpartum	_	
90-33	18438-18445	mothers	_	
90-34	18445-18446	,	_	
90-35	18447-18452	using	_	
90-36	18453-18462	bivariate	_	
90-37	18463-18470	Pearson	_	
90-38	18470-18471	’	_	
90-39	18471-18472	s	_	
90-40	18473-18474	r	_	
90-41	18475-18486	correlation	_	
90-42	18487-18495	analysis	_	
90-43	18496-18498	in	_	
90-44	18499-18503	SPSS	_	
90-45	18503-18504	,	_	
90-46	18505-18512	version	_	
90-47	18513-18515	24	_	
90-48	18516-18517	(	_	
90-49	18517-18520	IBM	_	
90-50	18521-18525	Corp	_	
90-51	18525-18526	.	_	
90-52	18526-18527	,	_	
90-53	18528-18534	Armonk	_	
90-54	18534-18535	,	_	
90-55	18536-18538	NY	_	
90-56	18538-18539	,	_	
90-57	18540-18543	USA	_	
90-58	18543-18544	)	_	
90-59	18544-18545	.	_	

#Text=RESULTS
#Text=Behavioural results
#Text=The participants in BT and CG did not differ with respect to their age (F1,30 = 0.081, MSerror = 70.25, P = .78), number of off-spring (F1,30 = 0.16, MSerror = 0.45, P = .69) and youngest child’s age in the early postpartum mothers (F1,8 = 1.00, MSerror = 0.01, P = .35).
91-1	18546-18553	RESULTS	_	
91-2	18554-18565	Behavioural	_	
91-3	18566-18573	results	_	
91-4	18574-18577	The	_	
91-5	18578-18590	participants	_	
91-6	18591-18593	in	_	
91-7	18594-18596	BT	_	
91-8	18597-18600	and	_	
91-9	18601-18603	CG	_	
91-10	18604-18607	did	_	
91-11	18608-18611	not	_	
91-12	18612-18618	differ	_	
91-13	18619-18623	with	_	
91-14	18624-18631	respect	_	
91-15	18632-18634	to	_	
91-16	18635-18640	their	_	
91-17	18641-18644	age	_	
91-18	18645-18646	(	_	
91-19	18646-18651	F1,30	_	
91-20	18652-18653	=	_	
91-21	18654-18659	0.081	_	
91-22	18659-18660	,	_	
91-23	18661-18668	MSerror	_	
91-24	18669-18670	=	_	
91-25	18671-18676	70.25	_	
91-26	18676-18677	,	_	
91-27	18678-18679	P	_	
91-28	18680-18681	=	_	
91-29	18682-18685	.78	_	
91-30	18685-18686	)	_	
91-31	18686-18687	,	_	
91-32	18688-18694	number	_	
91-33	18695-18697	of	_	
91-34	18698-18708	off-spring	_	
91-35	18709-18710	(	_	
91-36	18710-18715	F1,30	_	
91-37	18716-18717	=	_	
91-38	18718-18722	0.16	_	
91-39	18722-18723	,	_	
91-40	18724-18731	MSerror	_	
91-41	18732-18733	=	_	
91-42	18734-18738	0.45	_	
91-43	18738-18739	,	_	
91-44	18740-18741	P	_	
91-45	18742-18743	=	_	
91-46	18744-18747	.69	_	
91-47	18747-18748	)	_	
91-48	18749-18752	and	_	
91-49	18753-18761	youngest	_	
91-50	18762-18767	child	_	
91-51	18767-18768	’	_	
91-52	18768-18769	s	_	
91-53	18770-18773	age	_	
91-54	18774-18776	in	_	
91-55	18777-18780	the	_	
91-56	18781-18786	early	_	
91-57	18787-18797	postpartum	_	
91-58	18798-18805	mothers	_	
91-59	18806-18807	(	_	
91-60	18807-18811	F1,8	_	
91-61	18812-18813	=	_	
91-62	18814-18818	1.00	_	
91-63	18818-18819	,	_	
91-64	18820-18827	MSerror	_	
91-65	18828-18829	=	_	
91-66	18830-18834	0.01	_	
91-67	18834-18835	,	_	
91-68	18836-18837	P	_	
91-69	18838-18839	=	_	
91-70	18840-18843	.35	_	
91-71	18843-18844	)	_	
91-72	18844-18845	.	_	

#Text=For demographics, see Table 1.
92-1	18846-18849	For	_	
92-2	18850-18862	demographics	_	
92-3	18862-18863	,	_	
92-4	18864-18867	see	_	
92-5	18868-18873	Table	_	
92-6	18874-18875	1	_	
92-7	18875-18876	.	_	

#Text=In a mixed model of GLM, we investigated the main effects of group (BT vs CG), Time (T1 and T2) and Time by Group interaction effect in three subscales of PBQ.
93-1	18877-18879	In	_	
93-2	18880-18881	a	_	
93-3	18882-18887	mixed	_	
93-4	18888-18893	model	_	
93-5	18894-18896	of	_	
93-6	18897-18900	GLM	_	
93-7	18900-18901	,	_	
93-8	18902-18904	we	_	
93-9	18905-18917	investigated	_	
93-10	18918-18921	the	_	
93-11	18922-18926	main	_	
93-12	18927-18934	effects	_	
93-13	18935-18937	of	_	
93-14	18938-18943	group	_	
93-15	18944-18945	(	_	
93-16	18945-18947	BT	_	
93-17	18948-18950	vs	_	
93-18	18951-18953	CG	_	
93-19	18953-18954	)	_	
93-20	18954-18955	,	_	
93-21	18956-18960	Time	_	
93-22	18961-18962	(	_	
93-23	18962-18964	T1	_	
93-24	18965-18968	and	_	
93-25	18969-18971	T2	_	
93-26	18971-18972	)	_	
93-27	18973-18976	and	_	
93-28	18977-18981	Time	_	
93-29	18982-18984	by	_	
93-30	18985-18990	Group	_	
93-31	18991-19002	interaction	_	
93-32	19003-19009	effect	_	
93-33	19010-19012	in	_	
93-34	19013-19018	three	_	
93-35	19019-19028	subscales	_	
93-36	19029-19031	of	_	
93-37	19032-19035	PBQ	_	
93-38	19035-19036	.	_	

#Text=We found that there were no significant group main effects for any of the PBQ subscales (IB: F1,6 = 0.002, MSerror = 35.90, P = .97; RFA: F1,6 = 0.026, MSerror = 9.63, P = .88; IFA: F1,6 = 1.49, MSerror = 5.06, P = .27); there was a significant main effect of Time in IFA (F1,6 = 21.00, MSerror = 0.15, P = .004), although not the other subscales (IB: F1,6 = 2.45, MSerror = 15.98, P = .17; RPA: F1,6 = 3.10, MSerror = 3.96, P = .13); there were no significant Time by Group interaction effects for any of the subscales, although there was a marginal trend for IFA (IB: F1,6 = 0.066, MSerror = 15.98, P = .45; RFA: F1,6 = 0.001, MSerror = 3.96, P = 1.00; IFA: F1,6 = 3.86, MSerror = 0.15, P = .10).
94-1	19037-19039	We	_	
94-2	19040-19045	found	_	
94-3	19046-19050	that	_	
94-4	19051-19056	there	_	
94-5	19057-19061	were	_	
94-6	19062-19064	no	_	
94-7	19065-19076	significant	_	
94-8	19077-19082	group	_	
94-9	19083-19087	main	_	
94-10	19088-19095	effects	_	
94-11	19096-19099	for	_	
94-12	19100-19103	any	_	
94-13	19104-19106	of	_	
94-14	19107-19110	the	_	
94-15	19111-19114	PBQ	_	
94-16	19115-19124	subscales	_	
94-17	19125-19126	(	_	
94-18	19126-19128	IB	_	
94-19	19128-19129	:	_	
94-20	19130-19134	F1,6	_	
94-21	19135-19136	=	_	
94-22	19137-19142	0.002	_	
94-23	19142-19143	,	_	
94-24	19144-19151	MSerror	_	
94-25	19152-19153	=	_	
94-26	19154-19159	35.90	_	
94-27	19159-19160	,	_	
94-28	19161-19162	P	_	
94-29	19163-19164	=	_	
94-30	19165-19168	.97	_	
94-31	19168-19169	;	_	
94-32	19170-19173	RFA	_	
94-33	19173-19174	:	_	
94-34	19175-19179	F1,6	_	
94-35	19180-19181	=	_	
94-36	19182-19187	0.026	_	
94-37	19187-19188	,	_	
94-38	19189-19196	MSerror	_	
94-39	19197-19198	=	_	
94-40	19199-19203	9.63	_	
94-41	19203-19204	,	_	
94-42	19205-19206	P	_	
94-43	19207-19208	=	_	
94-44	19209-19212	.88	_	
94-45	19212-19213	;	_	
94-46	19214-19217	IFA	_	
94-47	19217-19218	:	_	
94-48	19219-19223	F1,6	_	
94-49	19224-19225	=	_	
94-50	19226-19230	1.49	_	
94-51	19230-19231	,	_	
94-52	19232-19239	MSerror	_	
94-53	19240-19241	=	_	
94-54	19242-19246	5.06	_	
94-55	19246-19247	,	_	
94-56	19248-19249	P	_	
94-57	19250-19251	=	_	
94-58	19252-19255	.27	_	
94-59	19255-19256	)	_	
94-60	19256-19257	;	_	
94-61	19258-19263	there	_	
94-62	19264-19267	was	_	
94-63	19268-19269	a	_	
94-64	19270-19281	significant	_	
94-65	19282-19286	main	_	
94-66	19287-19293	effect	_	
94-67	19294-19296	of	_	
94-68	19297-19301	Time	_	
94-69	19302-19304	in	_	
94-70	19305-19308	IFA	_	
94-71	19309-19310	(	_	
94-72	19310-19314	F1,6	_	
94-73	19315-19316	=	_	
94-74	19317-19322	21.00	_	
94-75	19322-19323	,	_	
94-76	19324-19331	MSerror	_	
94-77	19332-19333	=	_	
94-78	19334-19338	0.15	_	
94-79	19338-19339	,	_	
94-80	19340-19341	P	_	
94-81	19342-19343	=	_	
94-82	19344-19348	.004	_	
94-83	19348-19349	)	_	
94-84	19349-19350	,	_	
94-85	19351-19359	although	_	
94-86	19360-19363	not	_	
94-87	19364-19367	the	_	
94-88	19368-19373	other	_	
94-89	19374-19383	subscales	_	
94-90	19384-19385	(	_	
94-91	19385-19387	IB	_	
94-92	19387-19388	:	_	
94-93	19389-19393	F1,6	_	
94-94	19394-19395	=	_	
94-95	19396-19400	2.45	_	
94-96	19400-19401	,	_	
94-97	19402-19409	MSerror	_	
94-98	19410-19411	=	_	
94-99	19412-19417	15.98	_	
94-100	19417-19418	,	_	
94-101	19419-19420	P	_	
94-102	19421-19422	=	_	
94-103	19423-19426	.17	_	
94-104	19426-19427	;	_	
94-105	19428-19431	RPA	_	
94-106	19431-19432	:	_	
94-107	19433-19437	F1,6	_	
94-108	19438-19439	=	_	
94-109	19440-19444	3.10	_	
94-110	19444-19445	,	_	
94-111	19446-19453	MSerror	_	
94-112	19454-19455	=	_	
94-113	19456-19460	3.96	_	
94-114	19460-19461	,	_	
94-115	19462-19463	P	_	
94-116	19464-19465	=	_	
94-117	19466-19469	.13	_	
94-118	19469-19470	)	_	
94-119	19470-19471	;	_	
94-120	19472-19477	there	_	
94-121	19478-19482	were	_	
94-122	19483-19485	no	_	
94-123	19486-19497	significant	_	
94-124	19498-19502	Time	_	
94-125	19503-19505	by	_	
94-126	19506-19511	Group	_	
94-127	19512-19523	interaction	_	
94-128	19524-19531	effects	_	
94-129	19532-19535	for	_	
94-130	19536-19539	any	_	
94-131	19540-19542	of	_	
94-132	19543-19546	the	_	
94-133	19547-19556	subscales	_	
94-134	19556-19557	,	_	
94-135	19558-19566	although	_	
94-136	19567-19572	there	_	
94-137	19573-19576	was	_	
94-138	19577-19578	a	_	
94-139	19579-19587	marginal	_	
94-140	19588-19593	trend	_	
94-141	19594-19597	for	_	
94-142	19598-19601	IFA	_	
94-143	19602-19603	(	_	
94-144	19603-19605	IB	_	
94-145	19605-19606	:	_	
94-146	19607-19611	F1,6	_	
94-147	19612-19613	=	_	
94-148	19614-19619	0.066	_	
94-149	19619-19620	,	_	
94-150	19621-19628	MSerror	_	
94-151	19629-19630	=	_	
94-152	19631-19636	15.98	_	
94-153	19636-19637	,	_	
94-154	19638-19639	P	_	
94-155	19640-19641	=	_	
94-156	19642-19645	.45	_	
94-157	19645-19646	;	_	
94-158	19647-19650	RFA	_	
94-159	19650-19651	:	_	
94-160	19652-19656	F1,6	_	
94-161	19657-19658	=	_	
94-162	19659-19664	0.001	_	
94-163	19664-19665	,	_	
94-164	19666-19673	MSerror	_	
94-165	19674-19675	=	_	
94-166	19676-19680	3.96	_	
94-167	19680-19681	,	_	
94-168	19682-19683	P	_	
94-169	19684-19685	=	_	
94-170	19686-19690	1.00	_	
94-171	19690-19691	;	_	
94-172	19692-19695	IFA	_	
94-173	19695-19696	:	_	
94-174	19697-19701	F1,6	_	
94-175	19702-19703	=	_	
94-176	19704-19708	3.86	_	
94-177	19708-19709	,	_	
94-178	19710-19717	MSerror	_	
94-179	19718-19719	=	_	
94-180	19720-19724	0.15	_	
94-181	19724-19725	,	_	
94-182	19726-19727	P	_	
94-183	19728-19729	=	_	
94-184	19730-19733	.10	_	
94-185	19733-19734	)	_	
94-186	19734-19735	.	_	

#Text=For the Time by Group line charts of PBQ subscales, see Figure 2.
95-1	19736-19739	For	_	
95-2	19740-19743	the	_	
95-3	19744-19748	Time	_	
95-4	19749-19751	by	_	
95-5	19752-19757	Group	_	
95-6	19758-19762	line	_	
95-7	19763-19769	charts	_	
95-8	19770-19772	of	_	
95-9	19773-19776	PBQ	_	
95-10	19777-19786	subscales	_	
95-11	19786-19787	,	_	
95-12	19788-19791	see	_	
95-13	19792-19798	Figure	_	
95-14	19799-19800	2	_	
95-15	19800-19801	.	_	

#Text=Neuroimaging results
#Text=Main effects of group at T1 and T2, time, and time by group interactions
#Text=We examined the main effects of Group at timepoint, the main effects of Time and the Time by Group interaction effects on the PAG-dependent resting-state functional connectivity (rs-FC) in SPM8.
96-1	19802-19814	Neuroimaging	_	
96-2	19815-19822	results	_	
96-3	19823-19827	Main	_	
96-4	19828-19835	effects	_	
96-5	19836-19838	of	_	
96-6	19839-19844	group	_	
96-7	19845-19847	at	_	
96-8	19848-19850	T1	_	
96-9	19851-19854	and	_	
96-10	19855-19857	T2	_	
96-11	19857-19858	,	_	
96-12	19859-19863	time	_	
96-13	19863-19864	,	_	
96-14	19865-19868	and	_	
96-15	19869-19873	time	_	
96-16	19874-19876	by	_	
96-17	19877-19882	group	_	
96-18	19883-19895	interactions	_	
96-19	19896-19898	We	_	
96-20	19899-19907	examined	_	
96-21	19908-19911	the	_	
96-22	19912-19916	main	_	
96-23	19917-19924	effects	_	
96-24	19925-19927	of	_	
96-25	19928-19933	Group	_	
96-26	19934-19936	at	_	
96-27	19937-19946	timepoint	_	
96-28	19946-19947	,	_	
96-29	19948-19951	the	_	
96-30	19952-19956	main	_	
96-31	19957-19964	effects	_	
96-32	19965-19967	of	_	
96-33	19968-19972	Time	_	
96-34	19973-19976	and	_	
96-35	19977-19980	the	_	
96-36	19981-19985	Time	_	
96-37	19986-19988	by	_	
96-38	19989-19994	Group	_	
96-39	19995-20006	interaction	_	
96-40	20007-20014	effects	_	
96-41	20015-20017	on	_	
96-42	20018-20021	the	_	
96-43	20022-20035	PAG-dependent	_	
96-44	20036-20049	resting-state	_	
96-45	20050-20060	functional	_	
96-46	20061-20073	connectivity	_	
96-47	20074-20075	(	_	
96-48	20075-20080	rs-FC	_	
96-49	20080-20081	)	_	
96-50	20082-20084	in	_	
96-51	20085-20089	SPM8	_	
96-52	20089-20090	.	_	

#Text=There were no Time main effects observed in the PAG-dependent rs-FC.
97-1	20091-20096	There	_	
97-2	20097-20101	were	_	
97-3	20102-20104	no	_	
97-4	20105-20109	Time	_	
97-5	20110-20114	main	_	
97-6	20115-20122	effects	_	
97-7	20123-20131	observed	_	
97-8	20132-20134	in	_	
97-9	20135-20138	the	_	
97-10	20139-20152	PAG-dependent	_	
97-11	20153-20158	rs-FC	_	
97-12	20158-20159	.	_	

#Text=The main effects of Group (BT vs CG) on PAG-dependent rs-FC at T1 are summarised in Table 2 and Figure 3.
98-1	20160-20163	The	_	
98-2	20164-20168	main	_	
98-3	20169-20176	effects	_	
98-4	20177-20179	of	_	
98-5	20180-20185	Group	_	
98-6	20186-20187	(	_	
98-7	20187-20189	BT	_	
98-8	20190-20192	vs	_	
98-9	20193-20195	CG	_	
98-10	20195-20196	)	_	
98-11	20197-20199	on	_	
98-12	20200-20213	PAG-dependent	_	
98-13	20214-20219	rs-FC	_	
98-14	20220-20222	at	_	
98-15	20223-20225	T1	_	
98-16	20226-20229	are	_	
98-17	20230-20240	summarised	_	
98-18	20241-20243	in	_	
98-19	20244-20249	Table	_	
98-20	20250-20251	2	_	
98-21	20252-20255	and	_	
98-22	20256-20262	Figure	_	
98-23	20263-20264	3	_	
98-24	20264-20265	.	_	

#Text=At T1, BT vs CG mothers showed greater PAG-dependent rs-FC in the right inferior temporal gyrus, dorsal caudate nucleus/septal area and right amygdala/ hippocampus complex; when examining a prior ROI using TFCE, we also found that the PAG-dependent rs-FC with the hypothalamus was stronger in BT compared to CG mothers at T1(MNI: [4, −4, −10], 25 voxels, TFCE = 27.00, P = .026 s.v.c.).
99-1	20266-20268	At	_	
99-2	20269-20271	T1	_	
99-3	20271-20272	,	_	
99-4	20273-20275	BT	_	
99-5	20276-20278	vs	_	
99-6	20279-20281	CG	_	
99-7	20282-20289	mothers	_	
99-8	20290-20296	showed	_	
99-9	20297-20304	greater	_	
99-10	20305-20318	PAG-dependent	_	
99-11	20319-20324	rs-FC	_	
99-12	20325-20327	in	_	
99-13	20328-20331	the	_	
99-14	20332-20337	right	_	
99-15	20338-20346	inferior	_	
99-16	20347-20355	temporal	_	
99-17	20356-20361	gyrus	_	
99-18	20361-20362	,	_	
99-19	20363-20369	dorsal	_	
99-20	20370-20377	caudate	_	
99-21	20378-20385	nucleus	_	
99-22	20385-20386	/	_	
99-23	20386-20392	septal	_	
99-24	20393-20397	area	_	
99-25	20398-20401	and	_	
99-26	20402-20407	right	_	
99-27	20408-20416	amygdala	_	
99-28	20416-20417	/	_	
99-29	20418-20429	hippocampus	_	
99-30	20430-20437	complex	_	
99-31	20437-20438	;	_	
99-32	20439-20443	when	_	
99-33	20444-20453	examining	_	
99-34	20454-20455	a	_	
99-35	20456-20461	prior	_	
99-36	20462-20465	ROI	_	
99-37	20466-20471	using	_	
99-38	20472-20476	TFCE	_	
99-39	20476-20477	,	_	
99-40	20478-20480	we	_	
99-41	20481-20485	also	_	
99-42	20486-20491	found	_	
99-43	20492-20496	that	_	
99-44	20497-20500	the	_	
99-45	20501-20514	PAG-dependent	_	
99-46	20515-20520	rs-FC	_	
99-47	20521-20525	with	_	
99-48	20526-20529	the	_	
99-49	20530-20542	hypothalamus	_	
99-50	20543-20546	was	_	
99-51	20547-20555	stronger	_	
99-52	20556-20558	in	_	
99-53	20559-20561	BT	_	
99-54	20562-20570	compared	_	
99-55	20571-20573	to	_	
99-56	20574-20576	CG	_	
99-57	20577-20584	mothers	_	
99-58	20585-20587	at	_	
99-59	20588-20590	T1	_	
99-60	20590-20591	(	_	
99-61	20591-20594	MNI	_	
99-62	20594-20595	:	_	
99-63	20596-20597	[	_	
99-64	20597-20598	4	_	
99-65	20598-20599	,	_	
99-66	20600-20601	−	_	
99-67	20601-20602	4	_	
99-68	20602-20603	,	_	
99-69	20604-20605	−	_	
99-70	20605-20607	10	_	
99-71	20607-20608	]	_	
99-72	20608-20609	,	_	
99-73	20610-20612	25	_	
99-74	20613-20619	voxels	_	
99-75	20619-20620	,	_	
99-76	20621-20625	TFCE	_	
99-77	20626-20627	=	_	
99-78	20628-20633	27.00	_	
99-79	20633-20634	,	_	
99-80	20635-20636	P	_	
99-81	20637-20638	=	_	
99-82	20639-20643	.026	_	
99-83	20644-20649	s.v.c	_	
99-84	20649-20650	.	_	
99-85	20650-20651	)	_	
99-86	20651-20652	.	_	

#Text=Conversely, BT vs CG mothers showed a less PAG-dependent rs-FC in the right supramarginal gyrus, bilateral middle temporal gyrus (MTG), precuneus/posterior cingulate cortex, bilateral pericentral gyrus and right insular cortex at T1.
100-1	20653-20663	Conversely	_	
100-2	20663-20664	,	_	
100-3	20665-20667	BT	_	
100-4	20668-20670	vs	_	
100-5	20671-20673	CG	_	
100-6	20674-20681	mothers	_	
100-7	20682-20688	showed	_	
100-8	20689-20690	a	_	
100-9	20691-20695	less	_	
100-10	20696-20709	PAG-dependent	_	
100-11	20710-20715	rs-FC	_	
100-12	20716-20718	in	_	
100-13	20719-20722	the	_	
100-14	20723-20728	right	_	
100-15	20729-20742	supramarginal	_	
100-16	20743-20748	gyrus	_	
100-17	20748-20749	,	_	
100-18	20750-20759	bilateral	_	
100-19	20760-20766	middle	_	
100-20	20767-20775	temporal	_	
100-21	20776-20781	gyrus	_	
100-22	20782-20783	(	_	
100-23	20783-20786	MTG	_	
100-24	20786-20787	)	_	
100-25	20787-20788	,	_	
100-26	20789-20798	precuneus	_	
100-27	20798-20799	/	_	
100-28	20799-20808	posterior	_	
100-29	20809-20818	cingulate	_	
100-30	20819-20825	cortex	_	
100-31	20825-20826	,	_	
100-32	20827-20836	bilateral	_	
100-33	20837-20848	pericentral	_	
100-34	20849-20854	gyrus	_	
100-35	20855-20858	and	_	
100-36	20859-20864	right	_	
100-37	20865-20872	insular	_	
100-38	20873-20879	cortex	_	
100-39	20880-20882	at	_	
100-40	20883-20885	T1	_	
100-41	20885-20886	.	_	

#Text=The main effects of Group (BT vs CG) on PAG-dependent rs-FC at T2 are summarised in Table 3 and Figure 4.
101-1	20887-20890	The	_	
101-2	20891-20895	main	_	
101-3	20896-20903	effects	_	
101-4	20904-20906	of	_	
101-5	20907-20912	Group	_	
101-6	20913-20914	(	_	
101-7	20914-20916	BT	_	
101-8	20917-20919	vs	_	
101-9	20920-20922	CG	_	
101-10	20922-20923	)	_	
101-11	20924-20926	on	_	
101-12	20927-20940	PAG-dependent	_	
101-13	20941-20946	rs-FC	_	
101-14	20947-20949	at	_	
101-15	20950-20952	T2	_	
101-16	20953-20956	are	_	
101-17	20957-20967	summarised	_	
101-18	20968-20970	in	_	
101-19	20971-20976	Table	_	
101-20	20977-20978	3	_	
101-21	20979-20982	and	_	
101-22	20983-20989	Figure	_	
101-23	20990-20991	4	_	
101-24	20991-20992	.	_	

#Text=At T2, BT mothers showed PAG-dependent rs-FC that was greater than those in CG mothers in the hypothalamus ROI (MNI: [−6, −4, −10], three voxels, TFCE = 19.61, P = .041 s.v.c.).
102-1	20993-20995	At	_	
102-2	20996-20998	T2	_	
102-3	20998-20999	,	_	
102-4	21000-21002	BT	_	
102-5	21003-21010	mothers	_	
102-6	21011-21017	showed	_	
102-7	21018-21031	PAG-dependent	_	
102-8	21032-21037	rs-FC	_	
102-9	21038-21042	that	_	
102-10	21043-21046	was	_	
102-11	21047-21054	greater	_	
102-12	21055-21059	than	_	
102-13	21060-21065	those	_	
102-14	21066-21068	in	_	
102-15	21069-21071	CG	_	
102-16	21072-21079	mothers	_	
102-17	21080-21082	in	_	
102-18	21083-21086	the	_	
102-19	21087-21099	hypothalamus	_	
102-20	21100-21103	ROI	_	
102-21	21104-21105	(	_	
102-22	21105-21108	MNI	_	
102-23	21108-21109	:	_	
102-24	21110-21111	[	_	
102-25	21111-21112	−	_	
102-26	21112-21113	6	_	
102-27	21113-21114	,	_	
102-28	21115-21116	−	_	
102-29	21116-21117	4	_	
102-30	21117-21118	,	_	
102-31	21119-21120	−	_	
102-32	21120-21122	10	_	
102-33	21122-21123	]	_	
102-34	21123-21124	,	_	
102-35	21125-21130	three	_	
102-36	21131-21137	voxels	_	
102-37	21137-21138	,	_	
102-38	21139-21143	TFCE	_	
102-39	21144-21145	=	_	
102-40	21146-21151	19.61	_	
102-41	21151-21152	,	_	
102-42	21153-21154	P	_	
102-43	21155-21156	=	_	
102-44	21157-21161	.041	_	
102-45	21162-21167	s.v.c	_	
102-46	21167-21168	.	_	
102-47	21168-21169	)	_	
102-48	21169-21170	.	_	

#Text=Conversely, BT mothers showed a less PAG-dependent rs-FC in the dorsal and ventral ACC (dACC and vACC).
103-1	21171-21181	Conversely	_	
103-2	21181-21182	,	_	
103-3	21183-21185	BT	_	
103-4	21186-21193	mothers	_	
103-5	21194-21200	showed	_	
103-6	21201-21202	a	_	
103-7	21203-21207	less	_	
103-8	21208-21221	PAG-dependent	_	
103-9	21222-21227	rs-FC	_	
103-10	21228-21230	in	_	
103-11	21231-21234	the	_	
103-12	21235-21241	dorsal	_	
103-13	21242-21245	and	_	
103-14	21246-21253	ventral	_	
103-15	21254-21257	ACC	_	
103-16	21258-21259	(	_	
103-17	21259-21263	dACC	_	
103-18	21264-21267	and	_	
103-19	21268-21272	vACC	_	
103-20	21272-21273	)	_	
103-21	21273-21274	.	_	

#Text=For the Time by Group interaction effects, the results are summarised in Table 4 and Figure 5.
104-1	21275-21278	For	_	
104-2	21279-21282	the	_	
104-3	21283-21287	Time	_	
104-4	21288-21290	by	_	
104-5	21291-21296	Group	_	
104-6	21297-21308	interaction	_	
104-7	21309-21316	effects	_	
104-8	21316-21317	,	_	
104-9	21318-21321	the	_	
104-10	21322-21329	results	_	
104-11	21330-21333	are	_	
104-12	21334-21344	summarised	_	
104-13	21345-21347	in	_	
104-14	21348-21353	Table	_	
104-15	21354-21355	4	_	
104-16	21356-21359	and	_	
104-17	21360-21366	Figure	_	
104-18	21367-21368	5	_	
104-19	21368-21369	.	_	

#Text=We found that, compared to CG mothers, BT mothers showed greater T1-to-T2 increases of the PAG-dependent rs-FC with the right MTG and insular cortex; conversely, there were greater T1-to-T2 decreases in the PAG-dependent rs-FC with the dorsal precuneus, left OFC, septal area and dACC.
105-1	21370-21372	We	_	
105-2	21373-21378	found	_	
105-3	21379-21383	that	_	
105-4	21383-21384	,	_	
105-5	21385-21393	compared	_	
105-6	21394-21396	to	_	
105-7	21397-21399	CG	_	
105-8	21400-21407	mothers	_	
105-9	21407-21408	,	_	
105-10	21409-21411	BT	_	
105-11	21412-21419	mothers	_	
105-12	21420-21426	showed	_	
105-13	21427-21434	greater	_	
105-14	21435-21437	T1	_	
105-15	21437-21438	-	_	
105-16	21438-21443	to-T2	_	
105-17	21444-21453	increases	_	
105-18	21454-21456	of	_	
105-19	21457-21460	the	_	
105-20	21461-21474	PAG-dependent	_	
105-21	21475-21480	rs-FC	_	
105-22	21481-21485	with	_	
105-23	21486-21489	the	_	
105-24	21490-21495	right	_	
105-25	21496-21499	MTG	_	
105-26	21500-21503	and	_	
105-27	21504-21511	insular	_	
105-28	21512-21518	cortex	_	
105-29	21518-21519	;	_	
105-30	21520-21530	conversely	_	
105-31	21530-21531	,	_	
105-32	21532-21537	there	_	
105-33	21538-21542	were	_	
105-34	21543-21550	greater	_	
105-35	21551-21553	T1	_	
105-36	21553-21554	-	_	
105-37	21554-21559	to-T2	_	
105-38	21560-21569	decreases	_	
105-39	21570-21572	in	_	
105-40	21573-21576	the	_	
105-41	21577-21590	PAG-dependent	_	
105-42	21591-21596	rs-FC	_	
105-43	21597-21601	with	_	
105-44	21602-21605	the	_	
105-45	21606-21612	dorsal	_	
105-46	21613-21622	precuneus	_	
105-47	21622-21623	,	_	
105-48	21624-21628	left	_	
105-49	21629-21632	OFC	_	
105-50	21632-21633	,	_	
105-51	21634-21640	septal	_	
105-52	21641-21645	area	_	
105-53	21646-21649	and	_	
105-54	21650-21654	dACC	_	
105-55	21654-21655	.	_	

#Text=PBQ associations with PAG-dependent rs-FC
#Text=We explored the associations between three subscales of PBQ (IB, RPA and IFA) and the PAG-dependent rs-FC with the brain regions reported in the results above in the early postpartum mothers, namely the hypothalamus, right amygdala/hippocampus, right MTG, right insular cortex, septal area/caudate nucleus, dACC, left OFC and dorsal precuneus (for the line charts of the parameter estimates of these regions by group and time, see Figure 6).
106-1	21656-21659	PBQ	_	
106-2	21660-21672	associations	_	
106-3	21673-21677	with	_	
106-4	21678-21691	PAG-dependent	_	
106-5	21692-21697	rs-FC	_	
106-6	21698-21700	We	_	
106-7	21701-21709	explored	_	
106-8	21710-21713	the	_	
106-9	21714-21726	associations	_	
106-10	21727-21734	between	_	
106-11	21735-21740	three	_	
106-12	21741-21750	subscales	_	
106-13	21751-21753	of	_	
106-14	21754-21757	PBQ	_	
106-15	21758-21759	(	_	
106-16	21759-21761	IB	_	
106-17	21761-21762	,	_	
106-18	21763-21766	RPA	_	
106-19	21767-21770	and	_	
106-20	21771-21774	IFA	_	
106-21	21774-21775	)	_	
106-22	21776-21779	and	_	
106-23	21780-21783	the	_	
106-24	21784-21797	PAG-dependent	_	
106-25	21798-21803	rs-FC	_	
106-26	21804-21808	with	_	
106-27	21809-21812	the	_	
106-28	21813-21818	brain	_	
106-29	21819-21826	regions	_	
106-30	21827-21835	reported	_	
106-31	21836-21838	in	_	
106-32	21839-21842	the	_	
106-33	21843-21850	results	_	
106-34	21851-21856	above	_	
106-35	21857-21859	in	_	
106-36	21860-21863	the	_	
106-37	21864-21869	early	_	
106-38	21870-21880	postpartum	_	
106-39	21881-21888	mothers	_	
106-40	21888-21889	,	_	
106-41	21890-21896	namely	_	
106-42	21897-21900	the	_	
106-43	21901-21913	hypothalamus	_	
106-44	21913-21914	,	_	
106-45	21915-21920	right	_	
106-46	21921-21929	amygdala	_	
106-47	21929-21930	/	_	
106-48	21930-21941	hippocampus	_	
106-49	21941-21942	,	_	
106-50	21943-21948	right	_	
106-51	21949-21952	MTG	_	
106-52	21952-21953	,	_	
106-53	21954-21959	right	_	
106-54	21960-21967	insular	_	
106-55	21968-21974	cortex	_	
106-56	21974-21975	,	_	
106-57	21976-21982	septal	_	
106-58	21983-21987	area	_	
106-59	21987-21988	/	_	
106-60	21988-21995	caudate	_	
106-61	21996-22003	nucleus	_	
106-62	22003-22004	,	_	
106-63	22005-22009	dACC	_	
106-64	22009-22010	,	_	
106-65	22011-22015	left	_	
106-66	22016-22019	OFC	_	
106-67	22020-22023	and	_	
106-68	22024-22030	dorsal	_	
106-69	22031-22040	precuneus	_	
106-70	22041-22042	(	_	
106-71	22042-22045	for	_	
106-72	22046-22049	the	_	
106-73	22050-22054	line	_	
106-74	22055-22061	charts	_	
106-75	22062-22064	of	_	
106-76	22065-22068	the	_	
106-77	22069-22078	parameter	_	
106-78	22079-22088	estimates	_	
106-79	22089-22091	of	_	
106-80	22092-22097	these	_	
106-81	22098-22105	regions	_	
106-82	22106-22108	by	_	
106-83	22109-22114	group	_	
106-84	22115-22118	and	_	
106-85	22119-22123	time	_	
106-86	22123-22124	,	_	
106-87	22125-22128	see	_	
106-88	22129-22135	Figure	_	
106-89	22136-22137	6	_	
106-90	22137-22138	)	_	
106-91	22138-22139	.	_	

#Text=Among the regions reported above, only the hypothalamus and right amygdala PAG-dependent rs-FC were associated with some of the subscales in PBQ, as described below.
107-1	22140-22145	Among	_	
107-2	22146-22149	the	_	
107-3	22150-22157	regions	_	
107-4	22158-22166	reported	_	
107-5	22167-22172	above	_	
107-6	22172-22173	,	_	
107-7	22174-22178	only	_	
107-8	22179-22182	the	_	
107-9	22183-22195	hypothalamus	_	
107-10	22196-22199	and	_	
107-11	22200-22205	right	_	
107-12	22206-22214	amygdala	_	
107-13	22215-22228	PAG-dependent	_	
107-14	22229-22234	rs-FC	_	
107-15	22235-22239	were	_	
107-16	22240-22250	associated	_	
107-17	22251-22255	with	_	
107-18	22256-22260	some	_	
107-19	22261-22263	of	_	
107-20	22264-22267	the	_	
107-21	22268-22277	subscales	_	
107-22	22278-22280	in	_	
107-23	22281-22284	PBQ	_	
107-24	22284-22285	,	_	
107-25	22286-22288	as	_	
107-26	22289-22298	described	_	
107-27	22299-22304	below	_	
107-28	22304-22305	.	_	

#Text=The BT and CG mothers did not differ with respect to the associations between any of the PBQ subscales and PAG-dependent rs-FC.
108-1	22306-22309	The	_	
108-2	22310-22312	BT	_	
108-3	22313-22316	and	_	
108-4	22317-22319	CG	_	
108-5	22320-22327	mothers	_	
108-6	22328-22331	did	_	
108-7	22332-22335	not	_	
108-8	22336-22342	differ	_	
108-9	22343-22347	with	_	
108-10	22348-22355	respect	_	
108-11	22356-22358	to	_	
108-12	22359-22362	the	_	
108-13	22363-22375	associations	_	
108-14	22376-22383	between	_	
108-15	22384-22387	any	_	
108-16	22388-22390	of	_	
108-17	22391-22394	the	_	
108-18	22395-22398	PBQ	_	
108-19	22399-22408	subscales	_	
108-20	22409-22412	and	_	
108-21	22413-22426	PAG-dependent	_	
108-22	22427-22432	rs-FC	_	
108-23	22432-22433	.	_	

#Text=Across both groups, the T1-to-T2 changes in the PAG-dependent rs-FC with the hypothalamus were associated with T1 PBQ IB (r = .70, P = .025) and RPA (r = .76, P = .011), but not IFA (r = .31, P = .38), and with T2 PBQ RPA (r = .81, P = .014), but not IB (r = .46, P = .25) and IFA (r = −.097, P = .82) (Figure 7).
109-1	22434-22440	Across	_	
109-2	22441-22445	both	_	
109-3	22446-22452	groups	_	
109-4	22452-22453	,	_	
109-5	22454-22457	the	_	
109-6	22458-22460	T1	_	
109-7	22460-22461	-	_	
109-8	22461-22466	to-T2	_	
109-9	22467-22474	changes	_	
109-10	22475-22477	in	_	
109-11	22478-22481	the	_	
109-12	22482-22495	PAG-dependent	_	
109-13	22496-22501	rs-FC	_	
109-14	22502-22506	with	_	
109-15	22507-22510	the	_	
109-16	22511-22523	hypothalamus	_	
109-17	22524-22528	were	_	
109-18	22529-22539	associated	_	
109-19	22540-22544	with	_	
109-20	22545-22547	T1	_	
109-21	22548-22551	PBQ	_	
109-22	22552-22554	IB	_	
109-23	22555-22556	(	_	
109-24	22556-22557	r	_	
109-25	22558-22559	=	_	
109-26	22560-22563	.70	_	
109-27	22563-22564	,	_	
109-28	22565-22566	P	_	
109-29	22567-22568	=	_	
109-30	22569-22573	.025	_	
109-31	22573-22574	)	_	
109-32	22575-22578	and	_	
109-33	22579-22582	RPA	_	
109-34	22583-22584	(	_	
109-35	22584-22585	r	_	
109-36	22586-22587	=	_	
109-37	22588-22591	.76	_	
109-38	22591-22592	,	_	
109-39	22593-22594	P	_	
109-40	22595-22596	=	_	
109-41	22597-22601	.011	_	
109-42	22601-22602	)	_	
109-43	22602-22603	,	_	
109-44	22604-22607	but	_	
109-45	22608-22611	not	_	
109-46	22612-22615	IFA	_	
109-47	22616-22617	(	_	
109-48	22617-22618	r	_	
109-49	22619-22620	=	_	
109-50	22621-22624	.31	_	
109-51	22624-22625	,	_	
109-52	22626-22627	P	_	
109-53	22628-22629	=	_	
109-54	22630-22633	.38	_	
109-55	22633-22634	)	_	
109-56	22634-22635	,	_	
109-57	22636-22639	and	_	
109-58	22640-22644	with	_	
109-59	22645-22647	T2	_	
109-60	22648-22651	PBQ	_	
109-61	22652-22655	RPA	_	
109-62	22656-22657	(	_	
109-63	22657-22658	r	_	
109-64	22659-22660	=	_	
109-65	22661-22664	.81	_	
109-66	22664-22665	,	_	
109-67	22666-22667	P	_	
109-68	22668-22669	=	_	
109-69	22670-22674	.014	_	
109-70	22674-22675	)	_	
109-71	22675-22676	,	_	
109-72	22677-22680	but	_	
109-73	22681-22684	not	_	
109-74	22685-22687	IB	_	
109-75	22688-22689	(	_	
109-76	22689-22690	r	_	
109-77	22691-22692	=	_	
109-78	22693-22696	.46	_	
109-79	22696-22697	,	_	
109-80	22698-22699	P	_	
109-81	22700-22701	=	_	
109-82	22702-22705	.25	_	
109-83	22705-22706	)	_	
109-84	22707-22710	and	_	
109-85	22711-22714	IFA	_	
109-86	22715-22716	(	_	
109-87	22716-22717	r	_	
109-88	22718-22719	=	_	
109-89	22720-22721	−	_	
109-90	22721-22725	.097	_	
109-91	22725-22726	,	_	
109-92	22727-22728	P	_	
109-93	22729-22730	=	_	
109-94	22731-22734	.82	_	
109-95	22734-22735	)	_	
109-96	22736-22737	(	_	
109-97	22737-22743	Figure	_	
109-98	22744-22745	7	_	
109-99	22745-22746	)	_	
109-100	22746-22747	.	_	

#Text=The T1-to-T2 changes in the PAG-dependent rs-FC with the right amygdala were associated with T1 PBQ RPA (r = .72, P = .019) and IFA (r = .65, P = .043), but not IB (r = .48, P = .17), and with T2 PBQ IB (r = .82, P = .013) and RPA (r = .73, P = .039), but not IFA (r = .41, P = .32) (Figure 8).
110-1	22748-22751	The	_	
110-2	22752-22754	T1	_	
110-3	22754-22755	-	_	
110-4	22755-22760	to-T2	_	
110-5	22761-22768	changes	_	
110-6	22769-22771	in	_	
110-7	22772-22775	the	_	
110-8	22776-22789	PAG-dependent	_	
110-9	22790-22795	rs-FC	_	
110-10	22796-22800	with	_	
110-11	22801-22804	the	_	
110-12	22805-22810	right	_	
110-13	22811-22819	amygdala	_	
110-14	22820-22824	were	_	
110-15	22825-22835	associated	_	
110-16	22836-22840	with	_	
110-17	22841-22843	T1	_	
110-18	22844-22847	PBQ	_	
110-19	22848-22851	RPA	_	
110-20	22852-22853	(	_	
110-21	22853-22854	r	_	
110-22	22855-22856	=	_	
110-23	22857-22860	.72	_	
110-24	22860-22861	,	_	
110-25	22862-22863	P	_	
110-26	22864-22865	=	_	
110-27	22866-22870	.019	_	
110-28	22870-22871	)	_	
110-29	22872-22875	and	_	
110-30	22876-22879	IFA	_	
110-31	22880-22881	(	_	
110-32	22881-22882	r	_	
110-33	22883-22884	=	_	
110-34	22885-22888	.65	_	
110-35	22888-22889	,	_	
110-36	22890-22891	P	_	
110-37	22892-22893	=	_	
110-38	22894-22898	.043	_	
110-39	22898-22899	)	_	
110-40	22899-22900	,	_	
110-41	22901-22904	but	_	
110-42	22905-22908	not	_	
110-43	22909-22911	IB	_	
110-44	22912-22913	(	_	
110-45	22913-22914	r	_	
110-46	22915-22916	=	_	
110-47	22917-22920	.48	_	
110-48	22920-22921	,	_	
110-49	22922-22923	P	_	
110-50	22924-22925	=	_	
110-51	22926-22929	.17	_	
110-52	22929-22930	)	_	
110-53	22930-22931	,	_	
110-54	22932-22935	and	_	
110-55	22936-22940	with	_	
110-56	22941-22943	T2	_	
110-57	22944-22947	PBQ	_	
110-58	22948-22950	IB	_	
110-59	22951-22952	(	_	
110-60	22952-22953	r	_	
110-61	22954-22955	=	_	
110-62	22956-22959	.82	_	
110-63	22959-22960	,	_	
110-64	22961-22962	P	_	
110-65	22963-22964	=	_	
110-66	22965-22969	.013	_	
110-67	22969-22970	)	_	
110-68	22971-22974	and	_	
110-69	22975-22978	RPA	_	
110-70	22979-22980	(	_	
110-71	22980-22981	r	_	
110-72	22982-22983	=	_	
110-73	22984-22987	.73	_	
110-74	22987-22988	,	_	
110-75	22989-22990	P	_	
110-76	22991-22992	=	_	
110-77	22993-22997	.039	_	
110-78	22997-22998	)	_	
110-79	22998-22999	,	_	
110-80	23000-23003	but	_	
110-81	23004-23007	not	_	
110-82	23008-23011	IFA	_	
110-83	23012-23013	(	_	
110-84	23013-23014	r	_	
110-85	23015-23016	=	_	
110-86	23017-23020	.41	_	
110-87	23020-23021	,	_	
110-88	23022-23023	P	_	
110-89	23024-23025	=	_	
110-90	23026-23029	.32	_	
110-91	23029-23030	)	_	
110-92	23031-23032	(	_	
110-93	23032-23038	Figure	_	
110-94	23039-23040	8	_	
110-95	23040-23041	)	_	
110-96	23041-23042	.	_	

#Text=DISCUSSION
#Text=In the context of an unprecedented opioid crisis in the USA, many peripartum women with OUD are treated with buprenorphine maintenance treatment, despite concerns for parenting among affected human mothers.
111-1	23043-23053	DISCUSSION	_	
111-2	23054-23056	In	_	
111-3	23057-23060	the	_	
111-4	23061-23068	context	_	
111-5	23069-23071	of	_	
111-6	23072-23074	an	_	
111-7	23075-23088	unprecedented	_	
111-8	23089-23095	opioid	_	
111-9	23096-23102	crisis	_	
111-10	23103-23105	in	_	
111-11	23106-23109	the	_	
111-12	23110-23113	USA	_	
111-13	23113-23114	,	_	
111-14	23115-23119	many	_	
111-15	23120-23130	peripartum	_	
111-16	23131-23136	women	_	
111-17	23137-23141	with	_	
111-18	23142-23145	OUD	_	
111-19	23146-23149	are	_	
111-20	23150-23157	treated	_	
111-21	23158-23162	with	_	
111-22	23163-23176	buprenorphine	_	
111-23	23177-23188	maintenance	_	
111-24	23189-23198	treatment	_	
111-25	23198-23199	,	_	
111-26	23200-23207	despite	_	
111-27	23208-23216	concerns	_	
111-28	23217-23220	for	_	
111-29	23221-23230	parenting	_	
111-30	23231-23236	among	_	
111-31	23237-23245	affected	_	
111-32	23246-23251	human	_	
111-33	23252-23259	mothers	_	
111-34	23259-23260	.	_	

#Text=Rodent research indicates that opioids can disrupt maternal behaviour by acting on the PAG and other maternal brain circuit regions including the hypothalamus.
112-1	23261-23267	Rodent	_	
112-2	23268-23276	research	_	
112-3	23277-23286	indicates	_	
112-4	23287-23291	that	_	
112-5	23292-23299	opioids	_	
112-6	23300-23303	can	_	
112-7	23304-23311	disrupt	_	
112-8	23312-23320	maternal	_	
112-9	23321-23330	behaviour	_	
112-10	23331-23333	by	_	
112-11	23334-23340	acting	_	
112-12	23341-23343	on	_	
112-13	23344-23347	the	_	
112-14	23348-23351	PAG	_	
112-15	23352-23355	and	_	
112-16	23356-23361	other	_	
112-17	23362-23370	maternal	_	
112-18	23371-23376	brain	_	
112-19	23377-23384	circuit	_	
112-20	23385-23392	regions	_	
112-21	23393-23402	including	_	
112-22	23403-23406	the	_	
112-23	23407-23419	hypothalamus	_	
112-24	23419-23420	.	_	

#Text=We investigated whether a group of women with OUD and buprenorphine treatment (BT mothers) differed from a comparison group (CG) of non-OUD mothers during the early postpartum with respect to the resting-state functional connectivity associated with the PAG (PAG-dependent rs-FC) in the maternal brain neurocircuit.
113-1	23421-23423	We	_	
113-2	23424-23436	investigated	_	
113-3	23437-23444	whether	_	
113-4	23445-23446	a	_	
113-5	23447-23452	group	_	
113-6	23453-23455	of	_	
113-7	23456-23461	women	_	
113-8	23462-23466	with	_	
113-9	23467-23470	OUD	_	
113-10	23471-23474	and	_	
113-11	23475-23488	buprenorphine	_	
113-12	23489-23498	treatment	_	
113-13	23499-23500	(	_	
113-14	23500-23502	BT	_	
113-15	23503-23510	mothers	_	
113-16	23510-23511	)	_	
113-17	23512-23520	differed	_	
113-18	23521-23525	from	_	
113-19	23526-23527	a	_	
113-20	23528-23538	comparison	_	
113-21	23539-23544	group	_	
113-22	23545-23546	(	_	
113-23	23546-23548	CG	_	
113-24	23548-23549	)	_	
113-25	23550-23552	of	_	
113-26	23553-23560	non-OUD	_	
113-27	23561-23568	mothers	_	
113-28	23569-23575	during	_	
113-29	23576-23579	the	_	
113-30	23580-23585	early	_	
113-31	23586-23596	postpartum	_	
113-32	23597-23601	with	_	
113-33	23602-23609	respect	_	
113-34	23610-23612	to	_	
113-35	23613-23616	the	_	
113-36	23617-23630	resting-state	_	
113-37	23631-23641	functional	_	
113-38	23642-23654	connectivity	_	
113-39	23655-23665	associated	_	
113-40	23666-23670	with	_	
113-41	23671-23674	the	_	
113-42	23675-23678	PAG	_	
113-43	23679-23680	(	_	
113-44	23680-23693	PAG-dependent	_	
113-45	23694-23699	rs-FC	_	
113-46	23699-23700	)	_	
113-47	23701-23703	in	_	
113-48	23704-23707	the	_	
113-49	23708-23716	maternal	_	
113-50	23717-23722	brain	_	
113-51	23723-23735	neurocircuit	_	
113-52	23735-23736	.	_	

#Text=We found that, at 1 month postpartum (T1), compared to CG, BT mothers showed greater PAG-dependent rs-FC in the right inferior temporal gyrus, septal area/caudate nucleus, right amygdala/hippocampus and hypothalamus; they also showed a less PAG-dependent rs-FC in the supramarginal gyrus, posterior cingulate cortex/precuneus, postcentral gyrus, middle cingulate cortex, insular cortex, precentral gyrus and dorsal precuneus.
114-1	23737-23739	We	_	
114-2	23740-23745	found	_	
114-3	23746-23750	that	_	
114-4	23750-23751	,	_	
114-5	23752-23754	at	_	
114-6	23755-23756	1	_	
114-7	23757-23762	month	_	
114-8	23763-23773	postpartum	_	
114-9	23774-23775	(	_	
114-10	23775-23777	T1	_	
114-11	23777-23778	)	_	
114-12	23778-23779	,	_	
114-13	23780-23788	compared	_	
114-14	23789-23791	to	_	
114-15	23792-23794	CG	_	
114-16	23794-23795	,	_	
114-17	23796-23798	BT	_	
114-18	23799-23806	mothers	_	
114-19	23807-23813	showed	_	
114-20	23814-23821	greater	_	
114-21	23822-23835	PAG-dependent	_	
114-22	23836-23841	rs-FC	_	
114-23	23842-23844	in	_	
114-24	23845-23848	the	_	
114-25	23849-23854	right	_	
114-26	23855-23863	inferior	_	
114-27	23864-23872	temporal	_	
114-28	23873-23878	gyrus	_	
114-29	23878-23879	,	_	
114-30	23880-23886	septal	_	
114-31	23887-23891	area	_	
114-32	23891-23892	/	_	
114-33	23892-23899	caudate	_	
114-34	23900-23907	nucleus	_	
114-35	23907-23908	,	_	
114-36	23909-23914	right	_	
114-37	23915-23923	amygdala	_	
114-38	23923-23924	/	_	
114-39	23924-23935	hippocampus	_	
114-40	23936-23939	and	_	
114-41	23940-23952	hypothalamus	_	
114-42	23952-23953	;	_	
114-43	23954-23958	they	_	
114-44	23959-23963	also	_	
114-45	23964-23970	showed	_	
114-46	23971-23972	a	_	
114-47	23973-23977	less	_	
114-48	23978-23991	PAG-dependent	_	
114-49	23992-23997	rs-FC	_	
114-50	23998-24000	in	_	
114-51	24001-24004	the	_	
114-52	24005-24018	supramarginal	_	
114-53	24019-24024	gyrus	_	
114-54	24024-24025	,	_	
114-55	24026-24035	posterior	_	
114-56	24036-24045	cingulate	_	
114-57	24046-24052	cortex	_	
114-58	24052-24053	/	_	
114-59	24053-24062	precuneus	_	
114-60	24062-24063	,	_	
114-61	24064-24075	postcentral	_	
114-62	24076-24081	gyrus	_	
114-63	24081-24082	,	_	
114-64	24083-24089	middle	_	
114-65	24090-24099	cingulate	_	
114-66	24100-24106	cortex	_	
114-67	24106-24107	,	_	
114-68	24108-24115	insular	_	
114-69	24116-24122	cortex	_	
114-70	24122-24123	,	_	
114-71	24124-24134	precentral	_	
114-72	24135-24140	gyrus	_	
114-73	24141-24144	and	_	
114-74	24145-24151	dorsal	_	
114-75	24152-24161	precuneus	_	
114-76	24161-24162	.	_	

#Text=At 4 months postpartum (T2), compared to CG, BT mothers showed a marginally greater PAG-dependent rs-FC in the hypothalamus and a significantly less PAG-dependent rs-FC in the ventral and dorsal anterior cingulate cortex.
115-1	24163-24165	At	_	
115-2	24166-24167	4	_	
115-3	24168-24174	months	_	
115-4	24175-24185	postpartum	_	
115-5	24186-24187	(	_	
115-6	24187-24189	T2	_	
115-7	24189-24190	)	_	
115-8	24190-24191	,	_	
115-9	24192-24200	compared	_	
115-10	24201-24203	to	_	
115-11	24204-24206	CG	_	
115-12	24206-24207	,	_	
115-13	24208-24210	BT	_	
115-14	24211-24218	mothers	_	
115-15	24219-24225	showed	_	
115-16	24226-24227	a	_	
115-17	24228-24238	marginally	_	
115-18	24239-24246	greater	_	
115-19	24247-24260	PAG-dependent	_	
115-20	24261-24266	rs-FC	_	
115-21	24267-24269	in	_	
115-22	24270-24273	the	_	
115-23	24274-24286	hypothalamus	_	
115-24	24287-24290	and	_	
115-25	24291-24292	a	_	
115-26	24293-24306	significantly	_	
115-27	24307-24311	less	_	
115-28	24312-24325	PAG-dependent	_	
115-29	24326-24331	rs-FC	_	
115-30	24332-24334	in	_	
115-31	24335-24338	the	_	
115-32	24339-24346	ventral	_	
115-33	24347-24350	and	_	
115-34	24351-24357	dorsal	_	
115-35	24358-24366	anterior	_	
115-36	24367-24376	cingulate	_	
115-37	24377-24383	cortex	_	
115-38	24383-24384	.	_	

#Text=In terms of Time by Group interaction, BT mothers, compared to CG, showed greater T1-to-T2 increases in the PAG-dependent rs-FC in the right middle temporal gyrus and insular cortex as a result of a reversal of the initial negative rs-FC with PAG in these regions; they also showed greater T1-to-T2 decreases in the PAG-dependent rs-FC in the septal area/caudate nucleus, dorsal anterior cingulate cortex, left orbital frontal cortex and dorsal precuneus as a result of a reversal of the initial positive rs-FC with PAG in these regions.
116-1	24385-24387	In	_	
116-2	24388-24393	terms	_	
116-3	24394-24396	of	_	
116-4	24397-24401	Time	_	
116-5	24402-24404	by	_	
116-6	24405-24410	Group	_	
116-7	24411-24422	interaction	_	
116-8	24422-24423	,	_	
116-9	24424-24426	BT	_	
116-10	24427-24434	mothers	_	
116-11	24434-24435	,	_	
116-12	24436-24444	compared	_	
116-13	24445-24447	to	_	
116-14	24448-24450	CG	_	
116-15	24450-24451	,	_	
116-16	24452-24458	showed	_	
116-17	24459-24466	greater	_	
116-18	24467-24469	T1	_	
116-19	24469-24470	-	_	
116-20	24470-24475	to-T2	_	
116-21	24476-24485	increases	_	
116-22	24486-24488	in	_	
116-23	24489-24492	the	_	
116-24	24493-24506	PAG-dependent	_	
116-25	24507-24512	rs-FC	_	
116-26	24513-24515	in	_	
116-27	24516-24519	the	_	
116-28	24520-24525	right	_	
116-29	24526-24532	middle	_	
116-30	24533-24541	temporal	_	
116-31	24542-24547	gyrus	_	
116-32	24548-24551	and	_	
116-33	24552-24559	insular	_	
116-34	24560-24566	cortex	_	
116-35	24567-24569	as	_	
116-36	24570-24571	a	_	
116-37	24572-24578	result	_	
116-38	24579-24581	of	_	
116-39	24582-24583	a	_	
116-40	24584-24592	reversal	_	
116-41	24593-24595	of	_	
116-42	24596-24599	the	_	
116-43	24600-24607	initial	_	
116-44	24608-24616	negative	_	
116-45	24617-24622	rs-FC	_	
116-46	24623-24627	with	_	
116-47	24628-24631	PAG	_	
116-48	24632-24634	in	_	
116-49	24635-24640	these	_	
116-50	24641-24648	regions	_	
116-51	24648-24649	;	_	
116-52	24650-24654	they	_	
116-53	24655-24659	also	_	
116-54	24660-24666	showed	_	
116-55	24667-24674	greater	_	
116-56	24675-24677	T1	_	
116-57	24677-24678	-	_	
116-58	24678-24683	to-T2	_	
116-59	24684-24693	decreases	_	
116-60	24694-24696	in	_	
116-61	24697-24700	the	_	
116-62	24701-24714	PAG-dependent	_	
116-63	24715-24720	rs-FC	_	
116-64	24721-24723	in	_	
116-65	24724-24727	the	_	
116-66	24728-24734	septal	_	
116-67	24735-24739	area	_	
116-68	24739-24740	/	_	
116-69	24740-24747	caudate	_	
116-70	24748-24755	nucleus	_	
116-71	24755-24756	,	_	
116-72	24757-24763	dorsal	_	
116-73	24764-24772	anterior	_	
116-74	24773-24782	cingulate	_	
116-75	24783-24789	cortex	_	
116-76	24789-24790	,	_	
116-77	24791-24795	left	_	
116-78	24796-24803	orbital	_	
116-79	24804-24811	frontal	_	
116-80	24812-24818	cortex	_	
116-81	24819-24822	and	_	
116-82	24823-24829	dorsal	_	
116-83	24830-24839	precuneus	_	
116-84	24840-24842	as	_	
116-85	24843-24844	a	_	
116-86	24845-24851	result	_	
116-87	24852-24854	of	_	
116-88	24855-24856	a	_	
116-89	24857-24865	reversal	_	
116-90	24866-24868	of	_	
116-91	24869-24872	the	_	
116-92	24873-24880	initial	_	
116-93	24881-24889	positive	_	
116-94	24890-24895	rs-FC	_	
116-95	24896-24900	with	_	
116-96	24901-24904	PAG	_	
116-97	24905-24907	in	_	
116-98	24908-24913	these	_	
116-99	24914-24921	regions	_	
116-100	24921-24922	.	_	

#Text=We also explored whether the PAG-dependent rs-FC in any of the brain regions, showing group differences, was associated with deficits in maternal behaviours, as measured by the PBQ.
117-1	24923-24925	We	_	
117-2	24926-24930	also	_	
117-3	24931-24939	explored	_	
117-4	24940-24947	whether	_	
117-5	24948-24951	the	_	
117-6	24952-24965	PAG-dependent	_	
117-7	24966-24971	rs-FC	_	
117-8	24972-24974	in	_	
117-9	24975-24978	any	_	
117-10	24979-24981	of	_	
117-11	24982-24985	the	_	
117-12	24986-24991	brain	_	
117-13	24992-24999	regions	_	
117-14	24999-25000	,	_	
117-15	25001-25008	showing	_	
117-16	25009-25014	group	_	
117-17	25015-25026	differences	_	
117-18	25026-25027	,	_	
117-19	25028-25031	was	_	
117-20	25032-25042	associated	_	
117-21	25043-25047	with	_	
117-22	25048-25056	deficits	_	
117-23	25057-25059	in	_	
117-24	25060-25068	maternal	_	
117-25	25069-25079	behaviours	_	
117-26	25079-25080	,	_	
117-27	25081-25083	as	_	
117-28	25084-25092	measured	_	
117-29	25093-25095	by	_	
117-30	25096-25099	the	_	
117-31	25100-25103	PBQ	_	
117-32	25103-25104	.	_	

#Text=Although the BT and CG mothers did not differ with respect to the subscales of PBQ, such as for IB, RPA and IFA, we found that the T1-to-T2 changes in PAG-dependent rs-FC with the hypothalamus and right amygdala were positively correlated with some of the subscales of PBQ at T1 and T2.
118-1	25105-25113	Although	_	
118-2	25114-25117	the	_	
118-3	25118-25120	BT	_	
118-4	25121-25124	and	_	
118-5	25125-25127	CG	_	
118-6	25128-25135	mothers	_	
118-7	25136-25139	did	_	
118-8	25140-25143	not	_	
118-9	25144-25150	differ	_	
118-10	25151-25155	with	_	
118-11	25156-25163	respect	_	
118-12	25164-25166	to	_	
118-13	25167-25170	the	_	
118-14	25171-25180	subscales	_	
118-15	25181-25183	of	_	
118-16	25184-25187	PBQ	_	
118-17	25187-25188	,	_	
118-18	25189-25193	such	_	
118-19	25194-25196	as	_	
118-20	25197-25200	for	_	
118-21	25201-25203	IB	_	
118-22	25203-25204	,	_	
118-23	25205-25208	RPA	_	
118-24	25209-25212	and	_	
118-25	25213-25216	IFA	_	
118-26	25216-25217	,	_	
118-27	25218-25220	we	_	
118-28	25221-25226	found	_	
118-29	25227-25231	that	_	
118-30	25232-25235	the	_	
118-31	25236-25238	T1	_	
118-32	25238-25239	-	_	
118-33	25239-25244	to-T2	_	
118-34	25245-25252	changes	_	
118-35	25253-25255	in	_	
118-36	25256-25269	PAG-dependent	_	
118-37	25270-25275	rs-FC	_	
118-38	25276-25280	with	_	
118-39	25281-25284	the	_	
118-40	25285-25297	hypothalamus	_	
118-41	25298-25301	and	_	
118-42	25302-25307	right	_	
118-43	25308-25316	amygdala	_	
118-44	25317-25321	were	_	
118-45	25322-25332	positively	_	
118-46	25333-25343	correlated	_	
118-47	25344-25348	with	_	
118-48	25349-25353	some	_	
118-49	25354-25356	of	_	
118-50	25357-25360	the	_	
118-51	25361-25370	subscales	_	
118-52	25371-25373	of	_	
118-53	25374-25377	PBQ	_	
118-54	25378-25380	at	_	
118-55	25381-25383	T1	_	
118-56	25384-25387	and	_	
118-57	25388-25390	T2	_	
118-58	25390-25391	.	_	

#Text=By contrast to group difference analysis, correlation analysis may have detected a difference because of the increased power resulting from data pooling across BT and CG groups.
119-1	25392-25394	By	_	
119-2	25395-25403	contrast	_	
119-3	25404-25406	to	_	
119-4	25407-25412	group	_	
119-5	25413-25423	difference	_	
119-6	25424-25432	analysis	_	
119-7	25432-25433	,	_	
119-8	25434-25445	correlation	_	
119-9	25446-25454	analysis	_	
119-10	25455-25458	may	_	
119-11	25459-25463	have	_	
119-12	25464-25472	detected	_	
119-13	25473-25474	a	_	
119-14	25475-25485	difference	_	
119-15	25486-25493	because	_	
119-16	25494-25496	of	_	
119-17	25497-25500	the	_	
119-18	25501-25510	increased	_	
119-19	25511-25516	power	_	
119-20	25517-25526	resulting	_	
119-21	25527-25531	from	_	
119-22	25532-25536	data	_	
119-23	25537-25544	pooling	_	
119-24	25545-25551	across	_	
119-25	25552-25554	BT	_	
119-26	25555-25558	and	_	
119-27	25559-25561	CG	_	
119-28	25562-25568	groups	_	
119-29	25568-25569	.	_	

#Text=For the PAG-hypothalamus rs-FC, the IB and RPA (but not IFA) at T1 were correlated with the T1-to-T2 increases in the PAG-hypothalamus rs-FC; furthermore, the T1-to-T2 increases in the PAG-hypothalamus rs-FC were correlated with the RPA (but not IB and IFA) at T1.
120-1	25570-25573	For	_	
120-2	25574-25577	the	_	
120-3	25578-25594	PAG-hypothalamus	_	
120-4	25595-25600	rs-FC	_	
120-5	25600-25601	,	_	
120-6	25602-25605	the	_	
120-7	25606-25608	IB	_	
120-8	25609-25612	and	_	
120-9	25613-25616	RPA	_	
120-10	25617-25618	(	_	
120-11	25618-25621	but	_	
120-12	25622-25625	not	_	
120-13	25626-25629	IFA	_	
120-14	25629-25630	)	_	
120-15	25631-25633	at	_	
120-16	25634-25636	T1	_	
120-17	25637-25641	were	_	
120-18	25642-25652	correlated	_	
120-19	25653-25657	with	_	
120-20	25658-25661	the	_	
120-21	25662-25664	T1	_	
120-22	25664-25665	-	_	
120-23	25665-25670	to-T2	_	
120-24	25671-25680	increases	_	
120-25	25681-25683	in	_	
120-26	25684-25687	the	_	
120-27	25688-25704	PAG-hypothalamus	_	
120-28	25705-25710	rs-FC	_	
120-29	25710-25711	;	_	
120-30	25712-25723	furthermore	_	
120-31	25723-25724	,	_	
120-32	25725-25728	the	_	
120-33	25729-25731	T1	_	
120-34	25731-25732	-	_	
120-35	25732-25737	to-T2	_	
120-36	25738-25747	increases	_	
120-37	25748-25750	in	_	
120-38	25751-25754	the	_	
120-39	25755-25771	PAG-hypothalamus	_	
120-40	25772-25777	rs-FC	_	
120-41	25778-25782	were	_	
120-42	25783-25793	correlated	_	
120-43	25794-25798	with	_	
120-44	25799-25802	the	_	
120-45	25803-25806	RPA	_	
120-46	25807-25808	(	_	
120-47	25808-25811	but	_	
120-48	25812-25815	not	_	
120-49	25816-25818	IB	_	
120-50	25819-25822	and	_	
120-51	25823-25826	IFA	_	
120-52	25826-25827	)	_	
120-53	25828-25830	at	_	
120-54	25831-25833	T1	_	
120-55	25833-25834	.	_	

#Text=For the PAG-amygdala rs-FC, the RPA and IFA (but not IB) at T1 were correlated with the T1-to-T2 increases in the PAG-amygdala rs-FC; furthermore, the T1-to-T2 increases in the PAG-amygdala rs-FC were correlated with the IB and RPA (but not IFA) at T1.
121-1	25835-25838	For	_	
121-2	25839-25842	the	_	
121-3	25843-25855	PAG-amygdala	_	
121-4	25856-25861	rs-FC	_	
121-5	25861-25862	,	_	
121-6	25863-25866	the	_	
121-7	25867-25870	RPA	_	
121-8	25871-25874	and	_	
121-9	25875-25878	IFA	_	
121-10	25879-25880	(	_	
121-11	25880-25883	but	_	
121-12	25884-25887	not	_	
121-13	25888-25890	IB	_	
121-14	25890-25891	)	_	
121-15	25892-25894	at	_	
121-16	25895-25897	T1	_	
121-17	25898-25902	were	_	
121-18	25903-25913	correlated	_	
121-19	25914-25918	with	_	
121-20	25919-25922	the	_	
121-21	25923-25925	T1	_	
121-22	25925-25926	-	_	
121-23	25926-25931	to-T2	_	
121-24	25932-25941	increases	_	
121-25	25942-25944	in	_	
121-26	25945-25948	the	_	
121-27	25949-25961	PAG-amygdala	_	
121-28	25962-25967	rs-FC	_	
121-29	25967-25968	;	_	
121-30	25969-25980	furthermore	_	
121-31	25980-25981	,	_	
121-32	25982-25985	the	_	
121-33	25986-25988	T1	_	
121-34	25988-25989	-	_	
121-35	25989-25994	to-T2	_	
121-36	25995-26004	increases	_	
121-37	26005-26007	in	_	
121-38	26008-26011	the	_	
121-39	26012-26024	PAG-amygdala	_	
121-40	26025-26030	rs-FC	_	
121-41	26031-26035	were	_	
121-42	26036-26046	correlated	_	
121-43	26047-26051	with	_	
121-44	26052-26055	the	_	
121-45	26056-26058	IB	_	
121-46	26059-26062	and	_	
121-47	26063-26066	RPA	_	
121-48	26067-26068	(	_	
121-49	26068-26071	but	_	
121-50	26072-26075	not	_	
121-51	26076-26079	IFA	_	
121-52	26079-26080	)	_	
121-53	26081-26083	at	_	
121-54	26084-26086	T1	_	
121-55	26086-26087	.	_	

#Text=In sum, we found that, among the three subscales of PBQ, RPA was related to the PAG-dependent rs-FC to the greatest extent.
122-1	26088-26090	In	_	
122-2	26091-26094	sum	_	
122-3	26094-26095	,	_	
122-4	26096-26098	we	_	
122-5	26099-26104	found	_	
122-6	26105-26109	that	_	
122-7	26109-26110	,	_	
122-8	26111-26116	among	_	
122-9	26117-26120	the	_	
122-10	26121-26126	three	_	
122-11	26127-26136	subscales	_	
122-12	26137-26139	of	_	
122-13	26140-26143	PBQ	_	
122-14	26143-26144	,	_	
122-15	26145-26148	RPA	_	
122-16	26149-26152	was	_	
122-17	26153-26160	related	_	
122-18	26161-26163	to	_	
122-19	26164-26167	the	_	
122-20	26168-26181	PAG-dependent	_	
122-21	26182-26187	rs-FC	_	
122-22	26188-26190	to	_	
122-23	26191-26194	the	_	
122-24	26195-26203	greatest	_	
122-25	26204-26210	extent	_	
122-26	26210-26211	.	_	

#Text=Because RPA reflect outward expression of maternal aggression towards the infants, we have found preliminary evidence for the roles of the PAG-hypothalamus and PAG-amygdala rs-FC in the dysregulation of maternal aggression, which may reflect an impairment in the reciprocal inhibition between PAG and the hypothalamus and their roles in maternal aggression and caregiving behaviours, respectively.
123-1	26212-26219	Because	_	
123-2	26220-26223	RPA	_	
123-3	26224-26231	reflect	_	
123-4	26232-26239	outward	_	
123-5	26240-26250	expression	_	
123-6	26251-26253	of	_	
123-7	26254-26262	maternal	_	
123-8	26263-26273	aggression	_	
123-9	26274-26281	towards	_	
123-10	26282-26285	the	_	
123-11	26286-26293	infants	_	
123-12	26293-26294	,	_	
123-13	26295-26297	we	_	
123-14	26298-26302	have	_	
123-15	26303-26308	found	_	
123-16	26309-26320	preliminary	_	
123-17	26321-26329	evidence	_	
123-18	26330-26333	for	_	
123-19	26334-26337	the	_	
123-20	26338-26343	roles	_	
123-21	26344-26346	of	_	
123-22	26347-26350	the	_	
123-23	26351-26367	PAG-hypothalamus	_	
123-24	26368-26371	and	_	
123-25	26372-26384	PAG-amygdala	_	
123-26	26385-26390	rs-FC	_	
123-27	26391-26393	in	_	
123-28	26394-26397	the	_	
123-29	26398-26411	dysregulation	_	
123-30	26412-26414	of	_	
123-31	26415-26423	maternal	_	
123-32	26424-26434	aggression	_	
123-33	26434-26435	,	_	
123-34	26436-26441	which	_	
123-35	26442-26445	may	_	
123-36	26446-26453	reflect	_	
123-37	26454-26456	an	_	
123-38	26457-26467	impairment	_	
123-39	26468-26470	in	_	
123-40	26471-26474	the	_	
123-41	26475-26485	reciprocal	_	
123-42	26486-26496	inhibition	_	
123-43	26497-26504	between	_	
123-44	26505-26508	PAG	_	
123-45	26509-26512	and	_	
123-46	26513-26516	the	_	
123-47	26517-26529	hypothalamus	_	
123-48	26530-26533	and	_	
123-49	26534-26539	their	_	
123-50	26540-26545	roles	_	
123-51	26546-26548	in	_	
123-52	26549-26557	maternal	_	
123-53	26558-26568	aggression	_	
123-54	26569-26572	and	_	
123-55	26573-26583	caregiving	_	
123-56	26584-26594	behaviours	_	
123-57	26594-26595	,	_	
123-58	26596-26608	respectively	_	
123-59	26608-26609	.	_	

#Text=Among human mothers, PAG regional responses have been related to observing pictures of a mother’s own child vs an unknown child.
124-1	26610-26615	Among	_	
124-2	26616-26621	human	_	
124-3	26622-26629	mothers	_	
124-4	26629-26630	,	_	
124-5	26631-26634	PAG	_	
124-6	26635-26643	regional	_	
124-7	26644-26653	responses	_	
124-8	26654-26658	have	_	
124-9	26659-26663	been	_	
124-10	26664-26671	related	_	
124-11	26672-26674	to	_	
124-12	26675-26684	observing	_	
124-13	26685-26693	pictures	_	
124-14	26694-26696	of	_	
124-15	26697-26698	a	_	
124-16	26699-26705	mother	_	
124-17	26705-26706	’	_	
124-18	26706-26707	s	_	
124-19	26708-26711	own	_	
124-20	26712-26717	child	_	
124-21	26718-26720	vs	_	
124-22	26721-26723	an	_	
124-23	26724-26731	unknown	_	
124-24	26732-26737	child	_	
124-25	26737-26738	.	_	

#Text=These task-based studies have not analysed the reciprocal inhibition between PAG and maternal care regions such as the hypothalamus.
125-1	26739-26744	These	_	
125-2	26745-26755	task-based	_	
125-3	26756-26763	studies	_	
125-4	26764-26768	have	_	
125-5	26769-26772	not	_	
125-6	26773-26781	analysed	_	
125-7	26782-26785	the	_	
125-8	26786-26796	reciprocal	_	
125-9	26797-26807	inhibition	_	
125-10	26808-26815	between	_	
125-11	26816-26819	PAG	_	
125-12	26820-26823	and	_	
125-13	26824-26832	maternal	_	
125-14	26833-26837	care	_	
125-15	26838-26845	regions	_	
125-16	26846-26850	such	_	
125-17	26851-26853	as	_	
125-18	26854-26857	the	_	
125-19	26858-26870	hypothalamus	_	
125-20	26870-26871	.	_	

#Text=It is possible that PAG activation in these studies was part of a balanced response to own infant cues, in which mothers may have been preparing to exhibit caring or defensive behaviours depending on other circumstances.
126-1	26872-26874	It	_	
126-2	26875-26877	is	_	
126-3	26878-26886	possible	_	
126-4	26887-26891	that	_	
126-5	26892-26895	PAG	_	
126-6	26896-26906	activation	_	
126-7	26907-26909	in	_	
126-8	26910-26915	these	_	
126-9	26916-26923	studies	_	
126-10	26924-26927	was	_	
126-11	26928-26932	part	_	
126-12	26933-26935	of	_	
126-13	26936-26937	a	_	
126-14	26938-26946	balanced	_	
126-15	26947-26955	response	_	
126-16	26956-26958	to	_	
126-17	26959-26962	own	_	
126-18	26963-26969	infant	_	
126-19	26970-26974	cues	_	
126-20	26974-26975	,	_	
126-21	26976-26978	in	_	
126-22	26979-26984	which	_	
126-23	26985-26992	mothers	_	
126-24	26993-26996	may	_	
126-25	26997-27001	have	_	
126-26	27002-27006	been	_	
126-27	27007-27016	preparing	_	
126-28	27017-27019	to	_	
126-29	27020-27027	exhibit	_	
126-30	27028-27034	caring	_	
126-31	27035-27037	or	_	
126-32	27038-27047	defensive	_	
126-33	27048-27058	behaviours	_	
126-34	27059-27068	depending	_	
126-35	27069-27071	on	_	
126-36	27072-27077	other	_	
126-37	27078-27091	circumstances	_	
126-38	27091-27092	.	_	

#Text=In support, in a recent study of mothers, PAG connectivity with OFC during own vs other baby picture task was inversely related to parenting stress.
127-1	27093-27095	In	_	
127-2	27096-27103	support	_	
127-3	27103-27104	,	_	
127-4	27105-27107	in	_	
127-5	27108-27109	a	_	
127-6	27110-27116	recent	_	
127-7	27117-27122	study	_	
127-8	27123-27125	of	_	
127-9	27126-27133	mothers	_	
127-10	27133-27134	,	_	
127-11	27135-27138	PAG	_	
127-12	27139-27151	connectivity	_	
127-13	27152-27156	with	_	
127-14	27157-27160	OFC	_	
127-15	27161-27167	during	_	
127-16	27168-27171	own	_	
127-17	27172-27174	vs	_	
127-18	27175-27180	other	_	
127-19	27181-27185	baby	_	
127-20	27186-27193	picture	_	
127-21	27194-27198	task	_	
127-22	27199-27202	was	_	
127-23	27203-27212	inversely	_	
127-24	27213-27220	related	_	
127-25	27221-27223	to	_	
127-26	27224-27233	parenting	_	
127-27	27234-27240	stress	_	
127-28	27240-27241	.	_	

#Text=Perhaps, in that study, stress reduces OFC regulation of defensive and aggressive drives from the PAG, in accordance with circumstances in which a stressed mother must prepare to defend their infant.
128-1	27242-27249	Perhaps	_	
128-2	27249-27250	,	_	
128-3	27251-27253	in	_	
128-4	27254-27258	that	_	
128-5	27259-27264	study	_	
128-6	27264-27265	,	_	
128-7	27266-27272	stress	_	
128-8	27273-27280	reduces	_	
128-9	27281-27284	OFC	_	
128-10	27285-27295	regulation	_	
128-11	27296-27298	of	_	
128-12	27299-27308	defensive	_	
128-13	27309-27312	and	_	
128-14	27313-27323	aggressive	_	
128-15	27324-27330	drives	_	
128-16	27331-27335	from	_	
128-17	27336-27339	the	_	
128-18	27340-27343	PAG	_	
128-19	27343-27344	,	_	
128-20	27345-27347	in	_	
128-21	27348-27358	accordance	_	
128-22	27359-27363	with	_	
128-23	27364-27377	circumstances	_	
128-24	27378-27380	in	_	
128-25	27381-27386	which	_	
128-26	27387-27388	a	_	
128-27	27389-27397	stressed	_	
128-28	27398-27404	mother	_	
128-29	27405-27409	must	_	
128-30	27410-27417	prepare	_	
128-31	27418-27420	to	_	
128-32	27421-27427	defend	_	
128-33	27428-27433	their	_	
128-34	27434-27440	infant	_	
128-35	27440-27441	.	_	

#Text=Future studies may be able to assess the timing of regional brain activity, aiming to describe the order by which brain regions influence each other.
129-1	27442-27448	Future	_	
129-2	27449-27456	studies	_	
129-3	27457-27460	may	_	
129-4	27461-27463	be	_	
129-5	27464-27468	able	_	
129-6	27469-27471	to	_	
129-7	27472-27478	assess	_	
129-8	27479-27482	the	_	
129-9	27483-27489	timing	_	
129-10	27490-27492	of	_	
129-11	27493-27501	regional	_	
129-12	27502-27507	brain	_	
129-13	27508-27516	activity	_	
129-14	27516-27517	,	_	
129-15	27518-27524	aiming	_	
129-16	27525-27527	to	_	
129-17	27528-27536	describe	_	
129-18	27537-27540	the	_	
129-19	27541-27546	order	_	
129-20	27547-27549	by	_	
129-21	27550-27555	which	_	
129-22	27556-27561	brain	_	
129-23	27562-27569	regions	_	
129-24	27570-27579	influence	_	
129-25	27580-27584	each	_	
129-26	27585-27590	other	_	
129-27	27590-27591	.	_	

#Text=In the only rs-FC rodent study of the homologous maternal brain, connectivity between PAG and ACC was decreased for dams with early-life chronic social stress and interpreted as a decrease the reward salience of pups, resulting in depressed maternal care during early lactation.
130-1	27592-27594	In	_	
130-2	27595-27598	the	_	
130-3	27599-27603	only	_	
130-4	27604-27609	rs-FC	_	
130-5	27610-27616	rodent	_	
130-6	27617-27622	study	_	
130-7	27623-27625	of	_	
130-8	27626-27629	the	_	
130-9	27630-27640	homologous	_	
130-10	27641-27649	maternal	_	
130-11	27650-27655	brain	_	
130-12	27655-27656	,	_	
130-13	27657-27669	connectivity	_	
130-14	27670-27677	between	_	
130-15	27678-27681	PAG	_	
130-16	27682-27685	and	_	
130-17	27686-27689	ACC	_	
130-18	27690-27693	was	_	
130-19	27694-27703	decreased	_	
130-20	27704-27707	for	_	
130-21	27708-27712	dams	_	
130-22	27713-27717	with	_	
130-23	27718-27728	early-life	_	
130-24	27729-27736	chronic	_	
130-25	27737-27743	social	_	
130-26	27744-27750	stress	_	
130-27	27751-27754	and	_	
130-28	27755-27766	interpreted	_	
130-29	27767-27769	as	_	
130-30	27770-27771	a	_	
130-31	27772-27780	decrease	_	
130-32	27781-27784	the	_	
130-33	27785-27791	reward	_	
130-34	27792-27800	salience	_	
130-35	27801-27803	of	_	
130-36	27804-27808	pups	_	
130-37	27808-27809	,	_	
130-38	27810-27819	resulting	_	
130-39	27820-27822	in	_	
130-40	27823-27832	depressed	_	
130-41	27833-27841	maternal	_	
130-42	27842-27846	care	_	
130-43	27847-27853	during	_	
130-44	27854-27859	early	_	
130-45	27860-27869	lactation	_	
130-46	27869-27870	.	_	

#Text=There was also an improvement in connectivity from early to late lactation (similar levels between groups during late lactation), which is considered to be the result of cumulative exposure to pup-related stimuli, such as that observed when nulliparous rats are induced to express maternal care by exposure to foster pups.
131-1	27871-27876	There	_	
131-2	27877-27880	was	_	
131-3	27881-27885	also	_	
131-4	27886-27888	an	_	
131-5	27889-27900	improvement	_	
131-6	27901-27903	in	_	
131-7	27904-27916	connectivity	_	
131-8	27917-27921	from	_	
131-9	27922-27927	early	_	
131-10	27928-27930	to	_	
131-11	27931-27935	late	_	
131-12	27936-27945	lactation	_	
131-13	27946-27947	(	_	
131-14	27947-27954	similar	_	
131-15	27955-27961	levels	_	
131-16	27962-27969	between	_	
131-17	27970-27976	groups	_	
131-18	27977-27983	during	_	
131-19	27984-27988	late	_	
131-20	27989-27998	lactation	_	
131-21	27998-27999	)	_	
131-22	27999-28000	,	_	
131-23	28001-28006	which	_	
131-24	28007-28009	is	_	
131-25	28010-28020	considered	_	
131-26	28021-28023	to	_	
131-27	28024-28026	be	_	
131-28	28027-28030	the	_	
131-29	28031-28037	result	_	
131-30	28038-28040	of	_	
131-31	28041-28051	cumulative	_	
131-32	28052-28060	exposure	_	
131-33	28061-28063	to	_	
131-34	28064-28075	pup-related	_	
131-35	28076-28083	stimuli	_	
131-36	28083-28084	,	_	
131-37	28085-28089	such	_	
131-38	28090-28092	as	_	
131-39	28093-28097	that	_	
131-40	28098-28106	observed	_	
131-41	28107-28111	when	_	
131-42	28112-28123	nulliparous	_	
131-43	28124-28128	rats	_	
131-44	28129-28132	are	_	
131-45	28133-28140	induced	_	
131-46	28141-28143	to	_	
131-47	28144-28151	express	_	
131-48	28152-28160	maternal	_	
131-49	28161-28165	care	_	
131-50	28166-28168	by	_	
131-51	28169-28177	exposure	_	
131-52	28178-28180	to	_	
131-53	28181-28187	foster	_	
131-54	28188-28192	pups	_	
131-55	28192-28193	.	_	

#Text=Below, we discuss the possible maternal brain roles for regions that we report to have PAG-dependent rs-FC differences between BT and CG at T1 and T2.
132-1	28194-28199	Below	_	
132-2	28199-28200	,	_	
132-3	28201-28203	we	_	
132-4	28204-28211	discuss	_	
132-5	28212-28215	the	_	
132-6	28216-28224	possible	_	
132-7	28225-28233	maternal	_	
132-8	28234-28239	brain	_	
132-9	28240-28245	roles	_	
132-10	28246-28249	for	_	
132-11	28250-28257	regions	_	
132-12	28258-28262	that	_	
132-13	28263-28265	we	_	
132-14	28266-28272	report	_	
132-15	28273-28275	to	_	
132-16	28276-28280	have	_	
132-17	28281-28294	PAG-dependent	_	
132-18	28295-28300	rs-FC	_	
132-19	28301-28312	differences	_	
132-20	28313-28320	between	_	
132-21	28321-28323	BT	_	
132-22	28324-28327	and	_	
132-23	28328-28330	CG	_	
132-24	28331-28333	at	_	
132-25	28334-28336	T1	_	
132-26	28337-28340	and	_	
132-27	28341-28343	T2	_	
132-28	28343-28344	.	_	

#Text=Connectivity of PAG with other regions of the care and defence subsystems of the MBN to orchestrate parenting in humans is consistent with task-based fMRI responses to infant stimuli in the amygdala, insular cortex, OFC and hypothalamus.
133-1	28345-28357	Connectivity	_	
133-2	28358-28360	of	_	
133-3	28361-28364	PAG	_	
133-4	28365-28369	with	_	
133-5	28370-28375	other	_	
133-6	28376-28383	regions	_	
133-7	28384-28386	of	_	
133-8	28387-28390	the	_	
133-9	28391-28395	care	_	
133-10	28396-28399	and	_	
133-11	28400-28407	defence	_	
133-12	28408-28418	subsystems	_	
133-13	28419-28421	of	_	
133-14	28422-28425	the	_	
133-15	28426-28429	MBN	_	
133-16	28430-28432	to	_	
133-17	28433-28444	orchestrate	_	
133-18	28445-28454	parenting	_	
133-19	28455-28457	in	_	
133-20	28458-28464	humans	_	
133-21	28465-28467	is	_	
133-22	28468-28478	consistent	_	
133-23	28479-28483	with	_	
133-24	28484-28494	task-based	_	
133-25	28495-28499	fMRI	_	
133-26	28500-28509	responses	_	
133-27	28510-28512	to	_	
133-28	28513-28519	infant	_	
133-29	28520-28527	stimuli	_	
133-30	28528-28530	in	_	
133-31	28531-28534	the	_	
133-32	28535-28543	amygdala	_	
133-33	28543-28544	,	_	
133-34	28545-28552	insular	_	
133-35	28553-28559	cortex	_	
133-36	28559-28560	,	_	
133-37	28561-28564	OFC	_	
133-38	28565-28568	and	_	
133-39	28569-28581	hypothalamus	_	
133-40	28581-28582	.	_	

#Text=In rodent studies, oxytocin neurones in the in mPOA of the hypothalamus regulate dopamine function in the ventral tegmental area and mediate the reward salience of pups.
134-1	28583-28585	In	_	
134-2	28586-28592	rodent	_	
134-3	28593-28600	studies	_	
134-4	28600-28601	,	_	
134-5	28602-28610	oxytocin	_	
134-6	28611-28619	neurones	_	
134-7	28620-28622	in	_	
134-8	28623-28626	the	_	
134-9	28627-28629	in	_	
134-10	28630-28634	mPOA	_	
134-11	28635-28637	of	_	
134-12	28638-28641	the	_	
134-13	28642-28654	hypothalamus	_	
134-14	28655-28663	regulate	_	
134-15	28664-28672	dopamine	_	
134-16	28673-28681	function	_	
134-17	28682-28684	in	_	
134-18	28685-28688	the	_	
134-19	28689-28696	ventral	_	
134-20	28697-28706	tegmental	_	
134-21	28707-28711	area	_	
134-22	28712-28715	and	_	
134-23	28716-28723	mediate	_	
134-24	28724-28727	the	_	
134-25	28728-28734	reward	_	
134-26	28735-28743	salience	_	
134-27	28744-28746	of	_	
134-28	28747-28751	pups	_	
134-29	28751-28752	.	_	

#Text=In another rat model, disrupted hypothalamus connectivity with PAG was related to impaired maternal care.
135-1	28753-28755	In	_	
135-2	28756-28763	another	_	
135-3	28764-28767	rat	_	
135-4	28768-28773	model	_	
135-5	28773-28774	,	_	
135-6	28775-28784	disrupted	_	
135-7	28785-28797	hypothalamus	_	
135-8	28798-28810	connectivity	_	
135-9	28811-28815	with	_	
135-10	28816-28819	PAG	_	
135-11	28820-28823	was	_	
135-12	28824-28831	related	_	
135-13	28832-28834	to	_	
135-14	28835-28843	impaired	_	
135-15	28844-28852	maternal	_	
135-16	28853-28857	care	_	
135-17	28857-28858	.	_	

#Text=Furthermore, rats that display low levels of maternal care exhibit lower oxytocin receptor binding in the mPOA of the hypothalamus, which strengthens the importance of this region with respect to regulating sensitive maternal care.
136-1	28859-28870	Furthermore	_	
136-2	28870-28871	,	_	
136-3	28872-28876	rats	_	
136-4	28877-28881	that	_	
136-5	28882-28889	display	_	
136-6	28890-28893	low	_	
136-7	28894-28900	levels	_	
136-8	28901-28903	of	_	
136-9	28904-28912	maternal	_	
136-10	28913-28917	care	_	
136-11	28918-28925	exhibit	_	
136-12	28926-28931	lower	_	
136-13	28932-28940	oxytocin	_	
136-14	28941-28949	receptor	_	
136-15	28950-28957	binding	_	
136-16	28958-28960	in	_	
136-17	28961-28964	the	_	
136-18	28965-28969	mPOA	_	
136-19	28970-28972	of	_	
136-20	28973-28976	the	_	
136-21	28977-28989	hypothalamus	_	
136-22	28989-28990	,	_	
136-23	28991-28996	which	_	
136-24	28997-29008	strengthens	_	
136-25	29009-29012	the	_	
136-26	29013-29023	importance	_	
136-27	29024-29026	of	_	
136-28	29027-29031	this	_	
136-29	29032-29038	region	_	
136-30	29039-29043	with	_	
136-31	29044-29051	respect	_	
136-32	29052-29054	to	_	
136-33	29055-29065	regulating	_	
136-34	29066-29075	sensitive	_	
136-35	29076-29084	maternal	_	
136-36	29085-29089	care	_	
136-37	29089-29090	.	_	

#Text=The ACC also plays a key role in mediating appropriate responses to infant stimuli.
137-1	29091-29094	The	_	
137-2	29095-29098	ACC	_	
137-3	29099-29103	also	_	
137-4	29104-29109	plays	_	
137-5	29110-29111	a	_	
137-6	29112-29115	key	_	
137-7	29116-29120	role	_	
137-8	29121-29123	in	_	
137-9	29124-29133	mediating	_	
137-10	29134-29145	appropriate	_	
137-11	29146-29155	responses	_	
137-12	29156-29158	to	_	
137-13	29159-29165	infant	_	
137-14	29166-29173	stimuli	_	
137-15	29173-29174	.	_	

#Text=In response to an infant cry, human mothers with lower depressive symptoms have increased activity in the dorsal ACC.
138-1	29175-29177	In	_	
138-2	29178-29186	response	_	
138-3	29187-29189	to	_	
138-4	29190-29192	an	_	
138-5	29193-29199	infant	_	
138-6	29200-29203	cry	_	
138-7	29203-29204	,	_	
138-8	29205-29210	human	_	
138-9	29211-29218	mothers	_	
138-10	29219-29223	with	_	
138-11	29224-29229	lower	_	
138-12	29230-29240	depressive	_	
138-13	29241-29249	symptoms	_	
138-14	29250-29254	have	_	
138-15	29255-29264	increased	_	
138-16	29265-29273	activity	_	
138-17	29274-29276	in	_	
138-18	29277-29280	the	_	
138-19	29281-29287	dorsal	_	
138-20	29288-29291	ACC	_	
138-21	29291-29292	.	_	

#Text=Perhaps depression interferes with ACC-related empathy that has been demonstrated with human neuroimaging meta-analyses and parental brain studies.
139-1	29293-29300	Perhaps	_	
139-2	29301-29311	depression	_	
139-3	29312-29322	interferes	_	
139-4	29323-29327	with	_	
139-5	29328-29339	ACC-related	_	
139-6	29340-29347	empathy	_	
139-7	29348-29352	that	_	
139-8	29353-29356	has	_	
139-9	29357-29361	been	_	
139-10	29362-29374	demonstrated	_	
139-11	29375-29379	with	_	
139-12	29380-29385	human	_	
139-13	29386-29398	neuroimaging	_	
139-14	29399-29412	meta-analyses	_	
139-15	29413-29416	and	_	
139-16	29417-29425	parental	_	
139-17	29426-29431	brain	_	
139-18	29432-29439	studies	_	
139-19	29439-29440	.	_	

#Text=Furthermore, depressed mothers have been shown to exhibit decreases in the ACC-dependent rs-FC compared to healthy controls.
140-1	29441-29452	Furthermore	_	
140-2	29452-29453	,	_	
140-3	29454-29463	depressed	_	
140-4	29464-29471	mothers	_	
140-5	29472-29476	have	_	
140-6	29477-29481	been	_	
140-7	29482-29487	shown	_	
140-8	29488-29490	to	_	
140-9	29491-29498	exhibit	_	
140-10	29499-29508	decreases	_	
140-11	29509-29511	in	_	
140-12	29512-29515	the	_	
140-13	29516-29529	ACC-dependent	_	
140-14	29530-29535	rs-FC	_	
140-15	29536-29544	compared	_	
140-16	29545-29547	to	_	
140-17	29548-29555	healthy	_	
140-18	29556-29564	controls	_	
140-19	29564-29565	.	_	

#Text=The present study is preliminary and has notable limitations.
141-1	29566-29569	The	_	
141-2	29570-29577	present	_	
141-3	29578-29583	study	_	
141-4	29584-29586	is	_	
141-5	29587-29598	preliminary	_	
141-6	29599-29602	and	_	
141-7	29603-29606	has	_	
141-8	29607-29614	notable	_	
141-9	29615-29626	limitations	_	
141-10	29626-29627	.	_	

#Text=First, given that the CG mothers were not affected by OUD at all and there was no placebo control, we could not control the influence of previous opioid use in confounding the effects of buprenorphine per se.
142-1	29628-29633	First	_	
142-2	29633-29634	,	_	
142-3	29635-29640	given	_	
142-4	29641-29645	that	_	
142-5	29646-29649	the	_	
142-6	29650-29652	CG	_	
142-7	29653-29660	mothers	_	
142-8	29661-29665	were	_	
142-9	29666-29669	not	_	
142-10	29670-29678	affected	_	
142-11	29679-29681	by	_	
142-12	29682-29685	OUD	_	
142-13	29686-29688	at	_	
142-14	29689-29692	all	_	
142-15	29693-29696	and	_	
142-16	29697-29702	there	_	
142-17	29703-29706	was	_	
142-18	29707-29709	no	_	
142-19	29710-29717	placebo	_	
142-20	29718-29725	control	_	
142-21	29725-29726	,	_	
142-22	29727-29729	we	_	
142-23	29730-29735	could	_	
142-24	29736-29739	not	_	
142-25	29740-29747	control	_	
142-26	29748-29751	the	_	
142-27	29752-29761	influence	_	
142-28	29762-29764	of	_	
142-29	29765-29773	previous	_	
142-30	29774-29780	opioid	_	
142-31	29781-29784	use	_	
142-32	29785-29787	in	_	
142-33	29788-29799	confounding	_	
142-34	29800-29803	the	_	
142-35	29804-29811	effects	_	
142-36	29812-29814	of	_	
142-37	29815-29828	buprenorphine	_	
142-38	29829-29832	per	_	
142-39	29833-29835	se	_	
142-40	29835-29836	.	_	

#Text=Given the ethical and feasibility barriers to a placebo control trial with OUD subjects, future studies may be able to approach the pure effects of opioids with longitudinal research in which subjects are their own controls at different doses and time points.
143-1	29837-29842	Given	_	
143-2	29843-29846	the	_	
143-3	29847-29854	ethical	_	
143-4	29855-29858	and	_	
143-5	29859-29870	feasibility	_	
143-6	29871-29879	barriers	_	
143-7	29880-29882	to	_	
143-8	29883-29884	a	_	
143-9	29885-29892	placebo	_	
143-10	29893-29900	control	_	
143-11	29901-29906	trial	_	
143-12	29907-29911	with	_	
143-13	29912-29915	OUD	_	
143-14	29916-29924	subjects	_	
143-15	29924-29925	,	_	
143-16	29926-29932	future	_	
143-17	29933-29940	studies	_	
143-18	29941-29944	may	_	
143-19	29945-29947	be	_	
143-20	29948-29952	able	_	
143-21	29953-29955	to	_	
143-22	29956-29964	approach	_	
143-23	29965-29968	the	_	
143-24	29969-29973	pure	_	
143-25	29974-29981	effects	_	
143-26	29982-29984	of	_	
143-27	29985-29992	opioids	_	
143-28	29993-29997	with	_	
143-29	29998-30010	longitudinal	_	
143-30	30011-30019	research	_	
143-31	30020-30022	in	_	
143-32	30023-30028	which	_	
143-33	30029-30037	subjects	_	
143-34	30038-30041	are	_	
143-35	30042-30047	their	_	
143-36	30048-30051	own	_	
143-37	30052-30060	controls	_	
143-38	30061-30063	at	_	
143-39	30064-30073	different	_	
143-40	30074-30079	doses	_	
143-41	30080-30083	and	_	
143-42	30084-30088	time	_	
143-43	30089-30095	points	_	
143-44	30095-30096	.	_	

#Text=Future studies will also require a full characterisation of participants with OUD, including the quantity and frequency of all prescriptions, as well as licit and illicit drug, using a “time-line follow back” interview with calendar prompts and other memory aids to facilitate accurate recall.
144-1	30097-30103	Future	_	
144-2	30104-30111	studies	_	
144-3	30112-30116	will	_	
144-4	30117-30121	also	_	
144-5	30122-30129	require	_	
144-6	30130-30131	a	_	
144-7	30132-30136	full	_	
144-8	30137-30153	characterisation	_	
144-9	30154-30156	of	_	
144-10	30157-30169	participants	_	
144-11	30170-30174	with	_	
144-12	30175-30178	OUD	_	
144-13	30178-30179	,	_	
144-14	30180-30189	including	_	
144-15	30190-30193	the	_	
144-16	30194-30202	quantity	_	
144-17	30203-30206	and	_	
144-18	30207-30216	frequency	_	
144-19	30217-30219	of	_	
144-20	30220-30223	all	_	
144-21	30224-30237	prescriptions	_	
144-22	30237-30238	,	_	
144-23	30239-30241	as	_	
144-24	30242-30246	well	_	
144-25	30247-30249	as	_	
144-26	30250-30255	licit	_	
144-27	30256-30259	and	_	
144-28	30260-30267	illicit	_	
144-29	30268-30272	drug	_	
144-30	30272-30273	,	_	
144-31	30274-30279	using	_	
144-32	30280-30281	a	_	
144-33	30282-30283	“	_	
144-34	30283-30292	time-line	_	
144-35	30293-30299	follow	_	
144-36	30300-30304	back	_	
144-37	30304-30305	”	_	
144-38	30306-30315	interview	_	
144-39	30316-30320	with	_	
144-40	30321-30329	calendar	_	
144-41	30330-30337	prompts	_	
144-42	30338-30341	and	_	
144-43	30342-30347	other	_	
144-44	30348-30354	memory	_	
144-45	30355-30359	aids	_	
144-46	30360-30362	to	_	
144-47	30363-30373	facilitate	_	
144-48	30374-30382	accurate	_	
144-49	30383-30389	recall	_	
144-50	30389-30390	.	_	

#Text=It will be also important to consider receptor occupancy as an important aspect of opioid dosing.
145-1	30391-30393	It	_	
145-2	30394-30398	will	_	
145-3	30399-30401	be	_	
145-4	30402-30406	also	_	
145-5	30407-30416	important	_	
145-6	30417-30419	to	_	
145-7	30420-30428	consider	_	
145-8	30429-30437	receptor	_	
145-9	30438-30447	occupancy	_	
145-10	30448-30450	as	_	
145-11	30451-30453	an	_	
145-12	30454-30463	important	_	
145-13	30464-30470	aspect	_	
145-14	30471-30473	of	_	
145-15	30474-30480	opioid	_	
145-16	30481-30487	dosing	_	
145-17	30487-30488	.	_	

#Text=Additional consideration will be required regarding the possible medical consequences of OUD, as well as sociodemographic and medical backgrounds, especially because we already know that parental stress, poverty, anxiety and postpartum depression affect the parental brain.
146-1	30489-30499	Additional	_	
146-2	30500-30513	consideration	_	
146-3	30514-30518	will	_	
146-4	30519-30521	be	_	
146-5	30522-30530	required	_	
146-6	30531-30540	regarding	_	
146-7	30541-30544	the	_	
146-8	30545-30553	possible	_	
146-9	30554-30561	medical	_	
146-10	30562-30574	consequences	_	
146-11	30575-30577	of	_	
146-12	30578-30581	OUD	_	
146-13	30581-30582	,	_	
146-14	30583-30585	as	_	
146-15	30586-30590	well	_	
146-16	30591-30593	as	_	
146-17	30594-30610	sociodemographic	_	
146-18	30611-30614	and	_	
146-19	30615-30622	medical	_	
146-20	30623-30634	backgrounds	_	
146-21	30634-30635	,	_	
146-22	30636-30646	especially	_	
146-23	30647-30654	because	_	
146-24	30655-30657	we	_	
146-25	30658-30665	already	_	
146-26	30666-30670	know	_	
146-27	30671-30675	that	_	
146-28	30676-30684	parental	_	
146-29	30685-30691	stress	_	
146-30	30691-30692	,	_	
146-31	30693-30700	poverty	_	
146-32	30700-30701	,	_	
146-33	30702-30709	anxiety	_	
146-34	30710-30713	and	_	
146-35	30714-30724	postpartum	_	
146-36	30725-30735	depression	_	
146-37	30736-30742	affect	_	
146-38	30743-30746	the	_	
146-39	30747-30755	parental	_	
146-40	30756-30761	brain	_	
146-41	30761-30762	.	_	

#Text=Indeed, stress response dysregulation has been established in other substance use disorders.
147-1	30763-30769	Indeed	_	
147-2	30769-30770	,	_	
147-3	30771-30777	stress	_	
147-4	30778-30786	response	_	
147-5	30787-30800	dysregulation	_	
147-6	30801-30804	has	_	
147-7	30805-30809	been	_	
147-8	30810-30821	established	_	
147-9	30822-30824	in	_	
147-10	30825-30830	other	_	
147-11	30831-30840	substance	_	
147-12	30841-30844	use	_	
147-13	30845-30854	disorders	_	
147-14	30854-30855	.	_	

#Text=As noted in the Introduction, changes in rs-FC must be interpreted with caution because they do not capture the directionality of effect, and instead reflect basic associations of brain activity at rest, which are themselves under study .
148-1	30856-30858	As	_	
148-2	30859-30864	noted	_	
148-3	30865-30867	in	_	
148-4	30868-30871	the	_	
148-5	30872-30884	Introduction	_	
148-6	30884-30885	,	_	
148-7	30886-30893	changes	_	
148-8	30894-30896	in	_	
148-9	30897-30902	rs-FC	_	
148-10	30903-30907	must	_	
148-11	30908-30910	be	_	
148-12	30911-30922	interpreted	_	
148-13	30923-30927	with	_	
148-14	30928-30935	caution	_	
148-15	30936-30943	because	_	
148-16	30944-30948	they	_	
148-17	30949-30951	do	_	
148-18	30952-30955	not	_	
148-19	30956-30963	capture	_	
148-20	30964-30967	the	_	
148-21	30968-30982	directionality	_	
148-22	30983-30985	of	_	
148-23	30986-30992	effect	_	
148-24	30992-30993	,	_	
148-25	30994-30997	and	_	
148-26	30998-31005	instead	_	
148-27	31006-31013	reflect	_	
148-28	31014-31019	basic	_	
148-29	31020-31032	associations	_	
148-30	31033-31035	of	_	
148-31	31036-31041	brain	_	
148-32	31042-31050	activity	_	
148-33	31051-31053	at	_	
148-34	31054-31058	rest	_	
148-35	31058-31059	,	_	
148-36	31060-31065	which	_	
148-37	31066-31069	are	_	
148-38	31070-31080	themselves	_	
148-39	31081-31086	under	_	
148-40	31087-31092	study	_	
148-41	31093-31094	.	_	

#Text=Next, as a result of the small sample size in the samples with PBQ, the results with respect to testing the group difference in PBQ and the associations between the PBQ subscales and PAG-dependent rs-FC warrant replication in future studies.
149-1	31095-31099	Next	_	
149-2	31099-31100	,	_	
149-3	31101-31103	as	_	
149-4	31104-31105	a	_	
149-5	31106-31112	result	_	
149-6	31113-31115	of	_	
149-7	31116-31119	the	_	
149-8	31120-31125	small	_	
149-9	31126-31132	sample	_	
149-10	31133-31137	size	_	
149-11	31138-31140	in	_	
149-12	31141-31144	the	_	
149-13	31145-31152	samples	_	
149-14	31153-31157	with	_	
149-15	31158-31161	PBQ	_	
149-16	31161-31162	,	_	
149-17	31163-31166	the	_	
149-18	31167-31174	results	_	
149-19	31175-31179	with	_	
149-20	31180-31187	respect	_	
149-21	31188-31190	to	_	
149-22	31191-31198	testing	_	
149-23	31199-31202	the	_	
149-24	31203-31208	group	_	
149-25	31209-31219	difference	_	
149-26	31220-31222	in	_	
149-27	31223-31226	PBQ	_	
149-28	31227-31230	and	_	
149-29	31231-31234	the	_	
149-30	31235-31247	associations	_	
149-31	31248-31255	between	_	
149-32	31256-31259	the	_	
149-33	31260-31263	PBQ	_	
149-34	31264-31273	subscales	_	
149-35	31274-31277	and	_	
149-36	31278-31291	PAG-dependent	_	
149-37	31292-31297	rs-FC	_	
149-38	31298-31305	warrant	_	
149-39	31306-31317	replication	_	
149-40	31318-31320	in	_	
149-41	31321-31327	future	_	
149-42	31328-31335	studies	_	
149-43	31335-31336	.	_	

#Text=Furthermore, there are complex caveats around the measurement of parental thoughts and behaviours.
150-1	31337-31348	Furthermore	_	
150-2	31348-31349	,	_	
150-3	31350-31355	there	_	
150-4	31356-31359	are	_	
150-5	31360-31367	complex	_	
150-6	31368-31375	caveats	_	
150-7	31376-31382	around	_	
150-8	31383-31386	the	_	
150-9	31387-31398	measurement	_	
150-10	31399-31401	of	_	
150-11	31402-31410	parental	_	
150-12	31411-31419	thoughts	_	
150-13	31420-31423	and	_	
150-14	31424-31434	behaviours	_	
150-15	31434-31435	.	_	

#Text=In the present study, we only used the PBQ, which is a self-report measure that may not capture aspects of parenting about which participants may be embarrassed or unaware.
151-1	31436-31438	In	_	
151-2	31439-31442	the	_	
151-3	31443-31450	present	_	
151-4	31451-31456	study	_	
151-5	31456-31457	,	_	
151-6	31458-31460	we	_	
151-7	31461-31465	only	_	
151-8	31466-31470	used	_	
151-9	31471-31474	the	_	
151-10	31475-31478	PBQ	_	
151-11	31478-31479	,	_	
151-12	31480-31485	which	_	
151-13	31486-31488	is	_	
151-14	31489-31490	a	_	
151-15	31491-31502	self-report	_	
151-16	31503-31510	measure	_	
151-17	31511-31515	that	_	
151-18	31516-31519	may	_	
151-19	31520-31523	not	_	
151-20	31524-31531	capture	_	
151-21	31532-31539	aspects	_	
151-22	31540-31542	of	_	
151-23	31543-31552	parenting	_	
151-24	31553-31558	about	_	
151-25	31559-31564	which	_	
151-26	31565-31577	participants	_	
151-27	31578-31581	may	_	
151-28	31582-31584	be	_	
151-29	31585-31596	embarrassed	_	
151-30	31597-31599	or	_	
151-31	31600-31607	unaware	_	
151-32	31607-31608	.	_	

#Text=Future work would benefit from more comprehensive interviews such as the working model of the child interview and parental interview of thoughts and behaviours, as well as video-based objective measures of parenting sensitivity, intrusiveness, interfering, forcing, overriding, anger/hostility and criticising of their child.
152-1	31609-31615	Future	_	
152-2	31616-31620	work	_	
152-3	31621-31626	would	_	
152-4	31627-31634	benefit	_	
152-5	31635-31639	from	_	
152-6	31640-31644	more	_	
152-7	31645-31658	comprehensive	_	
152-8	31659-31669	interviews	_	
152-9	31670-31674	such	_	
152-10	31675-31677	as	_	
152-11	31678-31681	the	_	
152-12	31682-31689	working	_	
152-13	31690-31695	model	_	
152-14	31696-31698	of	_	
152-15	31699-31702	the	_	
152-16	31703-31708	child	_	
152-17	31709-31718	interview	_	
152-18	31719-31722	and	_	
152-19	31723-31731	parental	_	
152-20	31732-31741	interview	_	
152-21	31742-31744	of	_	
152-22	31745-31753	thoughts	_	
152-23	31754-31757	and	_	
152-24	31758-31768	behaviours	_	
152-25	31768-31769	,	_	
152-26	31770-31772	as	_	
152-27	31773-31777	well	_	
152-28	31778-31780	as	_	
152-29	31781-31792	video-based	_	
152-30	31793-31802	objective	_	
152-31	31803-31811	measures	_	
152-32	31812-31814	of	_	
152-33	31815-31824	parenting	_	
152-34	31825-31836	sensitivity	_	
152-35	31836-31837	,	_	
152-36	31838-31851	intrusiveness	_	
152-37	31851-31852	,	_	
152-38	31853-31864	interfering	_	
152-39	31864-31865	,	_	
152-40	31866-31873	forcing	_	
152-41	31873-31874	,	_	
152-42	31875-31885	overriding	_	
152-43	31885-31886	,	_	
152-44	31887-31892	anger	_	
152-45	31892-31893	/	_	
152-46	31893-31902	hostility	_	
152-47	31903-31906	and	_	
152-48	31907-31918	criticising	_	
152-49	31919-31921	of	_	
152-50	31922-31927	their	_	
152-51	31928-31933	child	_	
152-52	31933-31934	.	_	

#Text=Finally, the translational validity of the MBN across species requires more ethologically valid neuroimaging paradigms connected to real-world behavioural condition.
153-1	31935-31942	Finally	_	
153-2	31942-31943	,	_	
153-3	31944-31947	the	_	
153-4	31948-31961	translational	_	
153-5	31962-31970	validity	_	
153-6	31971-31973	of	_	
153-7	31974-31977	the	_	
153-8	31978-31981	MBN	_	
153-9	31982-31988	across	_	
153-10	31989-31996	species	_	
153-11	31997-32005	requires	_	
153-12	32006-32010	more	_	
153-13	32011-32024	ethologically	_	
153-14	32025-32030	valid	_	
153-15	32031-32043	neuroimaging	_	
153-16	32044-32053	paradigms	_	
153-17	32054-32063	connected	_	
153-18	32064-32066	to	_	
153-19	32067-32077	real-world	_	
153-20	32078-32089	behavioural	_	
153-21	32090-32099	condition	_	
153-22	32099-32100	.	_	

#Text=Although preliminary, the present study probes potential buprenorphine effects on mothers affected by OUD.
154-1	32101-32109	Although	_	
154-2	32110-32121	preliminary	_	
154-3	32121-32122	,	_	
154-4	32123-32126	the	_	
154-5	32127-32134	present	_	
154-6	32135-32140	study	_	
154-7	32141-32147	probes	_	
154-8	32148-32157	potential	_	
154-9	32158-32171	buprenorphine	_	
154-10	32172-32179	effects	_	
154-11	32180-32182	on	_	
154-12	32183-32190	mothers	_	
154-13	32191-32199	affected	_	
154-14	32200-32202	by	_	
154-15	32203-32206	OUD	_	
154-16	32206-32207	.	_	

#Text=BT is currently the best practice for pregnant women suffering OUD, despite the potential adverse effects of any exogenous opioids on maternal behaviour.
155-1	32208-32210	BT	_	
155-2	32211-32213	is	_	
155-3	32214-32223	currently	_	
155-4	32224-32227	the	_	
155-5	32228-32232	best	_	
155-6	32233-32241	practice	_	
155-7	32242-32245	for	_	
155-8	32246-32254	pregnant	_	
155-9	32255-32260	women	_	
155-10	32261-32270	suffering	_	
155-11	32271-32274	OUD	_	
155-12	32274-32275	,	_	
155-13	32276-32283	despite	_	
155-14	32284-32287	the	_	
155-15	32288-32297	potential	_	
155-16	32298-32305	adverse	_	
155-17	32306-32313	effects	_	
155-18	32314-32316	of	_	
155-19	32317-32320	any	_	
155-20	32321-32330	exogenous	_	
155-21	32331-32338	opioids	_	
155-22	32339-32341	on	_	
155-23	32342-32350	maternal	_	
155-24	32351-32360	behaviour	_	
155-25	32360-32361	.	_	

#Text=It is therefore important to examine whether buprenorphine treatment for OUD, as a partial mu-opioid agonist and kappa-opioid antagonist, exerts beneficial or harmful effects on maternal brain and behaviour during the postpartum.
156-1	32362-32364	It	_	
156-2	32365-32367	is	_	
156-3	32368-32377	therefore	_	
156-4	32378-32387	important	_	
156-5	32388-32390	to	_	
156-6	32391-32398	examine	_	
156-7	32399-32406	whether	_	
156-8	32407-32420	buprenorphine	_	
156-9	32421-32430	treatment	_	
156-10	32431-32434	for	_	
156-11	32435-32438	OUD	_	
156-12	32438-32439	,	_	
156-13	32440-32442	as	_	
156-14	32443-32444	a	_	
156-15	32445-32452	partial	_	
156-16	32453-32462	mu-opioid	_	
156-17	32463-32470	agonist	_	
156-18	32471-32474	and	_	
156-19	32475-32487	kappa-opioid	_	
156-20	32488-32498	antagonist	_	
156-21	32498-32499	,	_	
156-22	32500-32506	exerts	_	
156-23	32507-32517	beneficial	_	
156-24	32518-32520	or	_	
156-25	32521-32528	harmful	_	
156-26	32529-32536	effects	_	
156-27	32537-32539	on	_	
156-28	32540-32548	maternal	_	
156-29	32549-32554	brain	_	
156-30	32555-32558	and	_	
156-31	32559-32568	behaviour	_	
156-32	32569-32575	during	_	
156-33	32576-32579	the	_	
156-34	32580-32590	postpartum	_	
156-35	32590-32591	.	_	

#Text=On the one hand, our work may have identified a brain mechanism for the potential benefits of buprenorphine treatment with respect to reversing abnormality of maternal brain function and behaviour: the initial group differences in PAG-dependent resting-state functional connectivity had dissipated by 4 months postpartum, perhaps representing postpartum adjustments in this sample of mothers with healthy infants who were receiving ongoing medical care.
157-1	32592-32594	On	_	
157-2	32595-32598	the	_	
157-3	32599-32602	one	_	
157-4	32603-32607	hand	_	
157-5	32607-32608	,	_	
157-6	32609-32612	our	_	
157-7	32613-32617	work	_	
157-8	32618-32621	may	_	
157-9	32622-32626	have	_	
157-10	32627-32637	identified	_	
157-11	32638-32639	a	_	
157-12	32640-32645	brain	_	
157-13	32646-32655	mechanism	_	
157-14	32656-32659	for	_	
157-15	32660-32663	the	_	
157-16	32664-32673	potential	_	
157-17	32674-32682	benefits	_	
157-18	32683-32685	of	_	
157-19	32686-32699	buprenorphine	_	
157-20	32700-32709	treatment	_	
157-21	32710-32714	with	_	
157-22	32715-32722	respect	_	
157-23	32723-32725	to	_	
157-24	32726-32735	reversing	_	
157-25	32736-32747	abnormality	_	
157-26	32748-32750	of	_	
157-27	32751-32759	maternal	_	
157-28	32760-32765	brain	_	
157-29	32766-32774	function	_	
157-30	32775-32778	and	_	
157-31	32779-32788	behaviour	_	
157-32	32788-32789	:	_	
157-33	32790-32793	the	_	
157-34	32794-32801	initial	_	
157-35	32802-32807	group	_	
157-36	32808-32819	differences	_	
157-37	32820-32822	in	_	
157-38	32823-32836	PAG-dependent	_	
157-39	32837-32850	resting-state	_	
157-40	32851-32861	functional	_	
157-41	32862-32874	connectivity	_	
157-42	32875-32878	had	_	
157-43	32879-32889	dissipated	_	
157-44	32890-32892	by	_	
157-45	32893-32894	4	_	
157-46	32895-32901	months	_	
157-47	32902-32912	postpartum	_	
157-48	32912-32913	,	_	
157-49	32914-32921	perhaps	_	
157-50	32922-32934	representing	_	
157-51	32935-32945	postpartum	_	
157-52	32946-32957	adjustments	_	
157-53	32958-32960	in	_	
157-54	32961-32965	this	_	
157-55	32966-32972	sample	_	
157-56	32973-32975	of	_	
157-57	32976-32983	mothers	_	
157-58	32984-32988	with	_	
157-59	32989-32996	healthy	_	
157-60	32997-33004	infants	_	
157-61	33005-33008	who	_	
157-62	33009-33013	were	_	
157-63	33014-33023	receiving	_	
157-64	33024-33031	ongoing	_	
157-65	33032-33039	medical	_	
157-66	33040-33044	care	_	
157-67	33044-33045	.	_	

#Text=On the other hand, our work may have identified a potential link between excessive PAG-hypothalamus functional connectivity and bonding impairments, for which the effects of buprenorphine remain undetermined.
158-1	33046-33048	On	_	
158-2	33049-33052	the	_	
158-3	33053-33058	other	_	
158-4	33059-33063	hand	_	
158-5	33063-33064	,	_	
158-6	33065-33068	our	_	
158-7	33069-33073	work	_	
158-8	33074-33077	may	_	
158-9	33078-33082	have	_	
158-10	33083-33093	identified	_	
158-11	33094-33095	a	_	
158-12	33096-33105	potential	_	
158-13	33106-33110	link	_	
158-14	33111-33118	between	_	
158-15	33119-33128	excessive	_	
158-16	33129-33145	PAG-hypothalamus	_	
158-17	33146-33156	functional	_	
158-18	33157-33169	connectivity	_	
158-19	33170-33173	and	_	
158-20	33174-33181	bonding	_	
158-21	33182-33193	impairments	_	
158-22	33193-33194	,	_	
158-23	33195-33198	for	_	
158-24	33199-33204	which	_	
158-25	33205-33208	the	_	
158-26	33209-33216	effects	_	
158-27	33217-33219	of	_	
158-28	33220-33233	buprenorphine	_	
158-29	33234-33240	remain	_	
158-30	33241-33253	undetermined	_	
158-31	33253-33254	.	_	

#Text=In the future, this work may be combined with brain models of other conditions that interfere with parenting, such as parental stress, poverty, anxiety and postpartum depression, as well as potential brain mechanisms at work in parenting interventions, to inform and optimise comprehensive interventions for BT mothers and fathers and identify the potential links between parental brain function and child outcomes.
159-1	33255-33257	In	_	
159-2	33258-33261	the	_	
159-3	33262-33268	future	_	
159-4	33268-33269	,	_	
159-5	33270-33274	this	_	
159-6	33275-33279	work	_	
159-7	33280-33283	may	_	
159-8	33284-33286	be	_	
159-9	33287-33295	combined	_	
159-10	33296-33300	with	_	
159-11	33301-33306	brain	_	
159-12	33307-33313	models	_	
159-13	33314-33316	of	_	
159-14	33317-33322	other	_	
159-15	33323-33333	conditions	_	
159-16	33334-33338	that	_	
159-17	33339-33348	interfere	_	
159-18	33349-33353	with	_	
159-19	33354-33363	parenting	_	
159-20	33363-33364	,	_	
159-21	33365-33369	such	_	
159-22	33370-33372	as	_	
159-23	33373-33381	parental	_	
159-24	33382-33388	stress	_	
159-25	33388-33389	,	_	
159-26	33390-33397	poverty	_	
159-27	33397-33398	,	_	
159-28	33399-33406	anxiety	_	
159-29	33407-33410	and	_	
159-30	33411-33421	postpartum	_	
159-31	33422-33432	depression	_	
159-32	33432-33433	,	_	
159-33	33434-33436	as	_	
159-34	33437-33441	well	_	
159-35	33442-33444	as	_	
159-36	33445-33454	potential	_	
159-37	33455-33460	brain	_	
159-38	33461-33471	mechanisms	_	
159-39	33472-33474	at	_	
159-40	33475-33479	work	_	
159-41	33480-33482	in	_	
159-42	33483-33492	parenting	_	
159-43	33493-33506	interventions	_	
159-44	33506-33507	,	_	
159-45	33508-33510	to	_	
159-46	33511-33517	inform	_	
159-47	33518-33521	and	_	
159-48	33522-33530	optimise	_	
159-49	33531-33544	comprehensive	_	
159-50	33545-33558	interventions	_	
159-51	33559-33562	for	_	
159-52	33563-33565	BT	_	
159-53	33566-33573	mothers	_	
159-54	33574-33577	and	_	
159-55	33578-33585	fathers	_	
159-56	33586-33589	and	_	
159-57	33590-33598	identify	_	
159-58	33599-33602	the	_	
159-59	33603-33612	potential	_	
159-60	33613-33618	links	_	
159-61	33619-33626	between	_	
159-62	33627-33635	parental	_	
159-63	33636-33641	brain	_	
159-64	33642-33650	function	_	
159-65	33651-33654	and	_	
159-66	33655-33660	child	_	
159-67	33661-33669	outcomes	_	
159-68	33669-33670	.	_	

#Text=In sum, our preliminary work calls for more attention to PAG-dependent functional connectivity in the MBN as a possible brain mechanism for better assessing opioid-sensitive parental brain functions in the context of parenting behaviours and parent-child bonding.
160-1	33671-33673	In	_	
160-2	33674-33677	sum	_	
160-3	33677-33678	,	_	
160-4	33679-33682	our	_	
160-5	33683-33694	preliminary	_	
160-6	33695-33699	work	_	
160-7	33700-33705	calls	_	
160-8	33706-33709	for	_	
160-9	33710-33714	more	_	
160-10	33715-33724	attention	_	
160-11	33725-33727	to	_	
160-12	33728-33741	PAG-dependent	_	
160-13	33742-33752	functional	_	
160-14	33753-33765	connectivity	_	
160-15	33766-33768	in	_	
160-16	33769-33772	the	_	
160-17	33773-33776	MBN	_	
160-18	33777-33779	as	_	
160-19	33780-33781	a	_	
160-20	33782-33790	possible	_	
160-21	33791-33796	brain	_	
160-22	33797-33806	mechanism	_	
160-23	33807-33810	for	_	
160-24	33811-33817	better	_	
160-25	33818-33827	assessing	_	
160-26	33828-33844	opioid-sensitive	_	
160-27	33845-33853	parental	_	
160-28	33854-33859	brain	_	
160-29	33860-33869	functions	_	
160-30	33870-33872	in	_	
160-31	33873-33876	the	_	
160-32	33877-33884	context	_	
160-33	33885-33887	of	_	
160-34	33888-33897	parenting	_	
160-35	33898-33908	behaviours	_	
160-36	33909-33912	and	_	
160-37	33913-33925	parent-child	_	
160-38	33926-33933	bonding	_	
160-39	33933-33934	.	_	

#Text=CONFLICT OF INTERESTS
#Text=The authors declare that have no conflicts of interest.
161-1	33935-33943	CONFLICT	_	
161-2	33944-33946	OF	_	
161-3	33947-33956	INTERESTS	_	
161-4	33957-33960	The	_	
161-5	33961-33968	authors	_	
161-6	33969-33976	declare	_	
161-7	33977-33981	that	_	
161-8	33982-33986	have	_	
161-9	33987-33989	no	_	
161-10	33990-33999	conflicts	_	
161-11	34000-34002	of	_	
161-12	34003-34011	interest	_	
161-13	34011-34012	.	_	

#Text=DATA AVAILABILITY STATEMENT
#Text=The data that support the findings of this study are available from the corresponding author upon reasonable request.
162-1	34013-34017	DATA	_	
162-2	34018-34030	AVAILABILITY	_	
162-3	34031-34040	STATEMENT	_	
162-4	34041-34044	The	_	
162-5	34045-34049	data	_	
162-6	34050-34054	that	_	
162-7	34055-34062	support	_	
162-8	34063-34066	the	_	
162-9	34067-34075	findings	_	
162-10	34076-34078	of	_	
162-11	34079-34083	this	_	
162-12	34084-34089	study	_	
162-13	34090-34093	are	_	
162-14	34094-34103	available	_	
162-15	34104-34108	from	_	
162-16	34109-34112	the	_	
162-17	34113-34126	corresponding	_	
162-18	34127-34133	author	_	
162-19	34134-34138	upon	_	
162-20	34139-34149	reasonable	_	
162-21	34150-34157	request	_	
162-22	34157-34158	.	_	

#Text=REFERENCES
#Text=Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic
#Text=Opioid use disorder documented at delivery hospitalization – United States, 1999– 2014
#Text=
#Text=Buprenorphine: a new player in neonatal withdrawal syndrome
#Text=Factors associated with buprenorphine versus methadone use in pregnancy
#Text=Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child
#Text=Opioid dependence and pregnancy: minimizing stress on the fetal brain
#Text=Medicaid coverage of methadone maintenance and the use of opioid agonist therapy among pregnant women in specialty treatment
#Text=Opioid dependence during pregnancy.
163-1	34159-34169	REFERENCES	_	
163-2	34170-34176	Opioid	_	
163-3	34177-34180	use	_	
163-4	34181-34189	disorder	_	
163-5	34190-34192	in	_	
163-6	34193-34202	pregnancy	_	
163-7	34202-34203	:	_	
163-8	34204-34210	health	_	
163-9	34211-34217	policy	_	
163-10	34218-34221	and	_	
163-11	34222-34230	practice	_	
163-12	34231-34233	in	_	
163-13	34234-34237	the	_	
163-14	34238-34243	midst	_	
163-15	34244-34246	of	_	
163-16	34247-34249	an	_	
163-17	34250-34258	epidemic	_	
163-18	34259-34265	Opioid	_	
163-19	34266-34269	use	_	
163-20	34270-34278	disorder	_	
163-21	34279-34289	documented	_	
163-22	34290-34292	at	_	
163-23	34293-34301	delivery	_	
163-24	34302-34317	hospitalization	_	
163-25	34318-34319	–	_	
163-26	34320-34326	United	_	
163-27	34327-34333	States	_	
163-28	34333-34334	,	_	
163-29	34335-34339	1999	_	
163-30	34339-34340	–	_	
163-31	34341-34345	2014	_	
163-32	34347-34360	Buprenorphine	_	
163-33	34360-34361	:	_	
163-34	34362-34363	a	_	
163-35	34364-34367	new	_	
163-36	34368-34374	player	_	
163-37	34375-34377	in	_	
163-38	34378-34386	neonatal	_	
163-39	34387-34397	withdrawal	_	
163-40	34398-34406	syndrome	_	
163-41	34407-34414	Factors	_	
163-42	34415-34425	associated	_	
163-43	34426-34430	with	_	
163-44	34431-34444	buprenorphine	_	
163-45	34445-34451	versus	_	
163-46	34452-34461	methadone	_	
163-47	34462-34465	use	_	
163-48	34466-34468	in	_	
163-49	34469-34478	pregnancy	_	
163-50	34479-34492	Buprenorphine	_	
163-51	34493-34501	compared	_	
163-52	34502-34506	with	_	
163-53	34507-34516	methadone	_	
163-54	34517-34519	to	_	
163-55	34520-34525	treat	_	
163-56	34526-34534	pregnant	_	
163-57	34535-34540	women	_	
163-58	34541-34545	with	_	
163-59	34546-34552	opioid	_	
163-60	34553-34556	use	_	
163-61	34557-34565	disorder	_	
163-62	34565-34566	:	_	
163-63	34567-34568	a	_	
163-64	34569-34579	systematic	_	
163-65	34580-34586	review	_	
163-66	34587-34590	and	_	
163-67	34591-34604	meta-analysis	_	
163-68	34605-34607	of	_	
163-69	34608-34614	safety	_	
163-70	34615-34617	in	_	
163-71	34618-34621	the	_	
163-72	34622-34628	mother	_	
163-73	34628-34629	,	_	
163-74	34630-34635	fetus	_	
163-75	34636-34639	and	_	
163-76	34640-34645	child	_	
163-77	34646-34652	Opioid	_	
163-78	34653-34663	dependence	_	
163-79	34664-34667	and	_	
163-80	34668-34677	pregnancy	_	
163-81	34677-34678	:	_	
163-82	34679-34689	minimizing	_	
163-83	34690-34696	stress	_	
163-84	34697-34699	on	_	
163-85	34700-34703	the	_	
163-86	34704-34709	fetal	_	
163-87	34710-34715	brain	_	
163-88	34716-34724	Medicaid	_	
163-89	34725-34733	coverage	_	
163-90	34734-34736	of	_	
163-91	34737-34746	methadone	_	
163-92	34747-34758	maintenance	_	
163-93	34759-34762	and	_	
163-94	34763-34766	the	_	
163-95	34767-34770	use	_	
163-96	34771-34773	of	_	
163-97	34774-34780	opioid	_	
163-98	34781-34788	agonist	_	
163-99	34789-34796	therapy	_	
163-100	34797-34802	among	_	
163-101	34803-34811	pregnant	_	
163-102	34812-34817	women	_	
163-103	34818-34820	in	_	
163-104	34821-34830	specialty	_	
163-105	34831-34840	treatment	_	
163-106	34841-34847	Opioid	_	
163-107	34848-34858	dependence	_	
163-108	34859-34865	during	_	
163-109	34866-34875	pregnancy	_	
163-110	34875-34876	.	_	

#Text=Effects and management
#Text=Buprenorphine during pregnancy reduces neonate distress
#Text=Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series
#Text=Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy
#Text=Methadone and buprenorphine for opioid dependence during pregnancy: a retro-spective cohort study
#Text=Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates
#Text=A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome
#Text=Neonatal abstinence syndrome: twelve years of experience at a regional re-ferral center
#Text=Methadone versus buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome
#Text=Prenatal buprenorphine versus methadone exposure and neonatal out-comes: systematic review and meta-analysis
#Text=Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes
#Text=Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review
#Text=Methadone and perinatal outcomes: a retrospective cohort study
#Text=Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?
164-1	34877-34884	Effects	_	
164-2	34885-34888	and	_	
164-3	34889-34899	management	_	
164-4	34900-34913	Buprenorphine	_	
164-5	34914-34920	during	_	
164-6	34921-34930	pregnancy	_	
164-7	34931-34938	reduces	_	
164-8	34939-34946	neonate	_	
164-9	34947-34955	distress	_	
164-10	34956-34969	Buprenorphine	_	
164-11	34970-34973	and	_	
164-12	34974-34983	methadone	_	
164-13	34984-34993	treatment	_	
164-14	34994-34996	of	_	
164-15	34997-35003	opiate	_	
164-16	35004-35014	dependence	_	
164-17	35015-35021	during	_	
164-18	35022-35031	pregnancy	_	
164-19	35031-35032	:	_	
164-20	35033-35043	comparison	_	
164-21	35044-35046	of	_	
164-22	35047-35052	fetal	_	
164-23	35053-35059	growth	_	
164-24	35060-35063	and	_	
164-25	35064-35072	neonatal	_	
164-26	35073-35081	outcomes	_	
164-27	35082-35084	in	_	
164-28	35085-35088	two	_	
164-29	35089-35100	consecutive	_	
164-30	35101-35105	case	_	
164-31	35106-35112	series	_	
164-32	35113-35126	Transitioning	_	
164-33	35127-35131	from	_	
164-34	35132-35141	methadone	_	
164-35	35142-35144	to	_	
164-36	35145-35158	buprenorphine	_	
164-37	35159-35170	maintenance	_	
164-38	35171-35173	in	_	
164-39	35174-35184	management	_	
164-40	35185-35187	of	_	
164-41	35188-35194	opioid	_	
164-42	35195-35198	use	_	
164-43	35199-35207	disorder	_	
164-44	35208-35214	during	_	
164-45	35215-35224	pregnancy	_	
164-46	35225-35234	Methadone	_	
164-47	35235-35238	and	_	
164-48	35239-35252	buprenorphine	_	
164-49	35253-35256	for	_	
164-50	35257-35263	opioid	_	
164-51	35264-35274	dependence	_	
164-52	35275-35281	during	_	
164-53	35282-35291	pregnancy	_	
164-54	35291-35292	:	_	
164-55	35293-35294	a	_	
164-56	35295-35309	retro-spective	_	
164-57	35310-35316	cohort	_	
164-58	35317-35322	study	_	
164-59	35323-35334	Differences	_	
164-60	35335-35337	in	_	
164-61	35338-35341	the	_	
164-62	35342-35349	profile	_	
164-63	35350-35352	of	_	
164-64	35353-35361	neonatal	_	
164-65	35362-35372	abstinence	_	
164-66	35373-35381	syndrome	_	
164-67	35382-35387	signs	_	
164-68	35388-35390	in	_	
164-69	35391-35400	methadone	_	
164-70	35400-35401	-	_	
164-71	35402-35408	versus	_	
164-72	35409-35430	buprenorphine-exposed	_	
164-73	35431-35439	neonates	_	
164-74	35440-35441	A	_	
164-75	35442-35448	cohort	_	
164-76	35449-35459	comparison	_	
164-77	35460-35462	of	_	
164-78	35463-35476	buprenorphine	_	
164-79	35477-35483	versus	_	
164-80	35484-35493	methadone	_	
164-81	35494-35503	treatment	_	
164-82	35504-35507	for	_	
164-83	35508-35516	neonatal	_	
164-84	35517-35527	abstinence	_	
164-85	35528-35536	syndrome	_	
164-86	35537-35545	Neonatal	_	
164-87	35546-35556	abstinence	_	
164-88	35557-35565	syndrome	_	
164-89	35565-35566	:	_	
164-90	35567-35573	twelve	_	
164-91	35574-35579	years	_	
164-92	35580-35582	of	_	
164-93	35583-35593	experience	_	
164-94	35594-35596	at	_	
164-95	35597-35598	a	_	
164-96	35599-35607	regional	_	
164-97	35608-35617	re-ferral	_	
164-98	35618-35624	center	_	
164-99	35625-35634	Methadone	_	
164-100	35635-35641	versus	_	
164-101	35642-35655	buprenorphine	_	
164-102	35656-35659	for	_	
164-103	35660-35666	opioid	_	
164-104	35667-35670	use	_	
164-105	35671-35681	dependence	_	
164-106	35682-35685	and	_	
164-107	35686-35690	risk	_	
164-108	35691-35693	of	_	
164-109	35694-35702	neonatal	_	
164-110	35703-35713	abstinence	_	
164-111	35714-35722	syndrome	_	
164-112	35723-35731	Prenatal	_	
164-113	35732-35745	buprenorphine	_	
164-114	35746-35752	versus	_	
164-115	35753-35762	methadone	_	
164-116	35763-35771	exposure	_	
164-117	35772-35775	and	_	
164-118	35776-35784	neonatal	_	
164-119	35785-35794	out-comes	_	
164-120	35794-35795	:	_	
164-121	35796-35806	systematic	_	
164-122	35807-35813	review	_	
164-123	35814-35817	and	_	
164-124	35818-35831	meta-analysis	_	
164-125	35832-35841	Comparing	_	
164-126	35842-35851	methadone	_	
164-127	35852-35855	and	_	
164-128	35856-35869	buprenorphine	_	
164-129	35870-35881	maintenance	_	
164-130	35882-35886	with	_	
164-131	35887-35905	methadone-assisted	_	
164-132	35906-35916	withdrawal	_	
164-133	35917-35920	for	_	
164-134	35921-35924	the	_	
164-135	35925-35934	treatment	_	
164-136	35935-35937	of	_	
164-137	35938-35944	opioid	_	
164-138	35945-35955	dependence	_	
164-139	35956-35962	during	_	
164-140	35963-35972	pregnancy	_	
164-141	35972-35973	:	_	
164-142	35974-35982	maternal	_	
164-143	35983-35986	and	_	
164-144	35987-35995	neonatal	_	
164-145	35996-36004	outcomes	_	
164-146	36005-36018	Buprenorphine	_	
164-147	36019-36028	treatment	_	
164-148	36029-36031	of	_	
164-149	36032-36048	opioid-dependent	_	
164-150	36049-36057	pregnant	_	
164-151	36058-36063	women	_	
164-152	36063-36064	:	_	
164-153	36065-36066	a	_	
164-154	36067-36080	comprehensive	_	
164-155	36081-36087	review	_	
164-156	36088-36097	Methadone	_	
164-157	36098-36101	and	_	
164-158	36102-36111	perinatal	_	
164-159	36112-36120	outcomes	_	
164-160	36120-36121	:	_	
164-161	36122-36123	a	_	
164-162	36124-36137	retrospective	_	
164-163	36138-36144	cohort	_	
164-164	36145-36150	study	_	
164-165	36151-36154	Are	_	
164-166	36155-36159	male	_	
164-167	36160-36168	neonates	_	
164-168	36169-36173	more	_	
164-169	36174-36184	vulnerable	_	
164-170	36185-36187	to	_	
164-171	36188-36196	neonatal	_	
164-172	36197-36207	abstinence	_	
164-173	36208-36216	syndrome	_	
164-174	36217-36221	than	_	
164-175	36222-36228	female	_	
164-176	36229-36237	neonates	_	
164-177	36237-36238	?	_	

#Text=Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study
#Text=Buprenorphine withdrawal syndrome in newborns: a report of 13 cases
#Text=Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy
#Text=Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome
#Text=Neonatal abstinence syndrome after methadone or buprenorphine exposure
#Text=An overview of available drugs for management of opioid abuse during pregnancy
#Text=Biopsychosocial determinants of opioid use disorder (OUD) and implications for maternal and child health research: a scoping review
#Text=Mothers with substance addictions show reduced reward responses when viewing their own infant’s face
#Text=Effects of opioids on the parental brain in health and disease
#Text=Preventing child abuse and neglect with parent training: evidence and opportunities
#Text=Parental substance use disorders and child maltreatment: overlap, gaps, and opportunities
#Text=Repeated morphine administration during pregnancy attenuates maternal behavior
#Text=Reversal of morphine disruption of maternal behavior by concurrent treatment with the opiate antagonist naloxone
#Text=Opiate regulation of maternal behavior in the rat
#Text=Opioid receptor subtype involvement in maternal behavior in lactating rats
#Text=Disruption of ongoing maternal responsiveness in rats by central administration of morphine sulfate
#Text=Opiate disruption of maternal behavior: morphine reduces, and naloxone restores, c-fos activity in the medial preoptic area of lactating rats
#Text=A role for the periaqueductal gray in switching adaptive behavioral responses
#Text=Periaqueductal gray mu and kappa opioid receptors determine behavioral selection from maternal to predatory behavior in lactating rats
#Text=Bimodal classification of aggression: affective defense and predatory attack
#Text=Neural mechanisms of mother-infant bonding and pair bonding: similarities, differences, and broader implications
#Text=A neural circuitry analysis of maternal behavior in the rat
#Text=Motivational systems and the neural circuitry of maternal behavior in the rat
#Text=Hypothalamic neural circuits regulating maternal responsiveness toward infants
#Text=Neuroanatomical circuitry for mammalian maternal behavior
#Text=Maternity: neural mechanisms, motivational processes, and physiological adaptations
#Text=Projection sites of medial preoptic area and ventral bed nucleus of the stria terminalis neurons that express Fos during maternal behavior in female rats
#Text=A functional neuroanatomical investigation of the role of the medial preoptic area in neural circuits regulating maternal behavior
#Text=Neuroendocrine mechanisms for parental sensitivity: overview, recent advances and future directions
#Text=Neurobiology of culturally common maternal responses to infant cry
#Text=The maternal brain and its plasticity in humans
#Text=The neurobiology of mammalian parenting and the bio-social context of human caregiving
#Text=Neural correlates of hypothalamic-pituitary-adrenal regulation of mothers with their infants
#Text=Right frontoinsular cortex and subcortical activity to infant cry is associated with maternal mental state talk
#Text=The development of parent-infant attachment through dynamic and interactive signaling loops of care and cry
#Text=Attachment in the brain: adult attachment representations predict amygdala and behavioral responses to infant crying
#Text=No laughing matter: intranasal oxytocin administration changes functional brain connectivity during exposure to infant laughter
#Text=Intranasal administration of oxytocin modulates behavioral and amygdala responses to infant crying in females with insecure attachment representations
#Text=Natural variation in maternal sensitivity is reflected in maternal brain responses to infant stimuli
#Text=Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial
#Text=Neuroendocrinology of parental response to baby-cry
#Text=Adult attachment predicts maternal brain and oxytocin response to infant cues
#Text=Empathy and stress related neural responses in maternal decision making
#Text=Maternal brain response to own baby-cry is affected by cesarean section delivery
#Text=
#Text=Parenting and addiction: neurobiological insights
#Text=Resting state fMRI: a personal history
#Text=Opportunities and limitations of intrinsic functional connectivity MRI
#Text=What is feasible with imaging human brain function and connectivity using functional magnetic resonance imaging
#Text=Advances and pitfalls in the analysis and interpretation of resting-state FMRI data
#Text=Resting-state brain networks: literature review and clinical applications
#Text=Childhood poverty and stress reactivity are associated with aberrant functional connectivity in default mode network
#Text=Early life social stress and resting state functional connectivity in postpartum rat anterior cingulate circuits
#Text=GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study
#Text=Disrupted posterior cingulate–amygdala connectivity in postpartum depressed women as measured with resting BOLD fMRI
#Text=On the relationship between the “default mode network” and the “social brain”
#Text=Dissociating medial frontal and posterior cingulate activity during self-reflection
#Text=In search of neural endophenotypes of postpartum psychopathology and disrupted maternal caregiving
#Text=The Postpartum Bonding Questionnaire: a validation
#Text=Mother-infant bonding disorders in patients with post-natal depression: the Postpartum Bonding Questionnaire in clinical practice
#Text=Validation and factor analysis of mother-infant bonding questionnaire in pregnant and postpartum women in Japan
#Text=Postpartum bonding disorder: factor structure, validity, reliability and a model comparison of the postnatal bonding questionnaire in Japanese mothers of infants
#Text=The German version of the Postpartum Bonding Instrument: psychometric properties and association with postpartum depression
#Text=Lifetime co-morbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions
#Text=Prescription opioid use among adults with mental health disorders in the United States
#Text=
#Text=Impact of postpartum depressive symptoms on mother and her 18-month-old infant
#Text=Maternal depressive symptoms at 2 to 4 months post partum and early parenting practices
#Text=Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes
#Text=The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature
#Text=Maternal depression and psychiatric outcomes in adolescent offspring: a 13-year longitudinal study
#Text=Maternal depression and child psychopathology: a meta-analytic review
#Text=Association of persistent and severe postnatal depression with child outcomes
#Text=Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity
#Text=A screening questionnaire for mother-infant bonding disorders
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=A fast diffeomorphic image registration algorithm
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Distinct neural signatures detected for ADHD subtypes after controlling for micro-movements in resting state functional connectivity MRI data
#Text=A component based noise correction method (CompCor) for BOLD and perfusion based fMRI
#Text=Anticorrelations in resting state networks without global signal regression
#Text=Connectivity-based segmentation of the periaqueductal gray matter in human with brainstem optimized diffusion MRI
#Text=fMRI functional connectivity of the periaqueductal gray in PTSD and its dissociative subtype
#Text=Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference
#Text=The neural correlates of maternal and romantic love
#Text=The functional neuroanatomy of maternal love: mother’s response to infant’s attachment behaviors
#Text=The orbitofrontal cortex modulates parenting stress in the maternal brain
#Text=Steroidal interactions in the regulation of maternal behaviour in virgin female rats: effects of testosterone, dihydrotestosterone, oestradiol, progesterone and the aromatase inhibitor, 1,4,6-androstatriene-3,17-dione
#Text=Oxytocin-dopamine interactions mediate variations in maternal behavior in the rat
#Text=Early postpartum pup preference is altered by gestational cocaine treatment: associations with infant cues and oxytocin expression in the MPOA
#Text=Maternal neglect with reduced depressive-like behavior and blunted c-fos activation in Brattleboro mothers, the role of central vasopressin
#Text=Variations in maternal behaviour are associated with differences in oxytocin receptor levels in the rat
#Text=A cry in the dark: depressed mothers show reduced neural activation to their own infant’s cry
#Text=The missing link: mothers’ neural response to infant cry related to infant attachment behaviors
#Text=Is there a core neural network in empathy?
165-1	36239-36248	Methadone	_	
165-2	36249-36255	versus	_	
165-3	36256-36269	buprenorphine	_	
165-4	36270-36272	in	_	
165-5	36273-36281	pregnant	_	
165-6	36282-36289	addicts	_	
165-7	36289-36290	:	_	
165-8	36291-36292	a	_	
165-9	36293-36305	double-blind	_	
165-10	36305-36306	,	_	
165-11	36307-36319	double-dummy	_	
165-12	36320-36330	comparison	_	
165-13	36331-36336	study	_	
165-14	36337-36350	Buprenorphine	_	
165-15	36351-36361	withdrawal	_	
165-16	36362-36370	syndrome	_	
165-17	36371-36373	in	_	
165-18	36374-36382	newborns	_	
165-19	36382-36383	:	_	
165-20	36384-36385	a	_	
165-21	36386-36392	report	_	
165-22	36393-36395	of	_	
165-23	36396-36398	13	_	
165-24	36399-36404	cases	_	
165-25	36405-36413	Neonatal	_	
165-26	36414-36421	outcome	_	
165-27	36422-36431	following	_	
165-28	36432-36445	buprenorphine	_	
165-29	36446-36457	maintenance	_	
165-30	36458-36464	during	_	
165-31	36465-36475	conception	_	
165-32	36476-36479	and	_	
165-33	36480-36490	throughout	_	
165-34	36491-36500	pregnancy	_	
165-35	36501-36514	Buprenorphine	_	
165-36	36515-36521	versus	_	
165-37	36522-36531	methadone	_	
165-38	36532-36534	in	_	
165-39	36535-36538	the	_	
165-40	36539-36548	treatment	_	
165-41	36549-36551	of	_	
165-42	36552-36560	pregnant	_	
165-43	36561-36577	opioid-dependent	_	
165-44	36578-36586	patients	_	
165-45	36586-36587	:	_	
165-46	36588-36595	effects	_	
165-47	36596-36598	on	_	
165-48	36599-36602	the	_	
165-49	36603-36611	neonatal	_	
165-50	36612-36622	abstinence	_	
165-51	36623-36631	syndrome	_	
165-52	36632-36640	Neonatal	_	
165-53	36641-36651	abstinence	_	
165-54	36652-36660	syndrome	_	
165-55	36661-36666	after	_	
165-56	36667-36676	methadone	_	
165-57	36677-36679	or	_	
165-58	36680-36693	buprenorphine	_	
165-59	36694-36702	exposure	_	
165-60	36703-36705	An	_	
165-61	36706-36714	overview	_	
165-62	36715-36717	of	_	
165-63	36718-36727	available	_	
165-64	36728-36733	drugs	_	
165-65	36734-36737	for	_	
165-66	36738-36748	management	_	
165-67	36749-36751	of	_	
165-68	36752-36758	opioid	_	
165-69	36759-36764	abuse	_	
165-70	36765-36771	during	_	
165-71	36772-36781	pregnancy	_	
165-72	36782-36797	Biopsychosocial	_	
165-73	36798-36810	determinants	_	
165-74	36811-36813	of	_	
165-75	36814-36820	opioid	_	
165-76	36821-36824	use	_	
165-77	36825-36833	disorder	_	
165-78	36834-36835	(	_	
165-79	36835-36838	OUD	_	
165-80	36838-36839	)	_	
165-81	36840-36843	and	_	
165-82	36844-36856	implications	_	
165-83	36857-36860	for	_	
165-84	36861-36869	maternal	_	
165-85	36870-36873	and	_	
165-86	36874-36879	child	_	
165-87	36880-36886	health	_	
165-88	36887-36895	research	_	
165-89	36895-36896	:	_	
165-90	36897-36898	a	_	
165-91	36899-36906	scoping	_	
165-92	36907-36913	review	_	
165-93	36914-36921	Mothers	_	
165-94	36922-36926	with	_	
165-95	36927-36936	substance	_	
165-96	36937-36947	addictions	_	
165-97	36948-36952	show	_	
165-98	36953-36960	reduced	_	
165-99	36961-36967	reward	_	
165-100	36968-36977	responses	_	
165-101	36978-36982	when	_	
165-102	36983-36990	viewing	_	
165-103	36991-36996	their	_	
165-104	36997-37000	own	_	
165-105	37001-37007	infant	_	
165-106	37007-37008	’	_	
165-107	37008-37009	s	_	
165-108	37010-37014	face	_	
165-109	37015-37022	Effects	_	
165-110	37023-37025	of	_	
165-111	37026-37033	opioids	_	
165-112	37034-37036	on	_	
165-113	37037-37040	the	_	
165-114	37041-37049	parental	_	
165-115	37050-37055	brain	_	
165-116	37056-37058	in	_	
165-117	37059-37065	health	_	
165-118	37066-37069	and	_	
165-119	37070-37077	disease	_	
165-120	37078-37088	Preventing	_	
165-121	37089-37094	child	_	
165-122	37095-37100	abuse	_	
165-123	37101-37104	and	_	
165-124	37105-37112	neglect	_	
165-125	37113-37117	with	_	
165-126	37118-37124	parent	_	
165-127	37125-37133	training	_	
165-128	37133-37134	:	_	
165-129	37135-37143	evidence	_	
165-130	37144-37147	and	_	
165-131	37148-37161	opportunities	_	
165-132	37162-37170	Parental	_	
165-133	37171-37180	substance	_	
165-134	37181-37184	use	_	
165-135	37185-37194	disorders	_	
165-136	37195-37198	and	_	
165-137	37199-37204	child	_	
165-138	37205-37217	maltreatment	_	
165-139	37217-37218	:	_	
165-140	37219-37226	overlap	_	
165-141	37226-37227	,	_	
165-142	37228-37232	gaps	_	
165-143	37232-37233	,	_	
165-144	37234-37237	and	_	
165-145	37238-37251	opportunities	_	
165-146	37252-37260	Repeated	_	
165-147	37261-37269	morphine	_	
165-148	37270-37284	administration	_	
165-149	37285-37291	during	_	
165-150	37292-37301	pregnancy	_	
165-151	37302-37312	attenuates	_	
165-152	37313-37321	maternal	_	
165-153	37322-37330	behavior	_	
165-154	37331-37339	Reversal	_	
165-155	37340-37342	of	_	
165-156	37343-37351	morphine	_	
165-157	37352-37362	disruption	_	
165-158	37363-37365	of	_	
165-159	37366-37374	maternal	_	
165-160	37375-37383	behavior	_	
165-161	37384-37386	by	_	
165-162	37387-37397	concurrent	_	
165-163	37398-37407	treatment	_	
165-164	37408-37412	with	_	
165-165	37413-37416	the	_	
165-166	37417-37423	opiate	_	
165-167	37424-37434	antagonist	_	
165-168	37435-37443	naloxone	_	
165-169	37444-37450	Opiate	_	
165-170	37451-37461	regulation	_	
165-171	37462-37464	of	_	
165-172	37465-37473	maternal	_	
165-173	37474-37482	behavior	_	
165-174	37483-37485	in	_	
165-175	37486-37489	the	_	
165-176	37490-37493	rat	_	
165-177	37494-37500	Opioid	_	
165-178	37501-37509	receptor	_	
165-179	37510-37517	subtype	_	
165-180	37518-37529	involvement	_	
165-181	37530-37532	in	_	
165-182	37533-37541	maternal	_	
165-183	37542-37550	behavior	_	
165-184	37551-37553	in	_	
165-185	37554-37563	lactating	_	
165-186	37564-37568	rats	_	
165-187	37569-37579	Disruption	_	
165-188	37580-37582	of	_	
165-189	37583-37590	ongoing	_	
165-190	37591-37599	maternal	_	
165-191	37600-37614	responsiveness	_	
165-192	37615-37617	in	_	
165-193	37618-37622	rats	_	
165-194	37623-37625	by	_	
165-195	37626-37633	central	_	
165-196	37634-37648	administration	_	
165-197	37649-37651	of	_	
165-198	37652-37660	morphine	_	
165-199	37661-37668	sulfate	_	
165-200	37669-37675	Opiate	_	
165-201	37676-37686	disruption	_	
165-202	37687-37689	of	_	
165-203	37690-37698	maternal	_	
165-204	37699-37707	behavior	_	
165-205	37707-37708	:	_	
165-206	37709-37717	morphine	_	
165-207	37718-37725	reduces	_	
165-208	37725-37726	,	_	
165-209	37727-37730	and	_	
165-210	37731-37739	naloxone	_	
165-211	37740-37748	restores	_	
165-212	37748-37749	,	_	
165-213	37750-37755	c-fos	_	
165-214	37756-37764	activity	_	
165-215	37765-37767	in	_	
165-216	37768-37771	the	_	
165-217	37772-37778	medial	_	
165-218	37779-37787	preoptic	_	
165-219	37788-37792	area	_	
165-220	37793-37795	of	_	
165-221	37796-37805	lactating	_	
165-222	37806-37810	rats	_	
165-223	37811-37812	A	_	
165-224	37813-37817	role	_	
165-225	37818-37821	for	_	
165-226	37822-37825	the	_	
165-227	37826-37840	periaqueductal	_	
165-228	37841-37845	gray	_	
165-229	37846-37848	in	_	
165-230	37849-37858	switching	_	
165-231	37859-37867	adaptive	_	
165-232	37868-37878	behavioral	_	
165-233	37879-37888	responses	_	
165-234	37889-37903	Periaqueductal	_	
165-235	37904-37908	gray	_	
165-236	37909-37911	mu	_	
165-237	37912-37915	and	_	
165-238	37916-37921	kappa	_	
165-239	37922-37928	opioid	_	
165-240	37929-37938	receptors	_	
165-241	37939-37948	determine	_	
165-242	37949-37959	behavioral	_	
165-243	37960-37969	selection	_	
165-244	37970-37974	from	_	
165-245	37975-37983	maternal	_	
165-246	37984-37986	to	_	
165-247	37987-37996	predatory	_	
165-248	37997-38005	behavior	_	
165-249	38006-38008	in	_	
165-250	38009-38018	lactating	_	
165-251	38019-38023	rats	_	
165-252	38024-38031	Bimodal	_	
165-253	38032-38046	classification	_	
165-254	38047-38049	of	_	
165-255	38050-38060	aggression	_	
165-256	38060-38061	:	_	
165-257	38062-38071	affective	_	
165-258	38072-38079	defense	_	
165-259	38080-38083	and	_	
165-260	38084-38093	predatory	_	
165-261	38094-38100	attack	_	
165-262	38101-38107	Neural	_	
165-263	38108-38118	mechanisms	_	
165-264	38119-38121	of	_	
165-265	38122-38135	mother-infant	_	
165-266	38136-38143	bonding	_	
165-267	38144-38147	and	_	
165-268	38148-38152	pair	_	
165-269	38153-38160	bonding	_	
165-270	38160-38161	:	_	
165-271	38162-38174	similarities	_	
165-272	38174-38175	,	_	
165-273	38176-38187	differences	_	
165-274	38187-38188	,	_	
165-275	38189-38192	and	_	
165-276	38193-38200	broader	_	
165-277	38201-38213	implications	_	
165-278	38214-38215	A	_	
165-279	38216-38222	neural	_	
165-280	38223-38232	circuitry	_	
165-281	38233-38241	analysis	_	
165-282	38242-38244	of	_	
165-283	38245-38253	maternal	_	
165-284	38254-38262	behavior	_	
165-285	38263-38265	in	_	
165-286	38266-38269	the	_	
165-287	38270-38273	rat	_	
165-288	38274-38286	Motivational	_	
165-289	38287-38294	systems	_	
165-290	38295-38298	and	_	
165-291	38299-38302	the	_	
165-292	38303-38309	neural	_	
165-293	38310-38319	circuitry	_	
165-294	38320-38322	of	_	
165-295	38323-38331	maternal	_	
165-296	38332-38340	behavior	_	
165-297	38341-38343	in	_	
165-298	38344-38347	the	_	
165-299	38348-38351	rat	_	
165-300	38352-38364	Hypothalamic	_	
165-301	38365-38371	neural	_	
165-302	38372-38380	circuits	_	
165-303	38381-38391	regulating	_	
165-304	38392-38400	maternal	_	
165-305	38401-38415	responsiveness	_	
165-306	38416-38422	toward	_	
165-307	38423-38430	infants	_	
165-308	38431-38446	Neuroanatomical	_	
165-309	38447-38456	circuitry	_	
165-310	38457-38460	for	_	
165-311	38461-38470	mammalian	_	
165-312	38471-38479	maternal	_	
165-313	38480-38488	behavior	_	
165-314	38489-38498	Maternity	_	
165-315	38498-38499	:	_	
165-316	38500-38506	neural	_	
165-317	38507-38517	mechanisms	_	
165-318	38517-38518	,	_	
165-319	38519-38531	motivational	_	
165-320	38532-38541	processes	_	
165-321	38541-38542	,	_	
165-322	38543-38546	and	_	
165-323	38547-38560	physiological	_	
165-324	38561-38572	adaptations	_	
165-325	38573-38583	Projection	_	
165-326	38584-38589	sites	_	
165-327	38590-38592	of	_	
165-328	38593-38599	medial	_	
165-329	38600-38608	preoptic	_	
165-330	38609-38613	area	_	
165-331	38614-38617	and	_	
165-332	38618-38625	ventral	_	
165-333	38626-38629	bed	_	
165-334	38630-38637	nucleus	_	
165-335	38638-38640	of	_	
165-336	38641-38644	the	_	
165-337	38645-38650	stria	_	
165-338	38651-38661	terminalis	_	
165-339	38662-38669	neurons	_	
165-340	38670-38674	that	_	
165-341	38675-38682	express	_	
165-342	38683-38686	Fos	_	
165-343	38687-38693	during	_	
165-344	38694-38702	maternal	_	
165-345	38703-38711	behavior	_	
165-346	38712-38714	in	_	
165-347	38715-38721	female	_	
165-348	38722-38726	rats	_	
165-349	38727-38728	A	_	
165-350	38729-38739	functional	_	
165-351	38740-38755	neuroanatomical	_	
165-352	38756-38769	investigation	_	
165-353	38770-38772	of	_	
165-354	38773-38776	the	_	
165-355	38777-38781	role	_	
165-356	38782-38784	of	_	
165-357	38785-38788	the	_	
165-358	38789-38795	medial	_	
165-359	38796-38804	preoptic	_	
165-360	38805-38809	area	_	
165-361	38810-38812	in	_	
165-362	38813-38819	neural	_	
165-363	38820-38828	circuits	_	
165-364	38829-38839	regulating	_	
165-365	38840-38848	maternal	_	
165-366	38849-38857	behavior	_	
165-367	38858-38872	Neuroendocrine	_	
165-368	38873-38883	mechanisms	_	
165-369	38884-38887	for	_	
165-370	38888-38896	parental	_	
165-371	38897-38908	sensitivity	_	
165-372	38908-38909	:	_	
165-373	38910-38918	overview	_	
165-374	38918-38919	,	_	
165-375	38920-38926	recent	_	
165-376	38927-38935	advances	_	
165-377	38936-38939	and	_	
165-378	38940-38946	future	_	
165-379	38947-38957	directions	_	
165-380	38958-38970	Neurobiology	_	
165-381	38971-38973	of	_	
165-382	38974-38984	culturally	_	
165-383	38985-38991	common	_	
165-384	38992-39000	maternal	_	
165-385	39001-39010	responses	_	
165-386	39011-39013	to	_	
165-387	39014-39020	infant	_	
165-388	39021-39024	cry	_	
165-389	39025-39028	The	_	
165-390	39029-39037	maternal	_	
165-391	39038-39043	brain	_	
165-392	39044-39047	and	_	
165-393	39048-39051	its	_	
165-394	39052-39062	plasticity	_	
165-395	39063-39065	in	_	
165-396	39066-39072	humans	_	
165-397	39073-39076	The	_	
165-398	39077-39089	neurobiology	_	
165-399	39090-39092	of	_	
165-400	39093-39102	mammalian	_	
165-401	39103-39112	parenting	_	
165-402	39113-39116	and	_	
165-403	39117-39120	the	_	
165-404	39121-39131	bio-social	_	
165-405	39132-39139	context	_	
165-406	39140-39142	of	_	
165-407	39143-39148	human	_	
165-408	39149-39159	caregiving	_	
165-409	39160-39166	Neural	_	
165-410	39167-39177	correlates	_	
165-411	39178-39180	of	_	
165-412	39181-39211	hypothalamic-pituitary-adrenal	_	
165-413	39212-39222	regulation	_	
165-414	39223-39225	of	_	
165-415	39226-39233	mothers	_	
165-416	39234-39238	with	_	
165-417	39239-39244	their	_	
165-418	39245-39252	infants	_	
165-419	39253-39258	Right	_	
165-420	39259-39272	frontoinsular	_	
165-421	39273-39279	cortex	_	
165-422	39280-39283	and	_	
165-423	39284-39295	subcortical	_	
165-424	39296-39304	activity	_	
165-425	39305-39307	to	_	
165-426	39308-39314	infant	_	
165-427	39315-39318	cry	_	
165-428	39319-39321	is	_	
165-429	39322-39332	associated	_	
165-430	39333-39337	with	_	
165-431	39338-39346	maternal	_	
165-432	39347-39353	mental	_	
165-433	39354-39359	state	_	
165-434	39360-39364	talk	_	
165-435	39365-39368	The	_	
165-436	39369-39380	development	_	
165-437	39381-39383	of	_	
165-438	39384-39397	parent-infant	_	
165-439	39398-39408	attachment	_	
165-440	39409-39416	through	_	
165-441	39417-39424	dynamic	_	
165-442	39425-39428	and	_	
165-443	39429-39440	interactive	_	
165-444	39441-39450	signaling	_	
165-445	39451-39456	loops	_	
165-446	39457-39459	of	_	
165-447	39460-39464	care	_	
165-448	39465-39468	and	_	
165-449	39469-39472	cry	_	
165-450	39473-39483	Attachment	_	
165-451	39484-39486	in	_	
165-452	39487-39490	the	_	
165-453	39491-39496	brain	_	
165-454	39496-39497	:	_	
165-455	39498-39503	adult	_	
165-456	39504-39514	attachment	_	
165-457	39515-39530	representations	_	
165-458	39531-39538	predict	_	
165-459	39539-39547	amygdala	_	
165-460	39548-39551	and	_	
165-461	39552-39562	behavioral	_	
165-462	39563-39572	responses	_	
165-463	39573-39575	to	_	
165-464	39576-39582	infant	_	
165-465	39583-39589	crying	_	
165-466	39590-39592	No	_	
165-467	39593-39601	laughing	_	
165-468	39602-39608	matter	_	
165-469	39608-39609	:	_	
165-470	39610-39620	intranasal	_	
165-471	39621-39629	oxytocin	_	
165-472	39630-39644	administration	_	
165-473	39645-39652	changes	_	
165-474	39653-39663	functional	_	
165-475	39664-39669	brain	_	
165-476	39670-39682	connectivity	_	
165-477	39683-39689	during	_	
165-478	39690-39698	exposure	_	
165-479	39699-39701	to	_	
165-480	39702-39708	infant	_	
165-481	39709-39717	laughter	_	
165-482	39718-39728	Intranasal	_	
165-483	39729-39743	administration	_	
165-484	39744-39746	of	_	
165-485	39747-39755	oxytocin	_	
165-486	39756-39765	modulates	_	
165-487	39766-39776	behavioral	_	
165-488	39777-39780	and	_	
165-489	39781-39789	amygdala	_	
165-490	39790-39799	responses	_	
165-491	39800-39802	to	_	
165-492	39803-39809	infant	_	
165-493	39810-39816	crying	_	
165-494	39817-39819	in	_	
165-495	39820-39827	females	_	
165-496	39828-39832	with	_	
165-497	39833-39841	insecure	_	
165-498	39842-39852	attachment	_	
165-499	39853-39868	representations	_	
165-500	39869-39876	Natural	_	
165-501	39877-39886	variation	_	
165-502	39887-39889	in	_	
165-503	39890-39898	maternal	_	
165-504	39899-39910	sensitivity	_	
165-505	39911-39913	is	_	
165-506	39914-39923	reflected	_	
165-507	39924-39926	in	_	
165-508	39927-39935	maternal	_	
165-509	39936-39941	brain	_	
165-510	39942-39951	responses	_	
165-511	39952-39954	to	_	
165-512	39955-39961	infant	_	
165-513	39962-39969	stimuli	_	
165-514	39970-39978	Oxytocin	_	
165-515	39979-39988	modulates	_	
165-516	39989-39997	amygdala	_	
165-517	39997-39998	,	_	
165-518	39999-40005	insula	_	
165-519	40005-40006	,	_	
165-520	40007-40010	and	_	
165-521	40011-40019	inferior	_	
165-522	40020-40027	frontal	_	
165-523	40028-40033	gyrus	_	
165-524	40034-40043	responses	_	
165-525	40044-40046	to	_	
165-526	40047-40053	infant	_	
165-527	40054-40060	crying	_	
165-528	40060-40061	:	_	
165-529	40062-40063	a	_	
165-530	40064-40074	randomized	_	
165-531	40075-40085	controlled	_	
165-532	40086-40091	trial	_	
165-533	40092-40110	Neuroendocrinology	_	
165-534	40111-40113	of	_	
165-535	40114-40122	parental	_	
165-536	40123-40131	response	_	
165-537	40132-40134	to	_	
165-538	40135-40143	baby-cry	_	
165-539	40144-40149	Adult	_	
165-540	40150-40160	attachment	_	
165-541	40161-40169	predicts	_	
165-542	40170-40178	maternal	_	
165-543	40179-40184	brain	_	
165-544	40185-40188	and	_	
165-545	40189-40197	oxytocin	_	
165-546	40198-40206	response	_	
165-547	40207-40209	to	_	
165-548	40210-40216	infant	_	
165-549	40217-40221	cues	_	
165-550	40222-40229	Empathy	_	
165-551	40230-40233	and	_	
165-552	40234-40240	stress	_	
165-553	40241-40248	related	_	
165-554	40249-40255	neural	_	
165-555	40256-40265	responses	_	
165-556	40266-40268	in	_	
165-557	40269-40277	maternal	_	
165-558	40278-40286	decision	_	
165-559	40287-40293	making	_	
165-560	40294-40302	Maternal	_	
165-561	40303-40308	brain	_	
165-562	40309-40317	response	_	
165-563	40318-40320	to	_	
165-564	40321-40324	own	_	
165-565	40325-40333	baby-cry	_	
165-566	40334-40336	is	_	
165-567	40337-40345	affected	_	
165-568	40346-40348	by	_	
165-569	40349-40357	cesarean	_	
165-570	40358-40365	section	_	
165-571	40366-40374	delivery	_	
165-572	40376-40385	Parenting	_	
165-573	40386-40389	and	_	
165-574	40390-40399	addiction	_	
165-575	40399-40400	:	_	
165-576	40401-40416	neurobiological	_	
165-577	40417-40425	insights	_	
165-578	40426-40433	Resting	_	
165-579	40434-40439	state	_	
165-580	40440-40444	fMRI	_	
165-581	40444-40445	:	_	
165-582	40446-40447	a	_	
165-583	40448-40456	personal	_	
165-584	40457-40464	history	_	
165-585	40465-40478	Opportunities	_	
165-586	40479-40482	and	_	
165-587	40483-40494	limitations	_	
165-588	40495-40497	of	_	
165-589	40498-40507	intrinsic	_	
165-590	40508-40518	functional	_	
165-591	40519-40531	connectivity	_	
165-592	40532-40535	MRI	_	
165-593	40536-40540	What	_	
165-594	40541-40543	is	_	
165-595	40544-40552	feasible	_	
165-596	40553-40557	with	_	
165-597	40558-40565	imaging	_	
165-598	40566-40571	human	_	
165-599	40572-40577	brain	_	
165-600	40578-40586	function	_	
165-601	40587-40590	and	_	
165-602	40591-40603	connectivity	_	
165-603	40604-40609	using	_	
165-604	40610-40620	functional	_	
165-605	40621-40629	magnetic	_	
165-606	40630-40639	resonance	_	
165-607	40640-40647	imaging	_	
165-608	40648-40656	Advances	_	
165-609	40657-40660	and	_	
165-610	40661-40669	pitfalls	_	
165-611	40670-40672	in	_	
165-612	40673-40676	the	_	
165-613	40677-40685	analysis	_	
165-614	40686-40689	and	_	
165-615	40690-40704	interpretation	_	
165-616	40705-40707	of	_	
165-617	40708-40721	resting-state	_	
165-618	40722-40726	FMRI	_	
165-619	40727-40731	data	_	
165-620	40732-40745	Resting-state	_	
165-621	40746-40751	brain	_	
165-622	40752-40760	networks	_	
165-623	40760-40761	:	_	
165-624	40762-40772	literature	_	
165-625	40773-40779	review	_	
165-626	40780-40783	and	_	
165-627	40784-40792	clinical	_	
165-628	40793-40805	applications	_	
165-629	40806-40815	Childhood	_	
165-630	40816-40823	poverty	_	
165-631	40824-40827	and	_	
165-632	40828-40834	stress	_	
165-633	40835-40845	reactivity	_	
165-634	40846-40849	are	_	
165-635	40850-40860	associated	_	
165-636	40861-40865	with	_	
165-637	40866-40874	aberrant	_	
165-638	40875-40885	functional	_	
165-639	40886-40898	connectivity	_	
165-640	40899-40901	in	_	
165-641	40902-40909	default	_	
165-642	40910-40914	mode	_	
165-643	40915-40922	network	_	
165-644	40923-40928	Early	_	
165-645	40929-40933	life	_	
165-646	40934-40940	social	_	
165-647	40941-40947	stress	_	
165-648	40948-40951	and	_	
165-649	40952-40959	resting	_	
165-650	40960-40965	state	_	
165-651	40966-40976	functional	_	
165-652	40977-40989	connectivity	_	
165-653	40990-40992	in	_	
165-654	40993-41003	postpartum	_	
165-655	41004-41007	rat	_	
165-656	41008-41016	anterior	_	
165-657	41017-41026	cingulate	_	
165-658	41027-41035	circuits	_	
165-659	41036-41045	GABAergic	_	
165-660	41046-41057	neuroactive	_	
165-661	41058-41066	steroids	_	
165-662	41067-41070	and	_	
165-663	41071-41084	resting-state	_	
165-664	41085-41095	functional	_	
165-665	41096-41108	connectivity	_	
165-666	41109-41111	in	_	
165-667	41112-41122	postpartum	_	
165-668	41123-41133	depression	_	
165-669	41133-41134	:	_	
165-670	41135-41136	a	_	
165-671	41137-41148	preliminary	_	
165-672	41149-41154	study	_	
165-673	41155-41164	Disrupted	_	
165-674	41165-41174	posterior	_	
165-675	41175-41193	cingulate–amygdala	_	
165-676	41194-41206	connectivity	_	
165-677	41207-41209	in	_	
165-678	41210-41220	postpartum	_	
165-679	41221-41230	depressed	_	
165-680	41231-41236	women	_	
165-681	41237-41239	as	_	
165-682	41240-41248	measured	_	
165-683	41249-41253	with	_	
165-684	41254-41261	resting	_	
165-685	41262-41266	BOLD	_	
165-686	41267-41271	fMRI	_	
165-687	41272-41274	On	_	
165-688	41275-41278	the	_	
165-689	41279-41291	relationship	_	
165-690	41292-41299	between	_	
165-691	41300-41303	the	_	
165-692	41304-41305	“	_	
165-693	41305-41312	default	_	
165-694	41313-41317	mode	_	
165-695	41318-41325	network	_	
165-696	41325-41326	”	_	
165-697	41327-41330	and	_	
165-698	41331-41334	the	_	
165-699	41335-41336	“	_	
165-700	41336-41342	social	_	
165-701	41343-41348	brain	_	
165-702	41348-41349	”	_	
165-703	41350-41362	Dissociating	_	
165-704	41363-41369	medial	_	
165-705	41370-41377	frontal	_	
165-706	41378-41381	and	_	
165-707	41382-41391	posterior	_	
165-708	41392-41401	cingulate	_	
165-709	41402-41410	activity	_	
165-710	41411-41417	during	_	
165-711	41418-41433	self-reflection	_	
165-712	41434-41436	In	_	
165-713	41437-41443	search	_	
165-714	41444-41446	of	_	
165-715	41447-41453	neural	_	
165-716	41454-41468	endophenotypes	_	
165-717	41469-41471	of	_	
165-718	41472-41482	postpartum	_	
165-719	41483-41498	psychopathology	_	
165-720	41499-41502	and	_	
165-721	41503-41512	disrupted	_	
165-722	41513-41521	maternal	_	
165-723	41522-41532	caregiving	_	
165-724	41533-41536	The	_	
165-725	41537-41547	Postpartum	_	
165-726	41548-41555	Bonding	_	
165-727	41556-41569	Questionnaire	_	
165-728	41569-41570	:	_	
165-729	41571-41572	a	_	
165-730	41573-41583	validation	_	
165-731	41584-41597	Mother-infant	_	
165-732	41598-41605	bonding	_	
165-733	41606-41615	disorders	_	
165-734	41616-41618	in	_	
165-735	41619-41627	patients	_	
165-736	41628-41632	with	_	
165-737	41633-41643	post-natal	_	
165-738	41644-41654	depression	_	
165-739	41654-41655	:	_	
165-740	41656-41659	the	_	
165-741	41660-41670	Postpartum	_	
165-742	41671-41678	Bonding	_	
165-743	41679-41692	Questionnaire	_	
165-744	41693-41695	in	_	
165-745	41696-41704	clinical	_	
165-746	41705-41713	practice	_	
165-747	41714-41724	Validation	_	
165-748	41725-41728	and	_	
165-749	41729-41735	factor	_	
165-750	41736-41744	analysis	_	
165-751	41745-41747	of	_	
165-752	41748-41761	mother-infant	_	
165-753	41762-41769	bonding	_	
165-754	41770-41783	questionnaire	_	
165-755	41784-41786	in	_	
165-756	41787-41795	pregnant	_	
165-757	41796-41799	and	_	
165-758	41800-41810	postpartum	_	
165-759	41811-41816	women	_	
165-760	41817-41819	in	_	
165-761	41820-41825	Japan	_	
165-762	41826-41836	Postpartum	_	
165-763	41837-41844	bonding	_	
165-764	41845-41853	disorder	_	
165-765	41853-41854	:	_	
165-766	41855-41861	factor	_	
165-767	41862-41871	structure	_	
165-768	41871-41872	,	_	
165-769	41873-41881	validity	_	
165-770	41881-41882	,	_	
165-771	41883-41894	reliability	_	
165-772	41895-41898	and	_	
165-773	41899-41900	a	_	
165-774	41901-41906	model	_	
165-775	41907-41917	comparison	_	
165-776	41918-41920	of	_	
165-777	41921-41924	the	_	
165-778	41925-41934	postnatal	_	
165-779	41935-41942	bonding	_	
165-780	41943-41956	questionnaire	_	
165-781	41957-41959	in	_	
165-782	41960-41968	Japanese	_	
165-783	41969-41976	mothers	_	
165-784	41977-41979	of	_	
165-785	41980-41987	infants	_	
165-786	41988-41991	The	_	
165-787	41992-41998	German	_	
165-788	41999-42006	version	_	
165-789	42007-42009	of	_	
165-790	42010-42013	the	_	
165-791	42014-42024	Postpartum	_	
165-792	42025-42032	Bonding	_	
165-793	42033-42043	Instrument	_	
165-794	42043-42044	:	_	
165-795	42045-42057	psychometric	_	
165-796	42058-42068	properties	_	
165-797	42069-42072	and	_	
165-798	42073-42084	association	_	
165-799	42085-42089	with	_	
165-800	42090-42100	postpartum	_	
165-801	42101-42111	depression	_	
165-802	42112-42120	Lifetime	_	
165-803	42121-42133	co-morbidity	_	
165-804	42134-42136	of	_	
165-805	42137-42143	DSM-IV	_	
165-806	42144-42148	mood	_	
165-807	42149-42152	and	_	
165-808	42153-42160	anxiety	_	
165-809	42161-42170	disorders	_	
165-810	42171-42174	and	_	
165-811	42175-42183	specific	_	
165-812	42184-42188	drug	_	
165-813	42189-42192	use	_	
165-814	42193-42202	disorders	_	
165-815	42202-42203	:	_	
165-816	42204-42211	results	_	
165-817	42212-42216	from	_	
165-818	42217-42220	the	_	
165-819	42221-42229	National	_	
165-820	42230-42243	Epidemiologic	_	
165-821	42244-42250	Survey	_	
165-822	42251-42253	on	_	
165-823	42254-42261	Alcohol	_	
165-824	42262-42265	and	_	
165-825	42266-42273	Related	_	
165-826	42274-42284	Conditions	_	
165-827	42285-42297	Prescription	_	
165-828	42298-42304	opioid	_	
165-829	42305-42308	use	_	
165-830	42309-42314	among	_	
165-831	42315-42321	adults	_	
165-832	42322-42326	with	_	
165-833	42327-42333	mental	_	
165-834	42334-42340	health	_	
165-835	42341-42350	disorders	_	
165-836	42351-42353	in	_	
165-837	42354-42357	the	_	
165-838	42358-42364	United	_	
165-839	42365-42371	States	_	
165-840	42373-42379	Impact	_	
165-841	42380-42382	of	_	
165-842	42383-42393	postpartum	_	
165-843	42394-42404	depressive	_	
165-844	42405-42413	symptoms	_	
165-845	42414-42416	on	_	
165-846	42417-42423	mother	_	
165-847	42424-42427	and	_	
165-848	42428-42431	her	_	
165-849	42432-42434	18	_	
165-850	42434-42435	-	_	
165-851	42435-42444	month-old	_	
165-852	42445-42451	infant	_	
165-853	42452-42460	Maternal	_	
165-854	42461-42471	depressive	_	
165-855	42472-42480	symptoms	_	
165-856	42481-42483	at	_	
165-857	42484-42485	2	_	
165-858	42486-42488	to	_	
165-859	42489-42490	4	_	
165-860	42491-42497	months	_	
165-861	42498-42502	post	_	
165-862	42503-42509	partum	_	
165-863	42510-42513	and	_	
165-864	42514-42519	early	_	
165-865	42520-42529	parenting	_	
165-866	42530-42539	practices	_	
165-867	42540-42550	Antepartum	_	
165-868	42551-42554	and	_	
165-869	42555-42565	postpartum	_	
165-870	42566-42574	exposure	_	
165-871	42575-42577	to	_	
165-872	42578-42586	maternal	_	
165-873	42587-42597	depression	_	
165-874	42597-42598	:	_	
165-875	42599-42608	different	_	
165-876	42609-42616	effects	_	
165-877	42617-42619	on	_	
165-878	42620-42629	different	_	
165-879	42630-42640	adolescent	_	
165-880	42641-42649	outcomes	_	
165-881	42650-42653	The	_	
165-882	42654-42660	effect	_	
165-883	42661-42663	of	_	
165-884	42664-42674	postpartum	_	
165-885	42675-42685	depression	_	
165-886	42686-42688	on	_	
165-887	42689-42694	child	_	
165-888	42695-42704	cognitive	_	
165-889	42705-42716	development	_	
165-890	42717-42720	and	_	
165-891	42721-42729	behavior	_	
165-892	42729-42730	:	_	
165-893	42731-42732	a	_	
165-894	42733-42739	review	_	
165-895	42740-42743	and	_	
165-896	42744-42752	critical	_	
165-897	42753-42761	analysis	_	
165-898	42762-42764	of	_	
165-899	42765-42768	the	_	
165-900	42769-42779	literature	_	
165-901	42780-42788	Maternal	_	
165-902	42789-42799	depression	_	
165-903	42800-42803	and	_	
165-904	42804-42815	psychiatric	_	
165-905	42816-42824	outcomes	_	
165-906	42825-42827	in	_	
165-907	42828-42838	adolescent	_	
165-908	42839-42848	offspring	_	
165-909	42848-42849	:	_	
165-910	42850-42851	a	_	
165-911	42852-42854	13	_	
165-912	42854-42855	-	_	
165-913	42855-42859	year	_	
165-914	42860-42872	longitudinal	_	
165-915	42873-42878	study	_	
165-916	42879-42887	Maternal	_	
165-917	42888-42898	depression	_	
165-918	42899-42902	and	_	
165-919	42903-42908	child	_	
165-920	42909-42924	psychopathology	_	
165-921	42924-42925	:	_	
165-922	42926-42927	a	_	
165-923	42928-42941	meta-analytic	_	
165-924	42942-42948	review	_	
165-925	42949-42960	Association	_	
165-926	42961-42963	of	_	
165-927	42964-42974	persistent	_	
165-928	42975-42978	and	_	
165-929	42979-42985	severe	_	
165-930	42986-42995	postnatal	_	
165-931	42996-43006	depression	_	
165-932	43007-43011	with	_	
165-933	43012-43017	child	_	
165-934	43018-43026	outcomes	_	
165-935	43027-43035	Maternal	_	
165-936	43036-43046	depression	_	
165-937	43047-43050	and	_	
165-938	43051-43058	anxiety	_	
165-939	43059-43065	across	_	
165-940	43066-43069	the	_	
165-941	43070-43080	postpartum	_	
165-942	43081-43085	year	_	
165-943	43086-43089	and	_	
165-944	43090-43096	infant	_	
165-945	43097-43103	social	_	
165-946	43104-43114	engagement	_	
165-947	43114-43115	,	_	
165-948	43116-43120	fear	_	
165-949	43121-43131	regulation	_	
165-950	43131-43132	,	_	
165-951	43133-43136	and	_	
165-952	43137-43143	stress	_	
165-953	43144-43154	reactivity	_	
165-954	43155-43156	A	_	
165-955	43157-43166	screening	_	
165-956	43167-43180	questionnaire	_	
165-957	43181-43184	for	_	
165-958	43185-43198	mother-infant	_	
165-959	43199-43206	bonding	_	
165-960	43207-43216	disorders	_	
165-961	43217-43225	Improved	_	
165-962	43226-43238	optimization	_	
165-963	43239-43242	for	_	
165-964	43243-43246	the	_	
165-965	43247-43253	robust	_	
165-966	43254-43257	and	_	
165-967	43258-43266	accurate	_	
165-968	43267-43273	linear	_	
165-969	43274-43286	registration	_	
165-970	43287-43290	and	_	
165-971	43291-43297	motion	_	
165-972	43298-43308	correction	_	
165-973	43309-43311	of	_	
165-974	43312-43317	brain	_	
165-975	43318-43324	images	_	
165-976	43325-43326	A	_	
165-977	43327-43331	fast	_	
165-978	43332-43345	diffeomorphic	_	
165-979	43346-43351	image	_	
165-980	43352-43364	registration	_	
165-981	43365-43374	algorithm	_	
165-982	43375-43383	Spurious	_	
165-983	43384-43387	but	_	
165-984	43388-43398	systematic	_	
165-985	43399-43411	correlations	_	
165-986	43412-43414	in	_	
165-987	43415-43425	functional	_	
165-988	43426-43438	connectivity	_	
165-989	43439-43442	MRI	_	
165-990	43443-43451	networks	_	
165-991	43452-43457	arise	_	
165-992	43458-43462	from	_	
165-993	43463-43470	subject	_	
165-994	43471-43477	motion	_	
165-995	43478-43486	Distinct	_	
165-996	43487-43493	neural	_	
165-997	43494-43504	signatures	_	
165-998	43505-43513	detected	_	
165-999	43514-43517	for	_	
165-1000	43518-43522	ADHD	_	
165-1001	43523-43531	subtypes	_	
165-1002	43532-43537	after	_	
165-1003	43538-43549	controlling	_	
165-1004	43550-43553	for	_	
165-1005	43554-43569	micro-movements	_	
165-1006	43570-43572	in	_	
165-1007	43573-43580	resting	_	
165-1008	43581-43586	state	_	
165-1009	43587-43597	functional	_	
165-1010	43598-43610	connectivity	_	
165-1011	43611-43614	MRI	_	
165-1012	43615-43619	data	_	
165-1013	43620-43621	A	_	
165-1014	43622-43631	component	_	
165-1015	43632-43637	based	_	
165-1016	43638-43643	noise	_	
165-1017	43644-43654	correction	_	
165-1018	43655-43661	method	_	
165-1019	43662-43663	(	_	
165-1020	43663-43670	CompCor	_	
165-1021	43670-43671	)	_	
165-1022	43672-43675	for	_	
165-1023	43676-43680	BOLD	_	
165-1024	43681-43684	and	_	
165-1025	43685-43694	perfusion	_	
165-1026	43695-43700	based	_	
165-1027	43701-43705	fMRI	_	
165-1028	43706-43722	Anticorrelations	_	
165-1029	43723-43725	in	_	
165-1030	43726-43733	resting	_	
165-1031	43734-43739	state	_	
165-1032	43740-43748	networks	_	
165-1033	43749-43756	without	_	
165-1034	43757-43763	global	_	
165-1035	43764-43770	signal	_	
165-1036	43771-43781	regression	_	
165-1037	43782-43800	Connectivity-based	_	
165-1038	43801-43813	segmentation	_	
165-1039	43814-43816	of	_	
165-1040	43817-43820	the	_	
165-1041	43821-43835	periaqueductal	_	
165-1042	43836-43840	gray	_	
165-1043	43841-43847	matter	_	
165-1044	43848-43850	in	_	
165-1045	43851-43856	human	_	
165-1046	43857-43861	with	_	
165-1047	43862-43871	brainstem	_	
165-1048	43872-43881	optimized	_	
165-1049	43882-43891	diffusion	_	
165-1050	43892-43895	MRI	_	
165-1051	43896-43900	fMRI	_	
165-1052	43901-43911	functional	_	
165-1053	43912-43924	connectivity	_	
165-1054	43925-43927	of	_	
165-1055	43928-43931	the	_	
165-1056	43932-43946	periaqueductal	_	
165-1057	43947-43951	gray	_	
165-1058	43952-43954	in	_	
165-1059	43955-43959	PTSD	_	
165-1060	43960-43963	and	_	
165-1061	43964-43967	its	_	
165-1062	43968-43980	dissociative	_	
165-1063	43981-43988	subtype	_	
165-1064	43989-43996	Cluster	_	
165-1065	43997-44004	failure	_	
165-1066	44004-44005	:	_	
165-1067	44006-44009	why	_	
165-1068	44010-44014	fMRI	_	
165-1069	44015-44025	inferences	_	
165-1070	44026-44029	for	_	
165-1071	44030-44037	spatial	_	
165-1072	44038-44044	extent	_	
165-1073	44045-44049	have	_	
165-1074	44050-44058	inflated	_	
165-1075	44059-44073	false-positive	_	
165-1076	44074-44079	rates	_	
165-1077	44080-44094	Threshold-free	_	
165-1078	44095-44102	cluster	_	
165-1079	44103-44114	enhancement	_	
165-1080	44114-44115	:	_	
165-1081	44116-44126	addressing	_	
165-1082	44127-44135	problems	_	
165-1083	44136-44138	of	_	
165-1084	44139-44148	smoothing	_	
165-1085	44148-44149	,	_	
165-1086	44150-44159	threshold	_	
165-1087	44160-44170	dependence	_	
165-1088	44171-44174	and	_	
165-1089	44175-44187	localisation	_	
165-1090	44188-44190	in	_	
165-1091	44191-44198	cluster	_	
165-1092	44199-44208	inference	_	
165-1093	44209-44212	The	_	
165-1094	44213-44219	neural	_	
165-1095	44220-44230	correlates	_	
165-1096	44231-44233	of	_	
165-1097	44234-44242	maternal	_	
165-1098	44243-44246	and	_	
165-1099	44247-44255	romantic	_	
165-1100	44256-44260	love	_	
165-1101	44261-44264	The	_	
165-1102	44265-44275	functional	_	
165-1103	44276-44288	neuroanatomy	_	
165-1104	44289-44291	of	_	
165-1105	44292-44300	maternal	_	
165-1106	44301-44305	love	_	
165-1107	44305-44306	:	_	
165-1108	44307-44313	mother	_	
165-1109	44313-44314	’	_	
165-1110	44314-44315	s	_	
165-1111	44316-44324	response	_	
165-1112	44325-44327	to	_	
165-1113	44328-44334	infant	_	
165-1114	44334-44335	’	_	
165-1115	44335-44336	s	_	
165-1116	44337-44347	attachment	_	
165-1117	44348-44357	behaviors	_	
165-1118	44358-44361	The	_	
165-1119	44362-44375	orbitofrontal	_	
165-1120	44376-44382	cortex	_	
165-1121	44383-44392	modulates	_	
165-1122	44393-44402	parenting	_	
165-1123	44403-44409	stress	_	
165-1124	44410-44412	in	_	
165-1125	44413-44416	the	_	
165-1126	44417-44425	maternal	_	
165-1127	44426-44431	brain	_	
165-1128	44432-44441	Steroidal	_	
165-1129	44442-44454	interactions	_	
165-1130	44455-44457	in	_	
165-1131	44458-44461	the	_	
165-1132	44462-44472	regulation	_	
165-1133	44473-44475	of	_	
165-1134	44476-44484	maternal	_	
165-1135	44485-44494	behaviour	_	
165-1136	44495-44497	in	_	
165-1137	44498-44504	virgin	_	
165-1138	44505-44511	female	_	
165-1139	44512-44516	rats	_	
165-1140	44516-44517	:	_	
165-1141	44518-44525	effects	_	
165-1142	44526-44528	of	_	
165-1143	44529-44541	testosterone	_	
165-1144	44541-44542	,	_	
165-1145	44543-44562	dihydrotestosterone	_	
165-1146	44562-44563	,	_	
165-1147	44564-44574	oestradiol	_	
165-1148	44574-44575	,	_	
165-1149	44576-44588	progesterone	_	
165-1150	44589-44592	and	_	
165-1151	44593-44596	the	_	
165-1152	44597-44606	aromatase	_	
165-1153	44607-44616	inhibitor	_	
165-1154	44616-44617	,	_	
165-1155	44618-44623	1,4,6	_	
165-1156	44623-44624	-	_	
165-1157	44624-44638	androstatriene	_	
165-1158	44638-44639	-	_	
165-1159	44639-44643	3,17	_	
165-1160	44643-44644	-	_	
165-1161	44644-44649	dione	_	
165-1162	44650-44667	Oxytocin-dopamine	_	
165-1163	44668-44680	interactions	_	
165-1164	44681-44688	mediate	_	
165-1165	44689-44699	variations	_	
165-1166	44700-44702	in	_	
165-1167	44703-44711	maternal	_	
165-1168	44712-44720	behavior	_	
165-1169	44721-44723	in	_	
165-1170	44724-44727	the	_	
165-1171	44728-44731	rat	_	
165-1172	44732-44737	Early	_	
165-1173	44738-44748	postpartum	_	
165-1174	44749-44752	pup	_	
165-1175	44753-44763	preference	_	
165-1176	44764-44766	is	_	
165-1177	44767-44774	altered	_	
165-1178	44775-44777	by	_	
165-1179	44778-44789	gestational	_	
165-1180	44790-44797	cocaine	_	
165-1181	44798-44807	treatment	_	
165-1182	44807-44808	:	_	
165-1183	44809-44821	associations	_	
165-1184	44822-44826	with	_	
165-1185	44827-44833	infant	_	
165-1186	44834-44838	cues	_	
165-1187	44839-44842	and	_	
165-1188	44843-44851	oxytocin	_	
165-1189	44852-44862	expression	_	
165-1190	44863-44865	in	_	
165-1191	44866-44869	the	_	
165-1192	44870-44874	MPOA	_	
165-1193	44875-44883	Maternal	_	
165-1194	44884-44891	neglect	_	
165-1195	44892-44896	with	_	
165-1196	44897-44904	reduced	_	
165-1197	44905-44920	depressive-like	_	
165-1198	44921-44929	behavior	_	
165-1199	44930-44933	and	_	
165-1200	44934-44941	blunted	_	
165-1201	44942-44947	c-fos	_	
165-1202	44948-44958	activation	_	
165-1203	44959-44961	in	_	
165-1204	44962-44973	Brattleboro	_	
165-1205	44974-44981	mothers	_	
165-1206	44981-44982	,	_	
165-1207	44983-44986	the	_	
165-1208	44987-44991	role	_	
165-1209	44992-44994	of	_	
165-1210	44995-45002	central	_	
165-1211	45003-45014	vasopressin	_	
165-1212	45015-45025	Variations	_	
165-1213	45026-45028	in	_	
165-1214	45029-45037	maternal	_	
165-1215	45038-45047	behaviour	_	
165-1216	45048-45051	are	_	
165-1217	45052-45062	associated	_	
165-1218	45063-45067	with	_	
165-1219	45068-45079	differences	_	
165-1220	45080-45082	in	_	
165-1221	45083-45091	oxytocin	_	
165-1222	45092-45100	receptor	_	
165-1223	45101-45107	levels	_	
165-1224	45108-45110	in	_	
165-1225	45111-45114	the	_	
165-1226	45115-45118	rat	_	
165-1227	45119-45120	A	_	
165-1228	45121-45124	cry	_	
165-1229	45125-45127	in	_	
165-1230	45128-45131	the	_	
165-1231	45132-45136	dark	_	
165-1232	45136-45137	:	_	
165-1233	45138-45147	depressed	_	
165-1234	45148-45155	mothers	_	
165-1235	45156-45160	show	_	
165-1236	45161-45168	reduced	_	
165-1237	45169-45175	neural	_	
165-1238	45176-45186	activation	_	
165-1239	45187-45189	to	_	
165-1240	45190-45195	their	_	
165-1241	45196-45199	own	_	
165-1242	45200-45206	infant	_	
165-1243	45206-45207	’	_	
165-1244	45207-45208	s	_	
165-1245	45209-45212	cry	_	
165-1246	45213-45216	The	_	
165-1247	45217-45224	missing	_	
165-1248	45225-45229	link	_	
165-1249	45229-45230	:	_	
165-1250	45231-45238	mothers	_	
165-1251	45238-45239	’	_	
165-1252	45240-45246	neural	_	
165-1253	45247-45255	response	_	
165-1254	45256-45258	to	_	
165-1255	45259-45265	infant	_	
165-1256	45266-45269	cry	_	
165-1257	45270-45277	related	_	
165-1258	45278-45280	to	_	
165-1259	45281-45287	infant	_	
165-1260	45288-45298	attachment	_	
165-1261	45299-45308	behaviors	_	
165-1262	45309-45311	Is	_	
165-1263	45312-45317	there	_	
165-1264	45318-45319	a	_	
165-1265	45320-45324	core	_	
165-1266	45325-45331	neural	_	
165-1267	45332-45339	network	_	
165-1268	45340-45342	in	_	
165-1269	45343-45350	empathy	_	
165-1270	45350-45351	?	_	

#Text=An fMRI based quantitative meta-analysis
#Text=Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain
#Text=What’s in a smile?
166-1	45352-45354	An	_	
166-2	45355-45359	fMRI	_	
166-3	45360-45365	based	_	
166-4	45366-45378	quantitative	_	
166-5	45379-45392	meta-analysis	_	
166-6	45393-45406	Meta-analytic	_	
166-7	45407-45415	evidence	_	
166-8	45416-45419	for	_	
166-9	45420-45426	common	_	
166-10	45427-45430	and	_	
166-11	45431-45439	distinct	_	
166-12	45440-45446	neural	_	
166-13	45447-45455	networks	_	
166-14	45456-45466	associated	_	
166-15	45467-45471	with	_	
166-16	45472-45480	directly	_	
166-17	45481-45492	experienced	_	
166-18	45493-45497	pain	_	
166-19	45498-45501	and	_	
166-20	45502-45509	empathy	_	
166-21	45510-45513	for	_	
166-22	45514-45518	pain	_	
166-23	45519-45523	What	_	
166-24	45523-45524	’	_	
166-25	45524-45525	s	_	
166-26	45526-45528	in	_	
166-27	45529-45530	a	_	
166-28	45531-45536	smile	_	
166-29	45536-45537	?	_	

#Text=Maternal brain responses to infant facial cues
#Text=Reliability and validity of the time-line follow-back interview among psychiatric outpatients: a preliminary report
#Text=Project MATCH: the time has come … to talk of many things
#Text=Reliability of a timeline method: assessing normal drinkers’ reports of recent drinking and a comparative evaluation across several populations
#Text=Depression alters maternal extended amygdala response and functional connectivity during distress signals in attachment relationship
#Text=Childhood social inequalities influences neural processes in young adult caregiving
#Text=Severity of anxiety moderates the association between neural circuits and maternal behaviors in the postpartum period
#Text=Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women
#Text=Interactive effects of cumulative stress and impulsivity on alcohol consumption
#Text=Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes
#Text=Peripheral immune system suppression in early abstinent alcohol-dependent individuals: links to stress and cue-related craving
#Text=Mothers’ representations of their infants assessed prenatally: stability and association with infants’ attachment classifications
#Text=Early postpartum parental preoccupation and positive parenting thoughts: relationship with parentinfant interaction
#Text=
#Text=The development of maternal touch across the first year of life
#Text=Testing a family intervention hypothesis: the contribution of mother-infant skin-to-skin contact (kangaroo care) to family interaction, proximity, and touch
#Text=Parent–child intervention decreases stress and increases maternal brain activity and connectivity during own baby-cry: an exploratory study
#Text=A prospective longitudinal study of perceived infant outcomes at 18–24 months: neural and psychological correlates of parental thoughts and actions assessed during the first month postpartum
#Text=The maternal behavior neurocircuit (MBN) is comprised of two reciprocally inhibiting subsystems for: (1) maternal care, mediated by the medial preoptic area (mPOA) of hypothalamus (HYP), ventral tegmental area (VTA), nucleus accumbens (NAc) and ventral pallidum (VP), and (2) maternal defense, mediated by periaqueductal grey (PAG).
167-1	45538-45546	Maternal	_	
167-2	45547-45552	brain	_	
167-3	45553-45562	responses	_	
167-4	45563-45565	to	_	
167-5	45566-45572	infant	_	
167-6	45573-45579	facial	_	
167-7	45580-45584	cues	_	
167-8	45585-45596	Reliability	_	
167-9	45597-45600	and	_	
167-10	45601-45609	validity	_	
167-11	45610-45612	of	_	
167-12	45613-45616	the	_	
167-13	45617-45626	time-line	_	
167-14	45627-45638	follow-back	_	
167-15	45639-45648	interview	_	
167-16	45649-45654	among	_	
167-17	45655-45666	psychiatric	_	
167-18	45667-45678	outpatients	_	
167-19	45678-45679	:	_	
167-20	45680-45681	a	_	
167-21	45682-45693	preliminary	_	
167-22	45694-45700	report	_	
167-23	45701-45708	Project	_	
167-24	45709-45714	MATCH	_	
167-25	45714-45715	:	_	
167-26	45716-45719	the	_	
167-27	45720-45724	time	_	
167-28	45725-45728	has	_	
167-29	45729-45733	come	_	
167-30	45734-45735	…	_	
167-31	45736-45738	to	_	
167-32	45739-45743	talk	_	
167-33	45744-45746	of	_	
167-34	45747-45751	many	_	
167-35	45752-45758	things	_	
167-36	45759-45770	Reliability	_	
167-37	45771-45773	of	_	
167-38	45774-45775	a	_	
167-39	45776-45784	timeline	_	
167-40	45785-45791	method	_	
167-41	45791-45792	:	_	
167-42	45793-45802	assessing	_	
167-43	45803-45809	normal	_	
167-44	45810-45818	drinkers	_	
167-45	45818-45819	’	_	
167-46	45820-45827	reports	_	
167-47	45828-45830	of	_	
167-48	45831-45837	recent	_	
167-49	45838-45846	drinking	_	
167-50	45847-45850	and	_	
167-51	45851-45852	a	_	
167-52	45853-45864	comparative	_	
167-53	45865-45875	evaluation	_	
167-54	45876-45882	across	_	
167-55	45883-45890	several	_	
167-56	45891-45902	populations	_	
167-57	45903-45913	Depression	_	
167-58	45914-45920	alters	_	
167-59	45921-45929	maternal	_	
167-60	45930-45938	extended	_	
167-61	45939-45947	amygdala	_	
167-62	45948-45956	response	_	
167-63	45957-45960	and	_	
167-64	45961-45971	functional	_	
167-65	45972-45984	connectivity	_	
167-66	45985-45991	during	_	
167-67	45992-46000	distress	_	
167-68	46001-46008	signals	_	
167-69	46009-46011	in	_	
167-70	46012-46022	attachment	_	
167-71	46023-46035	relationship	_	
167-72	46036-46045	Childhood	_	
167-73	46046-46052	social	_	
167-74	46053-46065	inequalities	_	
167-75	46066-46076	influences	_	
167-76	46077-46083	neural	_	
167-77	46084-46093	processes	_	
167-78	46094-46096	in	_	
167-79	46097-46102	young	_	
167-80	46103-46108	adult	_	
167-81	46109-46119	caregiving	_	
167-82	46120-46128	Severity	_	
167-83	46129-46131	of	_	
167-84	46132-46139	anxiety	_	
167-85	46140-46149	moderates	_	
167-86	46150-46153	the	_	
167-87	46154-46165	association	_	
167-88	46166-46173	between	_	
167-89	46174-46180	neural	_	
167-90	46181-46189	circuits	_	
167-91	46190-46193	and	_	
167-92	46194-46202	maternal	_	
167-93	46203-46212	behaviors	_	
167-94	46213-46215	in	_	
167-95	46216-46219	the	_	
167-96	46220-46230	postpartum	_	
167-97	46231-46237	period	_	
167-98	46238-46241	Sex	_	
167-99	46242-46253	differences	_	
167-100	46254-46256	in	_	
167-101	46257-46269	drug-related	_	
167-102	46270-46283	stress-system	_	
167-103	46284-46291	changes	_	
167-104	46291-46292	:	_	
167-105	46293-46305	implications	_	
167-106	46306-46309	for	_	
167-107	46310-46319	treatment	_	
167-108	46320-46322	in	_	
167-109	46323-46340	substance-abusing	_	
167-110	46341-46346	women	_	
167-111	46347-46358	Interactive	_	
167-112	46359-46366	effects	_	
167-113	46367-46369	of	_	
167-114	46370-46380	cumulative	_	
167-115	46381-46387	stress	_	
167-116	46388-46391	and	_	
167-117	46392-46403	impulsivity	_	
167-118	46404-46406	on	_	
167-119	46407-46414	alcohol	_	
167-120	46415-46426	consumption	_	
167-121	46427-46434	Effects	_	
167-122	46435-46437	of	_	
167-123	46438-46445	adrenal	_	
167-124	46446-46457	sensitivity	_	
167-125	46457-46458	,	_	
167-126	46459-46465	stress	_	
167-127	46465-46466	-	_	
167-128	46467-46470	and	_	
167-129	46471-46482	cue-induced	_	
167-130	46483-46490	craving	_	
167-131	46490-46491	,	_	
167-132	46492-46495	and	_	
167-133	46496-46503	anxiety	_	
167-134	46504-46506	on	_	
167-135	46507-46517	subsequent	_	
167-136	46518-46525	alcohol	_	
167-137	46526-46533	relapse	_	
167-138	46534-46537	and	_	
167-139	46538-46547	treatment	_	
167-140	46548-46556	outcomes	_	
167-141	46557-46567	Peripheral	_	
167-142	46568-46574	immune	_	
167-143	46575-46581	system	_	
167-144	46582-46593	suppression	_	
167-145	46594-46596	in	_	
167-146	46597-46602	early	_	
167-147	46603-46612	abstinent	_	
167-148	46613-46630	alcohol-dependent	_	
167-149	46631-46642	individuals	_	
167-150	46642-46643	:	_	
167-151	46644-46649	links	_	
167-152	46650-46652	to	_	
167-153	46653-46659	stress	_	
167-154	46660-46663	and	_	
167-155	46664-46675	cue-related	_	
167-156	46676-46683	craving	_	
167-157	46684-46691	Mothers	_	
167-158	46691-46692	’	_	
167-159	46693-46708	representations	_	
167-160	46709-46711	of	_	
167-161	46712-46717	their	_	
167-162	46718-46725	infants	_	
167-163	46726-46734	assessed	_	
167-164	46735-46745	prenatally	_	
167-165	46745-46746	:	_	
167-166	46747-46756	stability	_	
167-167	46757-46760	and	_	
167-168	46761-46772	association	_	
167-169	46773-46777	with	_	
167-170	46778-46785	infants	_	
167-171	46785-46786	’	_	
167-172	46787-46797	attachment	_	
167-173	46798-46813	classifications	_	
167-174	46814-46819	Early	_	
167-175	46820-46830	postpartum	_	
167-176	46831-46839	parental	_	
167-177	46840-46853	preoccupation	_	
167-178	46854-46857	and	_	
167-179	46858-46866	positive	_	
167-180	46867-46876	parenting	_	
167-181	46877-46885	thoughts	_	
167-182	46885-46886	:	_	
167-183	46887-46899	relationship	_	
167-184	46900-46904	with	_	
167-185	46905-46917	parentinfant	_	
167-186	46918-46929	interaction	_	
167-187	46931-46934	The	_	
167-188	46935-46946	development	_	
167-189	46947-46949	of	_	
167-190	46950-46958	maternal	_	
167-191	46959-46964	touch	_	
167-192	46965-46971	across	_	
167-193	46972-46975	the	_	
167-194	46976-46981	first	_	
167-195	46982-46986	year	_	
167-196	46987-46989	of	_	
167-197	46990-46994	life	_	
167-198	46995-47002	Testing	_	
167-199	47003-47004	a	_	
167-200	47005-47011	family	_	
167-201	47012-47024	intervention	_	
167-202	47025-47035	hypothesis	_	
167-203	47035-47036	:	_	
167-204	47037-47040	the	_	
167-205	47041-47053	contribution	_	
167-206	47054-47056	of	_	
167-207	47057-47070	mother-infant	_	
167-208	47071-47083	skin-to-skin	_	
167-209	47084-47091	contact	_	
167-210	47092-47093	(	_	
167-211	47093-47101	kangaroo	_	
167-212	47102-47106	care	_	
167-213	47106-47107	)	_	
167-214	47108-47110	to	_	
167-215	47111-47117	family	_	
167-216	47118-47129	interaction	_	
167-217	47129-47130	,	_	
167-218	47131-47140	proximity	_	
167-219	47140-47141	,	_	
167-220	47142-47145	and	_	
167-221	47146-47151	touch	_	
167-222	47152-47164	Parent–child	_	
167-223	47165-47177	intervention	_	
167-224	47178-47187	decreases	_	
167-225	47188-47194	stress	_	
167-226	47195-47198	and	_	
167-227	47199-47208	increases	_	
167-228	47209-47217	maternal	_	
167-229	47218-47223	brain	_	
167-230	47224-47232	activity	_	
167-231	47233-47236	and	_	
167-232	47237-47249	connectivity	_	
167-233	47250-47256	during	_	
167-234	47257-47260	own	_	
167-235	47261-47269	baby-cry	_	
167-236	47269-47270	:	_	
167-237	47271-47273	an	_	
167-238	47274-47285	exploratory	_	
167-239	47286-47291	study	_	
167-240	47292-47293	A	_	
167-241	47294-47305	prospective	_	
167-242	47306-47318	longitudinal	_	
167-243	47319-47324	study	_	
167-244	47325-47327	of	_	
167-245	47328-47337	perceived	_	
167-246	47338-47344	infant	_	
167-247	47345-47353	outcomes	_	
167-248	47354-47356	at	_	
167-249	47357-47359	18	_	
167-250	47359-47360	–	_	
167-251	47360-47362	24	_	
167-252	47363-47369	months	_	
167-253	47369-47370	:	_	
167-254	47371-47377	neural	_	
167-255	47378-47381	and	_	
167-256	47382-47395	psychological	_	
167-257	47396-47406	correlates	_	
167-258	47407-47409	of	_	
167-259	47410-47418	parental	_	
167-260	47419-47427	thoughts	_	
167-261	47428-47431	and	_	
167-262	47432-47439	actions	_	
167-263	47440-47448	assessed	_	
167-264	47449-47455	during	_	
167-265	47456-47459	the	_	
167-266	47460-47465	first	_	
167-267	47466-47471	month	_	
167-268	47472-47482	postpartum	_	
167-269	47483-47486	The	_	
167-270	47487-47495	maternal	_	
167-271	47496-47504	behavior	_	
167-272	47505-47517	neurocircuit	_	
167-273	47518-47519	(	_	
167-274	47519-47522	MBN	_	
167-275	47522-47523	)	_	
167-276	47524-47526	is	_	
167-277	47527-47536	comprised	_	
167-278	47537-47539	of	_	
167-279	47540-47543	two	_	
167-280	47544-47556	reciprocally	_	
167-281	47557-47567	inhibiting	_	
167-282	47568-47578	subsystems	_	
167-283	47579-47582	for	_	
167-284	47582-47583	:	_	
167-285	47584-47585	(	_	
167-286	47585-47586	1	_	
167-287	47586-47587	)	_	
167-288	47588-47596	maternal	_	
167-289	47597-47601	care	_	
167-290	47601-47602	,	_	
167-291	47603-47611	mediated	_	
167-292	47612-47614	by	_	
167-293	47615-47618	the	_	
167-294	47619-47625	medial	_	
167-295	47626-47634	preoptic	_	
167-296	47635-47639	area	_	
167-297	47640-47641	(	_	
167-298	47641-47645	mPOA	_	
167-299	47645-47646	)	_	
167-300	47647-47649	of	_	
167-301	47650-47662	hypothalamus	_	
167-302	47663-47664	(	_	
167-303	47664-47667	HYP	_	
167-304	47667-47668	)	_	
167-305	47668-47669	,	_	
167-306	47670-47677	ventral	_	
167-307	47678-47687	tegmental	_	
167-308	47688-47692	area	_	
167-309	47693-47694	(	_	
167-310	47694-47697	VTA	_	
167-311	47697-47698	)	_	
167-312	47698-47699	,	_	
167-313	47700-47707	nucleus	_	
167-314	47708-47717	accumbens	_	
167-315	47718-47719	(	_	
167-316	47719-47722	NAc	_	
167-317	47722-47723	)	_	
167-318	47724-47727	and	_	
167-319	47728-47735	ventral	_	
167-320	47736-47744	pallidum	_	
167-321	47745-47746	(	_	
167-322	47746-47748	VP	_	
167-323	47748-47749	)	_	
167-324	47749-47750	,	_	
167-325	47751-47754	and	_	
167-326	47755-47756	(	_	
167-327	47756-47757	2	_	
167-328	47757-47758	)	_	
167-329	47759-47767	maternal	_	
167-330	47768-47775	defense	_	
167-331	47775-47776	,	_	
167-332	47777-47785	mediated	_	
167-333	47786-47788	by	_	
167-334	47789-47803	periaqueductal	_	
167-335	47804-47808	grey	_	
167-336	47809-47810	(	_	
167-337	47810-47813	PAG	_	
167-338	47813-47814	)	_	
167-339	47814-47815	.	_	

#Text=These opposing subsystems are regulated by the amygdala (AMY), insula, and orbitofrontal cortex (OFC).
168-1	47816-47821	These	_	
168-2	47822-47830	opposing	_	
168-3	47831-47841	subsystems	_	
168-4	47842-47845	are	_	
168-5	47846-47855	regulated	_	
168-6	47856-47858	by	_	
168-7	47859-47862	the	_	
168-8	47863-47871	amygdala	_	
168-9	47872-47873	(	_	
168-10	47873-47876	AMY	_	
168-11	47876-47877	)	_	
168-12	47877-47878	,	_	
168-13	47879-47885	insula	_	
168-14	47885-47886	,	_	
168-15	47887-47890	and	_	
168-16	47891-47904	orbitofrontal	_	
168-17	47905-47911	cortex	_	
168-18	47912-47913	(	_	
168-19	47913-47916	OFC	_	
168-20	47916-47917	)	_	
168-21	47917-47918	.	_	

#Text=Research from our lab and others has established that human MCN’s volumes and responses to ethologically pertinent own-baby cry correlate with adaptive parental thoughts and behaviors
#Text=The group by timeline charts for three subscales of postpartum bonding questionnaire (PBQ).
169-1	47919-47927	Research	_	
169-2	47928-47932	from	_	
169-3	47933-47936	our	_	
169-4	47937-47940	lab	_	
169-5	47941-47944	and	_	
169-6	47945-47951	others	_	
169-7	47952-47955	has	_	
169-8	47956-47967	established	_	
169-9	47968-47972	that	_	
169-10	47973-47978	human	_	
169-11	47979-47982	MCN	_	
169-12	47982-47983	’	_	
169-13	47983-47984	s	_	
169-14	47985-47992	volumes	_	
169-15	47993-47996	and	_	
169-16	47997-48006	responses	_	
169-17	48007-48009	to	_	
169-18	48010-48023	ethologically	_	
169-19	48024-48033	pertinent	_	
169-20	48034-48042	own-baby	_	
169-21	48043-48046	cry	_	
169-22	48047-48056	correlate	_	
169-23	48057-48061	with	_	
169-24	48062-48070	adaptive	_	
169-25	48071-48079	parental	_	
169-26	48080-48088	thoughts	_	
169-27	48089-48092	and	_	
169-28	48093-48102	behaviors	_	
169-29	48103-48106	The	_	
169-30	48107-48112	group	_	
169-31	48113-48115	by	_	
169-32	48116-48124	timeline	_	
169-33	48125-48131	charts	_	
169-34	48132-48135	for	_	
169-35	48136-48141	three	_	
169-36	48142-48151	subscales	_	
169-37	48152-48154	of	_	
169-38	48155-48165	postpartum	_	
169-39	48166-48173	bonding	_	
169-40	48174-48187	questionnaire	_	
169-41	48188-48189	(	_	
169-42	48189-48192	PBQ	_	
169-43	48192-48193	)	_	
169-44	48193-48194	.	_	

#Text=A, The impaired bonding subscale (IB).
170-1	48195-48196	A	_	
170-2	48196-48197	,	_	
170-3	48198-48201	The	_	
170-4	48202-48210	impaired	_	
170-5	48211-48218	bonding	_	
170-6	48219-48227	subscale	_	
170-7	48228-48229	(	_	
170-8	48229-48231	IB	_	
170-9	48231-48232	)	_	
170-10	48232-48233	.	_	

#Text=B, The rejection and pathological anger subscale (RPA).
171-1	48234-48235	B	_	
171-2	48235-48236	,	_	
171-3	48237-48240	The	_	
171-4	48241-48250	rejection	_	
171-5	48251-48254	and	_	
171-6	48255-48267	pathological	_	
171-7	48268-48273	anger	_	
171-8	48274-48282	subscale	_	
171-9	48283-48284	(	_	
171-10	48284-48287	RPA	_	
171-11	48287-48288	)	_	
171-12	48288-48289	.	_	

#Text=C, The infant-focused anxiety subscale (IFA).
172-1	48290-48291	C	_	
172-2	48291-48292	,	_	
172-3	48293-48296	The	_	
172-4	48297-48311	infant-focused	_	
172-5	48312-48319	anxiety	_	
172-6	48320-48328	subscale	_	
172-7	48329-48330	(	_	
172-8	48330-48333	IFA	_	
172-9	48333-48334	)	_	
172-10	48334-48335	.	_	

#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group.
173-1	48336-48349	Abbreviations	_	
173-2	48349-48350	:	_	
173-3	48351-48353	BT	_	
173-4	48353-48354	,	_	
173-5	48355-48368	buprenorphine	_	
173-6	48369-48378	treatment	_	
173-7	48379-48382	for	_	
173-8	48383-48389	opioid	_	
173-9	48390-48393	use	_	
173-10	48394-48402	disorder	_	
173-11	48402-48403	;	_	
173-12	48404-48406	CG	_	
173-13	48406-48407	,	_	
173-14	48408-48418	comparison	_	
173-15	48419-48424	group	_	
173-16	48424-48425	.	_	

#Text=T1, 1 month postpartum; T2, 4 months postpartum
#Text=The group main effects on the periaqueductal gray (PAG)-dependent resting-state functional connectivity (rs-FC) at 1 month postpartum.
174-1	48426-48428	T1	_	
174-2	48428-48429	,	_	
174-3	48430-48431	1	_	
174-4	48432-48437	month	_	
174-5	48438-48448	postpartum	_	
174-6	48448-48449	;	_	
174-7	48450-48452	T2	_	
174-8	48452-48453	,	_	
174-9	48454-48455	4	_	
174-10	48456-48462	months	_	
174-11	48463-48473	postpartum	_	
174-12	48474-48477	The	_	
174-13	48478-48483	group	_	
174-14	48484-48488	main	_	
174-15	48489-48496	effects	_	
174-16	48497-48499	on	_	
174-17	48500-48503	the	_	
174-18	48504-48518	periaqueductal	_	
174-19	48519-48523	gray	_	
174-20	48524-48525	(	_	
174-21	48525-48528	PAG	_	
174-22	48528-48529	)	_	
174-23	48529-48530	-	_	
174-24	48530-48539	dependent	_	
174-25	48540-48553	resting-state	_	
174-26	48554-48564	functional	_	
174-27	48565-48577	connectivity	_	
174-28	48578-48579	(	_	
174-29	48579-48584	rs-FC	_	
174-30	48584-48585	)	_	
174-31	48586-48588	at	_	
174-32	48589-48590	1	_	
174-33	48591-48596	month	_	
174-34	48597-48607	postpartum	_	
174-35	48607-48608	.	_	

#Text=The red/warm coloured clusters indicate buprenorphine treatment for opioid use disorder (BT) > comparison group (CG) differences and the blue/winter colored clusters indicate CG > BT differences; all clusters shown are whole-brain corrected at the cluster level, except the a prior region of interest, hypothalamus*.
175-1	48609-48612	The	_	
175-2	48613-48616	red	_	
175-3	48616-48617	/	_	
175-4	48617-48621	warm	_	
175-5	48622-48630	coloured	_	
175-6	48631-48639	clusters	_	
175-7	48640-48648	indicate	_	
175-8	48649-48662	buprenorphine	_	
175-9	48663-48672	treatment	_	
175-10	48673-48676	for	_	
175-11	48677-48683	opioid	_	
175-12	48684-48687	use	_	
175-13	48688-48696	disorder	_	
175-14	48697-48698	(	_	
175-15	48698-48700	BT	_	
175-16	48700-48701	)	_	
175-17	48702-48703	>	_	
175-18	48704-48714	comparison	_	
175-19	48715-48720	group	_	
175-20	48721-48722	(	_	
175-21	48722-48724	CG	_	
175-22	48724-48725	)	_	
175-23	48726-48737	differences	_	
175-24	48738-48741	and	_	
175-25	48742-48745	the	_	
175-26	48746-48750	blue	_	
175-27	48750-48751	/	_	
175-28	48751-48757	winter	_	
175-29	48758-48765	colored	_	
175-30	48766-48774	clusters	_	
175-31	48775-48783	indicate	_	
175-32	48784-48786	CG	_	
175-33	48787-48788	>	_	
175-34	48789-48791	BT	_	
175-35	48792-48803	differences	_	
175-36	48803-48804	;	_	
175-37	48805-48808	all	_	
175-38	48809-48817	clusters	_	
175-39	48818-48823	shown	_	
175-40	48824-48827	are	_	
175-41	48828-48839	whole-brain	_	
175-42	48840-48849	corrected	_	
175-43	48850-48852	at	_	
175-44	48853-48856	the	_	
175-45	48857-48864	cluster	_	
175-46	48865-48870	level	_	
175-47	48870-48871	,	_	
175-48	48872-48878	except	_	
175-49	48879-48882	the	_	
175-50	48883-48884	a	_	
175-51	48885-48890	prior	_	
175-52	48891-48897	region	_	
175-53	48898-48900	of	_	
175-54	48901-48909	interest	_	
175-55	48909-48910	,	_	
175-56	48911-48923	hypothalamus	_	
175-57	48923-48924	*	_	
175-58	48924-48925	.	_	

#Text=Abbreviations: AMY/HIP, amygdala/hippocampus; dPrC, dorsal precuneus; IC, insular cortex; ITG, inferior temporal gyrus; MTG, middle temporal gyrus; PCC/Prc, posterior cingulate cortex/precuneus; PosCG, postcentral gyrus; PreCG, precentral gyrus; SA/CN, septal area/caudate nucleus; SMG, supramarginal gyrus.
176-1	48926-48939	Abbreviations	_	
176-2	48939-48940	:	_	
176-3	48941-48944	AMY	_	
176-4	48944-48945	/	_	
176-5	48945-48948	HIP	_	
176-6	48948-48949	,	_	
176-7	48950-48958	amygdala	_	
176-8	48958-48959	/	_	
176-9	48959-48970	hippocampus	_	
176-10	48970-48971	;	_	
176-11	48972-48976	dPrC	_	
176-12	48976-48977	,	_	
176-13	48978-48984	dorsal	_	
176-14	48985-48994	precuneus	_	
176-15	48994-48995	;	_	
176-16	48996-48998	IC	_	
176-17	48998-48999	,	_	
176-18	49000-49007	insular	_	
176-19	49008-49014	cortex	_	
176-20	49014-49015	;	_	
176-21	49016-49019	ITG	_	
176-22	49019-49020	,	_	
176-23	49021-49029	inferior	_	
176-24	49030-49038	temporal	_	
176-25	49039-49044	gyrus	_	
176-26	49044-49045	;	_	
176-27	49046-49049	MTG	_	
176-28	49049-49050	,	_	
176-29	49051-49057	middle	_	
176-30	49058-49066	temporal	_	
176-31	49067-49072	gyrus	_	
176-32	49072-49073	;	_	
176-33	49074-49077	PCC	_	
176-34	49077-49078	/	_	
176-35	49078-49081	Prc	_	
176-36	49081-49082	,	_	
176-37	49083-49092	posterior	_	
176-38	49093-49102	cingulate	_	
176-39	49103-49109	cortex	_	
176-40	49109-49110	/	_	
176-41	49110-49119	precuneus	_	
176-42	49119-49120	;	_	
176-43	49121-49126	PosCG	_	
176-44	49126-49127	,	_	
176-45	49128-49139	postcentral	_	
176-46	49140-49145	gyrus	_	
176-47	49145-49146	;	_	
176-48	49147-49152	PreCG	_	
176-49	49152-49153	,	_	
176-50	49154-49164	precentral	_	
176-51	49165-49170	gyrus	_	
176-52	49170-49171	;	_	
176-53	49172-49174	SA	_	
176-54	49174-49175	/	_	
176-55	49175-49177	CN	_	
176-56	49177-49178	,	_	
176-57	49179-49185	septal	_	
176-58	49186-49190	area	_	
176-59	49190-49191	/	_	
176-60	49191-49198	caudate	_	
176-61	49199-49206	nucleus	_	
176-62	49206-49207	;	_	
176-63	49208-49211	SMG	_	
176-64	49211-49212	,	_	
176-65	49213-49226	supramarginal	_	
176-66	49227-49232	gyrus	_	
176-67	49232-49233	.	_	

#Text=The z- or y-coordinates of the slices are listed below the images, which are rendered in neurological convention (the right side of image is the right hemisphere)
#Text=The group main effects on the periaqueductal gray (PAG)-dependent resting-state functional connectivity (rs-FC) at 4 months postpartum.
177-1	49234-49237	The	_	
177-2	49238-49239	z	_	
177-3	49239-49240	-	_	
177-4	49241-49243	or	_	
177-5	49244-49257	y-coordinates	_	
177-6	49258-49260	of	_	
177-7	49261-49264	the	_	
177-8	49265-49271	slices	_	
177-9	49272-49275	are	_	
177-10	49276-49282	listed	_	
177-11	49283-49288	below	_	
177-12	49289-49292	the	_	
177-13	49293-49299	images	_	
177-14	49299-49300	,	_	
177-15	49301-49306	which	_	
177-16	49307-49310	are	_	
177-17	49311-49319	rendered	_	
177-18	49320-49322	in	_	
177-19	49323-49335	neurological	_	
177-20	49336-49346	convention	_	
177-21	49347-49348	(	_	
177-22	49348-49351	the	_	
177-23	49352-49357	right	_	
177-24	49358-49362	side	_	
177-25	49363-49365	of	_	
177-26	49366-49371	image	_	
177-27	49372-49374	is	_	
177-28	49375-49378	the	_	
177-29	49379-49384	right	_	
177-30	49385-49395	hemisphere	_	
177-31	49395-49396	)	_	
177-32	49397-49400	The	_	
177-33	49401-49406	group	_	
177-34	49407-49411	main	_	
177-35	49412-49419	effects	_	
177-36	49420-49422	on	_	
177-37	49423-49426	the	_	
177-38	49427-49441	periaqueductal	_	
177-39	49442-49446	gray	_	
177-40	49447-49448	(	_	
177-41	49448-49451	PAG	_	
177-42	49451-49452	)	_	
177-43	49452-49453	-	_	
177-44	49453-49462	dependent	_	
177-45	49463-49476	resting-state	_	
177-46	49477-49487	functional	_	
177-47	49488-49500	connectivity	_	
177-48	49501-49502	(	_	
177-49	49502-49507	rs-FC	_	
177-50	49507-49508	)	_	
177-51	49509-49511	at	_	
177-52	49512-49513	4	_	
177-53	49514-49520	months	_	
177-54	49521-49531	postpartum	_	
177-55	49531-49532	.	_	

#Text=The blue/winter colored clusters indicate comparison group (CG) > buprenorphine treatment for opioid use disorder (BT) differences, all clusters shown are whole-brain corrected at the cluster level.
178-1	49533-49536	The	_	
178-2	49537-49541	blue	_	
178-3	49541-49542	/	_	
178-4	49542-49548	winter	_	
178-5	49549-49556	colored	_	
178-6	49557-49565	clusters	_	
178-7	49566-49574	indicate	_	
178-8	49575-49585	comparison	_	
178-9	49586-49591	group	_	
178-10	49592-49593	(	_	
178-11	49593-49595	CG	_	
178-12	49595-49596	)	_	
178-13	49597-49598	>	_	
178-14	49599-49612	buprenorphine	_	
178-15	49613-49622	treatment	_	
178-16	49623-49626	for	_	
178-17	49627-49633	opioid	_	
178-18	49634-49637	use	_	
178-19	49638-49646	disorder	_	
178-20	49647-49648	(	_	
178-21	49648-49650	BT	_	
178-22	49650-49651	)	_	
178-23	49652-49663	differences	_	
178-24	49663-49664	,	_	
178-25	49665-49668	all	_	
178-26	49669-49677	clusters	_	
178-27	49678-49683	shown	_	
178-28	49684-49687	are	_	
178-29	49688-49699	whole-brain	_	
178-30	49700-49709	corrected	_	
178-31	49710-49712	at	_	
178-32	49713-49716	the	_	
178-33	49717-49724	cluster	_	
178-34	49725-49730	level	_	
178-35	49730-49731	.	_	

#Text=Abbreviations: dACC, dorsal anterior cingulate cortex; vACC, ventral anterior cingulate cortex.
179-1	49732-49745	Abbreviations	_	
179-2	49745-49746	:	_	
179-3	49747-49751	dACC	_	
179-4	49751-49752	,	_	
179-5	49753-49759	dorsal	_	
179-6	49760-49768	anterior	_	
179-7	49769-49778	cingulate	_	
179-8	49779-49785	cortex	_	
179-9	49785-49786	;	_	
179-10	49787-49791	vACC	_	
179-11	49791-49792	,	_	
179-12	49793-49800	ventral	_	
179-13	49801-49809	anterior	_	
179-14	49810-49819	cingulate	_	
179-15	49820-49826	cortex	_	
179-16	49826-49827	.	_	

#Text=The z-coordinates of the slices are listed below the images, which are rendered in neurological convention (the right side of image is the right hemisphere)
#Text=The group by time interaction effects on the periaqueductal gray (PAG)-dependent resting-state functional connectivity (rs-FC).
180-1	49828-49831	The	_	
180-2	49832-49845	z-coordinates	_	
180-3	49846-49848	of	_	
180-4	49849-49852	the	_	
180-5	49853-49859	slices	_	
180-6	49860-49863	are	_	
180-7	49864-49870	listed	_	
180-8	49871-49876	below	_	
180-9	49877-49880	the	_	
180-10	49881-49887	images	_	
180-11	49887-49888	,	_	
180-12	49889-49894	which	_	
180-13	49895-49898	are	_	
180-14	49899-49907	rendered	_	
180-15	49908-49910	in	_	
180-16	49911-49923	neurological	_	
180-17	49924-49934	convention	_	
180-18	49935-49936	(	_	
180-19	49936-49939	the	_	
180-20	49940-49945	right	_	
180-21	49946-49950	side	_	
180-22	49951-49953	of	_	
180-23	49954-49959	image	_	
180-24	49960-49962	is	_	
180-25	49963-49966	the	_	
180-26	49967-49972	right	_	
180-27	49973-49983	hemisphere	_	
180-28	49983-49984	)	_	
180-29	49985-49988	The	_	
180-30	49989-49994	group	_	
180-31	49995-49997	by	_	
180-32	49998-50002	time	_	
180-33	50003-50014	interaction	_	
180-34	50015-50022	effects	_	
180-35	50023-50025	on	_	
180-36	50026-50029	the	_	
180-37	50030-50044	periaqueductal	_	
180-38	50045-50049	gray	_	
180-39	50050-50051	(	_	
180-40	50051-50054	PAG	_	
180-41	50054-50055	)	_	
180-42	50055-50056	-	_	
180-43	50056-50065	dependent	_	
180-44	50066-50079	resting-state	_	
180-45	50080-50090	functional	_	
180-46	50091-50103	connectivity	_	
180-47	50104-50105	(	_	
180-48	50105-50110	rs-FC	_	
180-49	50110-50111	)	_	
180-50	50111-50112	.	_	

#Text=The red/warm colored clusters indicate buprenorphine treatment for opioid use disorder (BT) > comparison group (CG) in 1 month postpartum (T1) to 4 months postpartum (T2) increases and the blue/ winter colored clusters indicate BT > CG in T1-to-T2 decreases, all clusters shown are whole-brain corrected at the cluster level.
181-1	50113-50116	The	_	
181-2	50117-50120	red	_	
181-3	50120-50121	/	_	
181-4	50121-50125	warm	_	
181-5	50126-50133	colored	_	
181-6	50134-50142	clusters	_	
181-7	50143-50151	indicate	_	
181-8	50152-50165	buprenorphine	_	
181-9	50166-50175	treatment	_	
181-10	50176-50179	for	_	
181-11	50180-50186	opioid	_	
181-12	50187-50190	use	_	
181-13	50191-50199	disorder	_	
181-14	50200-50201	(	_	
181-15	50201-50203	BT	_	
181-16	50203-50204	)	_	
181-17	50205-50206	>	_	
181-18	50207-50217	comparison	_	
181-19	50218-50223	group	_	
181-20	50224-50225	(	_	
181-21	50225-50227	CG	_	
181-22	50227-50228	)	_	
181-23	50229-50231	in	_	
181-24	50232-50233	1	_	
181-25	50234-50239	month	_	
181-26	50240-50250	postpartum	_	
181-27	50251-50252	(	_	
181-28	50252-50254	T1	_	
181-29	50254-50255	)	_	
181-30	50256-50258	to	_	
181-31	50259-50260	4	_	
181-32	50261-50267	months	_	
181-33	50268-50278	postpartum	_	
181-34	50279-50280	(	_	
181-35	50280-50282	T2	_	
181-36	50282-50283	)	_	
181-37	50284-50293	increases	_	
181-38	50294-50297	and	_	
181-39	50298-50301	the	_	
181-40	50302-50306	blue	_	
181-41	50306-50307	/	_	
181-42	50308-50314	winter	_	
181-43	50315-50322	colored	_	
181-44	50323-50331	clusters	_	
181-45	50332-50340	indicate	_	
181-46	50341-50343	BT	_	
181-47	50344-50345	>	_	
181-48	50346-50348	CG	_	
181-49	50349-50351	in	_	
181-50	50352-50354	T1	_	
181-51	50354-50355	-	_	
181-52	50355-50360	to-T2	_	
181-53	50361-50370	decreases	_	
181-54	50370-50371	,	_	
181-55	50372-50375	all	_	
181-56	50376-50384	clusters	_	
181-57	50385-50390	shown	_	
181-58	50391-50394	are	_	
181-59	50395-50406	whole-brain	_	
181-60	50407-50416	corrected	_	
181-61	50417-50419	at	_	
181-62	50420-50423	the	_	
181-63	50424-50431	cluster	_	
181-64	50432-50437	level	_	
181-65	50437-50438	.	_	

#Text=Abbreviations: dACC, dorsal anterior cingulate cortex; IC, insular cortex; MTG, middle temporal gyrus; SA/CN, septal area/caudate nucleus; OFC, orbital frontal cortex.
182-1	50439-50452	Abbreviations	_	
182-2	50452-50453	:	_	
182-3	50454-50458	dACC	_	
182-4	50458-50459	,	_	
182-5	50460-50466	dorsal	_	
182-6	50467-50475	anterior	_	
182-7	50476-50485	cingulate	_	
182-8	50486-50492	cortex	_	
182-9	50492-50493	;	_	
182-10	50494-50496	IC	_	
182-11	50496-50497	,	_	
182-12	50498-50505	insular	_	
182-13	50506-50512	cortex	_	
182-14	50512-50513	;	_	
182-15	50514-50517	MTG	_	
182-16	50517-50518	,	_	
182-17	50519-50525	middle	_	
182-18	50526-50534	temporal	_	
182-19	50535-50540	gyrus	_	
182-20	50540-50541	;	_	
182-21	50542-50544	SA	_	
182-22	50544-50545	/	_	
182-23	50545-50547	CN	_	
182-24	50547-50548	,	_	
182-25	50549-50555	septal	_	
182-26	50556-50560	area	_	
182-27	50560-50561	/	_	
182-28	50561-50568	caudate	_	
182-29	50569-50576	nucleus	_	
182-30	50576-50577	;	_	
182-31	50578-50581	OFC	_	
182-32	50581-50582	,	_	
182-33	50583-50590	orbital	_	
182-34	50591-50598	frontal	_	
182-35	50599-50605	cortex	_	
182-36	50605-50606	.	_	

#Text=The z-coordinates of the slices are listed below the images, which are rendered in neurological convention (the right side of image is the right hemisphere)
#Text=The group by timeline charts for brain regions showing group differences in their resting-state functional connectivity (rs-FC) with the periaqueductal gray (PAG), as indicated in Figures 3–5.
183-1	50607-50610	The	_	
183-2	50611-50624	z-coordinates	_	
183-3	50625-50627	of	_	
183-4	50628-50631	the	_	
183-5	50632-50638	slices	_	
183-6	50639-50642	are	_	
183-7	50643-50649	listed	_	
183-8	50650-50655	below	_	
183-9	50656-50659	the	_	
183-10	50660-50666	images	_	
183-11	50666-50667	,	_	
183-12	50668-50673	which	_	
183-13	50674-50677	are	_	
183-14	50678-50686	rendered	_	
183-15	50687-50689	in	_	
183-16	50690-50702	neurological	_	
183-17	50703-50713	convention	_	
183-18	50714-50715	(	_	
183-19	50715-50718	the	_	
183-20	50719-50724	right	_	
183-21	50725-50729	side	_	
183-22	50730-50732	of	_	
183-23	50733-50738	image	_	
183-24	50739-50741	is	_	
183-25	50742-50745	the	_	
183-26	50746-50751	right	_	
183-27	50752-50762	hemisphere	_	
183-28	50762-50763	)	_	
183-29	50764-50767	The	_	
183-30	50768-50773	group	_	
183-31	50774-50776	by	_	
183-32	50777-50785	timeline	_	
183-33	50786-50792	charts	_	
183-34	50793-50796	for	_	
183-35	50797-50802	brain	_	
183-36	50803-50810	regions	_	
183-37	50811-50818	showing	_	
183-38	50819-50824	group	_	
183-39	50825-50836	differences	_	
183-40	50837-50839	in	_	
183-41	50840-50845	their	_	
183-42	50846-50859	resting-state	_	
183-43	50860-50870	functional	_	
183-44	50871-50883	connectivity	_	
183-45	50884-50885	(	_	
183-46	50885-50890	rs-FC	_	
183-47	50890-50891	)	_	
183-48	50892-50896	with	_	
183-49	50897-50900	the	_	
183-50	50901-50915	periaqueductal	_	
183-51	50916-50920	gray	_	
183-52	50921-50922	(	_	
183-53	50922-50925	PAG	_	
183-54	50925-50926	)	_	
183-55	50926-50927	,	_	
183-56	50928-50930	as	_	
183-57	50931-50940	indicated	_	
183-58	50941-50943	in	_	
183-59	50944-50951	Figures	_	
183-60	50952-50953	3	_	
183-61	50953-50954	–	_	
183-62	50954-50955	5	_	
183-63	50955-50956	.	_	

#Text=A, Hypothalamus.
184-1	50957-50958	A	_	
184-2	50958-50959	,	_	
184-3	50960-50972	Hypothalamus	_	
184-4	50972-50973	.	_	

#Text=B, Right amygdala/hippocampus.
185-1	50974-50975	B	_	
185-2	50975-50976	,	_	
185-3	50977-50982	Right	_	
185-4	50983-50991	amygdala	_	
185-5	50991-50992	/	_	
185-6	50992-51003	hippocampus	_	
185-7	51003-51004	.	_	

#Text=C, Right middle temporal gyrus.
186-1	51005-51006	C	_	
186-2	51006-51007	,	_	
186-3	51008-51013	Right	_	
186-4	51014-51020	middle	_	
186-5	51021-51029	temporal	_	
186-6	51030-51035	gyrus	_	
186-7	51035-51036	.	_	

#Text=D, Right insular cortex.
187-1	51037-51038	D	_	
187-2	51038-51039	,	_	
187-3	51040-51045	Right	_	
187-4	51046-51053	insular	_	
187-5	51054-51060	cortex	_	
187-6	51060-51061	.	_	

#Text=E, Septal area/caudate nucleus.
188-1	51062-51063	E	_	
188-2	51063-51064	,	_	
188-3	51065-51071	Septal	_	
188-4	51072-51076	area	_	
188-5	51076-51077	/	_	
188-6	51077-51084	caudate	_	
188-7	51085-51092	nucleus	_	
188-8	51092-51093	.	_	

#Text=F, Dorsal anterior cingulate cortex.
189-1	51094-51095	F	_	
189-2	51095-51096	,	_	
189-3	51097-51103	Dorsal	_	
189-4	51104-51112	anterior	_	
189-5	51113-51122	cingulate	_	
189-6	51123-51129	cortex	_	
189-7	51129-51130	.	_	

#Text=G, Left orbital frontal cortex.
190-1	51131-51132	G	_	
190-2	51132-51133	,	_	
190-3	51134-51138	Left	_	
190-4	51139-51146	orbital	_	
190-5	51147-51154	frontal	_	
190-6	51155-51161	cortex	_	
190-7	51161-51162	.	_	

#Text=H, Dorsal precuneus.
191-1	51163-51164	H	_	
191-2	51164-51165	,	_	
191-3	51166-51172	Dorsal	_	
191-4	51173-51182	precuneus	_	
191-5	51182-51183	.	_	

#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group.
192-1	51184-51197	Abbreviations	_	
192-2	51197-51198	:	_	
192-3	51199-51201	BT	_	
192-4	51201-51202	,	_	
192-5	51203-51216	buprenorphine	_	
192-6	51217-51226	treatment	_	
192-7	51227-51230	for	_	
192-8	51231-51237	opioid	_	
192-9	51238-51241	use	_	
192-10	51242-51250	disorder	_	
192-11	51250-51251	;	_	
192-12	51252-51254	CG	_	
192-13	51254-51255	,	_	
192-14	51256-51266	comparison	_	
192-15	51267-51272	group	_	
192-16	51272-51273	.	_	

#Text=T1, 1 month postpartum; T2, 4 months postpartum
#Text=The scatter plots relating the 1 month postpartum (T1) to 4 months postpartum (T2) changes in the periaqueductal gray (PAG)-hypothalamus resting-state functional connectivity (rs-FC) to T1/T2 Postpartum Bonding Questionnaire (PBQ) subscales of impaired bonding (IB) (A, B), rejection and pathological anger (RPA) (C, D) and infant-focused anxiety (IFA) (E, F).
193-1	51274-51276	T1	_	
193-2	51276-51277	,	_	
193-3	51278-51279	1	_	
193-4	51280-51285	month	_	
193-5	51286-51296	postpartum	_	
193-6	51296-51297	;	_	
193-7	51298-51300	T2	_	
193-8	51300-51301	,	_	
193-9	51302-51303	4	_	
193-10	51304-51310	months	_	
193-11	51311-51321	postpartum	_	
193-12	51322-51325	The	_	
193-13	51326-51333	scatter	_	
193-14	51334-51339	plots	_	
193-15	51340-51348	relating	_	
193-16	51349-51352	the	_	
193-17	51353-51354	1	_	
193-18	51355-51360	month	_	
193-19	51361-51371	postpartum	_	
193-20	51372-51373	(	_	
193-21	51373-51375	T1	_	
193-22	51375-51376	)	_	
193-23	51377-51379	to	_	
193-24	51380-51381	4	_	
193-25	51382-51388	months	_	
193-26	51389-51399	postpartum	_	
193-27	51400-51401	(	_	
193-28	51401-51403	T2	_	
193-29	51403-51404	)	_	
193-30	51405-51412	changes	_	
193-31	51413-51415	in	_	
193-32	51416-51419	the	_	
193-33	51420-51434	periaqueductal	_	
193-34	51435-51439	gray	_	
193-35	51440-51441	(	_	
193-36	51441-51444	PAG	_	
193-37	51444-51445	)	_	
193-38	51445-51446	-	_	
193-39	51446-51458	hypothalamus	_	
193-40	51459-51472	resting-state	_	
193-41	51473-51483	functional	_	
193-42	51484-51496	connectivity	_	
193-43	51497-51498	(	_	
193-44	51498-51503	rs-FC	_	
193-45	51503-51504	)	_	
193-46	51505-51507	to	_	
193-47	51508-51510	T1	_	
193-48	51510-51511	/	_	
193-49	51511-51513	T2	_	
193-50	51514-51524	Postpartum	_	
193-51	51525-51532	Bonding	_	
193-52	51533-51546	Questionnaire	_	
193-53	51547-51548	(	_	
193-54	51548-51551	PBQ	_	
193-55	51551-51552	)	_	
193-56	51553-51562	subscales	_	
193-57	51563-51565	of	_	
193-58	51566-51574	impaired	_	
193-59	51575-51582	bonding	_	
193-60	51583-51584	(	_	
193-61	51584-51586	IB	_	
193-62	51586-51587	)	_	
193-63	51588-51589	(	_	
193-64	51589-51590	A	_	
193-65	51590-51591	,	_	
193-66	51592-51593	B	_	
193-67	51593-51594	)	_	
193-68	51594-51595	,	_	
193-69	51596-51605	rejection	_	
193-70	51606-51609	and	_	
193-71	51610-51622	pathological	_	
193-72	51623-51628	anger	_	
193-73	51629-51630	(	_	
193-74	51630-51633	RPA	_	
193-75	51633-51634	)	_	
193-76	51635-51636	(	_	
193-77	51636-51637	C	_	
193-78	51637-51638	,	_	
193-79	51639-51640	D	_	
193-80	51640-51641	)	_	
193-81	51642-51645	and	_	
193-82	51646-51660	infant-focused	_	
193-83	51661-51668	anxiety	_	
193-84	51669-51670	(	_	
193-85	51670-51673	IFA	_	
193-86	51673-51674	)	_	
193-87	51675-51676	(	_	
193-88	51676-51677	E	_	
193-89	51677-51678	,	_	
193-90	51679-51680	F	_	
193-91	51680-51681	)	_	
193-92	51681-51682	.	_	

#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group
#Text=The scatter plots relating the 1 month postpartum (T1) to 4 months postpartum (T2) changes in the periaqueductal gray (PAG)-right amygdala resting-state functional connectivity (rs-FC) to T1/T2 Postpartum Bonding Questionnaire (PBQ) subscales of impaired bonding (IB) (A, B), rejection and pathological anger (RPA) (C, D) and infant-focused anxiety (IFA) (E, F).
194-1	51683-51696	Abbreviations	_	
194-2	51696-51697	:	_	
194-3	51698-51700	BT	_	
194-4	51700-51701	,	_	
194-5	51702-51715	buprenorphine	_	
194-6	51716-51725	treatment	_	
194-7	51726-51729	for	_	
194-8	51730-51736	opioid	_	
194-9	51737-51740	use	_	
194-10	51741-51749	disorder	_	
194-11	51749-51750	;	_	
194-12	51751-51753	CG	_	
194-13	51753-51754	,	_	
194-14	51755-51765	comparison	_	
194-15	51766-51771	group	_	
194-16	51772-51775	The	_	
194-17	51776-51783	scatter	_	
194-18	51784-51789	plots	_	
194-19	51790-51798	relating	_	
194-20	51799-51802	the	_	
194-21	51803-51804	1	_	
194-22	51805-51810	month	_	
194-23	51811-51821	postpartum	_	
194-24	51822-51823	(	_	
194-25	51823-51825	T1	_	
194-26	51825-51826	)	_	
194-27	51827-51829	to	_	
194-28	51830-51831	4	_	
194-29	51832-51838	months	_	
194-30	51839-51849	postpartum	_	
194-31	51850-51851	(	_	
194-32	51851-51853	T2	_	
194-33	51853-51854	)	_	
194-34	51855-51862	changes	_	
194-35	51863-51865	in	_	
194-36	51866-51869	the	_	
194-37	51870-51884	periaqueductal	_	
194-38	51885-51889	gray	_	
194-39	51890-51891	(	_	
194-40	51891-51894	PAG	_	
194-41	51894-51895	)	_	
194-42	51895-51896	-	_	
194-43	51896-51901	right	_	
194-44	51902-51910	amygdala	_	
194-45	51911-51924	resting-state	_	
194-46	51925-51935	functional	_	
194-47	51936-51948	connectivity	_	
194-48	51949-51950	(	_	
194-49	51950-51955	rs-FC	_	
194-50	51955-51956	)	_	
194-51	51957-51959	to	_	
194-52	51960-51962	T1	_	
194-53	51962-51963	/	_	
194-54	51963-51965	T2	_	
194-55	51966-51976	Postpartum	_	
194-56	51977-51984	Bonding	_	
194-57	51985-51998	Questionnaire	_	
194-58	51999-52000	(	_	
194-59	52000-52003	PBQ	_	
194-60	52003-52004	)	_	
194-61	52005-52014	subscales	_	
194-62	52015-52017	of	_	
194-63	52018-52026	impaired	_	
194-64	52027-52034	bonding	_	
194-65	52035-52036	(	_	
194-66	52036-52038	IB	_	
194-67	52038-52039	)	_	
194-68	52040-52041	(	_	
194-69	52041-52042	A	_	
194-70	52042-52043	,	_	
194-71	52044-52045	B	_	
194-72	52045-52046	)	_	
194-73	52046-52047	,	_	
194-74	52048-52057	rejection	_	
194-75	52058-52061	and	_	
194-76	52062-52074	pathological	_	
194-77	52075-52080	anger	_	
194-78	52081-52082	(	_	
194-79	52082-52085	RPA	_	
194-80	52085-52086	)	_	
194-81	52087-52088	(	_	
194-82	52088-52089	C	_	
194-83	52089-52090	,	_	
194-84	52091-52092	D	_	
194-85	52092-52093	)	_	
194-86	52094-52097	and	_	
194-87	52098-52112	infant-focused	_	
194-88	52113-52120	anxiety	_	
194-89	52121-52122	(	_	
194-90	52122-52125	IFA	_	
194-91	52125-52126	)	_	
194-92	52127-52128	(	_	
194-93	52128-52129	E	_	
194-94	52129-52130	,	_	
194-95	52131-52132	F	_	
194-96	52132-52133	)	_	
194-97	52133-52134	.	_	

#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group
#Text=Demographics
#Text=\tBT\tCG\t \tAge\t \t Mean\t29.86\t27.62\t \t SD\t6.62\t8.46\t \tInfant age at T1 scan\t \t Mean\t0.08\t0.07\t \t SD\t0.01\t0.027\t \tNumber of child\t \t Mean\t1.71\t1.60\t \t SD\t0.76\t0.66\t \tRace\t \t European American\t6\t13\t \t African American\t0\t12\t \t Native American\t1\t0\t \tSocial economic status\t \t Low (under $20K household income)\t4\t14\t \t Middle\t3\t11\t \t
#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group.
195-1	52135-52148	Abbreviations	_	
195-2	52148-52149	:	_	
195-3	52150-52152	BT	_	
195-4	52152-52153	,	_	
195-5	52154-52167	buprenorphine	_	
195-6	52168-52177	treatment	_	
195-7	52178-52181	for	_	
195-8	52182-52188	opioid	_	
195-9	52189-52192	use	_	
195-10	52193-52201	disorder	_	
195-11	52201-52202	;	_	
195-12	52203-52205	CG	_	
195-13	52205-52206	,	_	
195-14	52207-52217	comparison	_	
195-15	52218-52223	group	_	
195-16	52224-52236	Demographics	_	
195-17	52238-52240	BT	_	
195-18	52241-52243	CG	_	
195-19	52246-52249	Age	_	
195-20	52253-52257	Mean	_	
195-21	52258-52263	29.86	_	
195-22	52264-52269	27.62	_	
195-23	52273-52275	SD	_	
195-24	52276-52280	6.62	_	
195-25	52281-52285	8.46	_	
195-26	52288-52294	Infant	_	
195-27	52295-52298	age	_	
195-28	52299-52301	at	_	
195-29	52302-52304	T1	_	
195-30	52305-52309	scan	_	
195-31	52313-52317	Mean	_	
195-32	52318-52322	0.08	_	
195-33	52323-52327	0.07	_	
195-34	52331-52333	SD	_	
195-35	52334-52338	0.01	_	
195-36	52339-52344	0.027	_	
195-37	52347-52353	Number	_	
195-38	52354-52356	of	_	
195-39	52357-52362	child	_	
195-40	52366-52370	Mean	_	
195-41	52371-52375	1.71	_	
195-42	52376-52380	1.60	_	
195-43	52384-52386	SD	_	
195-44	52387-52391	0.76	_	
195-45	52392-52396	0.66	_	
195-46	52399-52403	Race	_	
195-47	52407-52415	European	_	
195-48	52416-52424	American	_	
195-49	52425-52426	6	_	
195-50	52427-52429	13	_	
195-51	52433-52440	African	_	
195-52	52441-52449	American	_	
195-53	52450-52451	0	_	
195-54	52452-52454	12	_	
195-55	52458-52464	Native	_	
195-56	52465-52473	American	_	
195-57	52474-52475	1	_	
195-58	52476-52477	0	_	
195-59	52480-52486	Social	_	
195-60	52487-52495	economic	_	
195-61	52496-52502	status	_	
195-62	52506-52509	Low	_	
195-63	52510-52511	(	_	
195-64	52511-52516	under	_	
195-65	52517-52521	$20K	_	
195-66	52522-52531	household	_	
195-67	52532-52538	income	_	
195-68	52538-52539	)	_	
195-69	52540-52541	4	_	
195-70	52542-52544	14	_	
195-71	52548-52554	Middle	_	
195-72	52555-52556	3	_	
195-73	52557-52559	11	_	
195-74	52563-52576	Abbreviations	_	
195-75	52576-52577	:	_	
195-76	52578-52580	BT	_	
195-77	52580-52581	,	_	
195-78	52582-52595	buprenorphine	_	
195-79	52596-52605	treatment	_	
195-80	52606-52609	for	_	
195-81	52610-52616	opioid	_	
195-82	52617-52620	use	_	
195-83	52621-52629	disorder	_	
195-84	52629-52630	;	_	
195-85	52631-52633	CG	_	
195-86	52633-52634	,	_	
195-87	52635-52645	comparison	_	
195-88	52646-52651	group	_	
195-89	52651-52652	.	_	

#Text=BT vs CG main effects on PAG-dependent rs-FC at T1
#Text=Brain region\tSide\tMNI coordinates\tNumber of voxels\tZ score\t \tx\ty\tz\t \tBT > CG\t\t\t\t\t\t\t \t Inferior temporal gyrus\tR\t68\t−28\t−24\t119\t5.21\t \t Septal area/caudate nucleus\tR/L\t−4\t16\t4\t478\t5.05\t \t Amygdala/hippocampus\tR\t24\t−14\t−12\t220\t4.88\t \t Hypothalamusa\tR/L\t4\t−2\t−12\t44\t2.42\t \tBT < CG\t \t Supramarginal gyrus\tR\t58\t−46\t30\t1111\t5.55\t \t Middle temporal gyrus\tL\t−46\t−58\t8\t487\t5.14\t \t Posterior cingulate cortex/precuneus\tR\t14\t−46\t12\t655\t4.94\t \t Postcentral gyrus\tL\t−68\t−14\t26\t108\t4.61\t \t Middle cingulate cortex\tR\t18\t−36\t40\t298\t4.59\t \t Insular cortex\tR\t48\t6\t−2\t122\t4.57\t \t Precentral gyrus\tR\t48\t−2\t50\t86\t4.51\t \t Precuneus, dorsal\tR/L\t−6\t−56\t60\t160\t4.49\t \t
#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group; PAG, periaqueductal gray; rs-FC, resting-state functional connectivity.
196-1	52653-52655	BT	_	
196-2	52656-52658	vs	_	
196-3	52659-52661	CG	_	
196-4	52662-52666	main	_	
196-5	52667-52674	effects	_	
196-6	52675-52677	on	_	
196-7	52678-52691	PAG-dependent	_	
196-8	52692-52697	rs-FC	_	
196-9	52698-52700	at	_	
196-10	52701-52703	T1	_	
196-11	52704-52709	Brain	_	
196-12	52710-52716	region	_	
196-13	52717-52721	Side	_	
196-14	52722-52725	MNI	_	
196-15	52726-52737	coordinates	_	
196-16	52738-52744	Number	_	
196-17	52745-52747	of	_	
196-18	52748-52754	voxels	_	
196-19	52755-52756	Z	_	
196-20	52757-52762	score	_	
196-21	52765-52766	x	_	
196-22	52767-52768	y	_	
196-23	52769-52770	z	_	
196-24	52773-52775	BT	_	
196-25	52776-52777	>	_	
196-26	52778-52780	CG	_	
196-27	52790-52798	Inferior	_	
196-28	52799-52807	temporal	_	
196-29	52808-52813	gyrus	_	
196-30	52814-52815	R	_	
196-31	52816-52818	68	_	
196-32	52819-52820	−	_	
196-33	52820-52822	28	_	
196-34	52823-52824	−	_	
196-35	52824-52826	24	_	
196-36	52827-52830	119	_	
196-37	52831-52835	5.21	_	
196-38	52839-52845	Septal	_	
196-39	52846-52850	area	_	
196-40	52850-52851	/	_	
196-41	52851-52858	caudate	_	
196-42	52859-52866	nucleus	_	
196-43	52867-52868	R	_	
196-44	52868-52869	/	_	
196-45	52869-52870	L	_	
196-46	52871-52872	−	_	
196-47	52872-52873	4	_	
196-48	52874-52876	16	_	
196-49	52877-52878	4	_	
196-50	52879-52882	478	_	
196-51	52883-52887	5.05	_	
196-52	52891-52899	Amygdala	_	
196-53	52899-52900	/	_	
196-54	52900-52911	hippocampus	_	
196-55	52912-52913	R	_	
196-56	52914-52916	24	_	
196-57	52917-52918	−	_	
196-58	52918-52920	14	_	
196-59	52921-52922	−	_	
196-60	52922-52924	12	_	
196-61	52925-52928	220	_	
196-62	52929-52933	4.88	_	
196-63	52937-52950	Hypothalamusa	_	
196-64	52951-52952	R	_	
196-65	52952-52953	/	_	
196-66	52953-52954	L	_	
196-67	52955-52956	4	_	
196-68	52957-52958	−	_	
196-69	52958-52959	2	_	
196-70	52960-52961	−	_	
196-71	52961-52963	12	_	
196-72	52964-52966	44	_	
196-73	52967-52971	2.42	_	
196-74	52974-52976	BT	_	
196-75	52977-52978	<	_	
196-76	52979-52981	CG	_	
196-77	52985-52998	Supramarginal	_	
196-78	52999-53004	gyrus	_	
196-79	53005-53006	R	_	
196-80	53007-53009	58	_	
196-81	53010-53011	−	_	
196-82	53011-53013	46	_	
196-83	53014-53016	30	_	
196-84	53017-53021	1111	_	
196-85	53022-53026	5.55	_	
196-86	53030-53036	Middle	_	
196-87	53037-53045	temporal	_	
196-88	53046-53051	gyrus	_	
196-89	53052-53053	L	_	
196-90	53054-53055	−	_	
196-91	53055-53057	46	_	
196-92	53058-53059	−	_	
196-93	53059-53061	58	_	
196-94	53062-53063	8	_	
196-95	53064-53067	487	_	
196-96	53068-53072	5.14	_	
196-97	53076-53085	Posterior	_	
196-98	53086-53095	cingulate	_	
196-99	53096-53102	cortex	_	
196-100	53102-53103	/	_	
196-101	53103-53112	precuneus	_	
196-102	53113-53114	R	_	
196-103	53115-53117	14	_	
196-104	53118-53119	−	_	
196-105	53119-53121	46	_	
196-106	53122-53124	12	_	
196-107	53125-53128	655	_	
196-108	53129-53133	4.94	_	
196-109	53137-53148	Postcentral	_	
196-110	53149-53154	gyrus	_	
196-111	53155-53156	L	_	
196-112	53157-53158	−	_	
196-113	53158-53160	68	_	
196-114	53161-53162	−	_	
196-115	53162-53164	14	_	
196-116	53165-53167	26	_	
196-117	53168-53171	108	_	
196-118	53172-53176	4.61	_	
196-119	53180-53186	Middle	_	
196-120	53187-53196	cingulate	_	
196-121	53197-53203	cortex	_	
196-122	53204-53205	R	_	
196-123	53206-53208	18	_	
196-124	53209-53210	−	_	
196-125	53210-53212	36	_	
196-126	53213-53215	40	_	
196-127	53216-53219	298	_	
196-128	53220-53224	4.59	_	
196-129	53228-53235	Insular	_	
196-130	53236-53242	cortex	_	
196-131	53243-53244	R	_	
196-132	53245-53247	48	_	
196-133	53248-53249	6	_	
196-134	53250-53251	−	_	
196-135	53251-53252	2	_	
196-136	53253-53256	122	_	
196-137	53257-53261	4.57	_	
196-138	53265-53275	Precentral	_	
196-139	53276-53281	gyrus	_	
196-140	53282-53283	R	_	
196-141	53284-53286	48	_	
196-142	53287-53288	−	_	
196-143	53288-53289	2	_	
196-144	53290-53292	50	_	
196-145	53293-53295	86	_	
196-146	53296-53300	4.51	_	
196-147	53304-53313	Precuneus	_	
196-148	53313-53314	,	_	
196-149	53315-53321	dorsal	_	
196-150	53322-53323	R	_	
196-151	53323-53324	/	_	
196-152	53324-53325	L	_	
196-153	53326-53327	−	_	
196-154	53327-53328	6	_	
196-155	53329-53330	−	_	
196-156	53330-53332	56	_	
196-157	53333-53335	60	_	
196-158	53336-53339	160	_	
196-159	53340-53344	4.49	_	
196-160	53348-53361	Abbreviations	_	
196-161	53361-53362	:	_	
196-162	53363-53365	BT	_	
196-163	53365-53366	,	_	
196-164	53367-53380	buprenorphine	_	
196-165	53381-53390	treatment	_	
196-166	53391-53394	for	_	
196-167	53395-53401	opioid	_	
196-168	53402-53405	use	_	
196-169	53406-53414	disorder	_	
196-170	53414-53415	;	_	
196-171	53416-53418	CG	_	
196-172	53418-53419	,	_	
196-173	53420-53430	comparison	_	
196-174	53431-53436	group	_	
196-175	53436-53437	;	_	
196-176	53438-53441	PAG	_	
196-177	53441-53442	,	_	
196-178	53443-53457	periaqueductal	_	
196-179	53458-53462	gray	_	
196-180	53462-53463	;	_	
196-181	53464-53469	rs-FC	_	
196-182	53469-53470	,	_	
196-183	53471-53484	resting-state	_	
196-184	53485-53495	functional	_	
196-185	53496-53508	connectivity	_	
196-186	53508-53509	.	_	

#Text=Except this a priori region of interest, all regions listed above were cluster-level whole-brain corrected (family-wise error correction < .05) at voxel-wise P = .001.
197-1	53510-53516	Except	_	
197-2	53517-53521	this	_	
197-3	53522-53523	a	_	
197-4	53524-53530	priori	_	
197-5	53531-53537	region	_	
197-6	53538-53540	of	_	
197-7	53541-53549	interest	_	
197-8	53549-53550	,	_	
197-9	53551-53554	all	_	
197-10	53555-53562	regions	_	
197-11	53563-53569	listed	_	
197-12	53570-53575	above	_	
197-13	53576-53580	were	_	
197-14	53581-53594	cluster-level	_	
197-15	53595-53606	whole-brain	_	
197-16	53607-53616	corrected	_	
197-17	53617-53618	(	_	
197-18	53618-53629	family-wise	_	
197-19	53630-53635	error	_	
197-20	53636-53646	correction	_	
197-21	53647-53648	<	_	
197-22	53649-53652	.05	_	
197-23	53652-53653	)	_	
197-24	53654-53656	at	_	
197-25	53657-53667	voxel-wise	_	
197-26	53668-53669	P	_	
197-27	53670-53671	=	_	
197-28	53672-53676	.001	_	
197-29	53676-53677	.	_	

#Text=BT vs CG main effects on PAG-dependent rs-FC at T2
#Text=\t\tMNI coordinates\t\t\t \tBrain region\tSide\tx\ty\tz\tNumber of voxels\tZ score\t \tBT > CG\t \t Hypothalamusa\tR/L\t−8\t−2\t−12\t5\t2.01\t \tBT < CG\t \t Anterior cingulate cortex, dorsal\tR/L\t2\t32\t2\t198\t4.48\t \t Anterior cingulate cortex, ventral\tL\t−12\t42\t−10\t89\t3.82\t \t
#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group; PAG, periaqueductal gray; rs-FC, resting-state functional connectivity.
198-1	53678-53680	BT	_	
198-2	53681-53683	vs	_	
198-3	53684-53686	CG	_	
198-4	53687-53691	main	_	
198-5	53692-53699	effects	_	
198-6	53700-53702	on	_	
198-7	53703-53716	PAG-dependent	_	
198-8	53717-53722	rs-FC	_	
198-9	53723-53725	at	_	
198-10	53726-53728	T2	_	
198-11	53731-53734	MNI	_	
198-12	53735-53746	coordinates	_	
198-13	53751-53756	Brain	_	
198-14	53757-53763	region	_	
198-15	53764-53768	Side	_	
198-16	53769-53770	x	_	
198-17	53771-53772	y	_	
198-18	53773-53774	z	_	
198-19	53775-53781	Number	_	
198-20	53782-53784	of	_	
198-21	53785-53791	voxels	_	
198-22	53792-53793	Z	_	
198-23	53794-53799	score	_	
198-24	53802-53804	BT	_	
198-25	53805-53806	>	_	
198-26	53807-53809	CG	_	
198-27	53813-53826	Hypothalamusa	_	
198-28	53827-53828	R	_	
198-29	53828-53829	/	_	
198-30	53829-53830	L	_	
198-31	53831-53832	−	_	
198-32	53832-53833	8	_	
198-33	53834-53835	−	_	
198-34	53835-53836	2	_	
198-35	53837-53838	−	_	
198-36	53838-53840	12	_	
198-37	53841-53842	5	_	
198-38	53843-53847	2.01	_	
198-39	53850-53852	BT	_	
198-40	53853-53854	<	_	
198-41	53855-53857	CG	_	
198-42	53861-53869	Anterior	_	
198-43	53870-53879	cingulate	_	
198-44	53880-53886	cortex	_	
198-45	53886-53887	,	_	
198-46	53888-53894	dorsal	_	
198-47	53895-53896	R	_	
198-48	53896-53897	/	_	
198-49	53897-53898	L	_	
198-50	53899-53900	2	_	
198-51	53901-53903	32	_	
198-52	53904-53905	2	_	
198-53	53906-53909	198	_	
198-54	53910-53914	4.48	_	
198-55	53918-53926	Anterior	_	
198-56	53927-53936	cingulate	_	
198-57	53937-53943	cortex	_	
198-58	53943-53944	,	_	
198-59	53945-53952	ventral	_	
198-60	53953-53954	L	_	
198-61	53955-53956	−	_	
198-62	53956-53958	12	_	
198-63	53959-53961	42	_	
198-64	53962-53963	−	_	
198-65	53963-53965	10	_	
198-66	53966-53968	89	_	
198-67	53969-53973	3.82	_	
198-68	53977-53990	Abbreviations	_	
198-69	53990-53991	:	_	
198-70	53992-53994	BT	_	
198-71	53994-53995	,	_	
198-72	53996-54009	buprenorphine	_	
198-73	54010-54019	treatment	_	
198-74	54020-54023	for	_	
198-75	54024-54030	opioid	_	
198-76	54031-54034	use	_	
198-77	54035-54043	disorder	_	
198-78	54043-54044	;	_	
198-79	54045-54047	CG	_	
198-80	54047-54048	,	_	
198-81	54049-54059	comparison	_	
198-82	54060-54065	group	_	
198-83	54065-54066	;	_	
198-84	54067-54070	PAG	_	
198-85	54070-54071	,	_	
198-86	54072-54086	periaqueductal	_	
198-87	54087-54091	gray	_	
198-88	54091-54092	;	_	
198-89	54093-54098	rs-FC	_	
198-90	54098-54099	,	_	
198-91	54100-54113	resting-state	_	
198-92	54114-54124	functional	_	
198-93	54125-54137	connectivity	_	
198-94	54137-54138	.	_	

#Text=Except this a priori region of interest, all regions listed above were cluster-level whole-brain corrected (family-wise error correction < .05) at voxel-wise P = .001.
199-1	54139-54145	Except	_	
199-2	54146-54150	this	_	
199-3	54151-54152	a	_	
199-4	54153-54159	priori	_	
199-5	54160-54166	region	_	
199-6	54167-54169	of	_	
199-7	54170-54178	interest	_	
199-8	54178-54179	,	_	
199-9	54180-54183	all	_	
199-10	54184-54191	regions	_	
199-11	54192-54198	listed	_	
199-12	54199-54204	above	_	
199-13	54205-54209	were	_	
199-14	54210-54223	cluster-level	_	
199-15	54224-54235	whole-brain	_	
199-16	54236-54245	corrected	_	
199-17	54246-54247	(	_	
199-18	54247-54258	family-wise	_	
199-19	54259-54264	error	_	
199-20	54265-54275	correction	_	
199-21	54276-54277	<	_	
199-22	54278-54281	.05	_	
199-23	54281-54282	)	_	
199-24	54283-54285	at	_	
199-25	54286-54296	voxel-wise	_	
199-26	54297-54298	P	_	
199-27	54299-54300	=	_	
199-28	54301-54305	.001	_	
199-29	54305-54306	.	_	

#Text=Group (BT vs CG) by Time interaction effects on PAG-dependent rs-FC
#Text=\t\tMNI coordinates\t\t\t \tBrain region\tSide\tx\ty\tz\tNumber of voxels\tZ score\t \tBT > CG in T1-to-T2 increases\t \t Middle temporal gyrus\tR\t60\t−40\t4\t211\t4.78\t \t Insular cortex\tR\t48\t10\t−6\t110\t4.51\t \tBT > CG in T1-to-T2 decreases\t \t Precuneus, dorsal\tL\t−26\t−74\t50\t137\t5.03\t \t Orbital frontal cortex\tL\t−18\t32\t−18\t169\t4.84\t \t Septal area/caudate nucleus\tR/L\t−10\t0\t6\t271\t4.78\t \t Anterior cingulate cortex, dorsal\tL\t−2\t30\t10\t175\t4.58\t \t
#Text=Note: All regions listed above were cluster-level whole-brain corrected (family-wise error correction < .05) at voxel-wise P = .001.
200-1	54307-54312	Group	_	
200-2	54313-54314	(	_	
200-3	54314-54316	BT	_	
200-4	54317-54319	vs	_	
200-5	54320-54322	CG	_	
200-6	54322-54323	)	_	
200-7	54324-54326	by	_	
200-8	54327-54331	Time	_	
200-9	54332-54343	interaction	_	
200-10	54344-54351	effects	_	
200-11	54352-54354	on	_	
200-12	54355-54368	PAG-dependent	_	
200-13	54369-54374	rs-FC	_	
200-14	54377-54380	MNI	_	
200-15	54381-54392	coordinates	_	
200-16	54397-54402	Brain	_	
200-17	54403-54409	region	_	
200-18	54410-54414	Side	_	
200-19	54415-54416	x	_	
200-20	54417-54418	y	_	
200-21	54419-54420	z	_	
200-22	54421-54427	Number	_	
200-23	54428-54430	of	_	
200-24	54431-54437	voxels	_	
200-25	54438-54439	Z	_	
200-26	54440-54445	score	_	
200-27	54448-54450	BT	_	
200-28	54451-54452	>	_	
200-29	54453-54455	CG	_	
200-30	54456-54458	in	_	
200-31	54459-54461	T1	_	
200-32	54461-54462	-	_	
200-33	54462-54467	to-T2	_	
200-34	54468-54477	increases	_	
200-35	54481-54487	Middle	_	
200-36	54488-54496	temporal	_	
200-37	54497-54502	gyrus	_	
200-38	54503-54504	R	_	
200-39	54505-54507	60	_	
200-40	54508-54509	−	_	
200-41	54509-54511	40	_	
200-42	54512-54513	4	_	
200-43	54514-54517	211	_	
200-44	54518-54522	4.78	_	
200-45	54526-54533	Insular	_	
200-46	54534-54540	cortex	_	
200-47	54541-54542	R	_	
200-48	54543-54545	48	_	
200-49	54546-54548	10	_	
200-50	54549-54550	−	_	
200-51	54550-54551	6	_	
200-52	54552-54555	110	_	
200-53	54556-54560	4.51	_	
200-54	54563-54565	BT	_	
200-55	54566-54567	>	_	
200-56	54568-54570	CG	_	
200-57	54571-54573	in	_	
200-58	54574-54576	T1	_	
200-59	54576-54577	-	_	
200-60	54577-54582	to-T2	_	
200-61	54583-54592	decreases	_	
200-62	54596-54605	Precuneus	_	
200-63	54605-54606	,	_	
200-64	54607-54613	dorsal	_	
200-65	54614-54615	L	_	
200-66	54616-54617	−	_	
200-67	54617-54619	26	_	
200-68	54620-54621	−	_	
200-69	54621-54623	74	_	
200-70	54624-54626	50	_	
200-71	54627-54630	137	_	
200-72	54631-54635	5.03	_	
200-73	54639-54646	Orbital	_	
200-74	54647-54654	frontal	_	
200-75	54655-54661	cortex	_	
200-76	54662-54663	L	_	
200-77	54664-54665	−	_	
200-78	54665-54667	18	_	
200-79	54668-54670	32	_	
200-80	54671-54672	−	_	
200-81	54672-54674	18	_	
200-82	54675-54678	169	_	
200-83	54679-54683	4.84	_	
200-84	54687-54693	Septal	_	
200-85	54694-54698	area	_	
200-86	54698-54699	/	_	
200-87	54699-54706	caudate	_	
200-88	54707-54714	nucleus	_	
200-89	54715-54716	R	_	
200-90	54716-54717	/	_	
200-91	54717-54718	L	_	
200-92	54719-54720	−	_	
200-93	54720-54722	10	_	
200-94	54723-54724	0	_	
200-95	54725-54726	6	_	
200-96	54727-54730	271	_	
200-97	54731-54735	4.78	_	
200-98	54739-54747	Anterior	_	
200-99	54748-54757	cingulate	_	
200-100	54758-54764	cortex	_	
200-101	54764-54765	,	_	
200-102	54766-54772	dorsal	_	
200-103	54773-54774	L	_	
200-104	54775-54776	−	_	
200-105	54776-54777	2	_	
200-106	54778-54780	30	_	
200-107	54781-54783	10	_	
200-108	54784-54787	175	_	
200-109	54788-54792	4.58	_	
200-110	54796-54800	Note	_	
200-111	54800-54801	:	_	
200-112	54802-54805	All	_	
200-113	54806-54813	regions	_	
200-114	54814-54820	listed	_	
200-115	54821-54826	above	_	
200-116	54827-54831	were	_	
200-117	54832-54845	cluster-level	_	
200-118	54846-54857	whole-brain	_	
200-119	54858-54867	corrected	_	
200-120	54868-54869	(	_	
200-121	54869-54880	family-wise	_	
200-122	54881-54886	error	_	
200-123	54887-54897	correction	_	
200-124	54898-54899	<	_	
200-125	54900-54903	.05	_	
200-126	54903-54904	)	_	
200-127	54905-54907	at	_	
200-128	54908-54918	voxel-wise	_	
200-129	54919-54920	P	_	
200-130	54921-54922	=	_	
200-131	54923-54927	.001	_	
200-132	54927-54928	.	_	

#Text=Abbreviations: BT, buprenorphine treatment for opioid use disorder; CG, comparison group; PAG, periaqueductal gray; rs-FC, resting-state functional connectivity.
201-1	54929-54942	Abbreviations	_	
201-2	54942-54943	:	_	
201-3	54944-54946	BT	_	
201-4	54946-54947	,	_	
201-5	54948-54961	buprenorphine	_	
201-6	54962-54971	treatment	_	
201-7	54972-54975	for	_	
201-8	54976-54982	opioid	_	
201-9	54983-54986	use	_	
201-10	54987-54995	disorder	_	
201-11	54995-54996	;	_	
201-12	54997-54999	CG	_	
201-13	54999-55000	,	_	
201-14	55001-55011	comparison	_	
201-15	55012-55017	group	_	
201-16	55017-55018	;	_	
201-17	55019-55022	PAG	_	
201-18	55022-55023	,	_	
201-19	55024-55038	periaqueductal	_	
201-20	55039-55043	gray	_	
201-21	55043-55044	;	_	
201-22	55045-55050	rs-FC	_	
201-23	55050-55051	,	_	
201-24	55052-55065	resting-state	_	
201-25	55066-55076	functional	_	
201-26	55077-55089	connectivity	_	
201-27	55089-55090	.	_	
